Molecular Pathogenesis of MALT lymphoma by Hamoudi, Rifat A
 
 
Department of Pathology 
 
 
 
 
 
 
Molecular Pathogenesis of MALT Lymphoma 
 
 
 
Rifat Akram Hamoudi 
 
 
 
Churchill College 
 
 
                                                      
                                  
 
 
 
 
 
Dissertation submitted for the degree of Doctor of Philosophy 
 
University of Cambridge, United Kingdom - September, 2010 
 ii 
 
 
 
 
Declarations .............................................................................................................. iii 
 
Table of contents ....................................................................................................... iv  
 
List of tables .............................................................................................................. xiv  
 
List of figures ............................................................................................................ xv 
 
Abbreviations ............................................................................................................ xviii 
 
Abstract ..................................................................................................................... xxi 
 
Publications ............................................................................................................... xxiii 
 
Acknowledgements ................................................................................................... xxiv 
 
 
 iii 
 
Declarations 
 
 
 
This dissertation is the result of my own work and includes nothing which is the outcome 
of work done in collaboration except where specifically indicated in the text. 
 
I also declare that this thesis is not substantially the same as any that I submitted for a 
degree or diploma or other qualification at any other University, and that no part has 
already been, or is currently being, submitted for any degree, diploma, or other 
qualification. 
 
This dissertation comprises a total of 264 pages. Excluding tables, figures, references and 
appendices, the number of pages corresponding to text is 195.  
 
 
 
 
      
      
 
 
 
 
  
Rifat Akram Hamoudi 
September 2010 
 iv 
 
Table of contents 
 
 
CHAPTER 1 - General introduction ....................................... 1 
 
1.1 Brief overview of lymphomas ................................................................................ 1 
 
1.2 Overview of MALT lymphoma .............................................................................. 3 
 
1.2.1                Aetiology of MALT lymphoma……………………………………… 3 
1.2.1.1             Chronic infection……………………………………………………...  4 
1.2.1.2             Autoimmune disease………………………………………………......  6 
 
1.2.2 Histopathology of MALT lymphoma…………………………………. 7 
1.2.2.1 Mucosa associated lymphoid tissue………………………………….... 7 
1.2.2.2 Extranodal marginal zone B-cell lymphoma of MALT……………….. 9 
 
1.2.3 Immunophenotype…………………………………………………….. 10 
 
1.2.4 Pathogenesis of MALT lymphoma……………………………………. 12 
1.2.4.1  H. pylori and its role in the development of gastric  
MALT lymphoma……………………………………………………... 12 
1.2.4.2 Immunological stimulation……………………………………………. 13 
1.2.4.2.1 Direct antigen stimulation……………………………………………... 13 
1.2.4.2.2 Indirect antigen stimulation……………………………………………. 14 
1.2.4.3 H. pylori virulent and host factors in the development of  
gastric MALT lymphoma…………………………………………....... 16 
1.2.4.3.1 Host factors……………………………………………………………. 16 
1.2.4.3.2 Bacterial virulence factors……………………………….……………. 17 
1.2.4.4 Role of anti-microbial and other therapies in the treatment of  
MALT lymphoma……………………………………………............... 19 
 
1.3 Genetics of MALT lymphoma………………………………………. 21 
1.3.1 Chromosomal translocations………………………………………….. 21 
1.3.1.1 t(11;18)(q21;q21)/API2-MALT1……………………………………… 23 
1.3.1.2 t(1;14)(p22;q32)/BCL10-IGH………………………………………… 25 
1.3.1.3 t(14;18)(q32;q21)/IGH-MALT1……………………………………….. 26 
1.3.1.4  BCL10 and MALT1 expression patterns in MALT lymphoma 
 with different translocation status……………………………………... 27 
1.3.1.5 t(3;14)(p13;q32)/FoxP1/IGH…………………………………………. 29 
1.3.2 Other chromosome translocations…………………………………….. 31 
1.3.3 Genetics of translocation negative MALT lymphoma………………... 31 
 
 
 
 v 
 
 
1.4 NF-κB pathway……………………………………………………… 33 
1.4.1 NF-κB family members………………………………………….......... 33 
1.4.2 NF-κB activation pathways…………………………………………... 34 
1.4.2.1 Canonical pathway…………………………………………………… 35 
1.4.2.2 Non-canonical pathway………………………………………………. 40 
1.4.3 NF-κB negative regulators……………………………………………. 44 
1.4.4 NF-κB target genes and their biological implications………………… 45 
 
1.5 MALT lymphoma associated translocations target common  
molecular pathways that cause NF-κB activation…………………. 48 
 
1.6 Summary of current understanding of  
gastric MALT lymphoma……………………………………………. 51 
 
1.7 Gene expression microarray………………………………………… 54 
1.7.1 Advantages of using gene expression microarray…………………….. 55 
1.7.2 Limitations of gene expression microarray…………………………… 55 
1.7.3 Microarray platforms…………………………………………………. 57 
1.7.3.1 The Affymetrix HG-U133 GeneChip………………………………… 57 
1.7.3.1.1 Probe versus probe set………………………………………………… 58 
1.7.4 Data analysis…………………………………………………………... 59 
1.7.5 Advances in lymphoma by gene expression  
microarray investigations……………………………………….……... 61 
1.7.6 Gene expression microarray studies of MALT lymphomas…………... 64 
 
1.8 Objectives of the thesis……………………………………………….. 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
CHAPTER 2.  Materials and methods ..................................... 67 
 
2.1 Materials……………………………………………………………. 67 
 
2.1.1 Tissue materials and clinical data………………………………....... 67 
2.1.1.1 Ethical considerations………………………………………………. 67 
2.1.1.2 Tissue material for expression microarray and  
phenotypic marker studies………………………………………….. 67 
2.1.1.3 Tissue material for qRT-PCR and immunohistochemistry………..… 69 
 
2.1.2 Reagents…………………………………………………………….. 69 
2.1.2.1 Reagents used in gene expression microarray and qRT-PCR………. 69 
2.1.2.2 Reagents used in immunohistochemistry……………………………. 70 
2.1.2.3 Reagents used in tissue culture……………………………………… 71 
2.1.2.4 Reagents used in Western blotting and co-immunoprecipitation…… 71 
2.1.2.5 Reagents used in cloning and DNA sequencing…………………….. 72 
 
2.1.3 Cell lines……………………………………………………………… 72 
 
2.2 Methods………………………………………………………………. 74 
 
2.2.1 Overview of the study plan……………………………………………. 74 
 
2.2.2 Crude microdissection…………………………………………………. 74 
 
2.2.3 RNA preparation………………………………………………………. 75 
2.2.3.1 RNA extraction from fresh frozen tissue……………………………… 75 
2.2.3.2 RNA extraction from formalin fixed paraffin-embedded tissue ……… 76 
2.2.3.3 RNA extraction from cell lines………………………………………... 76 
2.2.3.4 RNA linear amplification……………………………………………… 76 
2.2.3.5 RNA quantification and quality control……………………………….. 77 
 
2.2.4 Expression microarray…………………………………………………. 78 
2.2.4.1 Affymetrix HG-U133 GeneChips…………………………………….. 78 
2.2.4.2 Preparation of biotinylated cRNA target for Affymetrix GeneChip...... 78 
2.2.4.2.1 Double stranded cDNA synthesis…………………………………....... 79 
2.2.4.2.2 cRNA labelling using IVT (In-Vitro Transcription)…………………... 79 
2.2.4.2.3 Fragmentation of cRNA………………………………………………. 80 
2.2.4.3  Hybridisation to HG-U133 Affymetrix GeneChips and data  
Acquisition…………………………………………………………….. 80 
2.2.4.3.1 Hybridisation mix preparation………………………………………… 80 
2.2.4.3.2 Hybridisation to HG-U133 GeneChips……………………………….. 80 
2.2.4.3.3 Hybridisation to Test3 GeneChip……………………………………... 81 
2.2.4.3.4 Staining of GeneChips………………………………………………… 81 
 
2.2.4.4 HG-U133 GeneChip data acquisition and quality control……………. 81 
 vii 
 
2.2.5  Bioinformatics and statistical analysis of gene 
expression microarray data………………………………………….. 83 
2.2.5.1 Normalisation………………………………………………………. 83 
2.2.5.2 Non-specific filtering……………………………………………….. 84 
2.2.5.3 Clustering analysis…………………………………………………. 84 
2.2.5.4 Gene Set Enrichment Analysis (GSEA)…………………………… 85 
2.2.5.5 Analysis of differential gene expression in MALT lymphomas with   
and without chromosome translocation……………………………… 86 
2.2.5.6 Functional annotation using gene ontology (GO)………………...…. 86 
2.2.5.7 Phenotypic marker analysis………………………………………….. 87 
2.2.5.8 Statistical analyses…………………………………………………… 87 
 
2.2.6 Quatitative Real-time RT-PCR………………………………….…. 88 
2.2.6.1 Primer design………………………………………………………. 88 
2.2.6.2 Complementary DNA (cDNA) synthesis……………………….….. 90 
2.2.6.3 Quantitative PCR (qPCR)…………………………………..……… 90 
 
2.2.7 Immunohistochemistry……………………………………………… 91 
 
2.2.8 Expression constructs preparation………………………………….. 92 
2.2.8.1  Modification of pIRES vectors containing HA and FLAG  
tag sequences……………………………………………………..… 92 
2.2.8.2 Generation of tagged BCL10, MALT1 and API2-MALT1  
Expression constructs……………………………………………..... 95  
2.2.8.2.1 Preparation of HA-tagged BCL10……………………………….… 96 
2.2.8.2.2 Preparation of FLAG-tagged API2-MALT1 and 
FLAG- tagged MALT1……………………………………………. 96 
2.2.8.2.3 Subcloning of oncogenes into pTRE2…………………………….. 97 
2.2.8.3 Toll-like receptors constructs……………………………………… 98 
2.2.8.4 DNA sequencing…………………………………………………… 98 
 
2.2.9 Cell culture…………………………………………………………. 99 
2.2.9.1 Protocols for freezing cells…………………………………………. 99 
2.2.9.2 Protocols for thawing cells………………………………………… 100 
2.2.9.3 Cell clot preparation………………………………………………. 100 
2.2.9.4 Transient transfection of cells……………………………………… 100 
2.2.9.5 Generation of stably inducible MALT lymphoma  
associated oncogenes cells………………………….……………… 101 
 
 
 
 
 
 
 
 
 viii 
 
2.2.10 Protein work……………………………………………………… 102 
2.2.10.1 Protein extraction from whole cell lysate……………………….. 102 
2.2.10.2 Preparation of protein homogenate from frozen tissue…………….. 102 
2.2.10.3 Protein extraction from nuclear and cytoplasmic fractions……….. 103 
2.2.10.4 Protein quantitation………………………………………………… 103 
2.2.10.5 Antibodies used for functional and cellular work ………………… 103 
2.2.10.6 Western blot………………………………………………………. 105 
2.2.10.7 Stripping of Western blot………………………………………….. 106 
2.2.10.8 Co-immunoprecipitation…………………………………………. 106 
 
2.2.11 Dual luciferase reporter assays…………………………………… 106 
2.2.11.1 NF-κB luciferase reporter assay…………………………………. 106 
2.2.11.2 AP-1 luciferase reporter assay……………………………………. 107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
 
CHAPTER 3 – Characterisation of the gene expression profiles 
of MALT lymphoma with and without chromosome 
translocation .............................................................................  108 
 
3.1   Introduction………………………………………………………... 108 
 
3.2  Aims of the study…………………………………………………... 109 
 
3.3 Experimental design……………………………………………….. 110 
3.3.1 Case selection……………………………………………………….. 110 
3.3.2 RNA quality check using Agilent nanochip………………………… 110 
3.3.3 Validation of the in house linear RNA amplification protocol……… 111 
3.3.4 Unsupervised clustering analysis……………………………………. 111 
3.3.5  Characterisation of gene expression features of MALT lymphoma 
 with and without chromosome translocation………………………... 111 
 
3.4  Results………..……………………………………………………... 112 
3.4.1 RNA quality control………………………………………….……… 112 
3.4.2 Comparison of total RNA with amplified RNA…………………...... 113 
3.4.3 Validation of microarray data using biological controls…………….. 114 
3.4.4  Unsupervised clustering between MALT, MCL and FL defines  
MALT lymphoma as a distinct entity……………………………….. 115 
3.4.5  Unsupervised clustering confirms overlapping features in gene  
 expression profiling between MALT lymphoma with and without 
chromosome translocation…………………………………………… 118 
3.4.6  Characterisation of gene expression profiles of MALT lymphoma  
with and without chromosome translocation………………………… 122 
3.4.6.1  NF-κB target genes are significantly differentially expressed  
between MALT lymphoma with and without chromosome 
translocation…………………..……………………………………… 125 
3.4.6.2 Other gene sets differentially enriched between MALT lymphoma  
with and without chromosome translocation………………………… 126 
3.4.6.3 Gene ontology annotations of genes differentially expressed  
between MALT lymphoma with and without chromosome  
translocation confirms findings by GSEA……………………………. 128 
3.4.7  Pathway analysis of molecules identified by gene expression  
 microarray and potentially important in MALT lymphoma 
pathogenesis…………………………………………………..……… 131 
 
3.5 Discussion…………………………………………………………….. 133 
3.5.1  Molecular mechanism of translocation positive MALT lymphoma…... 133 
3.5.2 Molecular mechanism of translocation negative MALT lymphoma….. 134 
3.5.3  Nuclear BCL10……………………………………………………….. 135 
3.5.4   Summary and conclusion………………………………………...……. 136 
 
 x 
 
CHAPTER 4 – Validation of the genes identified by expression 
microarray of MALT lymphoma with and without 
chromosome translocation using qRT-PCR and 
immunohistochemistry ............................................................  138 
 
 
4.1 Introduction……………………………………………………………… 138 
 
4.2  Aims of the study………………………………………………………… 138 
 
4.3 Experimental design…………………………………………..…………. 139 
4.3.1 Case selection…………………………………………………….……….. 139 
4.3.2 Validation of gene expression by qRT-PCR……………………………… 139 
4.3.3  BCL2, CD69, MUM1, MALT1, BCL10 and CD86 
 immunohistochemistry…………………………………………….............. 140 
4.3.4 Validation of TLR6 using Western blotting………………………............. 141 
 
4.4 Results…………………………………………………………………….. 142 
 
4.4.1  Correlation of mRNA expression of CD69, CCR2A, CCR5, TLR6, BCL2,  
 MUM1, CD86, NR4A3, BCL10 and MALT1 genes in MALT  
 lymphoma with and without chromosomal translocation………………….. 142 
4.4.2  Comparison of protein expression of CD69, BCL2, CD86, MUM1,  
 BCL10 and MALT1 in MALT lymphoma with and without 
  chromosomal translocation using immunohistochemistry…………………. 146 
4.4.3 Comparison of protein expression of TLR6 in MALT lymphoma with and 
without chromosome translocation using Western blotting………………... 148 
 
 
4.5 Discussion…………………………………………………………………. 150 
 
 
 
 
 
 
 
 
 
 
 xi 
 
CHAPTER 5 – Cooperation between MALT lymphoma 
oncogenes and immunological stimulation in activating the  
NF-κB  pathway………………………………………………. 155 
 
5.1 Introduction……………………………………………………………….. 155 
 
5.2  Aims of the study………………………………………………………….. 156 
 
5.3 Experimental design………………………………………………………. 157 
5.3.1  Cell lines………………………………………………………………….… 157 
5.3.2   Investigation of the cooperation between BCL10, MALT1 and  
API2-MALT1 and TLR6 on NF-κB activation with and without LPS 
stimulation…………………………………………………………………. 157 
5.3.3   Investigation of the effect of BCL10, MALT1 and API2-MALT1 expression  
  and antigen receptor stimulation on NF-κB activation…………………..… 158 
5.3.4  Investigation of the effect of MALT lymphoma associated oncogenes  
 expression on canonical NF-κB pathway activation……………………...... 158 
5.3.5  Investigation of the effect of BCL10 and MALT1 expression on their sub-
cellular localization.…………………………………………………………  159 
 
5.4 Results…………………………………………………………………….. 160 
5.4.1  TLR6 (in the presence of TLR2), enhances BCL10 and API2-MALT1  
 mediated NF-κB activation in Jurkat T cells…………………….……...…. 160 
5.4.2  Cooperation of BCL10, MALT1, API2-MALT1 and immune receptor  
 signalling in NF-κB activation in B-cells………………………………….. 163 
5.4.3  Cooperation between  BCL10, MALT1, API2-MALT1 immune receptor 
signalling on NF-κB activation in Jurkat T cells…………………………… 166 
5.4.4  Investigation of the effect of BCL10 and MALT1 expression on their sub-
cellular localisation……………………………………………………......... 168 
5.4.5   Effect of BCL10, MALT1 and API2-MALT1 expression on canonical  
  NF-κB pathway activation ……………………………….…………............ 171 
 
5.5 Discussion………………………………………………………………….. 173 
5.5.1 Cooperation between the expression of MALT lymphoma associated  
 oncogenes and TLR stimulation……………………………………………. 173 
5.5.2  Effect of antigen receptor stimulation on MALT lymphomagenesis……….. 174 
5.5.3  BCL10 expression associated with IκBβ degradation……………………… 175 
5.5.4  BCL10 sub-cellular localisation and its relationship with  
 MALT1 expression………………………………………………………….. 176 
 
 
 
 
 
 
 xii 
 
CHAPTER 6 - Identification of MALT lymphoma 
specific phenotypic markers using gene expression 
microarray…………………………………………………..    179 
 
6.1 Introduction……………………………………………………………. 179 
 
6.2  Aims of the study…………………………………………………......... 180 
 
6.3 Experimental design…………………………………………………… 180 
6.3.1 Case selection……………………………………………………..…….. 180 
6.3.2  Identification of genes highly and specifically expressed in 
 MALT lymphoma by gene expression microarray analysis……………. 181 
6.3.3  Validation of genes highly and specifically expressed in MALT 
 lymphoma by qRT-PCR and immunohistochemistry…………………... 181 
 
6.4 Results………………………………………………………………….. 183 
6.4.1  Identification of genes highly and specifically expressed in  
 MALT lymphoma……………………………………………………….. 183 
6.4.2  Validation of Lactoferrin expression in MALT lymphoma…………….. 187 
 
6.5 Discussion………………………………………………………………. 190 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii 
 
CHAPTER 7 - General Discussion .........................................  193 
 
7.1 MALT lymphoma is a distinct entity within the lymphomas but with 
heterogeneity between MALT lymphoma with and without 
 chromosome translocation as indicated by gene expression profiling … 193 
 
7.2 Overview of the molecular mechanisms underlying the pathogenesis  
 of MALT lymphoma………………………………………………………. 193 
 
7.2.1 Aberrant molecular mechanisms of translocation positive  
 MALT lymphoma……………………………………..………………..…. 194 
 
7.2.2 Aberrant molecular mechanism of translocation negative 
 MALT lymphoma………………………………………………….……… 200 
 
7.2.3 Molecular mechanisms of BCL10, MALT1 and API2-MALT1  
 mediated NF-κB activation……………………………………………….. 202 
 
7.3 MALT lymphoma specific phenotypic marker identification…………. 206 
 
7.4  Conclusions……………………………………………………………….. 208 
 
7.5 Future perspectives…………………………………………………..…… 209 
 
 
7.5.1  CCR2  involvement in the molecular mechanism of  
 MALT lymphomagenesis…………………………………………………... 209 
 
7.5.2 Nuclear BCL10 function…………………………………………………… 210 
 
7.5.3 Lactoferrin expression in MALT lymphoma by immunohistochemistry…... 211 
 
 
References…………………………………………………………………………… 212 
 
 
Appendices…………………………………………………………………………... 241 
 
 
 
 
 
 
 
 
 xiv 
 
 
List of tables 
 
Table Title Page 
   
1.1 Typical immunophenotyping of MALT lymphoma cells 11 
 
 
2.1 Summary of clinico-pathological, molecular and immunohistochemical 
data of MALT lymphoma cases used in gene expression microarray 
studies 
 
 
68 
 
2.2 Primers used to investigate candidate genes by qRT-PCR 89 
 
2.3 Immunohistochemistry antibodies and conditions 92 
 
2.4 Primers used in construct preparation 95 
 
2.5 Primary and secondary antibodies used in co-immunoprecipitation and 
Western blotting 
 
104 
 
 
3.1 Gene sets differentially over-represented between MALT lymphoma 
with and without chromosome translocation 
 
124 
 
3.2 Representation of gene ontology terms in over-expressed genes in 
MALT lymphoma with and without chromosome translocation 
 
130 
 
 
4.1 Correlation of BCL2, CD69 and CD86 expression in MALT lymphoma 
with and without chromosome translocation 
 
147 
 
 
6.1 Descriptive statistical properties of the 5 potential phenotypic marker 
probes calculated for MALT and other lymphomas separately 
 
186 
 
 
 
 
 
 
 
 
 
 
 xv 
 
List of figures 
 
Figure Title Page 
   
1.1 Morphology of MALT and gastric MALT lymphoma from the 
gastrointestinal tract 
 
8 
 
1.2 Cytological and histological features of MALT lymphoma 9 
 
1.3 The role of T- and B- cell interaction in the development of MALT 
lymphoma 
 
15 
 
1.4 Schematic representation of chromosome translocations implicated in 
MALT lymphoma 
22 
 
1.5 Incidence of MALT lymphoma translocations in various sites 27 
 
1.6 BCL10 and MALT1 staining patterns in MALT lymphoma 
translocations 
 
28 
 
1.7 Canonical (classical) and non-canonical (alternative) NF-κB pathway 42 
 
1.8 B-cell receptor mediated NF-κB activation and constitutive NF-κB 
activation by MALT lymphoma associated translocations 
 
43 
1.9 Role of NF-κB target genes in immune response, cell proliferation and 
survival and maintaining cellular homeostasis 
 
47 
1.10 Multistep development of gastric MALT lymphoma 52 
 
 
2.1 Summary of the study plan 74 
2.2 Crude microdissection of gastric MALT lymphoma 75 
2.3 Strategy for generating hybridisation target from total RNA 78 
 
2.4 pIRESpuro vector 94 
 
2.5 pTRE vector 97 
 
 
3.1 Typical good quality data of total, complementary and fragment RNA 
on RNA nanochip 
 
112 
3.2 Correlation between total and amplified RNA from the same fresh 
frozen specimen of t(11;18) positive MALT lymphoma 
 
113 
3.3 Expression of hallmark genes in MALT lymphoma, FL and MCL 114 
 xvi 
 
 
 
 
3.4 
 
Summary of bioinformatics strategy to combine FL and MCL with 
MALT  microarray GeneChips 
 
 
115 
 
3.5 MALT lymphoma shows distinct gene expression profiles from 
follicular lymphoma and mantle cell lymphoma using unsupervised 
hierarchical clustering 
 
 
116 
3.6 Summary of bioinformatics strategy used to compare MALT lymphoma 
with and without chromosome translocations 
 
118 
3.7 Unsupervised hierarchical clustering of MALT lymphoma with different 
translocation status 
 
119 
3.8 Supervised hierarchical clustering of MALT lymphoma with different 
translocation status 
 
121 
3.9 Summary of bioinformatics strategy used for GSEA on MALT 
lymphoma with and without chromosome translocation 
 
122 
3.10 Gene set enrichment analysis (GSEA) of NF-κB target genes in MALT 
lymphomas with and without chromosome translocation 
 
126 
3.11 Presence of high proportion of NF-κB target genes in the leading edge 
core set of various gene sets related to inflammation and immune 
responses 
 
 
127 
3.12 Summary of bioinformatics strategy used for Gene Ontology analysis on 
MALT lymphoma with and without chromosome translocation 
 
128 
3.13 analysis of molecules derived from MALT lymphoma microarray 
analysis 
 
132 
 
 
4.1 Validation of gene expression in MALT lymphoma with and without 
chromosome translocation by real-time quantitative RT-PCR 
 
143 
4.2 Unsupervised hierarchical clustering of qRT-PCR data on MALT 
lymphoma cases with various translocation status 
 
144 
4.3 Immunohistochemistry of BCL2, CD69, CD86 and MUM1 146 
 
4.4 TLR6 expression in MALT lymphoma with and without chromosomal 
translocation using Western blot analysis 
 
149 
 
 
 
 
 
 
 xvii 
 
5.1 TLR6 enhances BCL10 and API2-MALT1 mediated NF-κB activation, 
in the presence of TLR2 but not TLR1, in Jurkat T-cells 
 
161 
5.2 BCL10, MALT1 and API2-MALT1 mediated NF-κB activation, with 
and without LPS stimulation in BaF3 murine B-cells 
 
163 
5.3 BCL10, MALT1 and API2-MALT1 mediated NF-κB activation, with 
and without 6 hours of LPS, anti-IgM and CD40-L stimulation in WEHI 
murine B-cells 
 
 
165 
 
5.4 BCL10, MALT1 and API2-MALT1 mediated NF-κB activation, with 
and without 6 hours of CD3/CD28 stimulation in Jurkat T cells 
 
166 
5.5 Immunohistochemistry on cell clots expressing various MALT 
lymphoma associated oncogenes 
 
168 
5.6 Co-immunoprecipitation showing that expression of BCL10 leads to 
increased interaction with MALT1 
 
170 
5.7 Activation of canonical NF-κB pathway by BCL10, MALT1 and API2-
MALT1 and association of IκBβ degradation with BCL10 expression 
 
171 
 
 
6.1 Summary of bioinformatics strategy to combine MALT lymphoma, FL, 
MCL, SMZL and CLL microarray data and identify the genes highly 
and specifically expressed in MALT lymphoma 
 
 
183 
6.2 (A) Supervised hierarchical clustering of MALT lymphoma, FL, MCL, 
SMZL and CLL (B) Volcano plot of MALT v other lymphomas 
showing Lactoferrin position near the top 
 
 
185 
6.3 Variation of the raw gene expression microarray data of Lactoferrin 
across the 5 lymphoma groups 
 
186 
6.4 Validation of Lactoferrin expression in MALT, FL and MCL 
lymphomas by real-time quantitative RT-PCR 
 
189 
6.5 Validation of Lactoferrin expression in MALT, FL and MCL 
lymphomas by immunohistochemistry 
 
189 
 
 
7.1 Summary and hypothesis on molecular mechanisms of MALT 
lymphoma with and without chromosomal translocation 
 
205 
 
 
 
 
 xviii 
 
Abbreviations 
 
Some abbreviations used only once or a few times, particularly with gene names, may not 
be included in this list, but are explained in the main text. In general gene names and 
translocations are written in italics. 
 
AP-1 Activator protein 1 
CCR Chemotactic cytokines receptor 
cDNA complementary DNA 
CLL Chronic lymphocytic leukaemia 
cRNA complementary RNA 
DLBCL Diffuse large B-cell lymphoma 
DLR Dual luciferase reporter assay 
FL Follicular lymphoma 
gcRMA GeneChip RMA 
GO Gene ontology 
GSEA Gene set enrichment analysis 
H. pylori Helicobactor pylori 
IκB Inhibitor of nuclear factor of kappa light polypeptide gene enhancer in B-cells 
MALT Mucosa associated lymphoid tissue 
MAPK Mitogen-activated protein kinases 
MAS5 Affymetrix Microarray Suite 5 
MCL Mantle cell lymphoma 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NHL Non-Hodgkin lymphoma 
PBS Phosphate buffered saline 
qPCR Quantitative PCR 
 xix 
 
qRT-PCR Quantitative real time PCR 
RMA Robust Multiarray Averaging 
RNA Ribonucleic acid 
RT-PCR Reverse transcriptase PCR 
SDS Sodium dodecyl sulphate 
SMZL Splenic marginal zone lymphoma 
TBS Tris-buffered saline  
TBST Tris-buffered saline with Tween 
TLR Toll-like receptor 
AP-1 Activator protein 1 
CCR Chemotactic cytokines receptor 
cDNA complementary DNA 
CLL Chronic lymphocytic leukaemia 
cRNA complementary RNA 
DLBCL Diffuse large B-cell lymphoma 
DLR Dual luciferase reporter assay 
FL Follicular lymphoma 
gcRMA GeneChip RMA 
GO Gene ontology 
GSEA Gene set enrichment analysis 
H. pylori Helicobactor pylori 
IκB Inhibitor of nuclear factor of kappa light polypeptide gene enhancer in B-cells 
MALT Mucosa associated lymphoid tissue 
MAPK Mitogen-activated protein kinases 
MAS5 Affymetrix Microarray Suite 5 
 xx 
 
MCL Mantle cell lymphoma 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NHL Non-Hodgkin lymphoma 
PBS Phosphate buffered saline 
qPCR Quantitative PCR 
qRT-PCR Quantitative real time PCR 
RMA Robust Multiarray Averaging 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxi 
 
Abstract 
 
Molecular Pathogenesis of MALT Lymphoma 
 
By Rifat Akram Hamoudi, Churchill College, University of Cambridge 
 
Mucosa associated lymphoid tissue (MALT) lymphoma is characterized by 
t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and 
t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the NF-κB pathway. Gastric 
MALT lymphomas harbouring such translocation do not respond to Helicobacter pylori 
eradication, while those without translocation can be cured by antibiotics. 
   
To understand the molecular mechanism of MALT lymphoma with and without 
chromosome translocation, 24 cases (15 translocation-positive and 9 translocation-
negative) of MALT lymphomas together with 7 follicular lymphomas and 7 mantle cell 
lymphomas were analysed by Affymetrix gene expression microarray platform.  
Unsupervised clustering showed that cases of MALT lymphoma were clustered as a 
single branch.  However, within the MALT lymphoma group, translocation-positive cases 
were intermingled with translocation-negative cases. Gene set enrichment analysis 
(GSEA) of the NF-κB target genes and 4394 additional gene sets covering various cellular 
pathways, biological processes and molecular functions showed that translocation-
positive MALT lymphomas were characterized by an enhanced expression of NF-κB 
target genes, particularly TLR6, CCR2, CD69 and BCL2, while translocation-negative 
cases were featured by active inflammatory and immune responses, such as IL8, CD86, 
CD28 and ICOS.  Separate analyses of the genes differentially expressed between 
translocation-positive and negative cases and measurement of gene ontology term in these 
differentially expressed genes by hypergeometric test reinforced the above findings by 
GSEA.  The differential expression of these NF-κB target genes between MALT 
lymphoma with and without translocation was confirmed by quantitative RT-PCR and 
immunohistochemistry or Western blot. 
 
 
 
 
 xxii 
 
 
Expression of TLR6, in the presence of TLR2, enhanced both API2-MALT1 and BCL10 
mediated NF-κB activation in vitro.  In addition, there was cooperation between 
expression of BCL10, MALT1 or API2-MALT1, and stimulation of the antigen receptor 
or CD40 or TLR in NF-κB activation as shown by both reporter assay and IκBα 
degradation.  Interestingly, expression of BCL10 but not API2-MALT1 and MALT1, in 
the presence of LPS stimulation, also triggered IκBβ degradation, suggesting activation of 
different NF-κB dimers between these oncogenic products.     
 
Study by co-immunoprecipitation showed that BCL10 directly interacts with MALT1. 
Sub-cellular localisation experiments in BJAB B-cells, showed that BCL10 localisation 
was affected by MALT1. When BCL10 was over-expressed, the protein was 
predominantly expressed in the nuclei, but when MALT1 was over-expressed, BCL10 
was mainly localised in the cytoplasm. When both BCL10 and MALT1 were over-
expressed, BCL10 was expressed in the cytoplasm in the early hours when the protein 
level was low, but in both the cytoplasm and nuclei after 9 hours when the protein level 
was high. Over-expression of API2-MALT1 did not shown any apparent effect on BCL10 
sub-cellular localisation in vitro. 
 
Finally, comparison of MALT lymphoma expression microarray with other lymphomas 
showed lactoferrin to be highly expressed in MALT lymphoma. This was confirmed by 
qRT-PCR, showing lactoferrin to be significantly over-expressed in MALT lymphoma 
compared to FL and MCL. Thus lactoferrin may be a potential marker for MALT 
lymphoma. 
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CHAPTER 1 – General introduction 
 
 
1.1 Brief overview of lymphomas 
 
Lymphoma is defined as a neoplastic proliferation of lymphoid cells. 90% of all lymphoid 
malignancies are of B-cell lineage, whilst a minority are of T-cell (7%) or NK-cell lineage 
(<2%). In 1832 Thomas Hodgkin first described what became known as Hodgkin lymphoma. 
Hodgkin lymphoma (HL) accounts for approximately 30% of all lymphomas and comprises 2 
distinct disease entities, the more frequent classical Hodgkin lymphoma (cHL) (95%) and the 
uncommon nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) (5%). In cHL, 
the neoplastic cells are usually a minority population whose survival appears to be dependent 
on the majority of reactive or inflammatory cells (Aldinucci et al., 2010). In the majority of 
cases the neoplastic (Reed-Sternberg (Reed, 1902)) cells appear to be of B-cell origin. 
NLPHL is characterised by lymphocytic and histocytic (L&H) or “popcorn” cells in that are 
distributed amidst abundant non-neoplastic inflammatory and accessory cells. 
Approximately 70% of lymphomas do not have the clinical and pathological features of HL 
and have therefore been categorised historically as non-Hodgkin lymphomas (NHL). NHL 
are frequently disseminated and are all considered malignant or potentially malignant. Some 
are aggressive from the outset, while others are indolent for varying lengths of time, but may 
transform to more aggressive tumours. According to the World Health Organisation (WHO) 
2008 classification (Swerdlow et al., 2008), these lymphoid neoplasms which together 
account for the majority of lymphomas are classified as distinct disease entities under the 
broader categories of precursor lymphoid neoplasms, mature B-cell neoplasms, mature T and 
NK-cell neoplasms, immunodeficiency-associated lymphoproliferative disorders and 
histocytic and dendritic cell neoplasms. 
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Most NHLs are mature B-cell neoplasms corresponding to a clonal proliferation of B cells at 
various stages of differentiation. They can be categorised into pre-germinal, germinal and 
post-germinal centre origin according to their differentiation stage using the germinal centre 
reaction as a reference. The most common type of NHL is diffuse large B-cell lymphoma 
(DLBCL) which represents 37% of all NHL and consists of a heterogeneous group of large 
B-cell tumours (Swerdlow et al., 2008), followed by follicular lymphoma (FL) which 
represents 29% of all NHL and is characterised by clonal expansion of neoplastic follicle 
centre-type cells. The third most frequent subtype of B-cell NHL is chronic lymphocytic 
leukaemia/small lymphocytic lymphoma (12%), followed closely by extranodal marginal 
zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) which accounts 
for 9% of all B-cell lymphomas. Both MALT and follicular lymphomas may transform to a 
high grade lymphoma, most frequently diffuse large B-cell lymphoma. Nodal marginal zone 
(MGZ) lymphoma and splenic MGZ lymphomas are separate rare entities that involve lymph 
nodes (nodal MGZ lymphoma) and spleen usually with bone marrow and blood involvement 
(splenic MGZ lymphoma) respectively (Swerdlow et al., 2008). 
MALT lymphoma can occur in a wide range of organs (Swerdlow et al., 2008). Amongst the 
various extranodal sites, gastric MALT lymphoma is the most common and thus the best 
characterised form of this disease (Du et al., 2002). Nodal MZL may be seen as an apparently 
primary disease as a result of either splenic MZL or extranodal MZL. 
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1.2 Overview of MALT lymphoma 
 
MALT (Mucosa associated lymphoid tissue) lymphoma is an indolent neoplasm where 
tumours tend to stay localised at their site of origin until the late phase of the disease. It 
occurs at various extra-nodal sites. The most common site is the gastrointestinal (GI) tract, 
comprising 50% of all cases, and within the GI tract, the stomach is the most common 
location accounting for 85% of GI MALT lymphomas. The small intestine is typically 
involved in patients with immunoproliferative small intestinal disease (IPSID). Other 
frequent sites include salivary gland, lung, ocular adnexa, skin, thyroid and breast (Swerdlow 
et al., 2008). Apart from the small intestine, these anatomical sites are normally devoid of 
organised lymphoid tissues, thus MALT lymphoma appears to arise from acquired MALT, 
commonly due to chronic immunological stimulation, resulting either from pathogen 
infection or autoimmune disorders (Du, 2007). Patients generally present with MALT 
lymphoma at stages I or II. The average age of disease onset is 61 and the 5-year survival rate 
of patients has been as high as 93% in some studies. The median time before progression of 
the disease is approximately 5 years although it is significantly longer for cases with a 
gastrointestinal origin compared to those from other sites (Thieblemont et al., 1997). 2-20% 
of patients have bone marrow involvement and up to 10% have lymphoma in multiple extra-
nodal sites (Isaacson et al., 1987; Wotherspoon et al., 1993), but they generally respond well 
to therapy and have a good overall prognosis (Fischbach et al., 2007). 
 
1.2.1 Aetiology of MALT lymphoma 
As mentioned in section 1.2, pathogen infection and autoimmune disorders play a major role 
in the development of MALT lymphoma. In this section, the aetiological role of pathogens 
such as Helicobacter pylori, Campylobacter jejuni, Borrelia burgdorferi and Chlamydia 
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psittaci and autoimmune disorders such as Sjögren’s syndrome and Hashimoto’s thyroiditis 
will be discussed. 
 
1.2.1.1 Chronic infection 
It has been shown that infection with certain microorganisms leads to the acquisition of 
lymphoid tissue at extra nodal sites that are normally devoid of any organised lymphoid 
tissues and hence plays a role in MALT lymphoma development (Banks, 2007).  
 
Helicobacter pylori 
In 1984 Marshall and Warren isolated a newly recognised bacterium, Helicobacter pylori, 
from patients with chronic gastritis and gastric ulcer (Marshall et al., 1984). H. pylori, 
originally called Campylobacter pylori, is a unipolar, multiflagellate spiral shaped, 
microaerophilic, gram negative bacterium that lives in the luminal surface of the stomach and 
duodenum (Bolin et al., 1995). H. pylori is widespread and has been implicated in several 
gastrointestinal diseases, such as chronic gastritis and peptic ulcer, (Howden et al., 1998) 
gastric adenocarcinoma, (Asaka et al., 1997) and MALT lymphoma (Hussell et al., 1993b). 
In 1987, Smith et al. showed monoclonal rearrangements of the Ig-heavy chains in IPSID, 
including cases that responded to antibiotics (Smith et al., 1987), and suggested the possible 
involvement of bacteria-driven antigen stimulation in the development of the lymphoma. 
Subsequent studies established that, in the stomach, MALT is acquired as a result of 
colonisation of the gastric mucosa by H. pylori (Stolte et al., 2002; Wotherspoon et al., 
1991). In 1991, Wotherspoon et al. demonstrated the presence of H. pylori in 101 of 110 
(92%) patients with gastric MALT lymphoma (Wotherspoon et al., 1991) and suggested for 
the first time that gastric MALT lymphoma may develop from the MALT acquired in 
response to H. pylori infection. 
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At least 80-90% of patients with gastric MALT lymphoma are infected with H. pylori, which 
is much higher than the frequency of infection in the rest of the population (Wotherspoon et 
al., 1991). The gastric mucosa is a hostile environment to most organisms due to its acidic 
environment. However, H. pylori secretes urease that raises the local pH so it is able to 
survive and colonise the gastric mucosa. The incidence of gastric MALT lymphoma was 
found to be high in North Eastern Italy where H. pylori infection is prevalent (Doglioni et al., 
1992).  
 
Campylobacter jejuni and Borrelia burgdorferi 
These were shown to be associated with a proportion of primary cutaneous MALT lymphoma 
and IPSID respectively (Cerroni et al., 1997; Lecuit et al., 2004).  
 
Chlamydia psittaci 
Chlamydia psittaci (C. psittaci) infection was recently shown to be associated with the 
development of ocular adnexal MALT lymphoma. In Italian studies, Chlamydia psittaci was 
detected in 80% of these lymphomas (Ferreri et al., 2004). However, the association between 
Chlamydia psittaci and ocular adnexal MALT lymphoma was not reproduced by several 
other studies from the USA (Vargas et al., 2006), Japan (Daibata et al., 2006) and the 
Netherlands (Mulder et al., 2006). Subsequently, Chanudet and co-workers confirmed 
geographical variation in the association between Chlamydia psittaci and ocular adnexal 
MALT lymphoma (Chanudet et al., 2006).   
Further investigations are needed to confirm or refute the causal association between the 
organisms described above and extranodal marginal zone lymphoma at various sites. 
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1.2.1.2 Autoimmune disease 
 
In addition to microbial infections discussed in section 1.2.1.1, autoimmune disease plays a 
role in MALT lymphomagenesis. For example, thyroid MALT lymphoma is associated with 
Hashimoto’s thyroiditis and salivary gland MALT lymphoma is associated with 
lymphoepithelial sialadenitis (Kassan et al., 1978; Kato et al., 1985). Patients with Sjögren’s 
syndrome, and a number of other autoimmune disorders such as rheumatoid arthritis show an 
increased risk of lymphoma development (Smedby et al., 2006). These autoimmune diseases 
result in chronic immune responses and the formation of acquired MALT. Patients with these 
diseases are approximately 40 times more likely to develop lymphoma, and 85% of the 
lymphomas developed are MALT lymphoma (Kassan et al., 1978; Talal et al., 1967). In both 
Hashimoto thyroiditis and Sjögren’s syndrome, lymphomagenesis is thought to be mediated 
by sustained T-cell dependent antigenic stimulation, similarly to that in H. pylori-driven 
gastric MALT lymphoma (Yamamoto, 2003). 
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1.2.2 Histopathology of MALT lymphoma 
 
Since the development of MALT lymphoma relies on the acquisition of organised MALT, it 
is best to describe MALT followed by MALT lymphoma. 
 
1.2.2.1 Mucosa associated lymphoid tissue 
 
The mucosa-associated lymphoid tissue is situated within mucosal tissues. The main function 
of MALT is to prevent foreign antigen invasion from the mucosal sites. In response to 
antigen specific T-cell activation, naïve B cells undergo clonal expansion, differentiation and 
become effector cells secreting immunoglobulins, thus conveying the mucosal immune 
response. Native MALT is found in the gastrointestinal tract where it is abundantly present in 
the Peyer’s patches of terminal ileum (Figure 1.1a). Typically, MALT in the Peyer’s patches 
consists of germinal centres where B cells encounter antigens and undergo a series of 
mutations to enhance their antigen specificity. Germinal centres contain activated B cells, 
named centroblasts, as well as their differentiated counterpart expressing immunoglobulins 
called centrocytes, macrophages and follicular dendritic cells essential to germinal centre 
reactions. The germinal centre is surrounded by a follicular mantle, formed by naïve B cells 
not yet exposed to antigen. Outer to the mantle zone is a marginal zone, where memory B 
cells reside. A distinct marginal zone, although a feature of Peyer’s patches is not present in 
human tonsillar tissue, and therefore not universally present in all MALT. However, there is 
evidence to show that intra-epithelial B-cells in tonsillar tissue could represent the equivalent 
of marginal zone B cells (Morente et al., 1992). 
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Figure 1.1 - Morphology of MALT and gastric MALT lymphoma from the gastrointestinal 
tract. 
a. The Peyer’s patches are characterised histologically by the presence of a germinal centre (GC) surrounded by 
a follicular mantle (FM) and a marginal-zone (MGZ). Intraepithelial marginal-zone B cells (IEBC) are observed 
within the epithelium covering the Peyer’s patch, forming the lymphoepithelium characteristic of MALT. 
b. The morphology of gastric MALT lymphoma. The germinal centre (GC), where B cells proliferate and 
mature following antigen stimulation, is surrounded by a follicular mantle (FM), which comprises naive B cells. 
The reactive B-cell follicle is surrounded by neoplastic marginal-zone (MGZ) B cells that infiltrate the 
neighbouring epithelium forming characteristic lymphoepithelial lesions (LEL). 
 
Figure adapted from Isaacson et al. (2004). Nature Review Cancer, 4, 644-653.  
 
 
 
 
 
 
 
 
 
 
 
a b 
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Figure 1.2 - Cytological and histological features of MALT lymphoma. 
a-c. Cytology: neoplastic cells can resemble small lymphocytes (a), or have the appearance of centrocytes but 
with more abundant cytoplasm (b), or rather have the features of monocytoid cells with abundant pale cytoplasm 
and well-defined borders (c). Scattered transformed centroblasts or immunoblast-like cells can also be observed 
(a). d-e. Histological features: MALT lymphoma can show prominent plasma cell differentiation (d). The 
neoplastic cells can infiltrate the surrounding epithelium, forming lymphoepithelial lesions (d), or invade B-cell 
reactive follicles (follicular colonisation) (e). 
 
Figure adapted from Isaacson et al. (2005). Journal of Pathology, 205, 255-274.  
 
 
1.2.2.2 Extranodal marginal zone B-cell lymphoma of MALT 
 
Histologically, MALT lymphoma mimics the features of normal MALT (Figure 1.1b). The 
striking histological resemblance between some low grade B-cell lymphomas of the stomach, 
IPSID and the morphology of the Peyer’s patches which led to the proposition of the MALT 
lymphoma entity by Isaacson and Wright in 1983 (Isaacson et al., 1983). Similar to the 
structure of Peyer’s patches, MALT lymphoma consists of neoplastic B-cell infiltrates that 
are primarily located in the marginal zone (which lies outer to the mantle zone that surrounds 
reactive germinal centres) and can extend into the interfollicular region (Figure 1.1b). An 
important feature of MALT lymphoma is the presence of aggregates of neoplastic cells 
a 
b 
c 
d e 
 - 10 -  
infiltrating individual mucosal glands or other epithelial structures. Such aggregates, referred 
to as lymphoepithelial lesions (Figure 1.1b, Figure 1.2d), resemble lymphoepithelium in 
Peyer’s patches (Figure 1.1b) (Isaacson et al., 2004). 
Cytologically, MALT lymphoma cells are variable in their appearance, resembling 
centrocyte-like cells, sometimes with round nuclei and pale staining cytoplasm, monocytoid 
B cells or small lymphocytes (Figure 1.2 a-c). Lymphoma cells may also show prominent 
plasma cell differentiation particularly in the sub-epithelial lamina propria (Figure 1.2d). In 
some cases the lymphoma cells may invade B-cell reactive follicles (Figure 1.2e). This so-
called follicular colonisation can lead to morphological resemblance to FL. 
 
1.2.3 Immunophenotype 
The typical immunophenotype of MALT lymphoma is detailed in Table 1.1. MALT 
lymphoma cells mostly share the immunophenotype of non-neoplastic MGZ cells (Isaacson 
et al., 1987). Currently there is no available marker specific to MALT lymphoma, 
nevertheless immunophenotyping is helpful for the differential diagnosis, notably from other 
small B-cell lymphomas (Table 1.1). 
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Table 1.1 - Typical immunophenotyping of MALT lymphoma cells. 
 
Cellular 
marker 
MALT 
lymphoma 
FL MCL SLL DLBCL 
CD20 + + + + + 
CD79a + + + + + 
BCL2 +/- + + + +/- 
CD43 +/- - + +  
CD5 - - + + +/- 
CD10 - + - - +/- 
CD23 - +/- - +/-  
Cyclin D1 - - + -  
BCL6 - + - - +/- 
Ig heavy 
chain 
M>>A>G G>M+D M+D M Variable 
CD21 and 
FDC 
meshwork 
+ + +/- - - 
 
Abbreviations: MALT, mucosa-associated lymphoid tissue; FL, follicular lymphoma; MCL, mantle-cell 
lymphoma; SLL, small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; CD, cluster of 
differentiation; FDC, follicular dendritic cell; + positive; - negative. 
 
 
The neoplastic cells of MALT lymphoma share the cytological features and 
immunophenotype (CD20+, IgM+, IgD-) of marginal zone B cells (Spencer et al., 1985). 
MALT lymphoma cells are typically negative for CD10 and BCL6, which are 
characteristically positive in FL. Unlike mantle cell lymphoma (MCL) and small lymphocytic 
lymphoma, MALT lymphoma is only infrequently positive for CD5. It is negative for cyclin 
D1, a feature which helps to distinguish it from MCL (Table 1.1). The most important 
immunophenotypic feature favouring MALT lymphoma diagnosis is the presence of a diffuse 
infiltrate of CD20+, IgM+, IgD- B cells outside the mantle zone of reactive follicles. Once the 
marginal zone phenotype is established, light chain restriction in this marginal zone 
population, or if present, within the plasma cells confirms the diagnosis. However, having a 
marker specific for MALT lymphoma would lead to more accurate MALT lymphoma 
diagnosis. 
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1.2.4 Pathogenesis of MALT lymphoma 
 
The development of MALT lymphoma is a multistage process which is best understood in the 
gastric disease (Isaacson et al., 1994; Isaacson et al., 1995; Isaacson, 1995). Both gastric 
MALT lymphoma and pre-lymphomatous lesions are aetiologically related to H. pylori 
infection. Understanding the role of H. pylori has provided insights into the pathogenesis of 
MALT lymphoma. 
 
1.2.4.1 H. pylori and its role in the development of gastric MALT lymphoma 
 
There is now strong evidence that H. pylori is causally linked to gastric MALT lymphoma 
and this fulfils all criteria of Koch’s postulates set in 1884 (Koch, 1884); Firstly, H. pylori 
was found in the majority of gastric MALT lymphomas (Eidt et al., 1994). Secondly, H. 
pylori could be isolated from gastric MALT lymphoma, and grown in culture. Thirdly, 
infecting the stomach of pathogen-free mice with H. pylori could induce the development of 
MALT lymphoma (Enno et al., 1995). 
Additionally, early functional and clinical studies provided evidence of the crucial role of H. 
pylori in the development of gastric MALT lymphoma. Hussell and colleagues demonstrated 
that lymphoma cell growth in vitro was dependent on H. pylori specific T cells (Hussell et 
al., 1996). Furthermore, Wotherspoon and colleagues first showed that H. pylori eradication 
by antibiotic treatment led to lymphoma regression in H. pylori–associated gastric MALT 
lymphomas (Wotherspoon et al., 1991). Taken together, these data established that H. pylori 
infection could cause gastric MALT lymphoma. 
It is now known that the inflammatory process triggered by H. pylori infection is directly 
responsible not only for the acquisition of MALT in the gastric mucosa, but also for 
subsequent malignant transformation and the development of gastric MALT lymphoma 
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(Isaacson et al., 2004). As in other bacterial diseases, the development of H. pylori-associated 
MALT lymphoma is hypothesised to be associated with the host response and bacterial 
status. However, the precise role of H. pylori in MALT lymphomas is not clear. 
 
1.2.4.2 Immunological stimulation 
Several histological features of MALT lymphoma including the presence of plasma-cell 
differentiation, blasts, follicular colonisation and proliferation, suggest that MALT lymphoma 
cells preserve B-cell properties and that their growth may be partially driven by antigenic 
stimulation via antigen receptors (Isaacson et al., 2004) and T-cell and B-cell interaction. 
Recent studies indicate that both direct and indirect antigen stimulation mechanisms are 
involved. 
 
1.2.4.2.1 Direct antigen stimulation 
MALT lymphomas invariably express surface immunoglobulin. The anti-idiotype antibody 
has been shown to stimulate MALT lymphoma cell proliferation and synergise with mitogen 
stimulation (Hussell et al., 1993b). The data also showed that the tumour-derived 
immunoglobulin does not recognise H. pylori, but recognises various autoantigens (Hussell et 
al., 1993a). Antibodies to gastric epithelial cells are commonly present in serum samples 
from patients with H. pylori gastritis (Negrini et al., 1996). An anti-idiotype antibody to 
immunoglobulin of a gastric MALT lymphoma cross-reacts specifically with reactive B cells 
in H. pylori-associated gastritis (Greiner et al., 1997). These findings suggest that gastric 
MALT lymphoma cells are transformed from autoreactive B cells, which are induced after H. 
pylori infection. 
Sequence analysis of the rearranged immunoglobulin of MALT lymphoma also reveals 
evidence that MALT lymphoma cells respond to direct antigen stimulation, indicating the 
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tumour clone has undergone antigen selection (Bertoni et al., 1997; Du et al., 1996b).  During 
the evolution of gastric MALT lymphoma, particularly in the early stage, the rearranged 
tumour immunoglobulin gene frequently showed further somatic mutations, commonly 
referred to as ongoing mutations (Bertoni et al., 1997; Du et al., 1996a). Since somatic 
mutations occurs in the rearranged immunoglobulin gene only during the germinal centre 
reaction, and depends on antigen and T cells, the finding of ongoing immunoglobulin 
mutations in MALT lymphoma suggests that tumour-cell growth is partially driven by direct 
antigen stimulation. 
 
1.2.4.2.2 Indirect antigen stimulation 
The close association of H. pylori infection with gastric MALT lymphoma development 
prompted research into the immunological responses of the tumour cells to H. pylori. By co-
culturing tumour cells with 13 clinical strains of heat-killed H. pylori, Hussell and co-workers 
demonstrated that H. pylori induced tumour cells to proliferate (Hussell et al., 1993b). The 
effect was strain-specific but was T-cell mediated and not due to specificity of lymphoma 
cells for H. pylori antigens. This effect was associated with expression of interleukin-2 (IL-2) 
receptors and secretion of immunoglobulin by tumour cells. Removal of tumour-infiltrating T 
cells before the experiment abolished all the effects of H. pylori on tumour cells. 
Furthermore, these authors confirmed that H. pylori did not directly stimulate tumour cells 
but did so via specifically activated tumour infiltrating T cells (Hussell et al., 1996). 
Furthermore, the stimulating effect of H. pylori on tumour B cells can be completely blocked 
by an antibody to CD40L. Thus, H. pylori stimulates lymphoma B cells through tumour-
infiltrating T cells, involving CD40 and CD40L. It is possible that CD80/CD86 costimulatory 
molecules promote T-cell-mediated neoplastic B-cell growth. 
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The active role of tumour-infiltrating T cells in the growth of tumour B cells is further 
supported by a study of T-cell clones isolated from gastric MALT lymphoma. T-cell clones 
responding to H. pylori stimulation were CD4-positive helper cells rather than CD8-positive 
cytotoxic cells. These specific T-cell clones activated tumour B cells in a dose dependent 
manner (D'Elios et al., 1997). 
Additionally, complete regression of gastric MALT lymphoma following H. pylori 
eradication strongly indicates the role of H. pylori stimulation in the survival and growth of 
gastric MALT lymphoma (Begum et al., 2000; Wotherspoon, 1996). Unlike low-grade 
tumour cells, high-grade tumour cells do not show any growth response to H. pylori mediated 
T-cell stimulation in vitro (Hussell et al., 1993b). High grade lymphomas tend to be resistant 
to H. pylori eradication therapy (Bayerdorffer et al., 1995; Thiede et al., 1997), though 
recently published reports show a complete remission rate of 62.5% with a median follow-up 
of over 30 months in gastric DLBCLs (Chen et al., 2001; Morgner et al., 2001). 
 
 
 
Figure 1.3 - The role of T- and B- cell interaction in the development of MALT lymphoma. 
FH: Follicular Helper cells, TCR: T-cell receptor, MZ: marginal zone. 
Figure adapted from Roulland et al. (2008). Trends in Immunology, 29, 25-33. 
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Therefore, it can be hypothesised that in MALT lymphomas, cells are autoreactive and can be 
stimulated at low levels by autoantigens, but additional stimuli are required for their 
enhanced proliferation and ultimate malignant transformation. In gastric MALT lymphoma, 
H. pylori infection may cause two main events. Firstly, T-cell dependent immune responses 
in reactive components lead to the generation of a sustained pool of polyclonal H. pylori-
specific T cells. Secondly, these H. pylori specific T cells in the marginal zone containing 
tumour cells provide non-cognate bystander T-cell help to the autoreactive MALT lymphoma 
cells (Figure 1.3). This working hypothesis explains how polyclonal H. pylori specific T cells 
can be critical for the growth and survival of monoclonal neoplastic B cells, which recognise 
autoantigens rather than H. pylori. 
 
1.2.4.3 H. pylori virulent factors and host genetics in the development of gastric MALT 
lymphoma 
 
The fact that the a majority of patients infected with H. pylori are asymptomatic and only a 
small proportion of them develop gastric MALT lymphoma, indicates a role of bacterial 
virulence factors and host genetic susceptibility. The interaction between the bacterium and 
the host immune reaction may determine the risk of MALT lymphoma development. 
 
1.2.4.3.1 Host factors 
A number of gene polymorphisms are associated with susceptibility to autoimmune disorders 
(Lettre et al., 2008) and some have been shown to be associated with MALT lymphoma 
development. Polymorphisms in immune regulators such as cytokines are commonly 
involved in auto-reactive conditions (Hajeer et al., 2000). A recent large case control study 
on 1172 patients with NHL and 982 population-based controls demonstrated a significantly 
higher susceptibility to NHL among patients with an autoimmune disorder and TNFA 
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(tumour necrosis factor A) G308A variant, or interleukin 10 (IL10) T3575A variant (Wang et 
al., 2007). TNFA G308A polymorphism associates with higher levels of TNFA expression 
which enhances chronic inflammatory responses (Bayley et al., 2004). Among NHLs, TNFA 
G308A polymorphism particularly increases the risk of several lymphoma subtypes, 
including MALT lymphoma and DLBCLs (Morton et al., 2008). 
A number of other genetic polymorphisms have been investigated, particularly in genes 
encoding molecules involved in immune or inflammatory responses. For example, gene 
polymorphisms in toll-like receptors (TLR) have been shown to be associated with an 
increased risk of lymphoma, including MALT lymphoma (Nieters et al., 2006). The TLR4 
Asp299Gly variant increases susceptibility to gram-negative bacteria infection, thus 
potentially representing one of the host factors affecting the risk of lymphoma among H. 
pylori infected individuals (Nieters et al., 2006). Likewise, polymorphisms in the T-cell 
receptor cytotoxic T-lymphocyte antigen 4 (CTLA4) gene, encoding a negative regulator of 
T-cell activation, increase the risk of gastric MALT lymphoma, especially in patients with H. 
pylori infection (Cheng et al., 2006).   
 
1.2.4.3.2 Bacterial virulence factors 
In addition to host genetic susceptibility, virulence factors associated with infectious agents 
also play a critical role in the outcome. The risk of developing gastric carcinoma has been 
shown to depend on the combined effect of pro-inflammatory cytokine gene polymorphisms 
in the host and virulence-associated genes in H. pylori (Figueiredo et al., 2002). Several H. 
pylori virulence factors are associated with an increased risk of gastric ulcer and gastric 
carcinoma (Maeda et al., 2007), especially the cytotoxin-associated antigen (CagA), 
vacuolating toxin (VacA) and outer membrane adhesion (BabA) virulence factors. CagA 
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antigens are known to induce a strong inflammatory response. CagA-positive strains contain 
a long pathogenicity island including over 30 genes (Prinz et al., 2003). Such pathogenesis-
associated genes are usually absent in H. pylori strains isolated from asymptomatic hosts 
(Baldwin et al., 2007). t(11;18)(q21;q21) associated gastric MALT lymphoma cases are 
significantly associated with infection by CagA strains of H. pylori (Ye et al., 2003). CagA-
positive strains of H. pylori are also associated with a strong response mediated by 
neutrophils. This is thought to increase the release of ROS (reactive oxygen species) within 
the environment of inflammation, which may not only promote cell growth via activation of 
kinases (Cerutti et al., 1991), but may also contribute to the genomic instability already 
inherent in B cells. H. pylori are strong inducers of interleukin-8, a potent chemokine for 
neutrophil activation. Activated neutrophils are known to release reactive oxygen species, 
which can cause a wide range of DNA damage, including double-strand breaks (Wiseman et 
al., 1996). H. pylori VacA strains can alter intracellular vesicular trafficking, ultimately 
inducing the formation of large intracellular vacuoles and mediating mucosal damage 
(Smoot, 1997). BabA strains express the BabA adherence factor that can bind to Lewis blood 
sugar molecules present on the membrane of gastric epithelial cells. This results in enhanced 
adhesion and higher colonisation capacity. Nonetheless, no differences in the above H. pylori 
virulent factors have yet been observed between patients with H. pylori-associated MALT 
lymphoma and those with H. pylori-induced gastritis (Lehours et al., 2004). Virulence factors 
associated with gastric MALT lymphoma remain largely unknown.  
Similarly, C. jejuni has been shown to produce a toxin that can directly cause DNA damage 
by inducing double-strand DNA breaks. This may be responsible for the truncated Ig 
observed in IPSID (Al Saleem et al., 2005).  
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1.2.4.4 Role of anti-microbial and other therapies in the treatment of MALT lymphoma 
 
The role of H. pylori infection in the development of gastric MALT lymphomas has led to the 
successful use of antibiotic treatment in the cases localised to the stomach and had a profound 
implication in the clinical management of MALT lymphoma. Evidence indicates that 
eradication of H. pylori with antibiotics such as metronidazole, tetracycline, clarithromycin 
and amoxicillin can be effectively employed as the first line therapy of localised gastric 
MALT lymphoma. H. pylori eradication is the primary therapy for stage I gastric MALT 
lymphoma. Multiple trials carried out in independent reference centres on large cohorts of 
patients with long follow-up, have demonstrated that complete histological remission can be 
obtained in roughly 80% of early stage gastric MALT lymphomas following H. pylori 
eradication (Morgner et al., 2007). Such a response is durable, as illustrated by the low 
incidence of lymphoma relapse (3%) at 75 months follow-up after H. pylori eradication 
(Wundisch et al., 2005). When they occur, relapses are often due to H. pylori re-infection 
(Fischbach et al., 2004; Montalban et al., 2006). Presence of histological residual disease or 
clonal neoplastic cells is seen in gastric biopsies after H. pylori eradication. The cells are 
detected by PCR in a proportion of antibiotic-responsive cases, but are not associated with 
lymphoma progression, nor with transformation into DLBCL (Fischbach et al., 2002; 
Fischbach et al., 2007), supporting a “watch and wait” strategy with regular monitoring 
instead of a systematic second line treatment.  
Overall, about 30% of gastric MALT lymphomas do not respond to H. pylori eradication, 
which suggests the acquisition of an antigen-independent autonomous growth. The majority 
of the non-responsive cases are at stage II or higher (Ruskone-Fourmestraux et al., 2001), 
while a high proportion of stage I cases show complete remission following H. pylori 
eradication (Stolte et al., 1989). Resistance to H. pylori treatment is mainly accompanied by 
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the presence of t(11;18)(q21;q21) (Liu et al., 2001a; Liu et al., 2002b) and infrequently to 
t(1;14)(p22;q32) (Ye et al., 2006). The role of H. pylori eradication in the treatment of 
transformed MALT lymphoma is controversial. Although gastric MALT lymphomas of stage 
II or higher are less likely to respond to H. pylori eradication (Ruskone-Fourmestraux et al., 
2001; Sackmann et al., 1997), antibiotic treatment showed noticeable success in some H. 
pylori-positive cases, particularly those with limited dissemination. If the presence of the 
bacterium is confirmed, concurrent eradication of H. pylori is recommended, along with other 
treatment approaches, in order to limit the risk of lymphoma relapse (Morgner et al., 2007). 
This strategy also applies to transformed MALT lymphoma. A significant proportion of stage 
I H. pylori positive transformed MALT lymphomas achieve complete lymphoma regression 
after H. pylori eradication (Morgner et al., 2007).  
MALT lymphoma that is non-responsive to antibiotic therapy can be treated with surgical 
resection alone or in combination with radiotherapy or chemotherapy. This treatment results 
in 90-100% 5-year survival for cases at stage IE and 82% survival at stage IIE (Du et al., 
2002; Schechter et al., 2000). Unfortunately, partial resection cannot remove all lymphoma 
cells, as they disseminate widely in the gastric mucosa. To completely remove the lymphoma, 
a total gastrectomy needs to be carried out which significantly reduces the patient’s quality of 
life (Zucca et al., 2000). Low-dose localised radiotherapy can be used alone to treat gastric 
MALT lymphoma. In a small study, patients with gastric MALT lymphoma with no evidence 
of H. pylori infection or with resistance to antibiotic therapy were treated with radiotherapy 
alone. 100% event-free survival was achieved by this treatment with a median follow-up time 
of 27 months (Parveen et al., 1993). Other treatments include the use of therapeutic 
monoclonal antibody drugs such as rituximab. The improvement of some autoimmune 
conditions following the administration of rituximab leads to new therapeutic strategies in the 
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treatment of autoimmune-related MALT lymphomas. A phase II clinical trial including 
patients with salivary gland MALT lymphoma associated with Sjögren’s syndrome showed 
that rituximab could lead to complete remission in 3 out of 7 patients (Pijpe et al., 2005). 
Further investigations are needed, especially as other B-cell targeting therapies are emerging. 
The therapeutic model of H. pylori-associated gastric MALT lymphoma may be extended to 
MALT lymphomas of other anatomical locations similarly associated with infectious agents. 
For example, eradication of Borrelia burgdorferi and Campylobacter jejuni infections has 
been shown to result in complete regression of some cases of cutaneous MALT lymphoma 
and IPSID respectively (Kutting et al., 1997; Lecuit et al., 2004). Ferreri and colleagues 
similarly demonstrated lymphoma regression in 13 out of 27 ocular adnexal MALT 
lymphomas (6 complete and 7 partial regressions) associated with Chlamydia psittaci 
infection, following eradicating antibiotic therapy with doxycycline (Ferreri et al., 2006). 
 
 
1.3  Genetics of MALT lymphoma 
 
1.3.1 Chromosomal translocations 
 
In addition to chronic immune stimulation, which plays an important role in the development 
of MALT lymphoma particularly at the early stages, the acquisition of genetic abnormalities 
contributes to both the genesis and the progression of the lymphoma. Four recurrent balanced 
chromosomal translocations have been described in MALT lymphoma (Du, 2007). Three of 
the four translocations involve MALT1 or BCL10 genes. 
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Figure 1.4. Structural domains of the oncogenic products resulting from MALT lymphoma 
associated chromosomal translocations. 
BIR = baculovirus IAP repeats; UBA = ubiquitin associated domain; CARD = caspase associated recruitment 
domain; RING = really interesting new gene domain; Ig = immunoglobulin-like domain; ZF = zinc finger 
domain; LZ = leucine zipper domain. Arrows indicate the distribution of sites of fusion between API2 and 
MALT1 in individual MALT lymphomas.  
API2 belongs to the inhibitor of apoptosis family and mediates apoptosis suppression by binding caspases via its 
caspase recruitment domain (CARD). API2 baculovirus inhibitor of apoptosis protein repeats (BIR) domains 
can mediate oligomerisation of BIR-domain containing proteins. MALT1 is a paracaspase. In addition to a 
caspase-like domain, MALT1 contains a death domain (DD) and 2 immunoglobulin-like domains (Ig). Although 
various breakpoints have been reported (Du, 2007), especially within the MALT1 gene, API2-MALT1 fusion 
transcript always contains the 3 intact BIR domains of API2 and the intact caspase-like domain of MALT1, 
suggesting a role for these domains in oncogenesis. BCL10 is an intracellular protein with a CARD domain and 
a serine/threonine-rich domain of unknown function. FOXP1 is a member of the FOX family of transcription 
factor containing both DNA-binding domains (zinc finger domains ZF; leucine zipper domain, LZ; winged 
helix) and protein-protein binding glutamine-rich domains. 
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1.3.1.1  t(11;18)(q21;q21)/API2-MALT1  
t(11;18)(q21;q21) fuses in frame the amino-terminal sequence of the baculovirus inhibitor of 
apoptosis protein repeats (BIR) containing 3 (BIRC3, also known as API2) gene (11q21), to 
the carboxyl-terminal caspase-like domain of the MALT lymphoma translocation gene 1 
(MALT1) (18q21) (Figure 1.4). API2 suppresses apoptosis by inhibiting specific caspases via 
its BIR domains (Roy et al., 1997). MALT1 is an essential component in the antigen-receptor-
mediated activation of the master transcription factor nuclear factor κB (NF-κB) (Ho et al., 
2005; Lin et al., 2004). t(11;18)(q21;q21) generates a functional fusion protein API2-MALT1 
capable of activating NF-κB  (Ho et al., 2005; Uren et al., 2000). An intact UBA (Ubiquitin 
Associated Domain) is present in roughly 98% of API2-MALT1 fusions and a functional 
UBA is required for efficient API2-MALT1 mediated NF-κB activation, although the precise 
molecular mechanism has yet to be established (Gyrd-Hansen et al., 2008). 
Incidence. t(11;18)(q21;q21) is the most common and specific structural chromosomal 
abnormality in MALT lymphoma. It has not been described in other B-cell lymphoma 
subtypes, including nodal and splenic MGZ lymphoma, nor in MALT lymphoma associated 
inflammatory conditions such as H. pylori associated gastritis, lymphoepithelial sialadenitis 
or Hashimoto’s thyroiditis (Du, 2007). t(11;18)(q21;q21) occurs frequently in MALT 
lymphomas of the lung (40%), stomach (25%) and ocular adnexa (~10%), but not in those of 
the salivary gland and thyroid   (Isaacson et al., 2004; Ye et al., 2003) (Figure 1.5). 
Clinical impact. In gastric MALT lymphoma, t(11;18)(q21;q21) is associated with advanced 
stages, but not transformation into DLBCL (Huang et al., 2003; Liu et al., 2001a). 
t(11;18)(q21;q21) is associated with gastric MALT lymphomas that do not respond to H. 
pylori eradication, irrespective of the clinical stage of the lymphoma (Liu et al., 2001b; Liu et 
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al., 2002a), and that are resistant to oral alkylating agents (Levy et al., 2005). The detection 
of t(11;18)(q21;q21) is thus critical for the clinical management of gastric MALT lymphoma. 
Genetic correlations. t(11;18)(q21;q21) is mutually exclusive from other MALT lymphoma-
associated chromosomal translocations (Du, 2007; Liu et al., 2004a). t(11;18) positive cases 
rarely show aneuploidies frequently associated with translocation negative MALT 
lymphoma, such as trisomies 3, 12 and 18 (Remstein et al., 2002; Starostik et al., 2002).  
Function. The biological importance of the API2–MALT1 fusion is indicated by the analysis 
of breakpoints at both the genomic and transcript levels. Although some genomic breakpoints 
were found to cause frameshifts, the API2–MALT1 fusion transcripts are always in frame, 
because of splicing out of the exon that causes the frameshift (Mestecky et al., 1999). The 
API2 gene contains three amino-terminal baculovirus IAP repeats, a central caspase 
recruitment domain (CARD) and a carboxy-terminal zinc-binding RING finger domain. The 
MALT1 protein comprises an N-terminal death domain, followed by two Ig-like domains and 
a caspase-like domain. Within the API2 gene, all breakpoints occur downstream of the third 
BIR domain, upstream of the C-terminal RING domain, with 91% occurring just before the 
CARD domain. In the MALT1 gene, the breakpoints occur in four different introns upstream 
of the caspase-like domain (Liu et al., 2004a). Therefore, the resulting API2–MALT fusion 
transcripts always comprise the N-terminal region of API2 with three intact BIR domains and 
the C-terminal MALT1 region containing an intact caspase-like domain. The specific 
selection of these domains of the API2 and MALT1 gene to form a fusion product strongly 
indicates that they are required for the oncogenic activities of the fusion product. API2-
MALT1 fusion product is capable of activating the NF-κB pathway in the absence of any 
surface receptor stimulation, although neither API2 nor MALT1 alone are able to activate 
NF-κB (Hu et al., 2006b). 
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1.3.1.2  t(1;14)(p22;q32)/BCL10-IGH  
t(1;14)(p22;q32) translocates the entire B-cell leukaemia/lymphoma 10 (BCL10) gene on 
chromosome 1p22 under the control of the immunoglobulin heavy chain locus (IGH) gene 
enhancer on chromosome 14q32 (Willis et al., 1999; Zhang et al., 1999). This translocation 
thus results in the over-expression of BCL10 which contains an N-terminal CARD, followed 
by a serine/threonine rich C-terminal. 
The CARD motif of BCL10 can interact with the Ig-Like domains of MALT1 (Figure 1.4). In 
vivo studies showed that BCL10 and MALT1 link antigen receptor signalling and NF-κB 
activation pathway (Ruland et al., 2001; Xue et al., 2003). 
Incidence. t(1;14)(p22;q32) is specifically associated with MALT lymphoma, though 
relatively infrequently. It is mostly seen in MALT lymphoma of the lung (7%) and stomach 
(4%) but not in those of other sites (Figure 1.5). 
Clinical impact. Strong BCL10 nuclear localisation, characteristic of t(1;14)(p22;q32)-
positive MALT lymphoma, correlates with gastric MALT lymphomas of advanced stages and 
those not responsive to H. pylori eradication (Ye et al., 2006). Also, nuclear BCL10 
expression is associated with advanced MALT lymphoma (Liu et al., 2001b), and associated 
with shorter treatment failure-free survival in ocular adnexal MALT lymphomas (Franco et 
al., 2006). 
Genetic correlations. t(1;14)(p22;q32) is mutually exclusive from other MALT lymphoma-
associated chromosomal translocations. Translocation positive cases commonly harbour 
trisomies 3, 12 and or 18 (Streubel et al., 2006).  
Function. BCL10-knockout mice showed that BCL10 is essential for both the development 
and function of mature B and T cells, linking antigen-receptor signalling to the NF-κB 
pathway (Ruland et al., 2001; Xue et al., 2003). Over-expression of BCL10 activates the IκB 
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kinase (IKK) complex through CARD domain-mediated oligomerisation, resulting in NF-κB 
activation (Hofmann et al., 1997). In line with these findings, a recent in vitro study indicated 
that BCL10 could prevent an immature B-cell line from antigen receptor induced apoptosis 
(Tian et al., 2005b). 
 
1.3.1.3  t(14;18)(q32;q21)/IGH-MALT1  
t(14;18)(q32;q21) brings the entire MALT1 gene (18q21) under the regulatory control of IGH 
(14q32), leading to the over-expression of MALT1 (Figure 1.4) (Streubel et al., 2003). The 
MALT1 gene is 5Mb away from the B-cell CLL/lymphoma 2 (BCL2) gene, targeted by 
t(14;18)(q32;q21) IGH/BCL2 characterising follicular lymphoma (Sagaert et al., 2007).  
Incidence. t(14;18)(q32;q21)/IGH-MALT1 is a rare translocation, mainly described in MALT 
lymphomas of the lung (6%) and ocular adnexa (7%) (Remstein et al., 2006; Ye et al., 2005) 
(Figure 1.5). It is also seen in some DLBCLs (Du, 2007). 
Clinical impact. As t(14;18)(q32;q21) occurs exclusively in extra-gastric MALT lymphoma, 
for which a specific therapy has not yet been established, the potential impact of this 
translocation in the clinical management of MALT lymphoma remains unknown. 
Genetic correlations. t(14;18)(q32;q21) is mutually exclusive from other MALT lymphoma-
associated chromosomal translocations. Translocation positive cases commonly harbour 
trisomies 3 and/or 18 (Streubel et al., 2003).  
Function. Initial studies of MALT1 demonstrated that the wild-type protein has no 
independent ability to activate NF-κB and shows only modest enhancement of BCL10-
mediated NF-κB activation, despite direct physical association with BCL10 (Uren et al., 
2000). MALT1 over-expression led to increased constitutive NF-κB activity and enhanced 
IκB kinase (IKK) activation induced by CD40 stimulation (Ho et al., 2005).  
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Sites of MALT lymphoma
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Figure 1.5 - Incidence of MALT lymphoma translocations in various sites 
 
Figure adapted from Ye et al. (2005). Journal of Pathology, 205, 293-301. 
 
1.3.1.4 BCL10 and MALT1 expression patterns in MALT lymphoma with different 
translocation status. 
 
MALT1 and BCL10 proteins are essential components of NF-κB activation signalling 
pathway (Thome, 2004). In normal MGZ B cells, both MALT1 and BCL10 are weakly 
expressed, predominantly in the cytoplasm (Ye et al., 2005). In MALT lymphoma, tumour 
cells with different translocations show distinct BCL10 and MALT1 expression patterns (Ye 
et al., 2005). MALT lymphoma cells with t(11;18)(q21;q21)/API2-MALT1 display moderate 
BCL10 nuclear expression and weak MALT1 cytoplasmic expression (Figure 1.6). Tumour 
cells with t(1;14)(p22;q32)/BCL10-IGH show strong BCL10 nuclear expression and 
weak/negative cytoplasmic expression of MALT1. Tumour cells with 
t(14;18)(q32;q21)/IGH-MALT1 show strong homogeneous cytoplasmic expression of both 
BCL10 and MALT1 (Figure 1.6). Around 20% of MALT lymphoma cases without 
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translocation show BCL10 nuclear expression and around 6% show high BCL10 nuclear 
expression similar to that seen in t(1;14) positive MALT lymphomas (Liu et al., 2001b). 
MALT1 BCL10
t(14;18) +ve
t(1;14) +ve
t(11;18) +ve
trans -ve
tonsil
 
Figure 1.6 - BCL10 and MALT1 staining patterns in MALT lymphoma translocations. 
BCL10 and MALT1 immunohistochemistry on FFPE translocation positive and negative MALT lymphoma 
tissue. 
 
Figure adapted from Ye et al. (2005). Journal of Pathology, 205, 293-301. 
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Nakagawa and colleagues demonstrated that MALT1, but not its fusion counterpart API2-
MALT1, was involved in BCL10 export from the nucleus to the cytoplasm, providing an 
explanation for the various BCL10 expression patterns observed in MALT lymphoma with 
different chromosomal translocations (Nakagawa et al., 2005). In cells with 
t(11;18)(q21;q21)/API2-MALT1, MALT1 expression is reduced by half due to the API2-
MALT1 fusion, hence an expected reduced efficiency of BCL10 nuclear export. In cells with 
t(1;14)(p22;q32)/BCL10-IGH, MALT1 normal expression may not be sufficient for the 
export of the over-expressed BCL10, resulting in BCL10 nuclear retention. Finally, in cells 
with t(14;18)(q32;q21)/IGH-MALT1, the over-expression of MALT1 results in an increased 
export of BCL10 from the nucleus to the cytoplasm, where both proteins are thus strongly 
expressed in the cytoplasm (Ye et al., 2005). The temporal interplay between API2-MALT1, 
MALT1 and BCL10 in cellular localisation in vivo remains to be investigated. 
 
1.3.1.5  t(3;14)(p13;q32)/FOXP1-IGH 
t(3;14)(p13;q32) is a newly described MALT lymphoma- associated translocation involving 
IGH (Streubel et al., 2005). It deregulates the forkhead box protein P1 (FOXP1) gene (3p13), 
a member of the FOX transcription factor family, which includes numerous proteins involved 
in a variety of functions such as cellular differentiation and immune regulation. Foxp1 has 
been recently shown to be an essential regulator of early B-cell development (Hu et al., 
2006a), but the molecular mechanism underlying its oncogenic activity in lymphoma remains 
to be investigated.   
Incidence. Streubel et al. (Streubel et al., 2005) initially showed that FOXP1 was involved in 
t(3;14)(p13;q32) in MALT lymphoma which was present in 10% of MALT lymphomas, in 
those from the ocular adnexa (20%), thyroid (50%) and skin (10%), but not in those from the 
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salivary gland, stomach and lung (Streubel et al., 2005). However, the translocation was not 
found in 122 extranodal MALT lymphomas from various sites (9 cutaneous, 13 salivary 
gland, 50 pulmonary, 36 ocular adnexa, 8 thyroid gland and 6 gastric tumors) (Haralambieva 
et al., 2006b). The t(3;14)(p13;q32) was subsequently found in one case of MALT lymphoma 
of the stomach (Wlodarska et al., 2005), seven cases of diffuse large B-cell lymphoma of the 
stomach, thyroid and lymph nodes and also in two cases of B-cell non-Hodgkin lymphoma 
unclassified (Haralambieva et al., 2006b; Wlodarska et al., 2005). On a larger series of 321 
MALT lymphomas, Goatly et al. showed that t(3;14)(p13;q32) is rare in MALT lymphoma, 
and primarily found in gastric cases (4%) (Goatly et al., 2008; Haralambieva et al., 2006a) 
(Figure 1.5). 
Clinical impact. No correlation has yet been established between the presence of 
t(3;14)(p13;q32) and response to H. pylori eradication in gastric MALT lymphoma. In 
DLBCL, strong expression of FOXP1 identifies cases with poor prognosis (Barrans et al., 
2004). Similarly, FOXP1 over-expression is associated with MALT lymphomas with poor 
clinical outcome (Sagaert et al., 2006a). MALT lymphomas with concurrent over-expression 
of FOXP1 and trisomies 3 and 18 may be at risk of transformation into DLBCL (Sagaert et 
al., 2006a).  
Genetic correlations. t(3;14)(p13;q32) is mutually exclusive from other MALT lymphoma-
associated chromosomal translocations. Cases with t(3;14)(p13;q32) often harbour additional 
genetic abnormalities, especially trisomy 3 (Streubel et al., 2005).  
Function. Activation of the NF-κB pathway by isoforms of FOXP1 has been investigated 
(unpublished data in Professor Ming Du’s laboratory). The full length FOXP1 protein and 2 
short isoforms were able to activate NF-κB both alone and synergistically with cell surface 
stimulation of B cells by LPS and T cells by CD3 and CD28.  The mechanism of NF-κB 
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activation is unknown but there is evidence that it is not through the classical or alternative 
pathways, in keeping with the nuclear localisation of FOXP1. 
 
1.3.2 Other chromosomal translocations 
In addition to the oncogenes mentioned in sections (1.3.1.1 – 1.3.1.4), novel translocations 
were identified using cytogenetics and long distance inverse PCR. Those include 
rearrangements of t(6;7)(q25;q11), t(1;14)(p22;q32)/CNN3-IGH, t(5;14)(q34;q32)/ODZ2-
IGH and t(9;14)(p24;q32)/JMJD2C-IGH  (Vinatzer et al., 2008), t(X;14)(p11;q32)/GPR34-
IGH (Novak et al., 2008; Wlodarska et al., 2009) and t(3;13)(q24;p11) (Aamot et al., 2005). 
It has been shown that over-expression of GPR34 activated NF-κB in vivo (Novak et al., 
2008). However no functional characterisation for any of the translocations listed above has 
been performed. Nonetheless, the translocations above illustrate the heterogeneous nature of 
genetic alterations in MALT lymphoma. 
 
1.3.3 Genetics of translocation negative MALT lymphoma 
 
Trisomies are frequently associated with MALT lymphoma, particularly those without 
t(11;18)(q21;q21) (Brynes et al., 1996; Streubel et al., 2004). Trisomies 3 and 18 are found in 
about 35% and 25% of cases respectively. However, beyond those numerical aberrations, the 
molecular genetics of MALT lymphoma, especially those without chromosomal 
translocation, is poorly understood (Isaacson et al., 2004). The chromosomal gains and losses 
in translocation negative MALT lymphomas of the stomach and salivary glands were 
investigated using metaphase comparative genomic hybridisation (CGH) and recurrent 
chromosomal gains involving the whole or major part of chromosomes 3, 12 and 18, as well 
as recurrent discrete gains at 9q34 and 11q11-13 were found (Zhou et al., 2006; Zhou et al., 
2007). Array comparative genomic hybridisation (aCGH) showed frequent microdeletions 
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involving 6p25.3 to be associated with outcome of H. pylori eradication in translocation 
negative gastric MALT lymphoma (Fukuhara et al., 2007). 
Recently, work in Professor Ming Du’s group showed that A20 deletion was associated with 
copy number gain at the TNFA/B/C locus and occurred preferentially in translocation 
negative MALT lymphoma of the ocular adnexa and salivary glands but not in the stomach, 
lung and skin (Chanudet et al., 2009). In addition to the A20 gene deletions and mutations, 
promoter methylation was shown to be an alternative mechanism for A20 inactivation in 
MALT lymphoma and A20 complete inactivation was significantly associated with a shorter 
lymphoma-free survival in ocular adnexal MALT lymphoma (Chanudet et al., 2010).  The 
A20 protein (also known as Tumour Necrosis Factor Alpha-Induced Protein 3 or TNFAIP3) 
is a key player in the negative feedback regulation of NF-κB signalling in response to 
multiple stimuli. For example, A20 regulates tumour necrosis factor (TNF)-induced NF-κB 
activation. Recent genetic studies demonstrated a clear association between several single 
nucleotide polymorphism (SNPs) in the A20 locus and autoimmune disorders such as Crohn’s 
disease, Rheumatoid arthritis, systemic lupus erythematosus, psoriasis and type 1 diabetes 
(Vereecke et al., 2009) further implicating its link with both autoimmune disease and 
lymphoma development. 
More recently, inactivating mutations predicting truncated A20 products were identified in 6 
(19%) of 32 marginal zone lymphomas, including 2 (18%) of 11 extranodal marginal zone 
lymphomas, 3 (33%) of 9 nodal marginal zone lymphomas, and 1 (8%) of 12 splenic 
marginal zone lymphomas (Novak et al., 2009). Another study identified inactivating 
mutations in A20 in 21% MALT lymphoma patients (Kato et al., 2009). Collectively, A20 
can be completely inactivated by homozygous deletion, hemizygous deletion plus mutation or 
promoter methylation and bi-allelic mutations. A20 inactivation abolishes the major negative 
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regulation of the NF-κB pathway, thus potentially contributing to the constitutive NF-κB 
activation in lymphoma subtypes such as DLBCL, particularly the (activated B-cell) ABC 
subtype, classic Hodgkin lymphoma and Burkitt’s lymphoma. 
 
1.4  NF-κB pathway 
As mentioned in section 1.3, MALT lymphoma associated oncogenes target the NF-κB 
pathway, thus in this section the NF-κB pathway will be discussed.  
Nuclear Factor-κB (NF-κB) (nuclear factor kappa-light-chain-enhancer of activated B cells) 
is a protein complex that controls the transcription of DNA. NF-κB was first discovered in 
the laboratory of Nobel Prize laureate David Baltimore via its interaction with an 11-base pair 
sequence in the immunoglobulin light-chain enhancer in B cells (Sen et al., 1986). NF-κB is a 
ubiquitous transcription factor found in almost all animal cell types and is involved in cellular 
responses to diverse stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, 
oxidized low density lipoproteins, and bacterial or viral antigens (Gilmore, 2006).  
 
1.4.1  NF-κB family members 
 
NF-κB is a family of 5 inducible transcription factors, sharing a highly conserved reticulo-
endotheliosis viral oncogene homology (REL) domain, REL homolog A (RelA, also known 
as p65), REL homolog B (RelB), NF-κB1 (also known as p50) and NF-κB2 (p52). All have a 
transactivation domain in their C-termini. 15 transcription factors can be formed from the 
homo- and heterodimerisation of the five NF-κB subunits (Gilmore, 2006). The NF-κB1 and 
NF-κB2 proteins are synthesised as large precursors, p105, and p100, which undergo 
processing to generate the mature NF-κB subunits, p50 and p52, respectively. The processing 
of p105 and p100 is mediated by the ubiquitin/proteasome pathway and involves selective 
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degradation of their C-terminal region containing ankyrin repeats. Whereas the generation of 
p52 from p100 is a tightly-regulated process, p50 is produced from constitutive processing of 
p105. The particular dimers present are dependent on the cell type, its stage of differentiation, 
and environmental signals (Hayden et al., 2004). As all dimers are able to bind to κB 
consensus sites in promoters and enhancers, they can all be termed as “NF-κB”. The 
components of each dimer affect its specificity for DNA binding, its interaction with other 
proteins, and the set of genes that it controls (Hayden et al., 2004). NF-κB dimers have the 
ability to activate or repress transcription of genes (Perkins, 2007). NF-κB dimers are 
sequestered in an inactive form in the cytoplasm by inhibitory proteins of the IκB family 
(also known as nuclear factor of κ light polypeptide gene enhancer in B-cell inhibitor, 
NFΚBI). Diverse surface receptor signalling can activate the molecular pathways that allow 
NF-κB nuclear translocation and activate its target gene expression. 
 
 
1.4.2  NF-κB activation pathways 
 
There are two main pathways within a cell that result in NF-κB activation, namely canonical 
and non-canonical pathways (Figure 1.7). Recent data indicate the existence of a third NF-κB 
activation mechanism, referred to as linear ubiquitin chain assembly complex (LUBAC) 
pathway (Tokunaga et al., 2009) though this needs further experimental validation. 
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1.4.2.1  Canonical pathway 
 
Receptor signalling 
Whilst many different stimuli are able to activate NF-κB via surface membrane receptor 
signalling, the major ones can be broadly categorised into the following groups (Hayden et 
al., 2008):  
1) Antigen receptors such as B-cell receptors (BCR) and T-cell receptors (TCR) which 
lead to NF-κB activation via antigenic stimulation 
2) Toll-like receptors (TLRs) which respond to stimulations by bacterial or fungal 
products such as lipopolysaccharide (LPS), CagA and CpG, leading to NF-κB 
activation 
3) Tumour necrosis factor receptor (TNFR) which lead to NF-κB activation by 
stimulation with TNF ligand and (TNF)-related apoptosis-inducing ligand (TRAIL) 
Irrespective of the stimulus involved, the key event of canonical NF-κB activation is the 
phosphorylation of IκBα protein by an IκB kinase complex (IKK). This targets IκBα for 
ubiquitination and subsequent degradation, thus releasing NF-κB. NF-κB then translocates to 
the nucleus and binds the promoters of target genes to regulate their transcription (Figure 
1.7a). 
 
Signal transduction 
As mentioned above, a number of surface receptor signals lead to activation of the canonical 
pathway in both B and T cells. In the context of this thesis, only the antigen receptor and TLR 
signalling will be outlined as this is most relevant to MALT lymphoma. Antigen receptor 
signalling triggers serial proximal signalling that causes the auto-phosphorylation of 
phosphoinositide-dependent kinase 1 (PDK1). In T cells, phosphorylated PDK1 binds Protein 
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Kinase Cθ (PKCθ), activating this kinase via phosphorylation of Thr538 (Lee et al., 2005; 
Park et al., 2009). Similarly, in B cells, antigen receptor signalling triggers phosphorylation 
and activation of PKCβ. Subsequently, PKCβ phosphorylates several residues in the “linker” 
region (also known as PKC receptor) of CARD11 (Matsumoto et al., 2005; Sommer et al., 
2005). This phosphorylation event triggers a conformational change in CARD11 allowing its 
CARD domain to interact with the CARD of BCL10. Because BCL10 and MALT1 are 
constitutively associated in the cytoplasm (Su et al., 2005), the CARD11-BCL10 interaction 
also brings MALT1 into the complex, thereby forming the CARD11-BCL10-MALT1 (CBM) 
complex (Figure 1.8) (Matsumoto et al., 2005).  CBM is further stabilised by a direct 
interaction between the coiled coil domain of CARD11 and the C-terminal portion of 
MALT1 (Che et al., 2004) (Figure 1.8).  
Coincident with or downstream of formation of the CBM complex,  a proportion of cellular 
BCL10 and MALT1 becomes oligomerised, as demonstrated by biochemical methodology 
(Sun et al., 2004) and FRET microscopy (Rossman et al., 2006), and it is these oligomeric 
species that are active in NF-κB signal transduction (Sun et al., 2004). 
The active/oligomeric forms of BCL10 and MALT1 elicit the E3 ubiquitin ligase activity of 
the TRAF6 RING domain to synthesize a K63-linked polyubiquitin chain on TRAF6 itself 
(Stilo et al., 2004) (Thome, 2004; Thome, 2008) (Rossman et al., 2006; Sun et al., 2004) 
(Figure 1.8). Auto-ubiquitination increases the catalytic activity of TRAF6, enabling TRAF6-
mediated K63-polyubiquitination of specific protein targets (Lamothe et al., 2007). Activated 
TRAF6 polyubiquitinates MALT1 on multiple C-terminal lysines  and BCL10 on Lys31 and 
Lys63 (Oeckinghaus et al., 2007; Wu et al., 2008). 
K63-polyubiquitination of BCL10 is enhanced by the presence of MALT1 (Wu et al., 2008), 
suggesting that MALT1-associated TRAF6 may contribute substantially to K63-
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polyubiquitin modification of BCL10 in the CBM complex. Wu and colleagues showed that 
K63-polyubiquitination of BCL10 is essential for CBM association with the IKK complex 
and for consequent activation of NF-κB (Wu et al., 2008), while Duwel and colleagues 
showed an inability to detect K63-polyubiquitination of CBM-associated BCL10 (Duwel et 
al., 2009). Overall, data are consistent with a model proposing that NEMO is able to bind to 
K63-polyubiquitin chains on both BCL10 and MALT1, and that blockade of either of these 
interactions impairs NF-κB activation, by preventing efficient physical association between 
the CBM and IKK complexes. However, it is also possible that ubiquitin modification of 
BCL10 and/or MALT1 affects the function of one or both proteins in other as yet 
unidentified ways that are crucial for maximal activation of the IKK complex and do not 
contribute directly to physical association with the CBM. 
CBM complex recruits the IKK complex through a recently identified ubiquitin binding 
domain (UBD) in the NEMO protein. This specialised UBD, called the UBAN (UBD in 
ABIN proteins and NEMO), facilitates association between the IKK complex and the K63-
polyubiquitinated CBM complex (Wagner et al., 2008; Wu et al., 2006; Wu et al., 2008). The 
association of the CBM and IKK complexes then allows TRAF6 (in cooperation with 
Ubc13/Uev1A) to add K63-polyubiquitin chains to the C-terminal Zn-finger domain of 
NEMO at Lys399 and possibly additional lysines (Perkins, 2006).  
Biochemical studies suggest that K63-polyubiquitination of NEMO enables physical 
association with the TAK1/TAB2/TAB3 kinase complex, via the UBD of TAB2. This 
association allows TAK1 to phosphorylate and activate the IKKβ catalytic subunit (Perkins, 
2006). However, a more recent T-cell study has provided evidence that the phosphorylation 
of IKKβ is independent of CBM-mediated signalling and NEMO ubiquitination, suggesting 
that the mechanism of TAK1 association with the IKK complex remains to be defined 
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(Shambharkar et al., 2007). Regardless of the details by which the IKK complex is modified, 
data from both groups strongly suggest that the combination of NEMO ubiquitination and 
IKKβ phosphorylation is required for activation of IKKβ kinase activity (Shambharkar et al., 
2007; Shinohara et al., 2005). IKKβ then phosphorylates IκBα, triggering the terminal 
activation events of the canonical NF-κB activation cascade, as described above (Figure 
1.7a).   
 
Toll-like receptor signalling pathway 
TLRs play a crucial role in the innate recognition of various molecular motifs in pathogens, 
termed pathogen associated molecular patterns (PAMPs) that are conserved in a large group 
of pathogens, including bacteria, viruses, fungi and parasites.  At least 13 TLR family 
members in vertebrates and 10 TLRs in humans have been reported (Barton et al., 2002). All 
of these TLRs have extracellular leucine-rich repeats and an intracellular Toll/IL-1 receptor 
homology (TIR) domain (Takeda et al., 2003). These receptors transmit signals via several 
intracellular molecules, including myeloid differentiation factor-88 (MyD88), IL-1 receptor-
associated kinases (IRAKs), TNF receptor-associated factor (TRAF) 6 and mitogen activated 
protein kinases (MAPKs). When associated with TLR, MyD88 recruits members of the 
IRAK family through (death domain-death domain) homophilic interactions. IRAK1 and 
IRAK4 are serine-threonine kinases involved in the phosphorylation and activation of 
TRAF6. After phosphorylation by IRAKs, TRAF6 forms a complex with Ubc13 and Uev1A, 
and activates a MAPK kinase kinase (MAPKKK) called transforming growth factor ß–
activated kinase (TAK-1) (Barton et al., 2003). Activated TAK-1, in turn, can phosphorylate 
MKK3 and MKK6, the kinases upstream of p38 MAPKs and JNK which in turn lead to the 
activation of AP-1 protein (Takeda et al., 2003). In addition, TAK-1 can activate the IKK 
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complex, which phosphorylates IκBα consequently leading to NF-κB activation as detailed 
above (Barton et al., 2003). 
Different TLRs show variable recognition for microbial lipo-polysaccharides (LPS). For 
example Escherichia coli (E. coli) LPS is a ligand for TLR4. H. pylori associated LPS is 
recognized by the receptor complex containing TLR2–TLR1 or TLR2–TLR6 but not that 
containing TLR4 (Yokota et al., 2007).  
 
Chemokine receptor signalling pathway  
Chemokines are small peptides that are potent activators and chemoattractants for leukocyte 
subpopulations and some non-haemopoietic cells. Their actions are mediated by a family of 
7-transmembrane G-protein–coupled receptors (Murphy et al., 2000). Chemokine receptors 
are divided into different families, CXC chemokine receptors, CC chemokine receptors, 
CX3C chemokine receptors and XC chemokine receptors that correspond to the 4 distinct 
subfamilies of chemokines they bind (Murphy et al., 2000). Some chemokine and cytokines 
activate central cellular pathways. For example, when CXCL8 (IL-8) binds to its specific 
receptors, CXCR1 or CXCR2, a rise in intracellular calcium activates the enzyme 
phospholipase D (PLD) that goes on to initiate an intracellular signalling cascade by 
activating the NF-κB and MAP kinase pathway. The initiated NF-κB and MAP kinase 
pathways activate specific cellular mechanisms involved in chemotaxis, degranulation, 
release of superoxide anions and changes in the avidity of cell adhesion molecules called 
integrins (Murdoch et al., 2000). In addition, the binding of chemokines to their respective 
leukocyte receptors initiates a series of cellular events including NF-κB and MAP kinase 
activation, all of which aim to eradicate the infiltrating inflammatory agents. These events 
include changes in cell shape leading to enhanced locomotion, secretion of lysosomal 
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enzymes, and production of superoxide anions. Once leukocytes reach the source of 
inflammation, a cytokine-rich milieu is generated that is sustained until the invading antigen 
is eliminated. In general, immune responses do not produce endothelial injury; however, on 
occasion acute or chronic inflammation may occur in which the endothelium and surrounding 
tissues become damaged (for example, by neutrophil generated products). 
Several homeostatic chemokines have been shown to play an important role in mucosal 
immunology via germinal centre formation, homing mechanisms and local retention of 
activated mucosal B cells and dissemination of B cells to extra-intestinal secretary effector 
sites. Homing mechanisms play a role in B-cell recruitment to secondary lymphoid tissue. 
For example, recent mouse studies suggested that although the CCR7 ligand operating 
together with the CXCR4 ligand (CXCL12) are crucial for endothelial B-cell adhesion in 
lymph nodes, B-cell entry into Peyer’s patches depends on CXCR5 (Okada et al., 2002). 
 
1.4.2.2  Non-canonical pathway 
 
Receptor signalling 
The non-canonical NF-κB pathway is activated largely through signalling via the following 
main receptors:  
1) CD40 receptor (a TNFR family member) which leads to NF-κB activation via CD40 
ligand stimulation 
2) B-cell activating factor family (BAFF) receptor (BAFF-R) 
3) lymphotoxin α and β (LTβ also known as TNFC) receptor (LTβ-R) 
Signal transduction 
Receptor signalling activates NF-κB inducing kinase (NIK), which phosphorylates IKKα. 
Activated IKKα induces the partial proteolysis of p100 into p52. Subsequently, p52 binds to 
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RelB, forming an NF-κB dimer, which migrates to the nucleus and transactivates its target 
genes (Figure 1.7b) (Jost et al., 2007).  
In contrast to the canonical signalling that relies upon NEMO-IKKβ mediated degradation of 
IκBα, -β, and –ε, the non-canonical signalling critically depends on NIK mediated processing 
of p100 into p52. Given their distinct modes of regulation, these two pathways were thought 
to be independent of each other. However, recent studies revealed that synthesis of the 
constituents of the non-canonical pathway, via RelB and p52, is controlled by the canonical 
IKKβ-IκB-RelA:p50 signalling (Basak et al., 2008). Moreover, generation of the canonical 
and non-canonical dimers, via RelA:p50 and RelB:p52, within the cellular milieu are also 
mechanistically interlinked (Basak et al., 2008). These data suggest that an integrated NF-κB 
system network underlies activation of both RelA and RelB containing dimer and that a 
malfunctioning canonical pathway will lead to an aberrant cellular response also through the 
non-canonical pathway. As with most cellular pathways, activation needs to be counter-
balanced by inhibition or damping. 
A variety of recent evidence, however, suggests that the control of the NF-κB pathway is 
more complex than simply IKK-mediated regulation of the IκB-NF-κB interaction. For 
example, RelA and p50 are regulated by ubiquitination, acetylation and prolyl isomerisation, 
and the transactivation activity of RelA and c-Rel can be affected by phosphorylation. In 
addition, as a consequence of the induction of NF-κB activity (at least by tumour necrosis 
factor), IKKα is also induced to enter the nucleus where it becomes associated with κB site 
promoters/enhancers to phosphorylate histone H3 which enhances the transcription of κB 
site-dependent genes (Chen et al., 2007). 
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     a) Canonical pathway   b) Non-canonical pathway 
 
  
Figure 6 
  
Figure 1.7 - Canonical (classical) and non-canonical (alternative) NF-κB pathway.  
Inactive NF-κB dimers are sequestrated in the cytoplasm by inhibitory proteins of the IκB family, which 
includes IκBα, IκBβ, IκBγ, IκBδ, IκBε and BCL3, as well as p100 and p105 respective precursor of p52 and 
p50. In the canonical pathway, sequestrated NF-κB mainly consists of heterodimer p50-RELA. The IKK 
complex is composed of two kinase subunits (IKKα and IKKβ) and a regulatory subunit, NEMO (also known as 
NF-κB essential modifier NEMO). The activation of the IKK complex by phosphorylation (P) of IKKβ leads to 
the phosphorylation of IκB. This targets IκB for ubiquitination (U) and subsequent degradation. In the non-
canoncial pathway, sequestrated NF-κB mainly consists of heterodimer p100-RELB. The IKK complex is a 
dimer of IKKα. Activated IKKα phosphorylates p100 and triggers its proteolysis, producing p52. This allows 
the formation of NF-κB active complex p52-RELB. Both the canonical and the non-canonical pathways 
ultimately lead to the translocation of NF-κB dimers into the nucleus, where they transactivate target genes 
critical for cellular mechanisms such as proliferation and survival. Some target gene products negatively 
regulate the NF-κB pathway. 
 - 43 -  
TRAF6
IKKα IKKβ
IKKγ
IkBα
IkBα p65/RelA
p52
RelA/cRel
p50
p65/RelA
p52
RelA/cRel
p50
BCL10
Ig
C
as
p-
L
MALT1
Ig
-l
D
D
Ig
-l
C
as
pa
se
-l
Ig
-l
D
D
Ig
-l
C
as
pa
se
-l
Ig
-l
Ig
D
D
Ig
-l
C
as
pa
se
-l
D
D
Ig
-l
D
D
Ig
C
as
pa
se
-L
C
A
R
D
C
A
R
D
C
A
R
D
C
A
R
D
C
A
R
D
Ig
-l
Ig
D
D
Ig
C
as
pa
se
-L
MALT1
C
as
p-
L
CARD11
BCL10
MALT1
Ig
-l
D
D
Ig
-l
C
as
pa
se
-l
C
A
R
D
C
A
R
D
Ig
-l
D
D
Ig
-l
C
as
pa
se
-l
C
A
R
D
C
A
R
D
Ig
-l
D
D
Ig
-l
C
as
pa
se
-l
C
A
R
D
C
A
R
D
Ig
-l
D
D
Ig
-l
C
as
pa
se
-l
Ig
-l
D
D
Ig
-l
C
as
pa
se
-l
Ig
-l
Ig
D
D
Ig
-l
C
as
pa
se
-l
D
D
Ig
-l
D
D
Ig
C
as
pa
se
-L
C
A
R
D
C
A
R
D
C
A
R
D
C
A
R
D
C
A
R
D
Proteasomal
degradation
t(1;14) / t(14;18)
transcription of
target genes
immune response
and regulation
cell survival
and proliferation
BIRBIRBIR
Caspase-L
BIRBIRBIR
t(11;18)
Caspase-L
Ig
Ig
A20
PKCβ
 
Figure 1.8 - B-cell receptor mediated NF-κB activation and constitutive NF-κB activation by 
MALT lymphoma associated translocations. 
Following antigen recognition via PKCβ, CARD11 recruits BCL10 and MALT1 to the lipid raft at the activated 
receptor. Subsequently MALT1 binds TRAF6 activating its ubiquitin ligase. This results in TRAF6 and NEMO 
polyubiquitination and recruitment of kinase complex that phosphorylates IKKβ leading to IκBα 
phosphorylation and degradation. NF-κB is released and translocated into the nucleus, activating the 
transcription of target genes. The 3 MALT lymphoma associated translocations are believed to oligomerise and 
similarly recruit TRAF6 inducing constitutive NF-κB activation. 
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1.4.3 NF-κB negative regulators 
As mentioned above, in unstimulated cells, the NF-κB dimers are sequestered in the 
cytoplasm by a family of inhibitors, called IκBs (Inhibitor of κB).  
IκBs are related proteins in that they all have an N-terminal regulatory domain, followed by 
six or more ankyrin repeats and a PEST domain near their C terminus. Although the IκB 
family consists of IκBα, IκBβ, IκBγ and IκBε, and BCL3, the best-studied and major IκB 
protein is IκBα. Due to the presence of ankyrin repeats in their C-terminal halves, p105 and 
p100 also function as IκB proteins. The multiple copies of ankyrin repeats can mask the 
nuclear localisation signals (NLS) of NF-κB proteins sequestering them in an inactive state in 
the cytoplasm (Jacobs et al., 1998). 
Of all the IκB members, IκBγ is unique in that it is synthesised from the NF-κB1 gene using 
an internal promoter, thereby resulting in a protein that is identical to the C-terminal half of 
p105 (Inoue et al., 1992). The C-terminal half of p100, that is often referred to as IκBδ, also 
functions as an inhibitor (Basak et al., 2007). IκBδ degradation in response to developmental 
stimuli, such as those transduced through LTβR, potentiate NF-κB dimer activation in of NIK 
dependent non-canonical pathway (Basak et al., 2007). Unlike other members of the IκB 
family, BCL3 was found to function as a transcriptional activator and enhance NF-κB 
activity, primarily via forming a complex with the NF-κB p50 heterodimer to block the 
latter’s mediated suppression of target gene expression (Li et al., 2006).  
Activation of NF-κB is initiated by the signal-induced degradation of IκB proteins via their 
ubiquitination by the proteosome. With the degradation of the IκB inhibitor, the NF-κB 
complex is then free to enter the nucleus where it can activate the expression of specific 
genes that have DNA-binding sites for NF-κB nearby. The activation of these genes by NF-
κB then leads to the given physiological response, for example, an inflammatory or immune 
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response, a cell survival response, or cellular proliferation. Interestingly, these IκBs are part 
of NF-κB target genes where the newly synthesised IκB repressors masks the NLS of NF-κB 
sequestering it in the cytoplasm thus, forming a negative feedback loop, which results in 
tighter control and hence oscillating levels of NF-κB activity (Nelson et al., 2004). This tight 
control is important as NF-κB regulates a multitude of target genes that play key roles in cell 
development and survival. In addition, NF-κB transactivates several other negative regulators 
such as A20 (Krikos et al., 1992) and its adaptor molecules such as ABIN-1 to 3 (Verstrepen 
et al., 2008). 
 
1.4.4 NF-κB target genes and their biological implications 
NF-κB activity is essential for development, activation, proliferation and survival of 
lymphocytes (Hoffmann et al., 2006). NF-κB has the ability to regulate the transcription of an 
extensive variety of genes with a κB site in their promoter. Promoters that respond to NF-κB 
also contain consensus-binding sites for other transcription factors and these may be clustered 
into enhancers. This indicates that NF-κB may not act alone in transactivating gene 
expression (Hoffmann et al., 2006). 
Over 300 genes are regulated by NF-κB (http://people.bu.edu/gilmore/nf-kb/index.html) 
(Pahl, 1999), including NF-κB family members such as p50, p52 and RelB (Figure 1.9). A 
number of these NF-κB target genes encode NF-κB positive regulators, while several target 
genes encode negative regulators. According to their function, these NF-κB target genes can 
be categorised into the following groups: 
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Cytokines, chemokines and their modulators 
NF-κB promotes the transcription of cytokines and chemokines (thus playing a critical role in 
inflammation) such as BAFF, TNF family members including TNFα, as well as numerous 
interleukins such as IL8 and IL2 and TRAIL (Apo2-Ligand) (Aggarwal, 2003). 
Immunoreceptors 
NF-κB target genes include those encoding immune system modulators such as Toll-like 
receptors (TLR) (TLR2 and TLR6), chemokine receptors (CCR5 and CCR2), CD40 (Hinz et 
al., 2001), CD86 (Zou et al., 2005), CD80 (Fong et al., 1996), CD69 (Lopez-Cabrera et al., 
1995) and IRF4 (Grumont et al., 2000). In all cell types studied thus far, the expression of 
most of the genes induced by inflammatory stimuli are upregulated by NF-κB (Li et al., 
2002) and interestingly the over-expression of surface immune receptor genes such as TLRs 
and CD40 can lead to positive feedback regulation of the NF-κB pathway. 
Apoptosis regulators 
NF-κB regulates genes involved in preventing apoptosis, such as GADD45β (Hoffmann et 
al., 2006) and BCL2 family members (Catz et al., 2001) as well as IAP, FLIP, TRAF1 and 
TRAF2 (Karin et al., 2002) 
Cell cycle genes 
NF-κB also regulates genes involved in cell cycle regulation cyclin D1 and MYC (Toualbi-
Abed et al., 2008) (Hoffmann et al., 2006). 
NF-κB negative regulators 
NF-κB regulates the expression of its own inhibitors such as IκBα (Sun et al., 1993), and 
IκBε (Tian et al., 2005a) and NF-κB negative regulator genes such as A20 (Krikos et al., 
1992) and ABIN (A20 binding and inhibitor of NF-B) gene family including ABIN-1 to 3 
(Verstrepen et al., 2008) playing an important role in negative feedback regulation. 
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Figure 1.9 - Role of NF-κB target genes in immune response, cell proliferation and survival and 
maintaining cellular homeostasis. 
NF-κB regulates the transcription (shown by the blue arrows) of many target genes involved in cell survival and 
proliferation as well as immune response and homeostasis. These can be broadly classed as positive and 
negative regulators of NF-κB. Positive regulators of NF-κB, shown in blue arrows, include immune surface 
receptors (shown in dotted blue box) that are essential for cell signalling such as chemokine receptors, TLRs, 
CD40, TNF receptor, BAFF receptor and lymphotoxin receptors. They respond to many pro-inflammatory and 
environmental stimuli such as LPS, chemokines and cytokines and ligands and lead to positive feedback loop 
causing constitutive NF-κB activation promoting tumour cell survival. Negative regulators of NF-κB include 
A20 and IκB family. Interactions between the pro-apoptotic and pro-survival pathways, as well as feedback 
loops within each pathway contribute to a tightly regulated balance of cell death and survival. B- and T- cell 
receptors are not target genes but lead to NF- κB activation via CARD11-MALT1-BCL10 (CBM) complex. 
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1.5  MALT lymphoma associated translocations target common 
molecular pathways that cause NF-κB activation 
 
BCL10 and MALT1 are central to the transduction of signals from cell surface immune 
receptors to the classical NF-κB activation pathway in both B and T cells (Farinha et al., 
2005). The three common chromosomal translocations recurrently found in MALT 
lymphomas that involve the BCL10 and MALT1 genes are clearly implicated in the oncogenic 
process via deregulation of the NF-κB activation pathway. Mounting evidence indicates that 
the oncogenic activity of the three MALT-lymphoma associated chromosomal translocations 
is linked by roles of BCL10 and MALT1 in activating the NF-κB pathway in lymphocytes 
(Section 1.4) (Figure 1.8). 
The API2-MALT1 fusion protein self oligomerises through a non-homotypic interaction 
mediated by the API2 region and is capable of activating NF-κB. However, neither MALT1 
nor API2 alone is able to activate NF-κB in vitro (Du, 2007). Among the three BIR domains, 
only the first, BIR1, is essential for NF-κB activation by API2-MALT1 (Garrison et al., 
2009; Zhou et al., 2005). BIR1 has been shown to contain an additional TRAF2/TRAF6 
binding site, as well as a region that interacts with the C-terminal MALT1 responsible for a 
heterotypic oligomerisation that is critical for NF-κB activation (Garrison et al., 2009). It is 
likely that the constituting oligomerisation of the API2-MALT1 fusion protein contributes to 
its ability to interact with and oligomerise downstream ubiquitin ligase such as 
TRAF2/TRAF6. TRAF2 and TRAF6 (together with the ubiquitin conjugating enzyme 
complex, Ubc13/Uev1A) trigger the K63-polyubiquitination of the API2-MALT1 fusion 
product and the K63-autoubiquitination of the TRAFs, themselves. The polyubiquitinated 
API2-MALT1 complex then binds to NEMO (Wagner et al., 2008; Wu et al., 2006). This 
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molecular association allows the TRAFs associated with API2-MALT1 to K63-ubiquitnate 
NEMO and causing the terminal events in the canonical NF-κB activation cascade. 
In addition to binding to TRAF2/TRAF6, the API2-MALT1 protein has further activities that 
can augment signals to NF-κB (Zhou et al., 2004). For example, some data suggest that 
API2-MALT1 itself possesses ubiquitin ligase activity that is capable of K63-
polyubiquitinating NEMO and triggering NF-κB activation (Zhou et al., 2005). Also, recent 
data indicate that the API2-MALT1 fusion protein binds to K63-polyubiquitinated NEMO 
via the UBA domain of API2 (Gyrd-Hansen et al., 2008). It is possible that this interaction 
protects the NEMO protein from de-ubiquitination, thereby prolonging activation of the IKK 
complex. Another possibility is that the UBA-NEMO interaction stabilises the interaction 
between API2-MALT1 and the IKK complex, increasing the efficiency of NEMO K63-
polyubiquitination by API2-MALT1-associated TRAF2 and TRAF6. There is also evidence 
that API2-MALT1, like MALT1, can mediate proteolytic cleavage of A20, a negative 
modulator of NF-κB signalling. This depends on the paracaspase activity of the caspase like 
domain (Coornaert et al., 2008). A point mutation that disrupts this proteolytic activity 
decreases API2-MALT1 mediated NF-κB activation by approximately 3-fold (Hu et al., 
2006b). Thus, the proteolytic activity of API2-MALT1 appears to augment NF-κB activation 
by interfering with normal homeostatic mechanisms that serve to limit NF-κB activation. It 
remains to be investigated whether A20 is also cleaved when BCL10 or MALT1 is over-
expressed. 
BCL10 has been reported to interact with the API2-MALT1 fusion protein and 
synergistically enhance NF-κB activation in the absence of appropriate stimuli (Hu et al., 
2006b). In this study, it was shown that BCL10 interacts with a sub-fragment of API2 (1-
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441), which contains the three BIR domains and the UBA domain (Gyrd-Hansen et al., 2008) 
(Figure 1.4).  
For the non-canonical (alternative) pathway, it has been shown that NF-κB signalling, once 
activated in a CD40-dependent immune response, is maintained and enhanced through 
deregulation of MALT1 or formation of an API2-MALT1 fusion (Ho et al., 2005). 
In contrast to MALT1 and API2-MALT1, BCL10 deregulation was demonstrated to promote 
survival of antigen-simulated B lymphocytes, by showing that over-expression of BCL10 in 
primary B cells activated ex vivo promoted the survival of these cells after removal of 
activating stimuli (Tian et al., 2005b). 
Although BCL10 and API2-MALT1 are potent activators of NF-κB, over-expression of these 
oncogenic products alone is not sufficient to induce malignant transformation. Transgenic 
mice expressing API2-MALT1 or BCL10 alone develop splenic marginal zone hyperplasia 
but not lymphoma (Baens et al., 2006; Macintyre et al., 2000; Li et al., 2009). However, 
when transgenic mice expressing the API2-MALT1 fusion protein are immunised with the 
Freund’s complete adjuvant, they develop splenic marginal zone lymphoma-like lymphoid 
hyperplasia (Sagaert et al., 2006a). In line with this, expression of either API2-MALT1 or 
MALT1 in BJAB B cells enhanced the activation of IKK and NF-κB by CD40/CD40L 
stimulation (Ho et al., 2005). 
FOXP1-involved translocation occurs recurrently in MALT lymphoma and it is hypothesised 
that it may also confer oncogenesis through activation of NF-κB. Support for this hypothesis 
is provided by the observation that FOXP1 is highly expressed in the activated B-cell subtype 
of DLBCL in which NF-κB is constitutively active. However, these separate findings may be 
unrelated and offer no insight into the mechanism by which FOXP1 promotes oncogenesis. 
The full length and two short isoforms of FOXP1 were able to activate NF-κB alone and 
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synergistically with cell surface stimulation of B cells by LPS and T cells by CD3 and CD28.  
The mechanism of NF-κB activation is unknown but there is no evidence of activation of the 
canonical or non-canonical pathways in the cytoplasm, in keeping with the nuclear 
localisation of FOXP1 (unpublished data in Professor Ming Du’s laboratory). 
The extent of the oncogenic activities of these  translocations is not yet fully understood as 
indicated by the aberrant pattern of BCL10 expression in some cases of MALT lymphoma. In 
normal B cells, including those of the marginal zone of B-cell follicles, BCL10 is expressed 
primarily in the cytoplasm (Ye et al., 2000). However, in MALT lymphoma with 
t(1;14)(p22;q32), BCL10 is strongly expressed in the nuclei (Ye et al., 2000). Moderate 
levels of nuclear BCL10 expression are also seen in up to 50% of t(1;14)(p22;q32)-negative 
MALT lymphomas, including almost all t(11;18)(q21;q21)-positive cases (Liu et al., 2001b; 
Maes et al., 2002; Ye et al., 2003). Furthermore, BCL10 was found to be expressed at high 
levels in the nuclei of splenic marginal-zone B cells in transgenic mice in which BCL10 
expression is driven by Ig enhancers (Li et al., 2009). These observations indicate that 
aberrant nuclear BCL10 expression might have a role in MALT lymphoma development. 
However, the biological activity of nuclear BCL10 remains to be investigated. 
 
1.6  Summary of  current understanding of  gastric MALT 
lymphoma 
 
The sequential development of H. pylori-associated chronic gastritis, acquisition of MALT, 
low grade MALT lymphoma and transformation into DLBCL, clearly indicates a multistep 
process in the development of MALT lymphoma (Figure 1.10), primarily demonstrated by 
the histological presentation of these pathological conditions (Wotherspoon et al., 1993). 
Recent studies provided further understanding at both the cellular and molecular levels. 
MALT lymphomagenesis recapitulates many aspects of the normal immune response and 
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lymphocyte development. The patterns of spread of lymphomas reflect the homing patterns 
of normal lymphocytes, both microscopically, within lymph nodes, and macroscopically, at a 
clinical level. 
Correlation of the genetic aberrations with clinical outcome will permit improved diagnostic, 
prognostic and therapeutic sub-classification of MALT lymphomas. Whilst NF-κB 
deregulation as a consequence of the MALT lymphoma translocations is clearly indicated, 
further investigation is necessary to clarify the role of these events in oncogenesis. The 
equivalent events in translocation negative lymphoma also require elucidation. 
Acquired MALT
Early phase
MALT lymphoma
H. Pylori
dependance
~4%
~68%
~24% ~4%
T-cell dependent
B ce ll proliferation 
Chronic H.pylori infection
Late phase
MALT lymphoma
Enhanced NF-kB
activation
H.pylori
independence
t(11;18)/API2-MALT1
MALT lymphoma
t(1;14)/BCL10-IGH
MALT lymphoma
t(3;14)/FOXP1-IGH
MALT lymphoma
Transformed
MALT lymphoma
 
 
 
Figure 1.10 - Multistep development of gastric MALT lymphoma. 
 
Figure adapted from Isaacson et al. (2004). Nature Review Cancer, 4, 644-653. 
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Infection by H. pylori first induces the formation of acquired mucosa-associated lymphoid 
tissue (MALT) in the gastric mucosa. The persistence of the bacterial infection results in 
chronic inflammation. Under sustained immunological stimulation, H. pylori-specific 
tumour-infiltrating T cells stimulate the proliferation of B cells. Genetic abnormalities such 
as chromosomal translocations (Figure 1.4) might be the result of oxidative stress associated 
with inflammation (Ye et al., 2003). The acquisition of genetic abnormalities leads to 
malignant transformation. At this early stage, clonal expansion is H. pylori-dependent and the 
resulting MALT lymphoma can be effectively treated by H. pylori eradication with 
antibiotics. However, MALT lymphoma cells can gain autonomous growth ability, 
presumably through the acquisition of chromosomal translocations such as t(11;18) and 
t(1;14) or secondary genetic abnormalities such as A20 mutations, and thus, do not respond to 
H. pylori eradication.  
The milieu of infection and chronic inflammation provide a common background for the 
development of MALT lymphomas. It is likely that NF-κB activation is involved in both 
translocation positive and negative MALT lymphoma. However despite the overlapping 
mechanisms there are important differences in the clinical and histological presentations 
between MALT lymphomas with and without chromosome translocation. Clinically, gastric 
MALT lymphomas with t(11;18) or t(1;14) are significantly associated with advanced 
clinical stages and resistance to H. pylori eradication (Liu et al., 2002b; Ye et al., 2006).  
Histologically, t(11;18) positive MALT lymphomas appear to be more monotonous, lacking 
apparent transformed blasts (Okabe et al., 2003).  These clinico-pathological characteristics 
may indicate the presence of significant differences in molecular mechanisms between 
MALT lymphomas with and without chromosome translocation. Thus, there are still many 
unanswered questions regarding MALT lymphomagenesis. Firstly, how chronic antigenic 
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stimulation in the presence of H. pylori or C. psittaci infection leads not only to chronic B-
cell proliferation, but also to DNA damage which can result in the specific translocations that 
characterise most MALT lymphomas. Secondly, what are the molecular mechanisms that 
determine the response to H. pylori eradication. Thirdly, what is the molecular basis of NF-
κB activation in MALT lymphoma. Fourthly, what are the molecular profiles and pathways 
targeted by MALT lymphoma with and without chromosomal translocations that can explain 
their differences in clinical and histological presentation. In order to answer some of these 
compelling questions, expression microarray investigations were applied in this thesis to 
MALT lymphoma cases with and without chromosomal translocation. 
 
 
1.7 Gene expression microarray 
 
Although all human somatic cells possess the same inherited genomic DNA, each cell 
transcribes different genes as mRNA according to the cell type. Further variation is provided 
by biological processes, both normal and abnormal conditions, amongst other parameters. 
The diversity in gene expression patterns has led to intensive research because of its 
biological and clinical relevance. Microarray technology allows the simultaneous profiling of 
the expression of tens of thousands of genes, thus painting a molecular portrait of the tissue 
or cell lines being studied.  The technology, based on the micro-spotting of DNA, protein, 
tissue or small organic compounds, which can be probed with various labelled binding 
ligands (Howbrook et al., 2003). Different microarray technologies are designed to address 
distinct biological questions. This thesis focuses on expression microarray technologies, 
which permit a broad overview of expression patterns. 
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1.7.1 Advantages of using gene expression microarray 
 
It can be hypothesised within limits that changes in the phenotype of a cell or cell population 
should be reflected by concomitant transcriptional changes. Large-scale assessment of 
mRNA transcript abundance should thus provide a molecular signature of the state of gene 
activity of the biological system in question. Such assessment of gene expression has been 
considered a useful tool in the study of cellular biology in health and disease. 
Currently, expression microarrays are much more reliable, optimised and permit higher 
throughput than any available proteome-assessing technology. Global and quantitative 
information on gene expression by measuring mRNA levels far outstrips the available 
proteomic technologies which are generally more technologically challenging and permit far 
lower throughput (Clarke et al., 2001). Indeed, expression microarray technology has 
matured impressively in the last 8 years and now has a resolution of approximately one 
transcript per known gene. Currently available expression microarray platforms can assess 
gene expression of over 300,000 distinct transcripts in any single experiment. Nonetheless, 
the complementation of expression with data from high throughput proteomic technologies 
such as high throughput crystallography and protein-based microarrays is eagerly awaited 
(Howbrook et al., 2003). 
 
1.7.2 Limitations of gene expression microarray 
 
The focus of expression microarray technology is the quantitative assessment of gene 
expression on a very large scale. Such an approach focusing on transcription is often 
questioned in relation to its ability to extrapolate findings at the protein level. This is one of 
the limitations of not only microarray-based, but all transcriptome-assessing technologies in 
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general. There is no doubt that results from expression technologies would be maximally 
effective if accompanied by and integrated with studies assessing global protein expression 
(Clarke et al., 2001). However, even this combined approach would not suffice to describe a 
given cellular biological phenomenon in its entirety as an accurate description but would at 
least also require extensive study of protein post-translational modification and localisation.  
Microarray technology is sensitive to cellular heterogeneity. In this context where RNA 
sample is obtained from complex tissues, expression results may relate to expression profiles 
from a number of distinct cell types. Thus it is important to use highly homogenous, carefully 
selected cell populations (for example lymphoma cells) as this can reduce the possibility of a 
given expression result being affected by cell types of secondary interest. The use of 
microdissected tissue may circumvent this problem by including mostly specific cell types in 
a given expression profiling experiment. Finally, the requirement of often large quantities of 
RNA (total or messenger) for these technologies may prove limiting especially for studies 
focusing on rare clinical material. The development of RNA amplification protocols, 
however, has addressed this issue successfully, significantly lowering the amount of RNA 
needed per microarray experiment. More recently, the discovery of microRNAs (miRNAs) 
(which are naturally occurring short non-coding RNA molecules that negative regulate 
eukaryotic expression through binding to the complementary sequences in the 3’-UTR of 
target mRNA) adds another limitation as some of the mRNA on the expression array may be 
negatively regulated by some of those miRNAs. Also studies have shown that some miRNAs 
such as miR-155, miR-210 and miR-21 are upregulated in the serum from DLBCL patients 
(Lawrie et al., 2008a) whereas miR-150, miR-189, miR-223 and miR-768-3p are 
downregulated in DLBCL and BL patients suggesting that dysfunctional expression of 
miRNAs might be a feature in some haematological malignancies (Lawrie et al., 2008b). 
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1.7.3 Microarray platforms 
 
There are several expression microarray platforms, including complementary DNA (cDNA) 
microarrays (Schena et al., 1995), oligonucleotide microarrays (Lockhart et al., 1996) and 
serial analysis of gene expression (SAGE) (Velculescu et al., 1995). The first two microarray 
technologies are the most commonly used platforms. The cDNA microarrays are based on 
standard microscopic glass slides on which cDNA fragments have been spotted. The 
oligonucleotide microarrays are constructed with oligonucleotides, 25- or 60-mer in length 
that are either synthesised in situ on a silicon wafer, or robotically spotted or injected on glass 
slides. The term commonly used to describe the DNA arrayed on a platform is “probe” and 
the cDNA or cRNA generated from a sample RNA, which represent the gene expression 
profile of the sample, are referred to as “target”. The types of probes and targets used in each 
microarray platform differ, but these differences are becoming less significant. The main 
difference between the two platforms is the method by which the mRNA levels are 
determined. In cDNA microarrays, the quantitation is made by comparing a selected  sample  
to  a ‘control’  sample,  while  in oligonucleotide  microarrays,  a  well-defined  arbitrary unit 
is produced without the need to compare with a different  sample. Generally, it has been 
shown that oligonucleotide arrays give better results than cDNA microarrays (Woo et al., 
2004). The most common oligonucleotide platform to study human genome expression is the 
Affymetrix HG-U133 GeneChip. 
 
1.7.3.1 The Affymetrix HG-U133 GeneChip 
 
The HG-U133 (Human Genome U133) GeneChip microarray set originally consisted of two 
GeneChips; HG-U133A and HG-U133B. Collectively, the HG-U133 set is capable of 
assessing a total of around 39,000 transcripts and variants, including more than 33,000 well-
 - 58 -  
substantiated human genes. The U133A chip alone assess 22,283 transcripts derived mostly 
from well-characterised genes and U133B can assess 22645 derived mostly from expressed 
sequence tags (ESTs). Sequences used in the design of the chip were selected from GenBank, 
dbEST and RefSeq. The sequence clusters were created from the UniGene database (Build 
133, April 20, 2001) and then refined by analysis and comparison with a number of other 
publicly available databases. Subsequently around 2005, Affymetrix commercialised a new 
GeneChip that includes the whole human genome on one chip, named HG-U133 plus 2.0. 
This is capable of analysing the expression level of over 47,000 transcripts and variants, 
including 38,500 well-characterised human genes. It comprises more than 54,000 probe sets 
and 1,300,000 distinct oligonucleotide features. In addition, there are 9,921 new probe sets 
representing approximately 6,500 new genes. These gene sequences were also selected from 
GenBank, dbEST, and RefSeq. Sequence clusters were created from the UniGene database 
(Build 159, January 25, 2003) from manufacturer’s datasheet at  
http://www.affymetrix.com/support/technical/datasheets/human_datasheet.pdf. 
The unit of expression interrogation of the U133 chip is the probe set. Throughout this thesis, 
for the purpose of clarity, all genes mentioned will be associated to their probe set(s). The 
terms gene and probe set may be used interchangeably. It is stressed, however, that all 
observations refer to probe set signal intensity changes. 
 
1.7.3.1.1  Probe versus Probe set 
 
A major difference between spotted and GeneChip microarray technologies relates to probe 
design. Spotted microarray technologies employ probes that may either be synthetic 
oligonucleotides, long PCR products or cloned cDNAs. In all cases however, a single 
transcript is assessed by a single probe. For Affymetrix GeneChips, transcripts are 
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interrogated not by a single probe, but by a combination of probes collectively forming a 
probe set. Each probe in a probe set is designed to be complementary to a distinct region of 
the transcript queried. For example, the U133A Genechip used in this thesis, employs a total 
of 11 probes in the interrogation of each transcript assessed. These probes are referred to as 
perfect match (PM) as they are designed to be perfectly complementary to their respective 
transcript. In addition, for each probe set, a second set of mismatch probes (MM) with a 
mutation in the middle of the probe’s sequence is employed to control for hybridisation 
specificity and background. 
The generation of probe set values from respective probe values can be addressed in a 
number of ways. These differ mainly in relation to the use of MM probes and the statistical 
approaches adopted for obtaining single probe set expression values from individual probe 
intensities. In the most simplistic scenario, probe set level data can be obtained by initially 
correcting for background by subtracting each MM probe from its respective PM one and 
then averaging corrected PM probe intensities. 
 
1.7.4 Data analysis 
 
Regardless of the microarray platform, each experiment produces a data set containing tens to 
hundreds of thousands of values of gene expression.  This overwhelming abundance of data 
requires the use of powerful statistical and analytical tools. After normalisation and non-
specific filtering, there are two basic approaches to analysing gene expression data set.  The 
supervised approach is based on determining genes that fit a predetermined pattern, usually 
used to correlate between gene expression and clinical data. The two most common 
supervised techniques are: nearest neighbour analysis (Golub et al., 1999) and support vector 
machines (Brown et al., 2000). The unsupervised approach is based on characterising the 
 - 60 -  
components of the data set without the a priori input or knowledge of a training signal. This 
approach is usually used to identify a distinct subgroup of tumours that share similar gene 
expression profiles. The four most common unsupervised techniques are: principle-
component analysis (Raychaudhuri et al., 2000), hierarchical clustering (Eisen et al., 1998), 
self organising maps (Tamayo et al., 1999) and relevance networks (Butte et al., 2000). 
The first study utilising microarray technology demonstrated the power of this tool to classify 
and predict human acute leukaemias. These classifications and predictions were based solely 
on gene expression monitoring and were independent of previous biological knowledge 
(Golub et al., 1999). Although histopathological evaluation, supplemented by cytogenetics 
and analysis of a few molecular markers, is still the gold standard in diagnosis and prognosis, 
gene expression profiling had proved capable of replacing these evaluations providing large 
numbers of patients are used in extracting the molecular signatures. 
The rate-limiting step in functional genomics experiments is neither the handling of the 
biological samples nor the actual analysis, but instead the post-analytical work in determining 
what the results actually mean. This is largely restricted by the lack of biological knowledge 
of the gene studied, reliable bioinformatics methods in mining and interpretation of the 
massive data generated. Some advances have been achieved, such as the development of 
ONCOMINE, a cancer microarray database and web-based data-mining platform aimed at 
facilitating discovery from genome-wide expression analyses. To date, ONCOMINE contains 
65 gene expression datasets comprising nearly 48 million gene expression measurements 
from over 4700 microarray experiments (Rhodes et al., 2007) (http://www.oncomine.org). 
Other pathway and data mining software such as Ingenuity Pathway Analysis 
(http://www.ingenuity.com) and GeneGO (http://www.genego.com) help in the interpretation 
of microarray data. However, a precise method to map the genes that are differentially 
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expressed from the microarray studies to cellular pathways relevant to the cellular and 
molecular mechanisms of disease is required. Gene set enrichment analysis (GSEA) goes 
some way to achieve this. GSEA measures whether the individual genes in a signature are 
differentially expressed in a consistent fashion between two groups of samples (Mootha et 
al., 2003). This method was originally used to demonstrate that genes involved in oxidative 
phosphorylation are decreased in expression in diabetic muscle (Mootha et al., 2003). A 
recent enhancement of the GSEA method places added emphasis on those genes in a 
signature that are the most differentially expressed between two groups (Subramanian et al., 
2005). 
 
1.7.5 Advances in lymphoma by gene expression microarray investigations  
 
Gene expression profiling using microarrays has made huge improvement in disease 
classification, disease sub-classification, biomarkers identification, and deciphering the 
molecular pathogenesis in a number of lymphoma subtypes. Highlighted below are examples 
of such advances: 
 
Disease sub-classification and characterisation 
The most prominent examples of gene expression microarray in lymphoma sub-classification 
are studies of DLBCL. These studies revealed new unexpected subgroups of DLBCL which 
cannot be classified by conventional histology and immunophenotype. While 40% of patients 
respond well to chemotherapy, the remaining 60% succumbs to the disease. Using 
unsupervised analysis of gene expression data, Alizadeh et al. (Alizadeh et al., 2000) 
identified two molecularly distinct forms of DLBCL, named germinal center B-cell-like 
(GCB) GCB-DLBCL and activated B-cell-like ABC-DLBCL. The different gene expression 
profiles apparently reflected the variation in tumour proliferation rate, host response and 
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differentiation state of the tumour. Importantly, this stratification proved to be clinically 
relevant in that activated B-cell (ABC) DLBCL is significantly associated with poor overall 
and event free survival. Subsequent studies showed that ABC-DLBCL is characterized by 
constitutive NF-κB activation and is more frequently associated with CARD11 and CD97B 
inactivating mutations (Lenz et al., 2008; Davis et al., 2010). 
 
Disease classification 
Identification of molecular profiles that differentiate the lymphoma in question from other B-
cell lymphomas can be seen in Burkitt’s lymphoma microarray studies. Burkitt’s lymphoma 
is a rare, aggressive B-cell lymphoma that accounts for 30% to 50% of lymphomas in 
children but only 1% to 2% of lymphomas in adults (NHL Lymphoma Classification Project, 
1997; Swerdlow et al., 2008). The main diagnostic challenge in Burkitt’s lymphoma is to 
distinguish it from diffuse large B-cell lymphoma. The tumour cells of Burkitt’s lymphoma 
are characteristically medium-sized (smaller than the cells of most diffuse large-B-cell 
lymphomas) and very high fractions are proliferating. Dave et al. (Dave et al., 2006) and 
Hummel et al. (Hummel et al., 2006), used gene expression microarray technology to 
improve the accuracy of the diagnosis of Burkitt’s lymphoma. The two studies differ in many 
important ways, but both reach the same conclusion: the gene-expression profiling of cases 
classified as Burkitt’s lymphoma by expert pathologists identifies a characteristic genetic 
signature that clearly distinguishes this tumour from cases of diffuse large-B-cell lymphoma. 
Furthermore, the microarray method seems to outperform the expert pathologists: 17% (Dave 
et al., 2006) and 34% (Hummel et al., 2006) of cases with the gene-expression signature of 
Burkitt’s lymphoma had been called diffuse large-B-cell lymphoma or unclassifiable high-
grade B-cell lymphoma; 0.4% (Dave et al., 2006) and 4% (Hummel et al., 2006) of cases 
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without the Burkitt’s signature had been called classic or atypical Burkitt’s lymphoma; and 
3% (Dave et al., 2006) and 8% (Hummel et al., 2006) of cases diagnosed as diffuse large B-
cell lymphoma or unclassifiable high-grade B-cell lymphoma had a Burkitt’s signature. 
 
Deciphering the molecular basis of lymphomagenesis 
Examples of the use of expression microarrays in understanding the molecular pathogenesis 
of lymphomas can be seen in mantle cell lymphoma (MCL) and follicular lymphoma (FL). 
The common cytogenetic alteration in MCL patients, t(11;14), leads to cyclin D1 over-
expression. Nevertheless, overexpressing cyclin D1 in transgenic mice was not sufficient to 
induce lymphomas, and other oncogenic factors, were required (Bodrug et al., 1994). Thus, 
different mechanisms must be required for the development and progression of MCL. The 
first use of microarrays in studying MCL demonstrated altered apoptosis pathways, in 
addition to the known over-expression of cyclin D1 (Hofmann et al., 2001). A comparison of 
MCL with normal human B cells revealed a distinct gene expression signature affecting 
lymphocyte trafficking, differentiation and growth regulation (Ek et al., 2002). In follicular 
lymphoma, gene expression profiling showed that an interaction of tumour cells and the 
microenvironment determine the clinical behaviour (Glas et al., 2007) and that 
transformation of follicular lymphoma to diffuse large B-cell lymphoma is preceded by 
distinct oncogenic mechanisms (Davies et al., 2007). 
 
Biomarker identification 
Blenk et al. (Blenk et al., 2007) analysed a large data set on DLBCL gene-expression (248 
patients, 12196 spots) and identified specific, activated B-cell-like (ABC) and germinal 
center B-cell-like (GCB) distinguishing genes. These include early (e.g. CDKN3) and late 
(e.g. CDKN2C) cell cycle genes. Independently from previous classification by marker genes 
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they confirmed a clear binary class distinction between the ABC and GCB subgroups. The 
biomarkers set distinguishing marked over-expression in ABC from that in GCB, is built by: 
ASB13, BCL2, BCL6, BCL7A, CCND2, COL3A1, CTGF, FN1, FOXP1, IGHM, IRF4, 
LMO2, LRMP, MAPK10, MME, MYBL1, NEIL1 and SH3BP5. It predicts and supports the 
aggressive behaviour of the ABC subgroup and help to understand target interactions, 
improve subgroup diagnosis, risk prognosis as well as therapy in the ABC and GCB DLBCL 
subgroups. 
 
1.7.6 Gene expression microarray studies of MALT lymphomas 
 
There are so far three gene expression microarray studies on MALT lymphomas. O’Rourke et 
al. (O'Rourke, 2008) investigated gastric mucosa of BALB/c mice infected with H. pylori and 
correlated transcriptional profile with histological changes during the progression from 
chronic inflammatory infiltrate to MALT lymphoma. Huynh et al. (Huynh et al., 2008) 
compared gene expression profiles of 21 gastric MALT lymphomas with corresponding H. 
pylori associated MALT B-cell follicles and aggregates. The study showed that gastric 
MALT lymphoma has a distinct gene expression profile, characterized by up-regulation of 
several surface receptor markers of haematopoietic cells such as CD1c, CD40, CD44, CD53, 
CD83 and CD86 and members of the HLA-D family, indicating antigen-dependent survival 
of lymphoma cells. Chng et al. (Chng et al., 2009) attempted to classify 35 cases of 
pulmonary MALT lymphoma (10 with t(11;18), 3 with t(14;18) translocations and 22 
negative for all known MALT lymphoma translocations) with other B- and T- cell 
lymphomas. They showed that MALT lymphoma is a distinct entity with a prominent T-cell 
signature and a marginal zone/memory B-cell profile. Fifty genes were differentially 
expressed between MALT lymphoma and all the other samples, 13 of which showed over-
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expression in MALT lymphoma. Only 4, MMP7, SIGLEC6, WSB1, and PRO1853, were 
specifically overexpressed in MALT lymphoma, and 2 of these, MMP7 and SIGLEC6 were 
validated using immunohistochemistry on MALT lymphoma tissue microarrays. Hierarchical 
clustering of pulmonary MALT lymphoma with and without translocations showed 
overlapping transcriptional profiles with over-expression of NF-κB and chemokine signalling 
pathways in MALT lymphomas with t(11;18). Additionally, spiked expression analysis 
showed high expression of MALT1 and RARA. Samples with plasmacytic differentiation had 
high FKBP11 expression, and samples with high RGS13 expression tended to have trisomy 3 
and reactive follicles. However, the main criticism of this study is that only 7 out of the 33 
cases used had 70% or higher tumour content and including cases that had tumour content as 
low as 15% (Chng et al., 2009). This can lead to false positives and under-powered study. In 
addition the study only focused on t(11;18) and t(14;18) in pulmonary MALT lymphomas 
only which can exclude other important genes implicated in MALT lymphoma such as 
BCL10.    
In summary, none of the MALT lymphoma microarray studies thus far, convincingly showed 
the key molecular events explaining its lymphomagenesis. 
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1.8 Objectives of the thesis 
1) To characterise the expression profile of MALT lymphoma with and without 
translocations with the aim to understand the common and unique molecular 
mechanisms underlying the disease; 
2) To investigate the cooperation between the expression of MALT lymphoma 
oncogenes and immunological stimulation on NF-κB activation; 
3) To identify novel phenotypic markers for MALT lymphoma by comparing expression 
microarray data of MALT lymphoma with other lymphomas such as FL, MCL, CLL 
and SMZL. 
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CHAPTER 2 – Materials and methods 
 
2.1 Materials 
2.1.1 Tissue materials and clinical data 
2.1.1.1 Ethical considerations 
 
The patient materials included in this study were archival fresh frozen and formalin-fixed 
paraffin-embedded tissues. Tissue material was retrieved from Professor Ming Du’s 
laboratory and his international collaborators. Local ethical guidelines were followed for the 
use of these archival tissues for research with the approval by the local ethics committees of 
the relevant institutions. 
2.1.1.2 Tissue materials for expression microarray and phenotypic marker studies 
 
A total of 26 well characterised MALT lymphomas, 14 SMZL, 7 nodal FL and 8 nodal MCL 
were used for the expression microarray study. The MALT lymphoma cases included 9 
positive for t(11;18)(q21;q21)/API2-MALT1 (8 gastric and 1 pulmonary), 4 positive for 
t(1;14)(p22;q32)/BCL10-IGH or t(1;2)(p22;p11)/BCL10-IGk (3 gastric and 1 pulmonary), 2 
positive for t(14;18)(q32;q21)/IGH-MALT1 (1 hepatic and 1 ocular adnexal), 1 positive for 
t(3;14)(p13;q32)/IGH-FOXP1 and 10 gastric cases negative for all known MALT lymphoma 
associated chromosome translocations (Table 2.1). In all cases, fresh frozen tissue from 
surgical resection specimens was available. Tumour content was checked based on 
histological examination of Haematoxylin and Eosin (H&E) slides and where necessary 
crude microdissection was performed to ensure at least 70% tumour cells were used for 
molecular investigations. The chromosomal translocation status in these cases was 
investigated in previous studies using conventional cytogenetics, interphase FISH and RT-
PCR where appropriate (Table 2.1). Extensive immunophenotyping including BCL10, 
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MALT1 and FOXP1 immunohistochemical data was available from previous studies (Goatly 
et al., 2008; Liu et al., 2001b; Liu et al., 2001a; Liu et al., 2004a; Ye et al., 2000; Ye et al., 
2006). 
 
Table 2.1 - Summary of clinico-pathological, molecular and immunohistochemical data of 
MALT lymphoma cases used in gene expression microarray studies. 
 
Case 
No. Sex Age Site Diagnosis Translocation status Stage Treatment Follow-up BCL10 immunohistochemistry
1 M 41 Stomach MALT lymphoma t(11;18)(q21;q21) IIIE   Moderate nuclear
2 F 72 Stomach MALT lymphoma t(11;18)(q21;q21) IVE   Moderate nuclear
3 M NA Stomach MALT lymphoma t(11;18)(q21;q21)    Moderate nuclear
4 F 52 Stomach MALT lymphoma t(11;18)(q21;q21) IIE   Moderate nuclear
5 F 75 Lung MALT lymphoma t(11;18)(q21;q21) I Surgical resection,  Moderate nuclear
6 M 51 Stomach MALT lymphoma t(11;18)(q21;q21) I total gastrectomy CR during 6 year follow up Cytomplasmic
7 M 54 Stomach MALT lymphoma t(11;18)(q21;q21) I total gastrectomy CR during 4 year follow up Cytomplasmic
8 M 48 Stomach MALT lymphoma t(11;18)(q21;q21) II1 total gastrectomy CR during 10 year follow up Cytomplasmic
9 F 62 Stomach MALT lymphoma t(11;18)(q21;q21) I Gastrectomy, no 
evidence of lymphoma 
during 3 years follow-
up   
 Cytomplasmic
10 M 71 Stomach MALT lymphoma t(1;14)(p22;q32) IVE Gastrectomy  Strong  nuclear
11 NA NA Lung MALT lymphoma t(1;14)(p22;q32)    Strong  nuclear
12 F 55 Stomach MALT lymphoma t(1;14)(p22;q32)    Strong  nuclear
13 M 67 Stomach MALT lymphoma t(1;2)(p22;q12) IIIE Total gastrectomy Strong  nuclear
14 F 62 Liver MALT lymphoma t(14;18)(q32;q21) I Surgical resection, no 
evidence of lymphoma 
during 6 years follow-
up 
 Strong cytoplasmic
15 F 56 Ocular 
adnexa
MALT lymphoma t(14;18)(q32;q21) I Treated by 
radiotherapy, no 
evidence of lymphoma 
during 10 years follow-
up 
 Strong cytoplasmic
16 M NA Stomach MALT lymphoma Negative      Moderate nuclear
17 M 62 Stomach MALT lymphoma Negative    Moderate nuclear
18 NA NA Stomach MALT lymphoma Negative    Moderate nuclear
19 M 64 Stomach MALT lymphoma Negative    Cytoplasmic
20 M NA Stomach MALT lymphoma Negative    Weak cytoplasmic
21 M 18 Stomach MALT lymphoma Negative    Cytoplasmic
22 M 57 Stomach MALT lymphoma Negative II1 Total gastrectomy CR during 13 year follow up Cytoplasmic
23 F 64 Stomach MALT lymphoma Negative I Total gastrectomy CR during 6 year follow up Cytoplasmic
24 M 50 Stomach MALT lymphoma Negative I Total gastrectomy CR during 2 year follow up Cytoplasmic
25 M 55 Stomach MALT lymphoma Negative    Cytoplasmic
26 NA NA Stomach MALT lymphoma t(3;14)(p14;q32) Cytoplasmic  
CR: complete remission 
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2.1.1.3 Tissue materials for qRT-PCR and immunohistochemistry 
 
For qRT-PCR and immunohistochemical validation of the microarray study, an additional 73 
cases of well-characterised MALT lymphoma were recruited. They included 18 cases 
positive for t(11;18), 8 cases positive for t(1;14) or variant, 9 cases positive for t(14;18), and 
38 cases negative for these translocations. 
 
2.1.2 Reagents 
2.1.2.1 Reagents used in gene expression microarray and qRT-PCR 
 
5x First Strand buffer for double stranded cDNA synthesis (Invitrogen) 
250mM Tris-HCl (pH 8.3), 375mM KCl, 15mM MgCl2 
 
5x Second Strand buffer for double stranded cDNA synthesis (Invitrogen) 
100mM Tris-HCl (pH 6.9), 450mM KCl, 23mM MgCl2, 0.75mM β-NAD+, 50mM 
(NH4)2SO4 
 
5x Fragmentation buffer 
200mM Tris acetate pH 8.2, 500mM potassium acetate, 150mM magnesium acetate 
 
1x Hybridisation buffer 
100mM MES, 1M [Na+], 20mM EDTA, 0.01% Tween20 
 
Hybridisation cocktail per chip 
3nM Control Oligonucleotide B2, Eukaryotic Hybridisation Controls (bioB, bioC, bioD and 
cre, prepared in concentrations of 1.5, 5, 25 and 100pM respectively), 0.1 mg/ml herring 
sperm DNA, 0.5 mg/ml acetylated BSA and 1x Hybridisation buffer to a final volume of 
275µl with ultrapure deionised water 
 
MES (2-(N-Morpholino) ethanesulfonic acid sodium salt) 
To make 12X MES Stock (1.22M MES, 0.89M [Na+]) in 1000 ml, add : 
70.4g MES free acid monohydrate (Sigma) 
193.3g MES Sodium Salt (Sigma) 
800ml of Molecular Biology Grade water 
Mix and adjust volume to 1000ml with DEPC-treated water  
The pH should be between 6.5 and 6.7. Filter through a 0.2 µm filter. 
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Wash buffer 
100mM MES, 0.1M [Na+], 0.01% Tween20 
 
Streptavidin-Phycoerythrin (SAPE) solution per chip 
10µg/ml SAPE stain, 1x MES stain buffer, 2mg/ml acetylated BSA to a final volume of 
600µl with double distilled water 
 
Biotinylated anti-streptavidin per chip 
2mg/ml acetylated BSA, 0.1mg/ml normal goat IgG (Sigma), 0.5mg/ml biotinylated antibody 
(Vector Lab, Burlingane, California, USA), 1x MES stain buffer to a final volume of 600µl 
with double distilled water 
 
2.1.2.2 Reagents used in immunohistochemistry 
 
PBS-Tween 
100μl of Tween 20 (Sigma-Aldrich) was added to 200ml of PBS to give a final concentration 
of 0.05% 
 
Diaminobezidine tetrahydrochloride (DAB) substrate solution (DAKO) 
20μl of Dako REAL DAB Chromogen (Dako Cytomation) was added to 1ml of Dako REAL 
Substrate Buffer (Dako Cytomation) to make the substrate working solution 
 
Diaminobezidine tetrahydrochloride (DAB) substrate solution (Kem-En-Tec) 
This solution was always prepared fresh just before use. One tablet of DAB (Kem-En-Tec, 
Denmark) was dissolved in 10ml of distilled water. 10μl of 30% hydrogen peroxide solution 
was added to the solution just before application 
 
Haematoxylin 
Mayers haematoxylin was filtered and two drops of Tween 20 (Sigma-Aldrich) were added 
per 500ml 
 
Citrate Buffer pH 6.0 
8.82g of sodium citrate tribasic dehydrate (Sigma-Aldrich) were dissolved in 3 litres of 
distilled water and the pH was adjusted to 6.0 with 1M HCl 
 
Peroxidase block solution 
This solution was prepared fresh before use and was composed of 200μl of 30% hydrogen 
peroxide (Sigma-Aldrich) in 12ml of methanol 
 
Tris-buffered saline pH 7.6 (TBS) 
6.05g of Tris (hydroxymethyl) aminomethane (Sigma-Aldrich) and 80g of NaCl were 
dissolved in 8 litres of distilled water, the pH was adjusted to 7.6 with 1M HCl and the 
volume brought up to 10 litres with distilled water 
 
TBS-Tween 
Tween 20 (Sigma-Aldrich) was added to TBS to give a final concentration of 0.05% 
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2.1.2.3 Reagents used in tissue culture 
 
RPMI 1640  10% fetal calf serum (FCS) medium & 10% P/S 
50ml of FCS (Invitrogen) were added to 450ml of RPMI 1640 medium (Invitrogen). When 
culturing BJAB Tet-On and TRex cells, tetracycline (Tet) free FCS was used to prevent 
inadvertent induction of expression. Add penicillin/streptomycin (P/S) to a final 
concentration of 100U/ml penicillin and 100µg/ml streptomycin 
 
10x Phosphate buffered saline (PBS)  
146.6g sodium chloride, 47.2g hydrogen phosphate and 26.4g sodium dihydrogen phosphate 
for 2 litres distilled water – pH 7.2 
 
Freezing medium 
2ml of DMSO were added to 18ml of FCS 
 
 
 
2.1.2.4 Reagents used in Western blotting and co-immunoprecipitation 
 
Triton Lysis Buffer 
5ml of 50mM Tris pH 7.4, 30ml of 300mM NaCl, 10ml of 1% Triton X-100 (Sigma-
Aldrich), and 400μl of 2mM EDTA were added to 100ml with sterile distilled water and 
mixed to make a stock solution. One tablet of Protease Inhibitor Cocktail (Roche, Penzberg, 
Germany) for inhibition of proteases was added to 10 ml of stock solution before use 
 
Protein lysis buffer (2X) 
Lysis buffer was composed of 100mM Tris-HCl (pH8.0), 300mM NaCl, 0.04% sodium 
azide, 0.2% sodium dodecyl sulphate (Sigma-Aldrich), 2% nonidet P-40 (BDH), 1% sodium 
deoxycholate (BDH), 2mM EDTA, 100mg/ml phenylmethylsulfonyl fluoride (Sigma-
Aldrich), and 1mg/ml leupeptin (Sigma-Aldrich) 
 
Sample loading buffer 
4μl of β-mercaptoethanol (BDH) was added to 96μl of 4X NuPAGE LDS Sample Loading 
Buffer (Invitrogen) 
 
Running Buffer 
50ml of 20X NuPAGE Running Buffer (Invitrogen) were added to 950ml of deionised water 
 
Transfer Buffer 
50ml of 20X NuPAGE Transfer Buffer (Invitrogen) and 100ml of methanol were added to 
850ml of deionised water 
 
TBST 
40ml of 1M Tris pH 7.4, 18g of NaCl and 2ml of Tween 20 (Sigma-Aldrich) were made up to 
2 litres with deionised water and mixed 
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4% milk/TBST 
4g of milk powder (Marvel, Premier Foods, UK) dissolved in 100ml of TBST 
 
Stripping buffer 
100ml of 10% SDS (10g in 100ml deionised water) were combined with 31.25ml of 1M Tris-
HCl pH 6.8 and made up to 500ml with deionised water 
 
 
2.1.2.5 Reagents used in cloning and DNA sequencing 
 
LB medium  
Autoclaved Luria-Bertani (LB) medium was provided in-house: 1% sodium chloride, 0.5% 
yeast extract and 1% tryptone (Sigma) 
 
LB agar plates 
15g/L bacteriological agar (Sigma) added to LB medium, autoclaved and poured into 
100*15mm Petri dishes (Sigma)  
 
1x Blue dextran mix 
100mg/ml blue dextran (Sigma), 25mM EDTA  
 
1x Tris-borate-EDTA electrophoresis buffer (TBE) 
89mM Tris base (Sigma), 89mM boric acid (BDH), 2mM EDTA 
 
Gel solution 
To 900ml of Automatrix 4.5% 29:1 acrylamide:bisacrylamide ready made 6M urea gel 
solution  (National Diagnostics, Hull) add 10ml of 1x TBE 
 
2.1.3 Cell lines 
BJAB cells: BJAB is a human Burkitt’s lymphoma cell line and is Epstein-Barr virus (EBV) 
negative (Steinitz et al., 1975). BJAB cells were a kind gift from Dr. Rolf Renne (University 
of Florida Shands Cancer Center, Florida, USA).  
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BJAB-TetON cells: BJAB-TetON cells were a kind gift from Dr. Rolf Renne (University of 
Florida Shands Cancer Center, Florida, USA) (An et al., 2005). Tetracycline free FCS was 
used when carrying out experiments involving inducible expression of the oncogene of 
interest. 
 
T-REx Jurkat cells: Jurkat cells are a human T-cell line derived from a patient with acute 
lymphoblastic leukemia (Schneider et al., 1977). T-REx Jurkat cells (Invitrogen, Paisley, 
UK) stably express the tetracycline repressor protein. Tetracycline free FCS was used when 
carrying out experiments involving inducible expression of the oncogene of interest. 
 
BaF-3 cells: An IL-3-independent clone of this murine pro-B cell line was established from 
the peripheral blood of a BALB/c mouse and was the kind gift of Dr Heike Laman, 
(University of Cambridge, UK). 
 
WEHI cells: Immature murine pro-B cell line established from the peripheral blood of 
BALB/c mouse and was the kind gift of Dr Heike Laman, (University of Cambridge, UK). 
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2.2 Methods 
2.2.1 Overview of the study plan 
Figure 2.1 outlines the study plan in this thesis integrating the investigations using the 
primary lymphoma materials and in vitro cell lines.  
Candidate genes for 
further validation 
RNA extraction from
fresh frozen cases
Gene Expression
Microarray
Validating candidate genes by 
qRT-PCR, IHC and Western 
blotting
RNA extraction  from FFPE cases
Bioinformatics   Analysis
Validation of candidate genes by in 
vitro experiments
Generation of stably 
inducible BCL10, MALT1 
and API2-MALT1 expressing 
cell lines
Preparation of
BCL10, MALT1 and 
API2-MALT1 expression 
vector
Study of their 
cellular 
localisation
Investigating their 
effect on NF-κB 
activation
 
Figure 2.1 - Summary of the study plan. 
 
 
2.2.2 Crude microdissection 
 
4μm sections of FFPE tissue were cut routinely and mounted on charged glass microscope 
slides. Sections were dried overnight at 56°C, deparaffinised in xylene and rehydrated using 
decreasing concentrations of ethanol (100%, 10 minutes; 95%, 5 minutes; 75%, 5 minutes) 
and immersed in distilled water for 5 minutes, and stained in Haematoxylin for 5 seconds. 
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The sections were covered in 50% ethanol and the unwanted tissue was scraped away using a 
needle (Figure 2.2). The selected cell populations were then scraped off the slide into sterile 
1.5ml Eppendorf tubes. The microdissected cells were dried and used for RNA extraction. 
   
(a)          (b) 
 
Figure 2.2 - Crude microdissection of gastric MALT lymphoma. 
(a) Gastric MALT lymphoma with constitutive normal tissues  
(b) Gastric MALT lymphoma after crude microdissection 
 
 
 
2.2.3 RNA preparation 
 
2.2.3.1 RNA extraction from fresh frozen tissue 
 
RNA extraction was carried out using RNeasy Mini kit (Qiagen, East Sussex, UK) 
according to the manufacturer’s instructions.  Briefly, crudely microdissected tumour cells 
from fresh frozen tissue sections (<5 µm) were lysed in 600 µl of RNeasy lysis buffer (Buffer 
RLT) containing 1% β-mercaptoethanol. The crude lysate was homogenised by spinning 
through a QIAshredder column (Qiagen, East Sussex, UK). After addition of absolute 
ethanol, the samples were applied onto an RNeasy spin column.  The column was washed 
with buffers RW1 and RPE before elution with RNase-free water. To remove all traces of 
DNA from the samples, they were treated with Turbo DNAse (Applied Biosystems, 
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Warrington, UK) for 30 minutes at 37°C. The DNAse was inactivated using the supplied 
Inactivation Reagent and the RNA yield was quantified. 
 
2.2.3.2 RNA extraction from formalin fixed paraffin-embedded tissue 
 
This was carried out on microdissected tissue using the Ambion RecoverAll Total Nucleic 
Acid Isolation kit (Applied Biosystems, Warrington, UK) essentially according to the 
manufacturer’s protocol with the exception that the tissue was digested in protease K at 50°C 
for 3.5 hours. 
 
2.2.3.3 RNA extraction from cell lines 
 
Around 7 million cells were centrifuged at 1200rpm for 5 minutes and the resulting pellet 
was resuspended in RLT buffer containing 1% β-mercaptoethanol before application to a 
QIAshredder column. RNA was extracted from cells and the contaminating DNA removed 
using the protocol described in section 2.2.3.1. The RNA quantity and quality were then 
measured (Section 2.2.3.5). 
 
2.2.3.4 RNA linear amplification 
For gene expression microarray using the HG-U133B GeneChips, there was insufficient 
RNA to carry out the hybridisation. Therefore a linear RNA amplification method was 
developed in house and tested with the RNA extracted from fresh frozen tissue. The in house 
method was based on data showing that reverse transcription using random pentadecamer 
primers increases yield and quality of resulting cDNA (Stangegaard et al., 2006) and the use 
of T7 and T3 RNA polymerase can be incorporated into the protocol to generate sense and 
anti-sense RNA (Marko et al., 2005; Xiang et al., 2003). The goal was to develop a strategy 
based upon the Eberwine method (Van Gelder et al., 1990) but with the ability to produce 
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sense RNA from small quantities of total or poly-(A)+ RNA extracted from both ideal 
samples (e.g. cell line RNA) and "real world" samples (e.g. tumours or tissues). This protocol 
avoids the need for PCR steps and requires two primers only. Additionally, the protocol is 
cost effective, efficient, and technically simple to perform. Finally, the method gives results 
consistent with similar amplification techniques when used with subsequent microarray 
analysis. The in house method used a T7 tagged oligo dT primer to generate a double 
stranded cDNA from the 3 prime end, followed by T3 tagged pentadecamer to generate a 
second cycle of double stranded cDNA. This avoided the problems of amplifying degraded 
RNA and allowed small amounts of RNA to be amplified faithfully for expression microarray 
studies. 1ng of total RNA was used to generate around 20µg of amplified anti-sense RNA 
ready to be used for the labelling step before hybridisation to microarray (Section 2.2.4). 
 
2.2.3.5 RNA quantification and quality control 
 
RNA concentration and quality were  assessed spectrophotometrically using the GeneQuant 
Pro (Amersham Pharmacia Biotech, Uppsala, Sweden), and considered to be acceptable for 
further analysis at a concentration of greater than 500ng/µl RNA with an A260/A280 ratio 
between 1.7 and 2.0. For gene expression microarray studies, the RNA quality was assessed 
further by running a 100-300ng aliquot on an Agilent 2100 Bioanalyser (Agilent, Berkshire, 
UK) using Agilent RNA Nano Labchips. RNA extracted from all 26 cases of MALT 
lymphoma for microarray studies was of good quality varying from 1µg to 5µg total RNA 
with an A260/A280 ratio between 1.7 and 2.0. 
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2.2.4 Expression microarray 
 
 
2.2.4.1 Affymetrix HG-U133 GeneChips 
 
Microarray experiments, during the early phase of the study, were carried out on MALT 
lymphoma cases using the HG-U133A and B, while in the latter phase of the study, FL and 
MCL cases were analysed using the updated HG-U133plus2 GeneChips. 
 
2.2.4.2 Preparation of biotinylated cRNA target for Affymetrix GeneChips 
 
Total RNA extracted was used to generate double stranded cDNA which acts as a template to 
generate biotin labelled cRNA that was fragmented using heat and high salt buffer and 
hybridised to the Affymetrix HG-U133 GeneChip as described below (Figure 2.3). 
 
 
Figure 2.3 - Strategy for generating hybridisation target from total RNA. 
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2.2.4.2.1 Double stranded cDNA synthesis 
 
First strand cDNA was synthesised from 5µg RNA using 100 pmol HPLC purified oligo(dT) 
primer conjugated to a T7 promoter (5’-GGC CAG TGA ATT GTA ATA CGA CTC ACT 
ATA GGG AGG CGG (dT)24-3’) (Thermo Scientific, Surrey, UK), hybridised to the poly-A 
tail of the mRNA primer. Samples were incubated at 70°C for 10 minutes to denature the 
secondary RNA structures and placed on ice for the primer to anneal. First strand synthesis 
was performed in a reaction mix containing; 1 First Strand Buffer, 10mM DTT, 500µM 
each dNTP (Invitrogen, Paisley, UK) and 100U Superscript II reverse transcriptase 
(Invitrogen, Paisley, UK) at 42°C for 1 hour.  The samples were incubated on ice for 2 
minutes followed by brief centrifugation. 
The second strand synthesis was carried out in a reaction mixture containing; 1 Second 
Strand Reaction Buffer, 200µM each dNTP, 10U E. coli DNA Ligase, 40U E. coli DNA 
Polymerase I, and 2U E. coli RNase H (Invitrogen, Paisley, UK) at 16oC for 2 hrs. T4 DNA 
Polymerase (Invitrogen, UK) was added at a final concentration of 10U followed by 
incubation at 16oC for a further 5 minutes.  The reaction was terminated by addition of 10µl 
0.5M EDTA, pH 8.0 and the double stranded cDNA immediately purified using the cDNA 
purification columns from the GeneChip sample cleanup module kit (Affymetrix, High 
Wycombe, UK). The purified cDNA was eluted with 12µl of ultrapure water. 
 
2.2.4.2.2 cRNA labelling using IVT (In-Vitro Transcription)  
 
The generation of cRNA target was carried out using the Enzo Bioarray HighYield RNA 
Transcript Labelling Kit (Affymetrix, High Wycombe, UK). The reaction was carried out in a 
40μl mixture containing:  12µl template cDNA from second strand synthesis reaction, 4µl 
10 HY Buffer, 4µl Biotin Labelled Ribonucleotides, 4µl DTT, 4µl RNase Inhibitor Mix, 
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2µl T7 RNA Polymerase, 10µl water at 37°C for 4.5 hours. The cRNA was purified using the 
cRNA purification columns from the GeneChip sample cleanup module kit (Affymetrix, 
High Wycombe, UK). 1µl of each cRNA sample was used to check for sample concentration 
and purity (Section 2.2.3.5) and the remainder stored at –20oC awaiting array hybridisation. 
 
2.2.4.2.3 Fragmentation of cRNA 
 
20µg biotinylated cRNA was fragmented by incubation in fragmentation buffer and RNase 
free water at 94oC for 40 minutes followed by 10 minutes incubation on ice. The fragmented 
cRNA was stored at –20oC until use for hybridisation. 
 
2.2.4.3 Hybridisation to HG-U133 Affymetrix GeneChips and Data Acquisition 
 
2.2.4.3.1 Hybridisation mix preparation 
A hybridisation cocktail was prepared in a microfuge tube by adding reagents at the 
following concentrations; 3nM Control Oligonucleotide B2, Eukaryotic Hybridisation 
Controls (bioB, bioC, bioD and cre, prepared in concentrations of 1.5, 5, 25 and 100pM 
respectively), 0.1 mg/ml herring sperm DNA, 0.5 mg/ml acetylated BSA and 1x hybridisation 
buffer to a final volume of 275µl. 
 
2.2.4.3.2 Hybridisation to HG-U133 GeneChips  
 
The cRNA target samples were hybridised to HG-U133 chips. The chips were pre-
equilibrated with 200µl 1x hybridisation buffer at 45oC for 10 minutes in a GeneChip 450 
Hybridisation Oven (Affymetrix, High Wycombe, UK). The hybridisation cocktail containing 
the biotinylated cRNA was denatured at 99oC for 5 minutes, and transferred to a 45oC heat 
block for 5 minutes to pre-equilibrate before being added to the hybridisation chamber and 
incubated in a 45°C oven for 16 hours with rotation at 60rpm. 
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2.2.4.3.3 Hybridisation to Test3 GeneChip 
A proportion of the biotinylated cRNA target samples was hybridised to Test chips 
(GeneChip Test3 Array) (Affymetrix, High Wycombe, UK) to ensure successful cRNA 
biotin labelling using IVT. This was similarly performed as above, with the exception that 
80µl 1 hybridisation buffer was used for gene chip pre-equilibration, followed by 80µl 
hybridisation cocktail. 
 
2.2.4.3.4 Staining of GeneChips 
Hybridisation cocktail was removed and replaced with a non-stringent wash buffer (6× SSPE, 
0.01% Tween 20). HG-U133A chips were placed in the corresponding slots of the Gene Chip 
Fluidics Station 450 (Affymetrix, High Wycombe, UK) and subjected to the washing and 
staining protocol EukGE WASH-WS2V4_450.  The GeneChips were washed with a series of 
non-stringent and stringent wash buffers. Staining was carried out using the following 
procedure; 40 minutes incubation in Streptavidin-Phycoerythrin (SAPE) solution, then by 20 
minutes incubation with biotinylated anti-streptavidin followed by a final 20 minutes 
incubation in SAPE solution. 
 
2.2.4.4 HG-U133 GeneChip data acquisition and quality control 
Chips were scanned at pixel value 2.5µm, wavelength 570 nm using argon laser Affymetrix 
GeneArray scanner 3000. Data were analysed using Affymetrix MAS and GCOS software. 
The array was inspected manually for image artefacts such as scratches, overall background, 
image intensity fluctuations and intensity of hybridisation controls. A grid was automatically 
placed over the image and correct alignment of grid to image was checked.  The Microarray 
suite (MAS) software (version 5.0) (Affymetrix, High Wycombe, UK) was used to analyse 
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the scanned image and generate transcript expression data.  To allow comparisons between 
samples, a global scaling technique was used to set the average intensity of each probe set 
within the array to a target intensity of 100. 
The quality control of gene expression microarray varies between different studies and 
different platforms. Based on Brune et al. (Brune et al., 2008) and similar papers involving 
human tissue, the following quality control parameters for the HG-U133A and HG-
U133plus2 GeneChips were used; overall background should be less than 130, scaling factor 
should be less than 10, the 5’/3’ ratio of the housekeeping genes β-actin and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) should be less than 4, hybridisation control bioB is 
called ‘present’ by the software at least 50% of the time and bioC, bioD and cre called 
‘present’ with increasing signal values representing their relative concentrations and 
percentage ‘present’ call of genes should be reproducible between tissues and higher than 
20%.  
In this study, the HG-U133B GeneChip samples were processed using RNA linear 
amplification protocol (Section 2.2.3.4) thus the quality control parameters according to (The 
Tumor Analysis Best Practices Working Group, 2004) and (Brune et al., 2008) were as 
follows; overall background should be less than 130, scaling factor should be less than 20, the 
5’/3’ ratio of the housekeeping genes β-actin and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) should be less than 13, hybridisation control bioB is called ‘present’ by the 
software at least 50% of the time and bioC, bioD and cre called ‘present’ with increasing 
signal values representing their relative concentrations and percentage ‘present’ call of genes 
should be reproducible between tissues and higher than 10%.  
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2.2.5 Bioinformatics and statistical analysis of gene expression microarray 
data 
 
In general, bioinformatics analysis of gene expression microarray starts with normalisation 
followed by elimination of non-variant probes. The remaining variant probes are the ones that 
are changing across the samples, and are used for downstream analyses such as unsupervised 
clustering and differential expression analysis. Full bioinformatics comparison of methods 
and strategies are presented in Appendix I. 
 
2.2.5.1 Normalisation 
After testing many different strategies as outlined in Appendix I.I, the best strategy for 
generating variant probes that are differentially expressed between the groups was to 
normalise the array sets using gcRMA and MAS5 and cross reference the probes that passed 
through non-specific filtering based on coefficient of variation and absolute value 
thresholding. Raw gene expression data from Affymetrix CEL files were uploaded to 
bioconductor where MAS5 and gcRMA normalisation were performed separately for each 
Affymetrix platform.  All MAS5 data were scaled to a target intensity of 100. The MAS5 
normalised data was imported into Genespring 7.3.1 where they were log-transformed and 
median centred for further analysis.  For comparison between microarray data obtained from 
HG-U133A&B and HG-U133 plus2 platforms, an additional median polishing normalisation 
step was applied. MAS5 normalised data were used for unsupervised clustering and fold 
change calculations; while gcRMA normalised data were used for gene set enrichment 
analysis (GSEA). Both MAS5 and gcRMA normalised data were subjected to non-specific 
filtering. 
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2.2.5.2 Non-specific filtering 
To filter out non-variant genes, a combination of noise and variance filtering was applied.  To 
filter out non-expressed genes, only probes with a value of 50 or higher in the MAS5 dataset 
in 2 or more samples were selected, since the minimum number of cases with a particular 
translocation, i.e. t(14;18)/IGH-MALT1, was two.   To eliminate non-variant genes, only 
those with a coefficient of variation (CV) value of 10% or higher in the gcRMA dataset 
across all cases were considered to be variant and thus selected.  CV was calculated as the 
mean / standard deviation of each gene across all cases.  Finally, the genes that passed the 
above two filtering methods were intersected to obtain a common set of variant genes.  
For comparison of microarray data between HG-U133A/B and HG-U133 plus2 platform 
where indicated, the non-specific filtering was similarly performed separately for each of 
these platforms as outlined above, then intersected to generate a final common set of variant 
genes.  All the above analyses were carried out using scripts written in R programming 
language (Appendix II.I). The above procedure for analysis of expression microarray data 
from HG-U133A/B and HG-U133 plus2 platform was validated by a serial empirical testing 
using the published pulmonary MALT lymphoma expression microarray data from the HG-
U133 plus2 platform as a reference (Gene Expression Omnibus: GSE13314) (Chng et al., 
2009). 
 
2.2.5.3 Clustering analysis 
The microarray dataset after the above normalisation and filtering was used for unsupervised 
clustering and this was carried out using Pearson correlation coefficient and average linkage 
as the similarity measure and clustering algorithm respectively with Genespring GX 7.3.1.  
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Separate clustering was performed among all MALT lymphoma, FL and MCL cases and also 
within the MALT lymphoma cases. 
 
2.2.5.4 Gene Set Enrichment Analysis (GSEA) 
GSEA was used to identify gene sets differentially regulated between MALT lymphoma with 
and without chromosome translocation and this was performed essentially as previously 
described with minor modification (Subramanian et al., 2005).  As the original GSEA only 
identifies the gene set showing either uniformly up or down regulation, for the gene sets 
displaying both up and down regulated genes, absolute GSEA was additionally performed as 
previously described (Saxena et al., 2006).  A total of 4395 gene sets were analysed and they 
included:  
1) NF-κB target genes, which were collated from online data base (http://www.nf-kb.org), 
published works (http://bioinfo.lifl.fr/NF-KB and http://people.bu.edu/gilmore/nf-
kb/target/index.html) and systematic bioinformatics search 
 
2) Biological pathways involved in inflammatory and immune response from human 
immunome database (http://bioinf.uta.fi/Immunome) (Ortutay et al., 2006; Ortutay et al., 
2009), Gene Ontology (http://wiki.geneontology.org/index.php/Immunology, 
http://www.geneontology.org/GO.immunology.shtml), and Ingenuity 
(http://www.ingenuity.com/) 
 
3) Gene sets from Molecular Signature database 
(http://www.broad.mit.edu/gsea/msigdb/index.jsp).  The GSEA results were ranked according 
to the nominal P value and False Discovery Rate (FDR) 
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For the gene sets differentially regulated between MALT lymphoma with and without 
translocation, leading edge analysis was carried out to identify the biologically important 
gene subset (Subramanian et al., 2005).  For absolute enrichment, a modification on the 
original GSEA was made to extract the leading edge set from either end of the list.  When 
generating gene sets, for each sample, only the maximum expression value of the multi-
probes for a given gene was used for GSEA as described previously (Subramanian et al., 
2005), thus avoiding any potential biased representation due to multiple probes for the same 
gene. 
 
2.2.5.5 Analysis of differential gene expression in MALT lymphomas with and without 
translocation 
 
Differential gene expression between MALT lymphomas with and without chromosome 
translocation was investigated using one-way ANOVA with Cross-Gene Error Model in 
GeneSpring with P value of ≤ 0.05 considered to be significant.   The MAS5 normalised and 
filtered dataset was used for this analysis and the genes differentially expressed between 
translocation positive and negative MALT lymphomas were obtained.  For each of these 
significantly differentially expressed genes, fold change calculation was carried out and those 
showing more than 2 fold differences were selected for functional annotation using gene 
ontology. 
 
2.2.5.6 Functional annotation using gene ontology (GO) 
 
To further assess the biological implications of differential gene expression in MALT 
lymphomas with and without chromosome translocation, we measured the representation of 
gene ontology (GO) terms (association of gene products with regard to their associated 
biological processes, cellular components, and molecular functions) in the above 
 - 87 -  
differentially expressed genes using Genespring and hypergeometric tests provided in the R 
package GOstats, version 2.8.0.  This allowed us to examine whether any GO term was over 
or under-represented as compared to chance variations. Independent analyses of GO 
categories were performed for both over and under-expressed genes in translocation positive 
MALT lymphoma. 
 
2.2.5.7 Phenotypic marker analysis 
 
The 26 MALT lymphoma cases were compared to 14 SMZL, 7 FL, 8 MCL and 22 CLL. All 
expression microarrays were performed in house except for CLL which was from a previous 
study by Calin et al. (Calin et al., 2008) and the raw CEL files downloaded from 
ArrayExpress (http://www.ebi.ac.uk/microarray-as/ae/) using the query “E-MEXP-1482“. 
Normalisation and non-specific filtering was carried out as in sections 2.2.4.1 and 2.2.4.2. 
The 26 MALT lymphoma HG-U133A and HG-U133B and FL, MCL and SMZL HG-
U133plus2 data were normalised separately using RMA algorithm (Irizarry et al., 2003) and 
combined using median polish step. Multivariate one-way ANOVA (Welch test) (using 
GeneSpring 7.3) and Bayesian statistical analysis (using in house R scripts) were carried out 
independently on all 77 lymphoma cases. The data from both algorithms were intersected to 
generate a list of common probes to both analyses. The common probes were subjected to 
SOM and Volcano plot analysis to further filter the gene set. Biological insight, literature 
search and pathway analysis were used to select the most meaningful phenotypic marker for 
the study. 
 
2.2.5.8 Statistical analyses 
 
Fisher’s exact test (“stats Package” in R version 2.8.0) is a non-parametric test used to assess 
the statistical significance of the association between two variables in a 2 by 2 contingency 
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table. The test is specifically adapted for small sample size, including unequally distributed 
data among the cells of the table, unlike a Chi-square test. Thus, it was more robust to 
compare categorical variables from the immunohistochemical staining of each antibody 
among the various MALT lymphomas with different translocation status. 
Student’s t-test is a statistical hypothesis test in which the test statistic follows a Student's t 
distribution if the null hypothesis is supported. It is most commonly applied when the test 
statistic would follow a normal distribution if the value of a scaling term in the test statistic 
were known. It was used to calculate the statistics for comparing reporter assay experiments. 
Mann–Whitney U is a non-parametric test for assessing whether two independent samples of 
observations have equally large values. It is one of the best known non-parametric 
significance tests. It is identical to performing an ordinary parametric two-sample t-test on the 
data after ranking over the combined samples. Thus it was used to compare the qRT-PCR 
data of each transcript between the MALT lymphomas with various translocation statuses. 
In all the above statistical methods, the null hypothesis corresponded to the independence of 
the chosen variables. The null hypothesis was rejected if the probability value of the test of 
association was less than 0.05, meaning the variables were significantly associated. 
 
2.2.6 Quantitative Real-time RT-PCR 
 
2.2.6.1 Primer design 
Primers were designed for RT-PCR to validate the expression of candidate genes obtained 
from expression microarray analysis. All primers were designed using primer3 software 
(http://frodo.wi.mit.edu/primer3) initially and for difficult regions such as GC rich, Oligos 
software (Institute of Biotechnology, Finland) was used. Where possible, primers were 
designed to contain a GC clamp at the 3’ end. All primers were checked for any possible 
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primer dimer formation or self-complementarity and primer sequences were checked using 
BLAST tools (http://www.ncbi.nlm.nih.gov/BLAST) from National Centre for 
Biotechnology Information (NCBI). Details of the primers used for each candidate gene are 
shown in Table 2.2. Where possible, all gene-specific primer pairs were designed to span 
exons in order to make them suitable for degraded paraffin-embedded tissue nucleic acid 
where amplicons of less than 150 base pairs are desired (Liu et al., 2002a). 
 
Table 2.2 - Primers used to investigate candidate genes by qRT-PCR. 
 
Gene name 
 
Exon targets 
 
Primer 
 
Primer sequence 
 
Amplicon 
size 
 
Accession 
Number 
 
18SrRNA N/A Sense    TGACTCAACACGGGAAACC 114bp NR_003286 
 N/A Anti-sense    TCGCTCCACCAACTAAGAAC 
N-MALT1 Exon1 Sense    CTCCGCCTCAGTTGCCTAGA 104bp NM_006785 
 Exon2 Anti-sense    CAACCTTTTTCACCCATTAACTTCA 
BCL10 Exon1 Sense    GAAGTGAAGAAGGACGCCTTAG 80bp NM_003921 
 Exon2 Anti-sense    AGATGATCAAAATGTCTCTCAGC 
NR4A3 Exon6 Sense    TTCCATCAGGTCAAACACTGC 84bp NM_173198 
 Exon7 Anti-sense    AATCCACGAAGGCACTGAAG 
CD86 Exon1 Sense    GGAATGCTGCTGTGCTTATGC 121bp NM_006889 
 Exon2/3 Anti-sense    AGCACCAGAGAGCAGGAAGG 
CD69 Exon2 Sense    CCACCAGTCCCCATTTCTCAA 125bp NM_001781 
 Exon3 Anti-sense    TTGGCCCACTGATAAGGCAAT 
TLR6 Only has  
one exon 
Sense    AACAAGTACCACAAGCTGAAG 100bp 
 
NM_006068 
 Anti-sense    CTCTAATGTTAGCCCAAAAGAG 
CCR5 Exon2 Sense    ATCCGTTCCCCTACAAGAAACTC 100bp NM_000579 
 Exon3 Anti-sense    GCAGGGCTCCGATGTATAATAA 
CCR2A Exon3 Sense    GCGTTTAATCACATTCGAGTGTTT 77bp 
 
NM_001123041 
 Exon3 Anti-sense    CCACTGGCAAATTAGGGAACAA 
BCL2 Exon3 Sense    TTGCTTTACGTGGCCTGTTTC 94bp NM_000633 
Exon3 Anti-sense    GAAGACCCTGAAGGACAGCCAT 
IRF4 Exon7 Sense    GCCCAACAAACTGGAGAGAG 123bp NM_002460 
Exon8 Anti-sense    AAGCATAGAGTCACCTGGAAT 
Lactoferrin Exon1 Sense    GCCACAAAATGCTTCCAATGG 116bp NM_002343 
Exon2 Anti-sense    GCCCTGTTTTCCGCAATGG 
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2.2.6.2 Complementary DNA (cDNA) synthesis 
cDNA was generated using the Superscript III Reverse Transcriptase kit (Invitrogen, Paisley, 
UK) with gene specific primers. Typically, the reaction mixture contained: 1μM of each 
gene-specific anti-sense primer, 1μl of 10mM dNTP, and 200ng of RNA per reverse primer. 
After incubation at 65°C for 5 minutes the following were added: 2μl of 10× RT buffer, 4μl 
of 25mM MgCl2, 2μl of 0.1M DTT, 1μl of RNAse inhibitor and 2U of Superscript III and 
incubated at 50oC for 50 minutes followed by incubation at 85°C for 15 minutes. RNAse H 
was added and the mixture incubated at 37°C for 20 minutes to remove the original RNA. 
 
2.2.6.3 Quantitative PCR (qRT-PCR) 
The expression of each target transcript was normalised against the level of expression of 18S 
rRNA in each case. Real-time PCR was performed using the iCycler IQ system (BioRad, 
Hertfordshire, UK) using SYBR Green I Supermix (BioRad, Hertfordshire, UK). 
The conditions for real-time PCR were optimised prior to result collection. The specificity of 
the primers in producing PCR products was confirmed by melt-curve analysis. The efficiency 
of each primer was designed to be between 95% and 110% by generating standard curves for 
each candidate gene from serial dilutions of cDNA produced from tonsillar RNA. All qRT-
PCR were carried out in triplicate and standard deviation of less than 0.5 was deemed to be 
acceptable. The average correlation coefficient value (R2) for each standard curve was above 
0.99. The slope of the standard curves was used to determine the exponential amplification 
and efficiency of the qPCR reaction by the following equation (Tichopad et al., 2003): 
Efficiency = 10(-1/slope) 
 cDNA was diluted 1/1000 for detection of 18S rRNA as it is highly expressed in most tissues 
(Ye et al., 2005). All samples were amplified by qRT-PCR on 96-well plates in triplicate 
using the following parameters: initial denaturation at 95oC for 3 minutes, followed by 45 
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cycles of denaturation at 95oC for 15 seconds and annealing and extension at 60oC for 1 
minute. To ensure minimal intra-plate variation, a calibrator sample consisting of high and 
low Ct values was used in triplicate on each plate and was used to adjust the Ct. Only those 
samples that showed specific amplification by melt curve analysis were used for data 
analysis. The ΔCt value for each sample was calculated by subtracting the Ct value for 18S 
from that of the target transcripts. The higher the ΔCt value, the lower the expression of a 
transcript and vice versa. For all qRT-PCR, two negative controls were included; a negative 
control of water instead of RNA that goes through the cDNA synthesis and qPCR step and a 
negative control of RNA in the qPCR step to ensure that there is no genomic DNA 
contamination. 
 
2.2.7 Immunohistochemistry 
 
Immunohistochemistry was carried out with the help of Dr. Hongtao Ye, using the protocol 
described below. Paraffin sections (4μm) were deparaffinised in xylene (BDH, Leicestershire, 
UK), rehydrated using decreasing concentrations of ethanol (BDH Leicestershire, UK), and 
incubated in peroxidase blocking solution for 10 minutes to block the endogenous peroxidase 
activity. Antigen retrieval was carried out prior to immunostaining. Antigen retrieval 
conditions and primary antibody dilutions are detailed in Table 2.3. Sections were incubated 
with primary antibody at an optimal dilution for 1 hour followed by biotinylated secondary 
antibody (1:200 – 1:300) and peroxidase conjugated ExtroAvidin (1: 200) for 30 minutes, 
respectively. Finally, the sites of antibody binding were visualised with DAB in H2O2 (Kem-
En-Tec, North Carolina, USA) and counter-stained with Mayer’s haematoxylin. The slides 
were washed in TBS-Tween, three times for 5 minutes each between all incubation steps and 
mounted with cover slips for viewing. 
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Table 2.3 - Immunohistochemistry antibodies and conditions. 
 
Protein Primary antibody Source Antigen retrieval method Conditions for immunohistochemistry or Western blot 
BCL10 
Mouse monoclonal 
antibody to human 
BCL10 (clone 151) 
In house 
Microwave in DAKO target 
retrieval solution pH 6.0 for 25-
35 minutes 
For immunohistochemistry:primary antibody (1/50), 1 hour at RT; 
biotinylated rabbit antimouse antibody, 30 mins at RT;peroxidase-
conjugated extroAvidin, 30 mins at RT. 
MALT1 
Mouse monoclonal 
antibody to human  
C-MALT1 
In house 
Microwave in DAKO target 
retrieval solution pH 9.9 for 25 
minutes 
For immunohistochemistry:primary antibody (1/50), 1 hour at RT; 
biotinylated rabbit antimouse antibody, 30 mins at RT;peroxidase-
conjugated extroAvidin, 30 mins at RT. 
BCL2 Mouse monoclonal antibody Novocastra 
Pressure cooking with citrate 
buffer pH 6.0 for 3 minutes 
For immunohistochemistry: primary antibody (1/120), 1 hr at RT; 
biotinylated rabbit antimouse antibody, 30 mins at RT;peroxidase-
conjugated extroAvidin, 30 mins at RT. 
CD69 Mouse monoclonal antibody NeoMarkers 
Pressure cooking with 1mM 
EDTA for 3 minutes 
For immunohistochemistry: primary antibody (1/20), 1hr at 
RT;followed by polymer amplification system. 
CD86 Sheep CD86 polyclonal antibody R & D 
Pressure cooking with citrate 
buffer pH 6.0 for 3 minutes 
For immunohistochemistry: primary antibody (1/60), 1 hr at RT; 
biotinylated donkey antisheep antibody, 30 mins at RT;peroxidase-
conjugated extroAvidin, 30 mins at RT. 
IRF4 Mouse monoclonal antibody 
Dako 
Cytomation 
Microwave in DAKO target 
retrieval solution pH 9.9 for 25 
minutes 
For immunohistochemistry: primary antibody (1/50), 1 hr at RT; 
biotinylated rabbit antimouse antibody, 30 mins at RT;peroxidase-
conjugated extroAvidin, 30 mins at RT. 
Lactoferrin    Rabbit polyclonal antibody Abcam 
Pressure cooking with citrate 
buffer pH 6.0 for 3 minutes 
For immunohistochemistry: primary antibody (1/50), 1 hr at RT; 
biotinylated rabbit antimouse antibody, 30 mins at RT;peroxidase-
conjugated extroAvidin, 30 mins at RT. 
 
 
 
2.2.8 Expression constructs preparation 
 
2.2.8.1 Modification of pIRES vectors containing HA and FLAG tag sequences 
 
pIRES contains internal ribosome entry site (IRES) of the encephalomyocarditis virus 
(ECMV), which permits the translation of two open reading frames from one mRNA thus 
ensuring that the gene of interest is expressed together with a puromycin antibiotic resistance 
gene in the vector. This reduces the rate of false positives by ensuring that after selection with 
puromycin, nearly all surviving colonies will stably express the gene of interest (Jang et al., 
1988). A forward oligo was designed containing the second half of the NheI restriction site, 
an ATG translation start site and the sequence of the FLAG tag  
 - 93 -  
(5’CTAGCATGGATTACAAGGATGACGACGATAAGG) or HA tag 
(5’CTAGCATGTACCCATACGATGTTCCAGATTACGCTG). A reverse oligo was 
designed containing the first half of the EcoRI restriction site, ATG translation start site and 
the sequence of the FLAG tag (5’AATTCCTTATCGTCGTCATCCTTGTAATCCTAG) or 
HA tag (5’AATTCAGCGTAATCTGGAACATCGTATGGGTACATG). The two oligos for 
each tag were annealed by mixing 1μg of each oligo with 100mM sodium chloride, 10mM 
Tris pH7.5 and 1mM EDTA and boiling for 90 seconds, before being allowed to cool at room 
temperature for 30 minutes. This generated a piece of double stranded sequence containing 
the NheI and EcoRI “sticky ends”. The pIRESpuro2 vector (Clontech Laboratories, UK) 
(Figure 2.4) was digested with NheI and EcoRI. The FLAG or HA tag sequence was ligated 
into the cut vector with T4 DNA ligase (NEB, UK) to generate FLAG and HA tagged 
pIRESpuro which were used to generate constructs to make the stable cell lines as described 
in section 2.2.9. 
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Figure 2.4 -  pIRESpuro vector. 
 
 
 
In order to generate cell lines that mimic the 3 main chromosome translocations; t(11;18), 
t(14;18) and t(1;14) three constructs were prepared, namely HA-tagged BCL10, FLAG-
tagged MALT1 and FLAG-tagged API2-MALT1 (Table 2.4). 
 
 
 
 
 
 
 
 
 
 - 95 -  
Table 2.4 - Primers used in construct preparation. 
 
 
Construct 
 
Primer Sequence (sense and antisense in 5’ to 3’) 
 
BCL10  Lead    EcoRI             BCL10  Exon1 
 TGAT GAATTC       ATGGAGCCCACCGCACCGTCC 
 Lead    NotI                 BCL10  Exon3 
TGAT GCGGCCGC  TCATTGTCGTGAAACAGTACGTG 
 
MALT1 Lead    BamHI             MALT1 Exon1 
TGAT GGATCC        ATGTCGCTGTTGGGGGACCCGCTACAG 
 Lead    NotI                 MALT1 Exon17 
TGAT GCGGCCGC  TCATTTTTCAGAAATTCTGAGCCTGTC 
 
API2-
MALT1 
Lead    EcoRI              API2 Exon1 
TGAT GAATTC        ATGAACATAGTAGAAAACAGCATATTC 
 Lead    NotI                 MALT1 Exon17 
TGAT GCGGCCGC  TCATTTTTCAGAAATTCTGAGCCTGTC 
 
pIRES ATCGATATCTGCGGCCTAGC 
 
 CCAGCACACTGGATCAGTTATC 
 
pTRE2 GGATCCTCTAGTCAGCTGACG 
 TCTAGAGATATCGTCGACAAGC 
 
 
2.2.8.2 Generation of tagged BCL10, MALT1 and API2-MALT1 expression constructs 
 
A standard 25μl PCR reaction was carried out using 2mM MgCl2, 0.2mM of each dNTP, 
0.2μM of each primer and 1 unit of Pfu polymerase (Stratagene, Leicestershire, UK) on a 
Hybaid Px2 thermal cycler (Thermo Scientific, Surrey, UK). The PCR reaction was heated to 
94°C for 2 minutes, followed by 30 cycles of denaturation for 45 seconds at 94°C, primer 
annealing for 45 seconds starting at 55°C and extension for 90 seconds at 72°C with a final 
extension time of 10 minutes at 72°C. PCR products were visualised by electrophoresis using 
1.5% agarose gels. 
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2.2.8.2.1 Preparation of HA-tagged BCL10 
 
The full length cDNA sequence of BCL10 was generated by RT-PCR of a t(1;14) MALT 
lymphoma and sub-cloned into TOPO-TA cloning vector (Invitrogen, Paisley, UK). The full 
length BCL10 cDNA sequence from the TOPO-TA cloning vector was then amplified by 
PCR using Pfu polymerase with sense primer containing an EcoRI site and anti-sense primer 
containing a NotI site. The PCR products were cut with EcoRI and NotI to produce “sticky 
ends” and cleaned by gel extraction using the QIAQuick Gel Extraction Kit (Qiagen, East 
Sussex, UK). The HA-tag containing pIRESpuro2 vector was linearised by PvuI restriction 
followed by EcoRI and NotI restriction and then ligated with the above BCL10 products. The 
vector sequences were checked for absence of mutations and to ensure that the gene of 
interest was in frame by sequencing in both directions. 
 
2.2.8.2.2 Preparation of FLAG-tagged API2-MALT1 and FLAG- tagged MALT1 
 
pcDNA3.1 vectors containing full length MALT1 and full length API2-MALT1 (joining 
nucleotides 1 to 2048 of API2 to nucleotides 814 to 2475 of MALT1 ) (Ho et al., 2005) were 
kindly provided by Dr. Liza Ho, Department of Clinical Pathology, Geneva, Switzerland. 
This API2-MALT1 product represents the most common breakpoint found in 93% of t(11;18) 
MALT lymphomas. Sense primer was designed with the addition of an EcoRI restriction site 
targeting exon1 of the API2 gene while an anti-sense primer was designed with an addition of 
a NotI site targeting exon 17 of the MALT1 gene. For the MALT1 construct, the sense primer 
has a BamHI restriction site targeting exon1 of MALT1 and the anti-sense primer has a NotI 
restriction site targeting exon 17. Both MALT1 and API2-MALT1 sequences were amplified 
by a standard PCR reaction using Pfu polymerase. The PCR products were cut with EcoRI 
(for API2-MALT1) or BamHI (for MALT1) and NotI to produce “sticky ends” and cleaned 
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by gel extraction using the QIAQuick Gel Extraction Kit (Qiagen). The FLAG-tag containing 
pIRESpuro2 vector was cut with EcoRI (API2-MALT1) or BamHI (MALT1) and NotI and 
the MALT1 or API2-MALT1 ligated with the above product using T4 DNA ligase. The 
vector sequences were checked for absence of mutations and to ensure that the gene of 
interest was in frame by sequencing in both directions. 
 
2.2.8.2.3 Sub-cloning of oncogenes into pTRE2 
 
pTRE2 vector (Clontech, Saint-Germain-en-Laye, France) is a response plasmid that can be 
used to express a gene of interest in Clontech’s Tet-On and Tet-Off cell lines. pTRE2 
contains a multiple cloning site (MCS) immediately downstream of the Tet-responsive 
promoter (Figure 2.5). 
 
Figure 2.5 - pTRE vector. 
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cDNA or genes inserted into the MCS will be responsive to the rTA and rtTA regulatory 
proteins in the Tet-Off and Tet-On systems respectively. Phcmv –1 contains the Tet response 
element (TRE), which consists of seven copies of the 42-bp tet operator sequence (tetO). The 
TRE is just upstream of the minimal CMV promoter (Pmin cmv), which lacks the enhancer that 
is part of the complete CMV promoter. Consequently, Phcmv –1 is silent in the absence of 
binding of TetR or rTetR to the TetOs’ sequences. pTRE2 puro and pTRE hygro were used to 
generate inducible BCL10, MALT1 and API2-MALT1 expression cell lines. 
In order to generate the cell lines, each oncogene construct and the pTRE vector was cut 
using NheI and NotI and the insert containing the oncogene in the correct reading frame was 
ligated into the pTRE vector with T4 DNA Ligase. Before transfection to the cell lines the 
vector containing the oncogene of interest was linearised by cutting with PvuI restriction 
enzyme to facilitate its integration into the host genome. 
 
2.2.8.3 Toll-like receptors expression constructs 
 
Toll-like receptor (TLR) 1, 2 and 6 in pFLAG-CMV-1 vector were a kind gift from Dr. 
Koichi Kuwano (Department of Bacteriology, Kurume University, Japan) (Shimizu et al., 
2007). pFLAG-CMV-1 expression vector is used for expression and secretion of N-terminal 
FLAG fusion proteins in mammalian cells, its MCS has preprotrypsin which binds the 
expressed protein to the plasma membrane. All 3 vectors were verified by sequencing from 
both ends using pFLAG-CMV-1 vector primers. 
 
2.2.8.4 DNA Sequencing 
 
The sequencing reaction was carried out according to Hamoudi et al. (Hamoudi et al., 2002) 
using the dRhodamine Dye Terminator Cycle Sequencing Kit (Applied Biosystems, 
Warrington, UK). The sequencing reaction was carried out in a 10μl reaction mixture 
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containing 500ng of plasmid DNA, 4μl dRhodamine, 2μl of 5μM primer and 4μl ultrapure 
water in a thermal cycler (Hybaid Px2 thermal cycler, Thermo Scientific) using the following 
cycling protocol; 96°C for 30 seconds, 50°C for 15 seconds and 60°C for one minute, for 25 
cycles. The products were precipitated with 3 volumes of ethanol and 0.5 volume of 3M 
sodium acetate at pH 5.2. DNA pellets were resuspended in 1µl of denaturing blue dye and 
denatured for 2 minutes at 90°C before loading on polyacrylamide gels (29:1 
acrylamide:bisacrylamide ready made 6M urea) (National Diagnostics, Hull, UK), and 
electrophoresis was carried out using an ABI 377 DNA Sequencer (Applied Biosystems). 
Data was collected via the associated DNA Sequencer Collection software version 2.0 
(Applied Biosystems) and the results were analysed using the BioEdit sequence alignment 
editor version 7 (Ibis Biosciences, California, USA), Sequence Navigator version 1.1 
(Applied Biosystems) and online BLAST tools (http://www.ncbi.nlm.nih.gov/BLAST). 
 
2.2.9 Cell culture 
 
Cells were cultured in RPMI 1640 with 10% Fetal Calf Serum (FCS) and incubated at 37°C, 
5% CO2 in a humidified, automatically controlled incubator. All cells were checked for the 
presence of mycoplasma by PCR using VenorGeM kit (Minverva Biolabs, Germany). 
 
2.2.9.1 Protocol for freezing cells 
 
The cells to be frozen were centrifuged at 1200rpm for 10 minutes and the pellet was 
resuspended in Freezing Medium then transferred to cryotubes (Corning, Dorset, UK). The 
cell suspension was placed at –80°C overnight and then in liquid nitrogen for storage. 
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2.2.9.2 Protocol for thawing cells 
 
The frozen cells were thawed at 37°C for 5 minutes with gentle shaking,  briefly washed with 
8ml of warm culture medium and transferred to a sterile tissue culture flask with appropriate 
culture medium and antibiotics. 
 
2.2.9.3 Cell clot preparation 
 
Around 5 105 cells were centrifuged at 1200rpm for 5 minutes and immediately placed on 
ice. Five drops of plasma were added to the cell pellet followed by gentle vortexing for 10 
seconds. Three drops of thrombin (Diagnostic Reagents Ltd, Oxford, UK) were added and 
mixed using a plastic pipette in order to clot the cells. The clotted cells were transferred to 
Speci-wrap paper, which was folded and placed inside a formalin cassette. The cassette was 
placed inside a formalin jar and left for 4 hours. The samples were processed using a 
Shandon Excelsior machine to generate formalin fixed paraffin embedded blocks. 
 
2.2.9.4 Transient transfection of cells 
 
Baf-3 and WEHI cell lines were transiently transfected. The required number of cells were 
centrifuged to form a pellet and washed in PBS (Invitrogen, Paisley, UK). The clean cell 
pellet was resuspended in 100μl of appropriate Amaxa Cell Line Nucleofector Solution 
(Lonza, Berkshire, UK). The vector DNA was added at a ratio of around 1µg of DNA to 1 
million cells and the cells were transfected using the appropriate programme on a 
Nucleofector I machine (Lonza, Berkshire, UK). The transfected cells were then routinely 
cultured. Nucleofector Solution T with programme T16 was used to transfect BJAB, Jurkat 
T-Rex and Baf-3 cells whereas solution V with programme T30 was used to transfect WEHI 
cells. These conditions were optimized by transfection of pmaxGFP and subsequent analysis 
 - 101 -  
of the transfected cells by Flow cytometry using FACSCalibur flow cytometer (Beckton 
Dickson, Oxford, UK). 
 
2.2.9.5 Generation of stably inducible MALT lymphoma associated oncogenes cells 
 
pTRE-BCL10, pTRE-MALT1, pTRE-API2-MALT1 and pTRE wild type were used to 
generate stable inducible cell lines, whilst pIRESpuro-BCL10 and pIRESpuro wild type were 
used to generate stable cell lines. 20µg of each different construct were linearised by 
digestion with PvuI, purified by phenol/chloroform extraction and resuspended in 20µl of 
sterile water to a final concentration of 1µg/µl. For each transfection, 2 107 of BJAB, 
BJAB-TetON or Jurkat TetON (T-REx) cells were washed with PBS, resuspended in 700µl 
of PBS, mixed with 20µl of the linearised construct and transferred to a 4mm Gene Pulser 
cuvette. After 5-10 minutes on ice, electroporation was carried out using the Gene Pulser 
Apparatus (BioRad) at 250 volts and 950µFD (a time between 15 and 20 milliseconds 
indicates successful electroporation). The samples were incubated on ice for 10 minutes and 
transferred to a Falcon tube containing 20ml of RPMI 1640 medium with 10% FCS, 30% 
conditioned medium containing 1mM sodium pyruvate, 50µM α-thioglycerol and 20nM 
bathocuproindisulfonic acid disodium salt (reagents needed for cell growth and survival) 
(Brielmeier et al., 1998). Various concentrations of transfected cells (1.5 105, 3.75 103 
and 1.25 103 cells) were seeded in 96-well plates for 24 hours in medium containing 4µg/ml 
puromycin. Clones were checked after 10 to 14 days, and transferred to a 24-well culture 
plate, then to a small 10ml flask. The cloned cells were subjected to Western blot analysis to 
check their oncogene expression. Induction of the oncogene expression was carried out by 
adding 1µg/ml of doxycycline. 
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A total of 14 cell lines expressing MALT lymphoma associated oncogenes were generated 
and they included : 
Inducible expression cell lines 
1) BJAB Tet-ON pTREpuro wild type (control) 
2) BJAB Tet-ON pTREpuro FLAG-MALT1 
3) BJAB Tet-ON pTREpuro FLAG-API2-MALT1 
4) BJAB Tet-ON pTREhygro HA-BCL10 
5) BJAB Tet-ON pTREhygro HA-BCL10 and pTREpuro FLAG-MALT1 
6) BJAB Tet-ON pTREhygro HA-BCL10 and pTREpuro FLAG-API2-MALT1 
7) Jurkat Tet-ON (T-REx) pTREpuro wild type (control) 
8) Jurkat Tet-ON (T-REx) pTREpuro FLAG-MALT1 
9) Jurkat Tet-ON (T-REx) pTREpuro FLAG-API2-MALT1 
10) Jurkat Tet-ON (T-REx) pTREhygro HA-BCL10 
11) Jurkat Tet-ON (T-REx) pTREhygro HA-BCL10 and pTREpuro FLAG-MALT1 
12) Jurkat Tet-ON (T-REx) pTREhygro HA-BCL10 and pTREpuro FLAG-API2-MALT1 
 
Stable expression cell lines 
 
13) pIRESpuro wild type (control) 
14) pIRESpuro HA-BCL10 
 
 
 
2.2.10 Protein analysis 
 
 
2.2.10.1 Protein extraction from whole cell lysate 
 
Cells were harvested by centrifugation and cell pellets were washed twice in 1×PBS then 
lysed in Triton Lysis Buffer, on ice for 30 minutes. The cell lysate was centrifuged at 
7300rpm for 20 minutes at 4°C, and the supernatant was transferred to a new tube and 
quantified (2.2.10.4). Samples were stored at -80°C until required. 
 
2.2.10.2 Preparation of protein homogenate from frozen tissue 
 
Frozen tissue sections were homogenised in Triton lysis buffer by gentle pipetting at 4°C for 
30 minutes. The lysate was centrifuged at 7300rpm for 20 minutes at 4°C and the supernatant 
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was transferred to a new tube and quantified as described in 2.2.10.4. Samples were stored at 
-80°C until required. 
 
2.2.10.3 Protein extraction from nuclear and cytoplasmic fractions 
 
Preparation of nuclear and cytoplasmic protein extracts from cells was carried using CelLytic 
NuCLEAR Extraction kit (Sigma, Dorset, UK) according to the manufacturer’s instructions. 
The procedure for nuclear protein extraction is to allow cells to swell with hypotonic buffer. 
The cells are then disrupted and cytoplasmic fraction is removed, and the nuclear proteins are 
released from the nuclei by a high salt buffer. 
 
2.2.10.4 Protein quantitation 
 
The concentrations of extracted proteins were measured using the Quant-iT Protein Assay kit 
(Invitrogen, Paisley, UK) according to the manufacturer’s instructions with the Victor 3 
illuminometer (Perkin Elmer, Warrington, UK). 
 
2.2.10.5 Antibodies used for functional and cellular work 
 
Monoclonal and polyclonal antibodies used in the functional studies described in this thesis 
are shown in Table 2.5. 
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Table 2.5 - Primary and secondary antibodies used in co-immunoprecipitation and Western 
blotting. 
 
Antibody Source 
(Part No.) 
Dilution Application 
 
Type 
 
Host species and 
(primary/secondary) 
C-MALT In-house  1:500 Co-IP and 
Western 
blotting 
Monoclonal Mouse - primary 
BCL10 In-house 1:10,000 Co-IP and 
Western 
blotting 
Monoclonal Mouse - primary 
HA Sigma-Aldrich 
(H9658) 
1:10,000 Western 
blotting 
Monoclonal Mouse - primary 
FLAG Sigma-Aldrich 
(F3165) 
1:10,000 Western 
blotting 
Monoclonal Mouse - primary 
β-actin Sigma-Aldrich 
(A5441) 
1:1,000,000 Western 
blotting 
Monoclonal Mouse - primary 
TLR6 Abcam 
(ab62569) 
1:10,000 Western 
blotting 
Polyclonal Rabbit - primary 
IκBβ Cell Signaling 
Technology  
(9248) 
1:20,000 Western 
blotting 
Polyclonal Rabbit - primary 
IκBα Santa Cruz 
Biotechnology  
(sc-203) 
1:10,000 Western 
blotting 
Polyclonal Rabbit - primary 
IκBε Cell Signaling 
Technology  
(9249) 
1:10,000 Western 
blotting 
Polyclonal Rabbit - primary 
p65 Santa Cruz 
Biotechnology  
(sc-7151) 
1:10,000 Western 
blotting 
Polyclonal Rabbit - primary 
p50/p105 Santa Cruz 
Biotechnology  
(sc-7178) 
1:10,000 Western 
blotting 
Polyclonal Rabbit - primary 
p100/p52  Cell Signaling 
Technology  
(3017) 
1:10,000 Western 
blotting 
Monoclonal Rabbit - primary 
c-Rel Cell Signaling 
Technology  
(4727) 
1:10,000 Western 
blotting 
Polyclonal Rabbit - primary 
RelB Cell Signaling 
Technology 
(4954) 
1:10,000 Western 
blotting 
Polyclonal Rabbit - primary 
CD3 eBioscience 
(16-0037) 
1:10,000 Western 
blotting 
Monoclonal Mouse - primary 
CD28 Sigma-Aldrich 
(C7831) 
1:10,000 Western 
blotting 
Monoclonal Mouse - primary 
Donkey anti-
rabbit HRP-
conjugated 
GE Healthcare 
(NA934) 
1:20,000 Western 
blotting 
Not applicable Donkey - secondary 
Sheep anti-
mouse HRP-
conjugated 
GE Healthcare 
(NA931) 
1:20,000 Western 
blotting 
Not applicable Sheep - secondary 
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2.2.10.6 Western blot 
 
Protein lysates were mixed with 4X NuPAGE (Invitrogen, Paisley, UK) loading buffer 
containing 4% β-mercaptoethanol (BDH, Leicestershire, UK), heated to 99oC for 5 minutes 
and left on ice for 2 minutes then separated on NuPAGE gels (Invitrogen, Paisley, UK) by 
electrophoresis at 120V for 90 minutes using SeeBlue size standard (Invitrogen, Paisley, 
UK). 
The proteins were transferred to an Immobilon-P Transfer Membrane (Millipore Corporation, 
Bedford, USA) using XCell II Blot Module (Invitrogen, Paisley, UK) running at 30V for 90 
minutes. 
The membrane was first placed in TBST for 10 minutes followed by 4% milk/TBST for 1 
hour whilst shaking to block non-specific binding then probed with primary antibody in 4% 
milk/TBST with 10% FCS overnight at 4°C. After washing in TBST, the membrane was 
incubated with an anti-species specific (according to Table 2.5) Horseradish Peroxidase 
(HRP)-conjugated secondary antibody in 4% milk/TBST for a minimum of 1 hour at room 
temperature. Finally, the protein was detected by the addition of an Immobilon HRP 
Substrate Peroxide Solution (Millipore Corporation, Watford, UK) and Immobilon HRP 
Substrate Luminol Reagent (Millipore Corporation, Watford, UK) for 5 minutes. The HRP 
chemiluminescent reaction resulted in the catalysed oxidation of luminol by peroxide. 
Oxidised luminol emits light as it decays. The chemiluminescence was detected by exposing 
an X-ray film to the membrane. 
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2.2.10.7 Stripping of Western blot 
 
Bound antibody was removed from membranes by immersion in Stripping Buffer at 62oC for 
2 hours, washed in TBST and placed in 4% milk/TBST for 1 hour, then probed and detected 
with the appropriate antibodies (Table 2.5) as described in section 2.2.10.6. The loading 
control antibody, β-actin was used on stripped blots. Also in section 5.4.5, IκBα were 
stripped and re-probed with IκBβ which was stripped and re-probed with β-actin. 
 
2.2.10.8 Co-immunoprecipitation 
 
Co-immunoprecipitation was carried out using the Anti-HA immunoprecipitation kit (Sigma, 
Dorset, UK) according to the manufacturer’s instructions. Some of the immunoprecipitated 
protein was then subjected to silver staining using the ProteoSilver Stain kit (Sigma, Dorset, 
UK) and dried for long term storage using the DryEase kit (Invitrogent, Paisley, UK) 
according to the manufacturer’s instructions. 
 
2.2.11  Dual luciferase reporter assays 
 
 
2.2.11.1 NF-κB luciferase reporter assay 
 
NF-κB activity was measured in tissue culture cells using the Dual Luciferase Reporter Assay 
System (Promega, Southampton, UK). Cells were resuspended in Nucleofector Solution 
(Lonza, Berkshire, UK) and transfected with the pRL-TK (Promega, Southampton, UK) and 
pNF-κB-luc (Stratagene, Leicestershire, UK) reporter vectors, in combination with a pIRES 
vector containing the oncogene of interest or the pIRES control vector by electroporation or 
using an inducible stable cell using the Amaxa Nucleofector I machine (Lonza, Berkshire, 
UK). Luciferase is expressed from pNF-κB-luc after binding of NF-κB subunits to the vector. 
pRL-TK contains a cDNA encoding Renilla luciferase which was used as a control for 
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normalisation of the data. These cells were incubated at 37°C and 5% CO2 overnight and then 
stimulated as follows : 
1) BaF3 cells with 10μg/ml LPS (Sigma, Dorset, UK) for 6 hours 
2) Jurkat cells with 1μg/ml anti-CD3 (Sigma, Dorset, UK) and 1μg/ml anti-CD28 (Sigma, 
Dorset, UK) for 6 hours. For TLRs experiments, cells were stimulated with 10µg/ml LPS 
(Sigma, Dorset, UK) for 6 hours 
 
3) WEHI cells with 10µg/ml LPS (Sigma, Dorset, UK) for 6 hours or 0.1µg/ml CD40 
ligand (with 1µg/ml CD40 enhancer) or 10µg/ml anti-IgM 
 
The cells were centrifuged to form a pellet and washed in 1X PBS before resuspension in 1X 
Passive Lysis Buffer (Promega, Southampton, UK). The cell suspension was rotated for 30 
minutes to allow the cells to lyse completely. 15μl of whole cell extract was added to 45μl of 
Luciferase Assay Reagent 2 (LAR) (Promega, Southampton, UK) and the level of 
fluorescence produced by the firefly luciferase was detected with the Victor 3 luminometer 
(Perkin Elmer, Warrington, UK). The reaction was stopped with the addition of 45μl of Stop 
and Glo (Promega, Southampton, UK) and the fluorescence level produced by the Renilla 
luciferase was measured by the luminometer. The reading for firefly luciferase divided by the 
reading for Renilla luciferase gave the NF-κB activity. 
 
2.2.11.2 AP-1 luciferase reporter assay 
 
AP-1 activity was measured in transiently transfected BJAB cells using the Dual Luciferase 
Reporter Assay System (Promega) similar to that described for NF-κB luciferase reporter 
assay in section 2.2.11.1. The AP-1 vector used was the AP-1 cis-Reporting system 
(Stratagene, Leicestershire, UK). pRL-TK was used as the normalisation vector. 
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CHAPTER 3 – Characterisation of the gene 
expression profiles of MALT lymphoma with and 
without chromosome translocation 
 
3.1 Introduction 
As detailed in chapter 1, t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/IGH-BCL10 and 
t(14;18)(q32;q21)/IGH-MALT1 are specifically associated with MALT lymphoma, occurring 
at variable frequencies in different anatomic sites.  Although these translocations involve 
different oncogenes, their resultant oncogenic products commonly target the canonical NF-
κB activation pathway.  Expression of API2-MALT1, BCL10 and MALT1 (in the presence 
of BCL10) induces the activation of the NF-κB transcriptional factor, which transactivates a 
number of genes important for cellular proliferation and survival.  The capacity of these 
oncogenic products to activate NF-κB is believed to be the crucial molecular mechanism 
underlying their oncogenic activity. Nonetheless, over-expression of these oncogenic 
products alone is insufficient for malignant transformation as both Eµ-API2-MALT1 and Eµ-
BCL10 transgenic mice developed splenic marginal zone hyperplasia, but not lymphoma 
(Morris, 2001; Sagaert et al., 2006b; Li et al., 2009). In vitro assay showed that expression of 
both API2-MALT1 and MALT1 enhanced by the CD40 induced NF-κB activation in B cells 
(Ho et al., 2005). It is possible that such immunological stimulation is operational in MALT 
lymphoma. The extent and the nature of potential cooperation between MALT lymphoma 
associated oncogenic products and immune surface receptor signalling remain to be 
investigated. 
There are important differences in the clinical and histological presentations between MALT 
lymphomas with and without chromosome translocation.  Clinically, gastric MALT 
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lymphomas with t(11;18) or t(1;14) are significantly associated with advanced clinical stages 
(Liu et al., 2001b; Ye et al., 2006) and resistance to H. pylori eradication (Isaacson et al., 
2004; Liu et al., 2001a; Liu et al., 2002b; Ye et al., 2006). Histologically, t(11;18) positive 
MALT lymphomas appear to be more monotonous, lacking apparent transformed blasts 
(Okabe et al., 2003). These distinct clinico-pathological characteristics indicate the presence 
of significant differences in molecular mechanisms between MALT lymphomas with and 
without chromosome translocation.  In order to investigate this and understand further the 
molecular mechanism of MALT lymphomagenesis, the transcriptional profiles of a well 
characterised series of MALT lymphomas with different chromosome translocation status 
were determined. 
 
 
3.2 Aims of the study 
 
1) To characterise gene expression profiling of MALT lymphoma with and without 
chromosome translocation 
 
2) To identify the molecular mechanisms involved in translocation positive MALT 
lymphoma 
 
3) To identify the molecular mechanisms involved in translocation negative MALT 
lymphoma 
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3.3 Experimental design 
 
3.3.1  Case  selection 
 
Fresh frozen tissues from 24 well-characterised MALT lymphomas (case numbers 1 to 24 in 
Table 2.1), 7 nodal follicular lymphomas (FL) and 8 nodal mantle cell lymphomas (MCL) 
were used for this part of the gene expression microarray analysis.  The MALT lymphoma 
cases included 9 positive for t(11;18)(q21;q21)/API2-MALT1 (8 from stomach and 1 from 
lung), 4 positive for t(1;14)(p22;q32)/BCL10-IGH or t(1;2)(p22;p11)/BCL10-IGκ (3 from 
stomach and 1 from lung), 2 positive for t(14;18)(q32;q21)/IGH-MALT1 (1 from liver and 1 
from ocular adnexa) and 9 cases negative for all known MALT lymphoma associated 
chromosome translocations (all from stomach with two having nuclear BCL10 staining).  
MALT lymphomas case number 25 was excluded from the analysis due to the fact that it was 
a mixture of MALT and diffuse large B-cell lymphoma and case number 26 was excluded 
due to the fact that it is the only fresh frozen case of t(3;14(p14;q32)/IGH-FOXP1 and a 
minimum of two cases are needed to obtain useful mechanistic information. However both 
cases were included in the phenotypic marker analysis carried out as described in chapter 6. 
The percentage of tumour cells are estimated on haematoxylin & eosin stained sections and 
where necessary, crude microdissection was carried out to enrich tumour cells and ensure that 
a sample containing at least 70% tumour cells was used for expression microarray analysis. 
 
3.3.2 RNA quality check using Agilent nanochip 
 
Total RNA, complementary RNA and fragmented RNA were subjected to quality control 
assessment using the Agilent nanochip. The criteria for passing the quality control were as 
follows: for total RNA both the 18S and 28S bands should be around 2000 and 4000bp 
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respectively, for cRNA the mean of the size distribution should be around 1000bp and for 
fragmented RNA, the mean of the size distribution should be around 60 to 100bp. 
 
3.3.3 Validation of the in house linear RNA amplification protocol 
 
To validate the fidelity of the linear amplification protocol developed in house, RNA from a 
fresh frozen tissue specimen of a t(11;18) positive MALT lymphoma was amplified, then 
labelled and hybridised to HG-U133A chip according to the method described in section 
2.2.5. Pearson correlation comparing the values of all 22283 probes from the amplified RNA 
and total RNA of HG-U133A GeneChip from the same case was carried out. 
 
3.3.4 Unsupervised clustering analysis 
 
After normalisation and non-specific filtering, the 24 MALT lymphoma cases derived from 
HG-U133A and HG-U133B, 7 FL and 8 MCL on the HG-U133plus2 platform were 
subjected to unsupervised clustering using Pearson correlation coefficient and average 
linkage as the similarity measure and clustering algorithm respectively within Genespring 
GX 7.3.1. Unsupervised clustering was also carried out within the MALT lymphoma group to 
investigate whether there are distinct subsets. 
 
3.3.5 Characterisation of gene expression features of MALT lymphoma 
with and without chromosome translocation 
 
Normalisation followed by non-specific filtering was used to derive set of variant probes 
which were collapsed and used in interrogating 4395 pathways using GSEA (Section 2.2.5.4). 
The same set of probes was subjected to one-way ANOVA multivariate analysis to derive a 
set of differentially expressed genes between MALT lymphoma with and without 
chromosomal translocation (Section 2.2.5.5). The differentially expressed genes were 
subjected to Gene Ontology (GO) analysis using hypergeometric testing (Section 2.2.5.6). 
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Results from both GSEA and GO analysis were compared to characterise the features of 
MALT lymphoma with and without translocation. 
3.4 Results 
Details of the bioinformatics analysis including choice of algorithms and software are given 
in Appendix I. In this section, results of the analysis of gene expression microarray of MALT 
lymphoma are presented. 
3.4.1 RNA quality control 
 
In each case the total RNA, complimentary RNA and fragmented RNA were of good quality 
as shown by electrophoresis on RNA nanochip (Figure 3.1). 
 
Figure 3.1 - Typical good quality data of total, complementary and fragment RNA on RNA 
nanochip. 
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3.4.2 Comparison of  total RNA with amplified RNA  
 
 
Total RNA and linearly amplified RNA from the same t(11;18) positive MALT lymphoma 
fresh frozen specimen were hybridised on a HG-U133A GeneChip. The Pearson correlation 
coefficient (R2) between the two RNA preparations was 97.2% with p < 0.001 (Figure 3.2), 
indicating that linearly amplified RNA faithfully amplifies the same distribution of the 
starting total RNA. 
 
 
 
Figure 3.2 - Correlation between total and amplified RNA from the same fresh frozen specimen 
of t(11;18) positive MALT lymphoma. 
Red line is the line of best fit through the points with a correlation coefficient of  97.2%. 
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3.4.3 Validation of microarray data using biological controls 
 
As expected, the hybridisation signal of the N-terminal MALT1 probe was the highest in the 
two cases of t(14;18) positive MALT lymphoma, whereas the signals of two C-terminal 
MALT1 probes were much higher in the cases with t(11;18) than those with t(1;14) or 
without translocation (Figure 3.3). Cyclin D1 was highly expressed in MCL, while CD10 and 
BCL6 showed the highest expression in FL. The CD10 expression in MALT lymphoma was 
low, suggesting the presence of minimal reactive B cells components in the fresh frozen 
materials used for expression microarray. Despite the fact that BCL2 t(14;18)(q32;q21)/IgH-
BCL2 translocation is the genetic hallmark of follicular lymphoma, it was not in the hallmark 
genes probably because BCL2 was shown to be highly expressed in translocation positive 
MALT lymphomas (Section 3.4.6.1). Overall, the expected results from the biological 
controls indicated that the labelling, hybridisation and basic bioinformatics analysis were 
successfully carried out. 
 
 
Figure 3.3 - Expression of hallmark genes in MALT lymphoma, FL and MCL. 
Correlation of known expression levels of genes with different lymphoma types. N-MALT1 probe (210017_at) detects only 
wild type MALT1 transcripts, while C-MALT (210018_x_at & 208309_s_at) probes detect both MALT1 and API2-MALT1 
transcripts. The chromosome translocation status of MALT lymphoma is indicated by colour. On the heatmap, red represents 
up-regulated genes and green down-regulated genes, with the scale showed at the bottom of the figure. 
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3.4.4 Unsupervised clustering between MALT, MCL and FL defines 
MALT lymphoma as a distinct entity 
 
The methodology used to combine MALT lymphoma HG-U133A with FL and MCL HG-
U133plus2 is summarised (Figure 3.4). 
gcRMA and MAS5 normalisation
Per Gene and Per Chip
Eliminate invariants by passing through
probes > 50 absolute value of MAS5
Eliminate invariants by passing through
probes > 10% CV (SD/Mean) of gcRMA 
Eliminate all Affymetrix 
housekeeping probes
A Chip 22283
A Chip 16481
A Chip 7819
A Chip 7793
gcRMA and MAS5 normalisation
Per Gene and Per Chip
Eliminate invariants by passing through
probes > 50 absolute value of MAS5
Eliminate invariants by passing through
probes > 10% CV (SD/Mean) of gcRMA
Eliminate all Affymetrix 
housekeeping probes
U133 plus2 Chip  54675
U133 plus2 Chip  20203
U133 plus2 Chip  10817
U133 plus2 Chip  10776
A Chip 3715
B Chip 3107
Median polish
transformation
B Chip 22645
B Chip 20439
B Chip 9097
B Chip 9065 Median polish
transformation
Total Probes for unsupervised 
clustering are : 6822  
 
 
Figure 3.4 - Summary of bioinformatics strategy to combine FL and MCL with MALT 
microarray GeneChips. 
Normalisation is followed by non-specific filtering and exclusion of housekeeping probes for both U133AB and 
U133plus2. The probes from the two platforms are combined using median polish transformation and the probes 
used for unsupervised clustering. 
 
Analysis of HG-U133A and B and plus2 were done separately then a median polish step was 
used to normalise the data from the two different platforms giving rise to 6822 probes. These 
were used for unsupervised clustering of the 24 MALT lymphomas, 7 follicular lymphoma 
(FL) and 8 mantle cell lymphoma (MCL). 
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Figure 3.5 - MALT lymphoma shows distinct gene expression profiles from follicular lymphoma 
and mantle cell lymphoma using unsupervised hierarchical clustering. 
After normalisation and filtering across both U133A&B and U133plus2 sets, a set of 6822 probes were obtained 
and used for unsupervised hierarchical clustering analysis. FL: follicular lymphoma; MCL: mantle cell 
lymphoma; NEG: translocation negative MALT lymphoma. The chromosome translocation status of MALT 
lymphoma, FL and MCL are indicated by colour. On the heatmap, red represents up-regulated genes and green 
down-regulated genes, with the scale shown at the bottom of the figure. 
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MALT lymphomas were clustered as a single branch, irrespective of their origin from 
different anatomic sites or chromosome translocation. Within the MALT lymphoma group, 
the chromosome translocation status appeared to have little impact on the hierarchical 
clustering as translocation positive MALT lymphomas were intermingled with translocation 
negative cases (Figure 3.5). The two translocation negative cases with BCL10 nuclear 
staining clustered together (Figure 3.5). 
In order to derive the functional groups in Figure 3.5, the gene tree was ordered according to 
biological processes defined by gene ontology, and the gene clusters enriched for a particular 
biological process in a lymphoma subtype as shown by hypergeometric testing as  indicated.  
The gene sets for cell cycle (GO:7049) and regulation of progression through cell cycle 
(GO:74) were highly enriched in MCL, while those for immune response (GO:6955) and 
immune response to biotic stimulus (GO:9607) were enriched in FL. The gene sets for 
immune response to external biotic stimulus such as pest, pathogen or parasite (GO:9613) 
and cellular defence response (GO:6968) were highly enriched in MALT lymphoma. 
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3.4.5 Unsupervised clustering confirms overlapping features in gene 
expression profiling between MALT lymphoma with and without 
chromosome translocation 
 
The strategy used to compare MALT lymphoma with and without translocation is 
summarised in Figure 3.6. 
Unsupervised clustering for pattern 
detection
Candidate genes for further 
validation 
gcRMA and MAS5 normalisation
Per Gene and Per Chip
Eliminate invariants by passing through
probes > 50 absolute value of MAS5
Eliminate invariants by passing 
through probes > 10% CV 
(SD/Mean) of gcRMA 
Eliminate all Affymetrix 
housekeeping  probes
Differentially expressed genes 
using multivariate statistics. 
Supervised clustering
A Chip 22283
A Chip 7793
B Chip 22645
A Chip 16481
A Chip 7819
B Chip 20439
B Chip 9097
B Chip 9065
Advanced Pathway analysis, 
GO hypergeometric test and 
GSEA 
In house 
software 
Database
qRT-PCR and IHC validation on 
73 MALT lymphomas
Combine A&B platform and carry out 
further non-specific filtering on the 16858 
probes from A&B chips
8107 probes
from A&B
B Chip 9065
A Chip 7793
 
 
Figure 3.6 - Summary of bioinformatics strategy used to compare MALT lymphoma with and 
without chromosome translocations. 
Normalisation is followed by non-specific filtering and exclusion of housekeeping probes. The probe sets were 
used to determine differentially expressed genes using multivariate analysis, this is followed by pathway 
analysis using GSEa and GO and in house datamining. Candidates form this analysis were validated further by 
qRT-PCR and immunohistochemistry (IHC). 
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Figure 3.7 - Unsupervised hierarchical clustering of MALT lymphoma with different 
translocation status. 
After normalisation and filtering, a set of 8107 probes were obtained and used for unsupervised hierarchical 
clustering analysis.  MALT lymphomas with and without chromosome translocation are intermingled together. 
The chromosome translocation status of MALT lymphoma is indicated by different colour scheme. On the 
heatmap, red represents up-regulated genes and green down-regulated genes, with the scale shown at the bottom 
of the figure. 
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The result of unsupervised clustering of MALT lymphoma cases again showed that the 
chromosome translocation status had little impact on the hierarchical clustering as 
translocation positive MALT lymphoma cases were intermingled with translocation negative 
cases (Figure 3.7). The results suggest an overlap in gene expression profile and hence 
molecular mechanisms between MALT lymphoma with and without chromosome 
translocation. The clustering showed that the two translocation negative cases with BCL10 
nuclear staining clustered together with a group consisting of predominantly translocation 
positive MALT lymphomas (Figure 3.7). In order to investigate this further, supervised 
clustering with 733 probes was carried out on the four t(1;14) and nine translocation negative 
cases including two with nuclear BCL10 staining. The 733 probes were derived by applying 
one-way ANOVA multivariate analysis across MALT lymphoma with and without 
translocation groups to the 8107 probes obtained after normalisation and non-specific 
filtering. The two translocation negative MALT lymphomas with nuclear BCL10 expression 
still clustered with the four cases with t(1;14) (Figure 3.8). 
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Figure 3.8. Supervised hierarchical clustering of MALT lymphoma with different translocation 
status. 
After normalisation and filtering, a set of 733 probes were obtained and used for supervised hierarchical 
clustering analysis.  MALT lymphoma cases without chromosome translocation but with nuclear BCL10 
staining are clustering with t(1;14) positive cases. The chromosome translocation status of MALT lymphoma is 
indicated by different colour scheme. On the heatmap, red represents up-regulated genes and green down-
regulated genes, with the scale shown at the bottom of the figure.  
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3.4.6 Characterisation of the gene expression profiles of MALT lymphoma 
with and without chromosome translocation 
 
To gain further insights into the potential difference in molecular mechanisms between 
MALT lymphomas with and without chromosome translocation, GSEA and absolute GSEA 
were performed on 4395 gene sets covering various cellular pathways, biological processes 
or molecular functions derived from in house analysis and molecular signature database 
(Subramanian et al., 2005) as described in Appendix I.III. Results of GSEA was cross 
validated using GO hypergeometric testing as described in section 2.2.5.6. Summary of the 
methodology used for GSEA (Figure 3.9). 
Map the genes from both U133A 
and U133B to the RMA normalised 
data from both platforms
gcRMA and MAS5 normalisation
Per Gene and Per Chip
Eliminate invariants by passing through
probes > 50 absolute value of MAS5
Eliminate invariants by passing 
through probes > 10% CV 
(SD/Mean) of gcRMA 
Eliminate all Affymetrix 
housekeeping  probes
A Chip 22283
A Chip 7793
B Chip 22645
A Chip 16481
A Chip 7819
B Chip 20439
B Chip 9097
B Chip 9065
Reformat the data to use as the 
DataSet
Expression
DataSet
Collapse data set by   taking the maximum
Data across multiple  probes for the same sample 
GeneSet
e.g. NFkB 
inducible genes
Phenotype
e.g. Translocation 
status
GSEA
10050 Genes dervied  from A&B chips
 
Figure 3.9 - Summary of bioinformatics strategy used for GSEA on MALT lymphoma with and 
without chromosome translocation. 
Normalisation is followed by non-specific filtering and exclusion of housekeeping probes. The probes were then 
combined and mapped to the RMA normalised data. The probes are collapsed and used as an expression dataset 
in GSEA together with the relevant geneset and phenotype. 
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GSEA identified a total of 51 gene sets (not including those with very general terms) with a 
statistical significance (P<0.05 and FDR<0.05) and were thus differentially over-represented 
between MALT lymphomas with and without translocation.  Remarkably, the NF-κB target 
gene signature was the most differentially enriched gene set (p < 0.0001 and FDR < 0.0001) 
(Table 3.1). 
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Table 3.1 - Gene sets differentially over-represented between MALT lymphoma with and 
without chromosome translocation. 
 
Gene Set Size Source ES Norm ES 
Nominal P 
value FDR q value 
FWER P 
value Tag % Gene % 
NF-κB related           
NF-κB target genes 167 Appendix III.I for details 0.531 1.826 0.0001 0.0001 0.0000 0.455 0.249 
positive regulation of IKK and NF-κB cascade 62 GO_0043123 0.466 1.541 0.0088 0.0446 0.1235 0.274 0.157 
Inflammation and immune responses          
Inflammation 73 Immunome database 0.590 1.865 0.0000 0.0065 0.0076 0.548 0.257 
Cellular cation homeostasis 56 GO:0030003 0.519 1.842 0.0000 0.0116 0.0710 0.429 0.264 
Inflammatory response  166 GO_0006954 0.530 1.775 0.0022 0.0116 0.0128 0.482 0.267 
Response to other organism 47 GO:0051707 0.575 1.829 0.0000 0.0124 0.0840 0.404 0.183 
Locomotory behaviour 54 GO:0007626 0.601 1.800 0.0000 0.0153 0.1210 0.556 0.257 
Chemokine 128 Immunome database 0.510 1.725 0.0022 0.0163 0.0293 0.367 0.175 
Immune responses 119 GO_0006955 0.517 1.648 0.0067 0.0185 0.0266 0.429 0.259 
Defence response 135 GO:0006952 0.511 1.757 0.0000 0.0210 0.1870 0.467 0.274 
B-cell activation  26 GO_0042113 0.623 1.779 0.0000 0.0222 0.0117 0.423 0.152 
Innate immune response  52 GO_0045087 0.506 1.595 0.0065 0.0311 0.0724 0.519 0.301 
Cell adhesion molecules 86 HSA04514 0.456 1.812 0.0000 0.0321 0.0480 0.326 0.209 
Lymphocyte activation 77 GO_0046649 0.525 1.647 0.0292 0.0322 0.0501 0.338 0.152 
Response to biotic stimulus 71 GO:0009607 0.507 1.687 0.0000 0.0378 0.3500 0.423 0.262 
Cellular homeostasis  74 GO:0019725 0.448 1.692 0.0000 0.0380 0.3310 0.351 0.264 
HumoralImmunity 65 Immunome database 0.545 1.526 0.0550 0.0395 0.1312 0.477 0.257 
Inflammatory response 66 GO:0006954 0.534 1.662 0.0065 0.0420 0.4020 0.455 0.274 
TLR sigalling pathway from GeneGo 33 GeneGO database 0.520 1.616 0.0088 0.0421 0.0674 0.606 0.366 
Cellular immunity 47 Immunome database 0.542 1.537 0.0214 0.0456 0.1269 0.489 0.262 
Chemokine  29 GO_0042379 0.638 1.519 0.0338 0.0463 0.1438 0.655 0.257 
Cell adhesion  50 GO:0016337 0.483 1.634 0.0058 0.0482 0.4860 0.42 0.259 
MAPK pathway realted          
Rceptor signalling protein activity 54 GO:0005057 0.529 2.061 0.0000 0.0015 0.0010 0.574 0.355 
Regulation of MAP kinase activity  41 GO:0043405 0.493 1.979 0.0000 0.0026 0.0140 0.537 0.292 
Regulation of protein kinase activity 95 GO:0045859 0.455 1.894 0.0000 0.0066 0.0340 0.453 0.316 
Regulation of kinase activity  96 GO:0043549 0.450 1.875 0.0000 0.0079 0.0420 0.448 0.316 
Activation of MAPK activity 22 GO:0000187 0.549 1.845 0.0020 0.0118 0.0690 0.591 0.287 
MAPKKK cascade 61 GO:0000165 0.443 1.847 0.0000 0.0121 0.0660 0.623 0.44 
Transmembrane receptor protein tyrosine kinase signalling pathway 48 GO:0007169 0.465 1.832 0.0000 0.0125 0.0820 0.354 0.213 
JNK cascade 28 GO:0007254 0.444 1.727 0.0000 0.0282 0.2550 0.5 0.343 
MAPK signalling pathway 152 HSA04010 0.442 1.826 0.0000 0.0383 0.0380 0.467 0.343 
G protein coupled receptor protein signalling pathway 125 GO:0007186 0.424 1.670 0.0061 0.0412 0.3870 0.32 0.256 
Protein kinase cascade 184 GO:0007243 0.421 1.672 0.0021 0.0414 0.3830 0.413 0.317 
JAK STAT cascade 20 GO:0007259 0.559 1.661 0.0151 0.0419 0.4070 0.55 0.3 
Peptide GPCRS 25 C2 genmapp 0.609 1.829 0.0020 0.0457 0.0200 0.32 0.107 
G protein signalling coupled to cyclic nucleotide second messenger 36 GO:0007187 0.502 1.644 0.0083 0.0475 0.4560 0.278 0.154 
Cell cycle related           
Regulation of cell growth 29 GO:0001558 0.632 2.014 0.0000 0.0013 0.0060 0.448 0.205 
Negative regulation of growth 24 GO:0045926 0.681 2.019 0.0000 0.0016 0.0060 0.458 0.183 
Positive regulation of cell proliferation 87 GO:0008284 0.500 1.958 0.0000 0.0027 0.0140 0.483 0.308 
Regulation of cell proliferation 179 GO:0042127 0.465 1.813 0.0000 0.0136 0.1030 0.43 0.308 
Negative regulation of cell cycle 49 GO:0045786 0.548 1.690 0.0000 0.0370 0.3380 0.51 0.282 
Cell cycle arrest 36 GO:0007050 0.564 1.640 0.0022 0.0480 0.4680 0.472 0.223 
Others          
Cation homeostasis 57 GO:0055080 0.509 1.820 0.0000 0.0131 0.0970 0.421 0.264 
Reproductive process 59 GO:0022414 0.516 1.803 0.0000 0.0150 0.1150 0.424 0.257 
Ion homeostasis 63 GO:0050801. 0.481 1.748 0.0021 0.0218 0.2010 0.54 0.377 
mitochondrion organization and biogenesis 30 GO:0007005 0.551 1.690 0.0000 0.0376 0.3360 0.4 0.23 
Positive regulation of transcription 80 GO:0045941 0.414 1.681 0.0000 0.0379 0.3620 0.325 0.282 
Angiogenesis 22 GO:0001525 0.563 1.648 0.0206 0.0474 0.4400 0.364 0.137 
Cyclic nucleotide mediated signalling 36 GO:0019935 0.502 1.644 0.0083 0.0475 0.4560 0.278 0.154 
Protein processing 26 GO:0016485 0.511 1.642 0.0019 0.0475 0.4600 0.385 0.26 
Carbohydrate biosynthetic process 20 GO:0016051 0.542 1.636 0.0200 0.0484 0.4810 0.45 0.294 
 
ES: Enrichment score;  Norm ES:  Normalised ES;  FDR: False discovery rate;  FWER: Family wise-error rate;   Tag%: the percentage of gene tags before (for 
positive ES) or after (for negative ES) the peak in the running enrichment score; Gene %: the percentage of genes in the gene list before (for positive ES) or after 
(for negative ES) the peak in the running enrichment score. 
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3.4.6.1 NF-κB target genes are significantly differentially expressed between MALT 
lymphoma with and without chromosome translocation 
 
GSEA showed that the expression of the NF-κB target genes was enhanced in both 
translocation positive and negative cases but with a different signature for each group.  A 
subset of the NF-κB target genes was over-represented in translocation positive MALT 
lymphomas, while another subset was enriched in translocation negative MALT lymphomas.  
Leading edge analysis showed that 20 core genes accounted for the significant enrichment in 
translocation positive MALT lymphomas including CCR2A, BCL2, TFEC, CD69, BCL10, 
TLR6, REL, LTB, IRF4, CCR7, CCR5 and MAP4K1 (Figure 3.10A). Similarly, 70 core genes 
underscored the significant enrichment in translocation negative MALT lymphomas and 
CXCL5, PTGIS2, NR4A3, CCL11, PTGIS, IL8, MMP3, CXCL2, CXCL1 and CD86 were the 
top 10 of this biologically significant gene subset (Figure 3.10A). The differential expression 
of these genes was clearly seen in the heatmap illustration of Figure 3.10A. 
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NF-κB target genes
P < 0.0001
FDR < 0.0001
P < 0.0007
FDR < 0.018
 
 
Figure 3.10 - Gene set enrichment analysis (GSEA) of NF-κB target genes in MALT lymphomas 
with and without chromosome translocation. 
(A) NF-κB target genes and (B) Immune response set.  
Left panel shows the distribution of NF-κB target genes according to their rank position. Right panel shows 
heatmap illustration of their expression between MALT lymphoma with and without chromosome translocation.   
The top 20 leading edge core genes are shown. trans -ve: translocation negative MALT lymphoma; trans +ve: 
translocation positive MALT lymphoma. 
3.4.6.2 Other gene sets differentially enriched between MALT lymphoma with and without 
chromosome translocation 
 
As there was considerable overlap among some of the gene sets that were associated with the 
related cellular pathways, biological processes or molecular functions, they were grouped 
according to their involvement in the NF-κB activation pathway, inflammation/immune 
responses, MAPK pathways, cell cycle and others as shown in Table 3.1. Leading edge 
analysis was carried out to identify the core subset genes that underscored the significant 
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enrichment and were thus most likely to be biologically important. The NF-κB target genes 
were frequently represented in each of these core subset genes, often on top end of the list 
particularly in the gene sets related to inflammation/immune responses (Figure 3.11). 
 
 
 
Figure 3.11 - Presence of high proportion of NF-κB target genes in the leading edge core set of 
various gene sets related to inflammation and immune responses. 
 
Leading edge analysis of the positive regulation NF-κB cascade group (GO:43123) shows 
CD40 as one of the leading edge genes enriched in translocation positive MALT lymphoma 
and leading edge analysis of immune response genes (GO:6955) (Figure 3.10B) shows CD1D 
enriched in the translocation positive MALT lymphoma group. 
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3.4.6.3 Gene Ontology annotations of genes differentially expressed between MALT 
lymphoma with and without chromosome translocation confirms findings by GSEA 
 
The strategy for analysis of differentially expressed genes between MALT lymphoma with 
and without chromosome translocation by Gene Ontology (GO) annotation is shown in 
Figure 3.12. 
Apply one way ANOVA with error model to 
obtain list of the genes significantly expressed 
between translocation positive and negative 
MALT lymphoma
Carry out Gene Ontology analysis using hypergeometric 
test to determine which of the GO terms are significantly
over represented in the translocation groups.
Do this for : 
1) Biological Process
2) Molecular Function
3) Cellular Component
gcRMA and MAS5 normalisation
Per Gene and Per Chip
Eliminate invariants by passing 
through probes > 50 absolute 
value of MAS5
Eliminate invariants by passing 
through probes > 10% CV 
(SD/Mean) of gcRMA 
Eliminate all Affymetrix 
housekeeping  probes
A Chip 22283
A Chip 7793
A Chip 16481
A Chip 7819
Map the probes to the MAS5 
normalised data from all the genes
Calculate the Fold Change by averaging the 
raw MAS5 values from each set and filtering 
the data on 2 fold change
 
 
 
Figure 3.12 - Summary of bioinformatics strategy used for Gene Ontology analysis on MALT 
lymphoma with and without chromosome translocation. 
After normalisation and non-specific filtering, the data is mapped to MAS5 normalised values and a one-way 
ANOVA was applied to it and reduced further by calculated fold change. The final probes are entered into GO 
to obtain any relevant pathways. 
 
To gain further insights into the molecular pathways affected by the oncogenic products of 
MALT lymphoma associated chromosome translocations, genes that were significantly over 
or under-expressed in translocation positive MALT lymphoma in comparison with 
translocation negative cases were identified using the one-way ANOVA test. These 
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differentially expressed genes were further filtered using 2-fold change as a threshold. Ninety 
six genes were over-expressed in translocation positive MALT lymphoma, while 174 genes 
were under-expressed in these cases, i.e. over-expressed in translocation negative cases. 
TLR6, CCR2, BCL2, CD1D and CD69 identified by GSEA were most highly expressed in 
translocation positive MALT lymphoma, and conversely IL8, NR4A3 and CXCL5 were on 
the most highly expressed in translocation negative MALT lymphoma as shown in Table 
(Appendix III.II).  
To further assess the biological implications of the differential gene expression in MALT 
lymphoma with and without chromosome translocation, the representation of gene ontology 
(GO) terms in the above gene sets that were over or under-represented in translocation 
positive MALT lymphoma were measured using hypergeometric tests (Falcon et al., 2007).  
Among the genes over-expressed in translocation positive MALT lymphoma, the GO terms 
relating to NF-κB pathway activation, defense/immune responses and CCR signalling were 
significantly over-represented (Table 3.2). While among the genes under-expressed in 
translocation positive MALT lymphoma, i.e. over-expressed in translocation negative cases, 
the GO terms relating to chemotaxis, inflammatory response and CCR signalling were 
significantly over-represented (Table 3.2). These findings from the analysis of differentially 
expressed genes between MALT lymphomas with and without chromosome translocation 
reinforce the GSEA results described in sections 3.2.6.1 and 3.2.6.2.   
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Table 3.2 - Representation of gene ontology terms in over-expressed genes in MALT lymphoma 
with and without chromosome translocation. 
 
 
Gene ontology term GO category Genes in Category 
% of 
Genes in 
Category 
Genes in 
List in 
Category 
% of 
Genes in 
List in 
Category 
P value 
Gene ontology term over-represented in translocation posittive MALT lymphoma 
GO:6952: defense response Biological process 1306 8.029 17 23.61 4.18E-05 
GO:9607: response to biotic stimulus Biological process 1361 8.367 17 23.61 7.02E-05 
GO:7243: protein kinase cascade Biological process 474 2.914 8 11.11 0.00114 
GO:7249: I-kappaB kinase/NF-kappaB cascade Biological process 181 1.113 5 6.944 0.00124 
GO:48522: positive regulation of cellular process Biological process 881 5.416 11 15.28 0.00161 
GO:48518: positive regulation of biological process Biological process 1028 6.32 12 16.67 0.00173 
GO:6955: immune response Biological process 1187 7.297 13 18.06 0.00193 
GO:42981: regulation of apoptosis Biological process 525 3.227 8 11.11 0.00218 
GO:43067: regulation of programmed cell death Biological process 531 3.264 8 11.11 0.00234 
GO:7250: activation of NF-kappaB-inducing kinase Biological process 17 0.105 2 2.778 0.00252 
GO:43123: positive regulation of I-kappaB kinase/NF-kappaB cascade Biological process 133 0.818 4 5.556 0.00286 
GO:43122: regulation of I-kappaB kinase/NF-kappaB cascade Biological process 141 0.867 4 5.556 0.00353 
GO:16493: C-C chemokine receptor activity Molecular function 22 0.128 2 2.857 3.58E-03 
GO:19957: C-C chemokine binding Molecular function 22 0.128 2 2.857 3.58E-03 
GO:4197: cystene-type endopeptidase activity Molecular function 155 0.901 4 5.714 3.67E-03 
Gene ontology term over-represented in translocation negative MALT lymphoma 
GO:46870: cadmium ion binding Molecular function 10 0.0582 5 3.378 1.07E-08 
GO:1664: G-protein-coupled receptor binding Molecular function 67 0.39 7 4.73 1.71E-06 
GO:5507: copper ion binding Molecular function 79 0.459 7 4.73 5.24E-06 
GO:42379: chemokine receptor binding Molecular function 58 0.337 6 4.054 1.03E-05 
GO:8009: chemokine activity Molecular function 58 0.337 6 4.054 1.03E-05 
GO:5102: receptor binding Molecular function 902 5.246 21 14.19 3.05E-05 
GO:42330: taxis Biological process 160 0.984 8 5.882 5.96E-05 
GO:6935: chemotaxis Biological process 160 0.984 8 5.882 5.96E-05 
GO:7155: cell adhesion Biological process 978 6.012 21 15.44 6.11E-05 
GO:6954: inflammatory response Biological process 263 1.617 10 7.353 7.33E-05 
GO:6817: phosphate transport Biological process 124 0.762 7 5.147 8.17E-05 
GO:9611: response to wounding Biological process 568 3.492 15 11.03 8.17E-05 
GO:7610: behaviour Biological process 465 2.859 13 9.559 1.43E-04 
GO:4295: trypsin activity Molecular function 14 0.0814 3 2.027 2.12E-04 
GO:5125: cytokine activity Molecular function 295 1.716 10 6.757 2.41E-04 
 
Category:  the name of the category within the ontology;   Genes in Category:  the total number of genes in the 
genome that have been assigned to the category;  % of Genes in Category:  the percentage of genes in this 
category assigned to this GO term;  Genes in List in Category: the total number of genes that are present both in 
the selected gene list and in the category;  % of Genes in List in Category: the percentage of genes of this 
category in the selected gene list that are assigned to this GO  term;   P-value (hypergeometric p-value) : this is a 
measure of the statistical significance of the overlap. i.e. the likelihood that it is a coincidence that this many 
genes were in both the gene list and the category.  Only the top 15 are shown. 
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3.4.7 Pathway analysis of molecules identified by gene expression 
microarray and potentially important in MALT lymphoma pathogenesis  
 
Basic pathway analysis was carried out to investigate the pathways linked to the molecules 
derived from the microarray analysis. 
For translocation positive MALT lymphoma, immune receptor molecules were TLR6, CD69 
and CD1D, chemokine receptors were CCR2, CXCR4, CCR5, CCR6 and CCR7 and the 
apoptosis inhibitor BCL2. For translocation negative MALT lymphoma, pro-inflammatory 
cytokines were IL8 and IL1B and co-stimulatory molecules were CD86, CD28 and ICOS. 
MALT lymphoma with and without translocation were analysed separately using Ingenuity 
Pathway Analysis.  
A 
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B 
 
 
 
Figure 3.13 - Pathway analysis of molecules derived from MALT lymphoma microarray 
analysis.  
Pathway analysis of molecules involved in (A) translocation negative MALT lymphoma and (B) translocation 
positive MALT lymphoma. The molecules highlighted with grey colour are derived from expression microarray 
results. A solid line indicates a direct interaction while a dashed line indicates an indirect interaction. 
 
Pathway analysis is highly dependent on existing literature knowledge and experimental data. 
There is not much understood about the mechanism of translocation positive MALT 
lymphoma, interestingly the pathway analysis showed a possible link to the JAK3 and 
STAT5 pathway most likely via NF-κB inducible genes (Figure 3.13B). However, 
translocation negative MALT lymphoma molecules also show involvement of the NF-κB 
pathway especially via IL8, IL1B and CD86 as shown in (Figure 3.13A). 
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3.5 Discussion 
 
 
By investigating the transcriptional profile, the present study demonstrated that MALT 
lymphoma is characterised by a distinct expression profile in comparison with FL and MCL, 
in line with the recent study by Chng et al. (Chng et al., 2009). Although there was 
considerable overlap in the gene expression profiles between MALT lymphomas with and 
without chromosome translocation as demonstrated by unsupervised clustering analyses, 
there were important differences in the expression of NF-κB target genes between these 
subgroups. Systematic GSEA of various molecular pathways and biological processes, 
showed that the NF-κB target genes are the most differentially over-represented gene set 
between MALT lymphomas with and without chromosome translocation, followed by those 
related to inflammation, cellular homeostasis and immune responses. Importantly, several of 
these molecular pathways or biological processes also lead to NF-κB activation. These 
findings were confirmed by independent analyses of differentially expressed genes between 
MALT lymphomas with and without chromosome translocation using hypergeometric tests 
of Gene Ontology groups.  Our observations provide several novel insights into the molecular 
mechanisms of both translocation positive and negative MALT lymphomas that potentially 
explain their different clinical and histological presentations.  
 
3.5.1 Molecular mechanism of translocation positive MALT lymphoma 
 
In comparison with translocation negative MALT lymphoma, GSEA and leading edge 
analysis revealed a common core subset genes that were enriched and over-expressed in 
translocation positive MALT lymphoma and a high proportion of these genes are NF-κB 
target genes involving multiple related biological processes or molecular pathways. The most 
 - 134 -  
significant ones included immune receptors such as TLR6, TLR7, CD40, CD83, CD1D and 
CD69, chemokine receptors such as CCR2, CXCR4, CCR6 and CCR7, the apoptosis 
inhibitor BCL2, positive regulators of the NF-κB pathway such as REL (a component of NF-
κB transcription factor), LTβ (a powerful proinflammatory cytokine) and molecules involved 
in MAPK pathways (Figure 3.10). All these molecules are involved in promoting tumour cell 
survival and proliferation either directly or indirectly.  Among these, the over-expression of 
the above immune surface receptors is particularly interesting as this enhances the interaction 
between tumour cells and their microenvironment, which is known to be critical for MALT 
lymphoma development.  
For example, TLRs are innate immune receptors critical for recognising the conserved 
microbial structures known as pathogen associated molecular patterns (PAMP), and are 
capable of activating the NF-κB pathway (Shimizu et al., 2007). CD40, CD83 and CD69 are 
activation markers and co-stimulating molecules which are also likely to play a role in NF-κB 
activation. BCL2 is a classic apoptosis inhibitor, and may account for the prolonged survival 
of tumour cells. 
The expression of these molecules was thus further investigated in independent cohorts of 
MALT lymphomas and discussed in the next chapter. 
 
3.5.2 Molecular mechanism of translocation negative MALT lymphoma 
In contrast to translocation positive MALT lymphoma, translocation negative cases were 
characterised by expression of a strong inflammatory gene signature. GSEA and leading edge 
analysis also revealed common core subset genes involving several related biological 
processes or molecular pathways, which were enriched and over-expressed in translocation 
negative MALT lymphoma. These included pro-inflammatory cytokines such IL8, IL1β and 
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LTA, molecules involved in B- and T- cell interaction such as CD86, CD28 and ICOS, 
several chemokine and chemokine receptors, TLR2 and NR4A3 (also known as MINOR, or 
NOR1) (Figure 3.10).  
IL8, IL1β and LTA are the hallmark of a pro-inflammatory cytokine profile in response to H. 
pylori infection.  IL8 is critical for neutrophil infiltration and activation, while IL1β and LTA 
induce gastrin release, inhibit acid secretion and promotes apoptosis of epithelial cells, thus 
affecting H. pylori colonisation (McNamara et al., 2008).  The finding of up-regulation of 
these pro-inflammatory cytokines in translocation negative MALT lymphomas, all from the 
stomach, indicates the presence of active H. pylori infection.  In line with this, the expression 
of a number of chemokines and chemokine receptors was enriched in translocation negative 
gastric MALT lymphoma.  This may reflect the trafficking and retention of various immune 
cells in response to an active H. pylori infection.  In keeping with this, translocation negative 
gastric MALT lymphomas show more frequently an increased number of blast cells than 
translocation positive cases (Okabe et al., 2003). 
Most importantly, GSEA showed that the expression of the surface molecules involved in B- 
and T- cell interaction, namely CD86, CD28 and ICOS was enriched in translocation 
negative gastric MALT lymphoma, and this was accompanied by unregulated IL10 
expression, a well known outcome of ICOS stimulation (van Berkel et al., 2006). 
 
3.5.3 Nuclear BCL10 
Both supervised and unsupervised clustering analysis showed that translocation negative 
MALT lymphoma cases with nuclear BCL10 staining clustered together with cases 
harbouring t(1;14)/BCL10-IGH (Figure 3.8). It was recently demonstrated that nuclear 
expression of BCL10 is significantly associated with resistance to gastric MALT lymphoma 
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to H. pylori eradication (Kuo et al., 2004). In ocular adnexal MALT lymphoma, nuclear 
BCL10 seemed to correlate with a shorter treatment failure-free survival (Franco et al., 
2006), although this could not be confirmed by other groups (Vejabhuti et al., 2005). 
Gallardo et al. (Gallardo et al., 2006) found a significant association between nuclear BCL10 
expression and a higher risk of extra-cutaneous involvement in primary cutaneous marginal 
zone B-cell lymphoma, whereas Li et al. (Li et al., 2003) reported that nuclear BCL10 was 
associated with the development of a locally aggressive course. Based on these observations, 
a role for nuclear BCL10 in lymphomagenesis is suggested, although the precise pathological 
significance remains unclear. Based on its interaction with transcription factor IIB and its 
ability to activate transcription as a fusion protein linked to the Gal4-DNA-binding domain in 
HeLa cells, Liu et al. (Liu et al., 2004d) suggested a role for BCL10 as a transcriptional 
activator, whereas Yeh et al. (Yeh et al., 2006) found nuclear BCL10 to be involved in the 
transcriptional activity of NF-κB following TNF-α signalling in MCF7 cells. The current 
microarray analysis further enforces a role for nuclear BCL10 in the development of MALT 
lymphoma. However, further functional studies on the role of BCL10 in the nucleus are 
needed to determine which pathways and interacting molecules are involved. 
 
3.5.4 Summary and conclusion 
In summary, gene expression microarray studies showed that MALT lymphoma is a distinct 
entity, but with overlapping gene expression signatures between MALT lymphoma with and 
without chromosomal translocation. In both supervised and unsupervised clustering analysis, 
translocation negative MALT lymphoma with nuclear BCL10 expression clustered with 
translocation positive MALT lymphoma cases suggesting a role of nuclear BCL10 in MALT 
lymphomagenesis. Gene set enrichment analysis and Gene Ontology hypergeometric 
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analysis, showed differences in the molecular pathways involved in MALT lymphoma with 
and without chromosome translocation. Many of these differences were attributed to different 
involvement of the of NF-κB target genes. Leading edge analysis identified a number of 
important molecules that are potentially important for the pathogenesis of MALT lymphoma 
with or without chromosome translocation which will be investigated and discussed in the 
next chapter. 
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CHAPTER 4 – Validation of the genes identified by 
expression microarray of MALT lymphoma with 
and without chromosome translocation using  
qRT-PCR and immunohistochemistry 
 
 
4.1 Introduction 
Gene expression microarray study of MALT lymphoma with and without chromosome 
translocation identified a number of genes preferentially over-expressed in either subset 
(Chapter 3). Translocation positive MALT lymphomas were highly enriched in the 
expression of CD69, CCR2A, CCR5, TLR6, BCL2 and IRF4 (also known as MUM1) in 
addition to the already characterised genes BCL10, specific to t(1;14), and MALT1 specific to 
t(11;18) and t(14;18). In contrast, translocation negative MALT lymphomas were highly 
enriched in the expression of CD86 and NR4A3. The differential expression of these 
molecules was thought to play an important role in the pathogenesis of the respective MALT 
lymphoma subgroups. Thus, it was necessary to validate further their differential expression 
in MALT lymphomas with and without chromosome translocation in independent cohorts by 
qRT-PCR and immunohistochemistry and Western blotting. 
 
 
4.2 Aims of the study 
 
To validate the molecules derived from gene expression microarray studies in a large cohort 
of MALT lymphoma specimens using qRT-PCR and immunohistochemistry or Western 
blotting and to correlate the transcript and protein expression with the chromosomal 
translocation status. 
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4.3 Experimental design 
 
4.3.1  Case selection 
 
A total of 73 cases of MALT lymphoma with known translocation status were investigated. 
These included 8 cases with t(1;14), 18 cases with t(11;18), 9 cases with t(14;18), 38 cases 
without MALT lymphoma associated chromosomal translocations including 10 with nuclear 
and 28 with cytoplasmic BCL10 expression. These MALT lymphomas originated from the 
stomach (48), liver (2), ocular adnexa (4), small intestine (4) and lung (15).  
 
4.3.2 Validation of gene expression by qRT-PCR 
 
The mRNA expression level of the genes differentially expressed between MALT 
lymphomas with and without chromosome translocation (CD69, CCR2A, CCR5, TLR6, 
BCL2, IRF4, CD86, NR4A3, BCL10 and N-terminal part of MALT1) was investigated by 
qRT-PCR. RNA was extracted from microdissected tumour cells of FFPE MALT lymphoma 
specimens and treated with Turbo DNAse to remove genomic DNA (Section 2.2.3.1). Where 
possible, primer pairs were designed to span exons to prevent amplification of any residual 
genomic DNA and to target up to 150bp (Table 2.2) (Section 2.2.6.1), and were thus suitable 
for FFPE tissues. This was the case for all genes except TLR6 which had only one coding 
exon and CCR2A which shared the sequence with CCR2B except for a small region. For 
those two primer pairs within exons, the negative control of the RNA that has undergone 
Turbo DNAase was checked to confirm the amplification was that of the cDNA rather than 
genomic DNA. All primers were checked on tonsillar RNA to ensure that they gave specific 
PCR products and ran on gels to ensure they amplified the expected size. The results are 
presented as ∆CT values calculated as (∆CT = TReference Gene – TTest Gene), so the higher the 
value, the lower the transcript expression and vice versa. Unsupervised clustering on subset 
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of the genes across all samples using Ward similarity measure and average linkage was 
carried out to determine the discriminatory power of those genes on the MALT lymphoma 
cases. Both BCL2 and IRF4 were excluded from clustering as their qRT-PCR was carried out 
on a smaller cohort of MALT lymphomas (25 and 24 cases respectively) due to lack of 
sufficient tissue in the remaining MALT lymphomas. 
The results of the qRT-PCR were correlated with the known chromosomal translocation 
established by conventional cytogenetics, interphase FISH and RT-PCR, as described in 
Chapter 3. The Mann-Whitney U Test determined whether there were statistically significant 
differences in the expression of particular transcripts between groups of cases with different 
chromosome translocation status.  
 
4.3.3 BCL2, CD69, IRF4, MALT1, BCL10 and CD86 
immunohistochemistry 
 
Immunohistochemistry was carried out by Dr. Hongtao Ye on all cases using the BCL2, 
CD69, IRF4 and CD86 antibodies. Data on BCL10 and MALT1 expression from same cases 
of MALT lymphoma subgroups was obtained from a previous immunohistochemistry based 
study (Ye et al., 2005) (Figure 1.6). The immunohistochemical conditions, including antigen 
retrieval, antibody dilution and incubation times, were systematically optimised as described 
in Chapter 2 (Table 2.3). The immunostaining was evaluated independently by two assessors 
(Professor Ming Du and Dr. Hongtao Ye) and scored according to the percentage of positive 
cells in a section (<30%, 30-70%, >70%) and the intensity of staining (weak, moderate, 
strong). Mr. Rifat Hamoudi helped in section cutting, slide preparation, scoring of 
immunohistochemistry under the guidance of Dr. Hongtao Ye, collation of the 
immunohistochemical data and analysis. Cases were considered positive if 30% or more 
tumour cells were stained. Cases with scoring discrepancies between the assessors were 
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reviewed. The results of the immunostaining were then correlated with the known 
chromosome translocation status as determined by qRT-PCR and interphase FISH (detailed 
in Chapter 3). Differences in the proportion of cases staining positive for each of the six 
proteins across the different chromosome translocation groups were assessed by the Fisher’s 
exact test. 
 
4.3.4 Validation of TLR6 using Western blotting 
Imunohistochemistry of TLR6 antibody did not yield satisfactory results thus, western 
blotting was carried out using the TLR6 antibody on 5 fresh frozen t(11;18) positive and 9 
translocation negative MALT lymphoma cases with one FL case and one Jurkat cell line used 
as control. Protein extraction and Western blotting were carried out as detailed in Chapter 2. 
The filter was stripped and re-probed with β-actin used as a loading control, followed by 
stripping and re-probing with MALT1 (97 kD) as an integrity control to ensure all archival 
samples used were adequate for investigation using TLR6 (92 kD). TLR6 and β-actin bands 
were quantified using AIDA (Advanced Image Data Analyzer, version 4.18) (Raytest, 
Straubenhardt, Germany), and normalised TLR6 expression was calculated as the ratio of 
TLR6 / β-actin. Differences in the cases with different TLR6 expression across the various 
chromosomal translocation groups were assessed by Fisher’s exact test. 
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4.4 Results 
 
4.4.1 Correlation of mRNA expression of CD69, CCR2A, CCR5, TLR6, 
BCL2, IRF4, CD86, NR4A3, BCL10 and MALT1 genes in MALT lymphoma 
with and without chromosomal translocation 
 
BCL10 transcript expression was highest in the t(1;14) group (p = 0.001) whereas 5‘ end of 
MALT1 (encoding the N-terminus of MALT1) was highest in the t(14;18) group (p = 0.02) 
reflecting the pattern seen in the gene expression microarray data and confirming the validity 
of the qRT-PCR methodology (Figure 4.1). In keeping with the results of the gene expression 
microarray study, CCR5 was highly expressed in t(1;14) and TLR6, CCR2A, BCL2, CD69 
and IRF4 were significantly highly expressed in t(1;14) and t(11;18) positive cases in 
comparison with translocation negative cases (Figure 4.1), whereas CD86 and NR4A3 were 
significantly highly expressed in translocation negative cases in comparison with 
translocation postive cases (Figure 4.1). 
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Figure 4.1 - Validation of gene expression in MALT lymphoma with and without chromosome  
translocation by real-time quantitative RT-PCR.  
This was performed in triplicate using RNA samples extracted from tumour cells microdissected from paraffin-
embedded tissue sections. Asterisk indicates statistically significant differences between various translocation 
positive groups and translocation negative group by Mann-Whitney non-parametric statistical test. The medians 
are indicated by horizontal bars in the rectangular boxes. Error bars show the standard deviation of the results in 
each group. Neg: translocation negative MALT lymphoma. High ΔCt values reflect low transcript expression 
and vice versa. 
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Figure 4.2 - Unsupervised hierarchical clustering of qRT-PCR data on MALT lymphoma cases 
with various translocation status. 
(A) Unsupervised clustering heatmap of the qRT-PCR genes that are differentially expressed between 
translocation positive and negative MALT lymphoma. Red colour indicates high expression and green low 
expression. (B) dendrogram of the MALT lymphoma cases shown in the heatmap of part A. 
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The unsupervised clustering analysis did not show clear segregation between MALT 
lymphoma with and without translocation. Nevertheless, the dendrogram (Figure 4.2 B) 
showed 3 main groups; the far right had mainly translocation negative MALT lymphomas 
(16 negative and 3 t(11;18) positive), the middle group contained a mixture of translocation 
positive and negative MALT lymphomas but with nuclear BCL10 expression (12 positive, 5 
negative with nuclear and 1 cytoplasmic BCL10 expression), and the far left contained 
mainly translocation positive MALT lymphomas (9 positive and 2 negative one with nuclear 
and the other with cytoplasmic BCL10 expression) (Figure 4.2B). Both the heatmap and 
dendrogram, revealed on the left, one MALT lymphoma negative case with cytoplasmic 
BCL10 expression labelled “NEG_Cyto_12” had high expression for all 8 genes but low 
expression for TLR6 (Figure 4.2 A and B). 
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4.4.2  Comparison of protein expression of CD69, BCL2, CD86 and IRF4, 
MALT1 and BCL10 in MALT lymphoma with and without chromosomal 
translocation using immunohistochemistry 
 
A 
CD86BCL2 CD69
FC
IRF4
t(11;18) 
positive
t(1;14) 
positive
Trans -ve
 
B 
0%
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75%
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Staining <30% cells or negative 
Weak staining in 30-70% cells 
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Weak staining in 70% cells
Strong – moderate staining in 70%
CD86BCL2 CD69  
Figure 4.3 - Immunohistochemistry of BCL2, CD69, CD86 and IRF4. 
(A) BCL2, CD69 and CD86 immunohistochemistry in MALT lymphomas with and without chromosome translocation. 
(B) Summaries of immunohistochemistry showing that BCL2 and CD69 are more strongly and homogeneously expressed in translocation 
positive than translocation negative MALT lymphoma (p < 6.9 × 10-5, p < 2.2 × 10-4 respectively by Fisher’s exact test), while CD86 is more 
strongly expressed in translocation negative than translocation positive MALT lymphoma  (p < 6.4 × 10-7 by Fisher’s exact test). IRF4 is 
typically expressed in activated B cells and cells showing plasma cell differentiation. 
FC: follicle centre;  Trans-ve: translocation negative. 
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Table 4.1 - Correlation of BCL2, CD69 and CD86 expression in MALT lymphoma with 
and without chromosome translocation. 
 
Marker 
MALT 
lymphoma 
translocation  
No. 
of 
cases 
Expression in >70% 
cells 
Expression in 30-70% 
cells Negative or 
expression in 
<30% 
Strong or 
moderate 
staining  
Weak 
staining  
Strong or 
moderate 
staining  
Weak 
staining  
BCL2 
Positive 28 27 (96%) 1 (4%) - - - 
Negative 26 3 (12%) 2 (8%) 6 (23%) 5 (19%) 10 (38%) 
CD69 
Positive 29 28 (97%) - 1 (3%) - - 
Negative 41 12 (29%) - 12 (29%) 1 (2%) 16 (39%) 
CD86 
Positive 33 - - 1 (3%) - 32 (97%) 
Negative 26 3 (12%) 2 (8%) 6 (23%) 5 (19%) 10 (38%) 
 
BCL10 and MALT1 staining were carried out as part of the study by Ye et al. (Ye et al., 
2005) and discussed in section 1.3.1.4. CD69, BCL2, CD86 and IRF4 protein expressions 
were further investigated by immunohistochemistry in MALT lymphomas (Table 4.1). IRF4, 
known to be expressed in activated B cells and plasma cells, was highly expressed in the 
neoplastic plasma cells (confirmed by immunoglobulin light chain staining) of t(1;14) 
positive MALT lymphoma, which were prominent in the lamina propria. Since BL10, 
MALT1 and IRF4 gave staining patterns similar to that reported in the literature, Both BCL2 
and CD69 showed homogeneous and strong expression in 97% (28/29) of both t(11;18) and 
t(1;14) translocation positive MALT lymphoma cases, whereas their expression was 
heterogenous and much weaker expression in 29% (12/41) of translocation negative cases 
(Figure 4.3 and Table 4.1). For example, BCL2 was strongly expressed in at least 70% 
tumour cells in 96% (27/28) of translocation positive cases but only in 12% (3/26) 
translocation negative cases. In contrast, CD86 showed heterogeneous and strong expression 
in translocation negative MALT lymphomas (Figure 4.2) but weak or negative staining in 
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most (97% or 32/33) translocation positive MALT lymphomas. Statistical analysis using the 
Fisher’s exact test showed that BCL2, CD69 and CD86 were significantly different between 
translocation positive and negative MALT lymphoma. 
 
 
4.4.3  Comparison of protein expression of TLR6 in MALT lymphoma with 
and without chromosome translocation using Western blotting 
 
All MALT lymphoma cases expressed a MALT1 protein of the expected molecular weight 
(approximately 90 kDa) indicating that the archival protein extracts are adequate for Western 
blot analysis (Figure 4.4A). TLR6 was highly expressed in translocation positive MALT 
lymphoma, but at low levels in translocation negative cases (Figure 4.4). Interestingly, case 
M6 which is a translocation negative MALT lymphoma with nuclear BCL10 showed 
relatively high expression of TLR6 (ratio of TLR6/actin = 0.67) comparable to t(11;18) 
positive cases (Figure 4.4B).  
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Figure 4.4 - TLR6 expression in MALT lymphoma with and without chromosomal 
translocation using Western blot analysis. 
(A) Western blot showing that TLR6 is highly expressed in translocation positive MALT lymphoma, but at low 
levels in translocation negative cases.  M: MALT lymphoma;  M6 and M7 are translocation negative MALT 
lymphoma with nuclear BCL10 staining: FL: follicular lymphoma. Jurkat cell line used as control.  
(B) Graphical representation of the ratio of TLR6 expression across MALT lymphoma cases with and without 
chromosomal translocation. 
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4.5 Discussion 
 
MALT1 was highly expressed in cases with t(11;18) and t(14;18) translocation. TLR6, 
CCR2A, CD69, BCL2 and IRF4 were highly expressed in cases with t(11;18) translocation. 
BCL10 and CCR5 were highly expressed in cases with t(1;14) translocation. CD86 and 
NR4A3 were highly expressed in translocation negative MALT lymphomas. This was the 
case for 20 MALT lymphoma cases that were subjected to microarray analysis, qRT-PCR 
and immunohistochemistry for MALT1, BCL10, BCL2, CD69 and CD86. Thus this shows 
that mRNA correlates with protein expression for the above proteins and validates both 
methodologies as well as providing further evidence of the reliability of the gene expression 
microarray results in this thesis.  
Translocation negative MALT lymphomas were characterised by high expression of CD86 
and N4RA3. CD86 is a surface molecule involved in B- and T- cell interaction and thus 
might play a role in response to H. pylori eradication. In line with this finding, a previous 
study showed significantly higher CD86 expression in gastric MALT lymphomas that 
responded to H. pylori eradication when compared with those resistant to the therapy (66% 
VS 10%) (de Jong et al., 2001).  Though the chromosome translocation status in these cases 
is not available, it is most likely that the cases that responded to H. pylori were translocation-
negative (Liu et al., 2002b). Although residual reactive follicles may be present and 
contribute to the high CD86 expression in translocation negative cases, the over-expression 
of CD86 in tumour cells was clearly demonstrated by microdissection, qRT-PCR and 
immunohistochemistry. Taken together, these findings suggest that there is an active immune 
response to H. pylori infection in translocation-negative gastric MALT lymphoma, and this 
most likely underscores the tumour cell survival and expansion and thus determines their 
response to H. pylori eradication. 
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NR4A3 is another molecule significantly enriched and over-expressed in translocation 
negative MALT lymphoma.  NR4A3 is a member of the nerve growth factor-1B (NGF1B, or 
NR4A1 or Nur77) subfamily of nuclear orphan receptors.  In T cells, NGF1B and NR4A3 are 
involved in TCR mediated cell death and thymocyte negative selection (He, 2002). These 
nuclear orphan receptors are also involved in the apoptotic process of other cell types in 
response to external signals (Hashida et al., 2007). The function of NR4A3 in B cells is 
currently unclear. Nonetheless, NR4A3 is one of the top over-expressed genes in curable, as 
opposed to fatal/refractory, DLBCL (Shipp et al., 2002). It is possible that over-expression of 
NR4A3 in lymphoma cells might sensitise their response to pro-apoptotic signals following 
H. pylori eradication and elimination of the microbial mediated immune stimulations. 
The over-expression of IRF4, BCL2, CD69, CCR2A, CCR5 and TLR6 in translocation 
positive cases was further confirmed in a separate cohort of MALT lymphomas by qRT-PCR 
and immunohistochemistry or Western blot analysis. 
IRF4 encodes a transcriptional factor and is expressed in activated B cells and cells showing 
plasma cell differentiation (Pernis, 2002). In line with its known expression pattern, IRF4 is 
highly expressed in the plasma cell component of MALT lymphoma. Among different 
subgroups of MALT lymphoma, plasma cell differentiation of neoplastic B cells is most 
prominent in those with t(1;14) translocation. IRF4 is transcriptionally activated by 
t(6;14)(p25;q32) in multiple myeloma and strong IRF4 expression has also been found in 
several lymphoma subtypes including lymphoplasmacytic lymphoma and 75% of diffuse 
large B-cell lymphoma and primary effusion lymphoma, which are not associated with 
t(6;14) (Falini et al., 2002).  IRF4 was one of the molecules found in the activated DLBCL 
signature profile using cDNA microarrays (Alizadeh et al., 2000). The oncogenic activity of 
IRF4 is thought to be related to its transcriptional repression of interferon (IFN) inducible 
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genes and thus suppression of the anti-proliferative effects of IFN (Hrdlickova et al., 2001; 
Pernis, 2002). Interestingly, NF-κB transactivates IFN and a simultaneous up-regulation of 
IRF4 may block the effect of NF-κB on IFN activation.  
BCL2 is an apoptosis inhibitor protein; its over-expression in lymphocytes alone was shown 
to be insufficient for malignant transformation, but simultaneous over-expression of BCL2 
and the proto-oncogene MYC may produce aggressive B-cell malignancies (Otake et al., 
2007). Hence in MALT lymphomas, over-expression of BCL2 may lead to oncogenesis by 
reducing cell death. Currently, the exact anti-apoptotic pathways through which BCL2 exerts 
its role are only partially understood, involving decreased mitochondrial release of 
cytochrome C, which in turn is required for the activation of procaspase-9 and the subsequent 
initiation of the apoptotic cascade (Adams et al., 1998). 
CD69, a type II transmembrane glycoprotein with an extracellular C-type lectin binding 
domain, is another potential co-stimulatory receptor and may also have an immunoregulatory 
role (Sancho et al., 2005). Although the precise function of CD69 in B cells is largely 
unknown, it is a well described activation marker in a number of cell types. CD69 is 
frequently expressed in low grade B-cell non-Hodgkin lymphomas and in follicular 
lymphoma, its expression on tumour cells is associated with poor treatment outcome (de Jong 
et al., 2009; Erlanson et al., 1998). The finding of enriched expression of CD69 in 
translocation positive MALT lymphoma in the present study further implicates its role in 
lymphoma pathogenesis. 
Other types of molecule enriched in translocation positive MALT lymphomas are chemokine 
receptors such as CCR2 and CCR5. These are G protein coupled receptors (GPR) whose 
major function is to regulate leukocyte trafficking and mediate immune cell migration and 
their retention in inflammatory sites (Murphy et al., 2000). Other functions include 
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angiogenic activity, apoptosis, T-cell differentiation and phagocyte activation. Following 
interaction with their specific chemokine ligands, chemokine receptors trigger a flux of 
intracellular calcium (Ca2+) ions (calcium signalling). This causes cellular responses, 
including the onset of a process known as chemotaxis that triggers cells to migrate to specific 
anatomical sites. Several homeostatic chemokines have been shown to play an important role 
in mucosal immunology including germinal centre formation, homing mechanisms, migration 
and retention of lymphocytes to the sites of inflammation. Recently a study showed that 
CCR2 is expressed in several haematopoetic cell lineages and is critical for migration of 
haematopoetic stem and progenitor cells to sites of inflammation (Si et al., 2010). Although 
the specific role of CCR2 in B-cell trafficking and homing is unclear, it forms a heterodimer 
with CXCR4 that is critical for B-cell homing to the Peyer’s patches and splenic marginal 
zone (Springael et al., 2005), thus potentially playing a role in mature B-cell homing 
processes. CCR5 is a receptor for a number of inflammatory CC-chemokines including MIP-
1-alpha, MIP-1-beta and RANTES, which may prove to be important in translocation positive 
MALT lymphoma. 
Another interesting molecule highly expressed in translocation positive MALT lymphoma is 
Toll-like receptor 6 (TLR6). Toll-like receptors play a role in innate immunity by recognising 
conserved microbial structures known as pathogen associated molecular patterns (PAMPs). 
TLR6 is activated by bacterial lipopolysaccharide (LPS) and signals through MyD88 to 
activate NFκB; the signalling pathway of TLR6 is similar to that of the IL-1 receptor upon 
activation by the cytokine IL-1.  In a mouse model, it has been shown that TLR signalling 
promotes marginal zone B-cell activation and migration (Rubtsov et al., 2008). TLR6 
typically forms heterodimers with TLR2 on the cell surface to recognize bacterial antigens 
(Gomariz et al., 2007).  TLR2/TLR6 signalling activates not only IKK complex that leads to 
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activation of the NF-κB transcriptional factor, but also the MAP kinase p38 and Jun amino-
terminal kinase (JNK) that leads to activation of the AP-1 transcriptional factor (Akira et al., 
2004). Hence, over-expression of TLR6 in translocation-positive MALT lymphoma could 
potentially augment the NF-κB activity mediated by MALT lymphoma associated oncogenic 
products and also activate the MAP kinase pathways. In order to test the former hypothesis, 
functional studies involving the expression of TLR6, in the presence of TLR2, were carried 
out to investigate whether they could enhance both BCL10 and API2-MALT1 mediated NF-
κB activation in vitro and whether this effect was particularly significant upon LPS 
stimulation. 
In summary, all of the key NF-κB target genes, found to be over-expressed by expression 
microarrays, were confirmed by qRT-PCR and immunohistochemistry. Those genes are 
involved in promoting tumour cell survival and proliferation either directly or indirectly and 
their over-expression may enhance the interaction between tumour cells and their 
microenvironment, which is known to be critical for MALT lymphoma development. Thus 
further investigation of the role of some of those genes in MALT lymphogenesis is warranted 
and the effect of some of the identified genes (such as TLR6) on NF-κB activation, will be 
investigated using in vitro model as described in the next chapter. 
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CHAPTER 5 – Cooperation between MALT 
lymphoma oncogenes and immunological 
stimulation in activating the NF-κB pathway 
 
 
5.1 Introduction 
MALT lymphoma commonly occurs in sites that are normally devoid of organised lymphoid 
tissues where the lymphoma is preceded by the accumulation of reactive lymphoid tissue, 
suggesting that the tumours arise during a chronic immune response. Several previous studies 
suggest that surface receptor stimulation may play an important role in MALT lymphoma 
pathogenesis. MALT lymphomas invariably express surface Ig. Stimulation by the anti-
idiotype antibody has been shown to enhance MALT lymphoma cell proliferation and this 
synergises with mitogenic stimulation in vitro (Hussell et al., 1993b). In line with this, 
expression of either API2-MALT1 or MALT1 in BJAB B-cells enhances the activation of IKK 
and NF-κB by CD40/CD40L stimulation (Ho et al., 2005). Both API2-MALT1 and BCL10 
transgenic mice acquired expansion of the white pulp of the spleen but not lymphoma (Baens 
et al., 2006). However, treatment of these mice with the Freund’s complete adjuvant led to 
the development of marginal zone hyperplasia reminiscent of human MALT lymphoma 
(Baens et al., 2006). 
Thus antigen stimulation may play a critical role in the clonal expansion and survival of 
MALT lymphoma cells. However, the surface receptors involved and the molecular 
mechanisms underlying the proliferation and survival of MALT lymphoma cells remain to be 
investigated. Also, TLR signalling activates the IKK complex that leads to activation of the 
NF-κB transcriptional factor, thus the effect of TLR6/2 on MALT lymphoma associated 
oncogenes mediated NF-κB activation was investigated. In addition, the potential cooperation 
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between MALT lymphoma associated oncogenes and immune receptor signalling such as 
those from TLR, B- and T-cell antigen receptors and CD40 was investigated. The possible 
molecular mechanisms underlying such cooperation were explored.  
In view of the finding of enriched TLR6 expression in translocation positive MALT 
lymphoma as described in chapter 4, cooperation between TLR6 and MALT lymphoma 
associated oncogenes in NF-κB activation in vivo was first investigated. 
 
 
5.2 Aims of the study 
 
1) To test the hypothesis that there is cooperation between BCL10, MALT1 and API2-
MALT1 and TLR6 on NF-κB activation; 
2) To investigate whether there is a synergistic effect between expression of MALT1, 
BCL10 and API2-MALT1 and antigen receptor stimulation on NF-κB activation; 
3) To explore the effect of expression of MALT1, BCL10 and API2-MALT1 on key 
regulators of canonical NF-κB activation pathway  in B- and T- cell lines; 
4) To determine BCL10 and MALT1 sub-cellular localisation and the effect of MALT1 
on BCL10 sub-cellular localisation. 
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5.3 Experimental design 
 
5.3.1 Cell lines 
 
Murine BaF3 and WEHI cell lines were selected to investigate the effect of expression of 
BCL10, MALT1 and API2-MALT1 on NF-κB with and without stimulation by LPS, anti-IgM 
and CD40L, as they are responsive to such stimulation. The BaF3 clone used was IL-3 
independent. Jurkat human T-cell line was selected to investigate the effect of expression of 
BCL10, MALT1 and API2-MALT1 on NF-κB with and without stimulation using anti-CD3 
and anti-CD28. BJAB human B-cell line was used to investigate the effect of expression of 
BCL10, MALT1 and API2-MALT1 on their sub-cellular localisation. It was not possible to use 
the BJAB B-cell line for NF-κB luciferase reporter assays as no increased activity has been 
observed in response to known NF-κB activators such as LPS, anti-IgM and CD40L. 
 
5.3.2 Investigation of the cooperation between BCL10, MALT1 and API2-
MALT1 and TLR6  on NF-κB activation with and without LPS stimulation 
 
BCL10, MALT1 and API2-MALT1 together with TLR2 and TLR6 or TLR1 and TLR6 
expression constructs along with a control vector pIRES were transiently transfected into 
human Jurkat T cells, which are known to be non-responsive to LPS stimulation and thus are 
a good model to investigate LPS mediated NF-κB activation. The transfected cells were 
seeded in multi-well plates, cultured for 18 hours and then treated with LPS or vehicle alone 
for 6 hours. Twenty four hours after transfection, the cells were harvested and measured for 
NF-κB activity using a luciferase assay (Section 2.2.11.1). NF-κB activities were measured in 
triplicate experiments and recorded as fold increase of the vector control. The experimental 
work in this section was carried out with the help of Dr. Alex Appert. 
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5.3.3 Investigation of the effect of BCL10, MALT1 and API2-MALT1 
expression and antigen receptor stimulation on NF-κB activation  
 
Murine B-cell lines BaF3, WEHI and Jurkat human T cells were transfected with BCL10, 
MALT1 and API2-MALT1 vectors and a control vector independently (Section 2.2.11.1). The 
transfected cells were seeded in multi-well plates, cultured for 18 hours. Prior to harvest for 
NF-κB luciferase assay, BaF3 cells were stimulated for 6 hours with LPS, WEHI cells were 
stimulated for 6 hours with LPS, anti-IgM or CD40L and Jurkat cells were stimulated for 6 
hours with anti-CD3 and anti-CD28. Each of these experiments was performed three times 
independently. NF-κB activities were measured in triplicate experiments and recorded as fold 
increase of the vector control. The experimental work in this section was carried out with the 
help of Dr. Alex Appert. 
 
5.3.4 Investigation of the effect of MALT lymphoma associated oncogenes 
expression on canonical NF-κB pathway activation  
 
This was carried out using BCL10, MALT1, API2-MALT1 and BCL10/MALT1 double 
inducible BJAB cells and BCL10 stably expressed BJAB cells. BJAB cells transfected with 
pIRES vector were used as control (Section 2.2.9.5). 
The following proteins were investigated by Western blotting 3 NF-κB negative regulators, 
IκBα, IκBβ and IκBε; 3 central molecules, IKKα, IKKβ and NEMO; and 5 NF-κB subunits 
including c-Rel, RelB, p65, p50/p105 and p52/p100. IκBα and IκBβ are phosphorylated and 
degraded during activation of the classical NF-κB pathway. p105 is cleaved into p50 and 
p100 is cleaved into p52 during activation of the canonical and non-canonical NF-κB 
pathway respectively. β-actin was used as loading control. Western blotting results were 
quantified (Section 4.3.4) and ratio of each molecule over β-actin was calculated. 
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5.3.5 Investigation of the effect of BCL10 and MALT1 expression on their 
sub-cellular localisation 
 
This was carried out using BCL10, MALT1, API2-MALT1 and BCL10/MALT1 double 
inducible BJAB cells and BCL10 stably expressed BJAB cells. BJAB cells transfected with 
pIRES vector were used as control. The expression of each of the oncogenes mentioned 
above in the BJAB cells was investigated at 9, 16 and 24 hours following induction by the 
addition of doxycycline to the culture medium. Cell clots were prepared (section 2.2.9.3) and 
the expression of these oncogenes was investigated by immunocytochemistry using the 
BCL10 and C-MALT1 antibodies. In addition, co-immunoprecipitation was carried out on 
BCL10 and MALT1-expressing BJAB cells (section 2.2.10.8). Western blots were probed 
with BCL10 and MALT1 antibodies. The immunostaining with BCL10 and C-MALT1 was 
carried out by Dr. Hongtao Ye. 
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5.4 Results 
 
 
5.4.1 TLR6 (in the presence of TLR2), enhances BCL10 and API2-MALT1 
mediated NF-κB activation in Jurkat T cells 
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Figure 5.1 - TLR6 enhances BCL10 and API2-MALT1 mediated NF-κB activation, in the 
presence of TLR2 but not TLR1, in Jurkat T cells.  
Jurkat T cells were co-transfected with vector (pIRESpuro2) or plasmids containing FLAG-tagged BCL10, 
API2-MALT1 (AM), MALT1, TLR6, TLR2 and TLR1 as indicated, together with NF-κB luciferase reporter gene. 
(A) NF-κB luciferase reporter assay data for each oncogene alone and in combination with TLR6 or TLR2 with 
and without LPS stimulation. 
(B) NF-κB luciferase reporter assay data for each oncogene alone and in combination with either TLR6/2 or 
TLR6/1 with and without LPS stimulation. 
The transfected cells were seeded in multi-well plate, cultured for 18 hours and then treated with 10μg/ml LPS 
or vehicle alone for 6 hours. NF-κB activities were measured in triplicate experiments and recorded as fold 
increase of the vector control. Western blots in (B) show the appropriate expression of the various constructs.  
*P<0.01 by Student’s t-test. Arrows show that API2-MALT1, MALT1 and TLRs expression were detected using 
the anti-FLAG antibody with MALT1 and TLRs having approximately 90 kDa (which is the expected molecular 
weight) and API2-MALT1 have slightly higher molecular weight of approximately 125 kDa (which is the 
expected molecular weight). 
 
Expression of TLR1, TLR2, TLR6 alone was insufficient to induce NF-κB reporter activity 
(Figure 5.1 A). TLR6 alone and TLR2 alone, both failed to enhance BCL10 and API2-
MALT1 mediated NF-κB activation in Jurkat cells even in the presence of LPS stimulation 
(Figure 5.1 A). However, the expression of both TLR6 and TLR2 significantly enhanced 
BCL10 (4.9 fold increase) and API2-MALT1 (19.6 fold increase), but not MALT1, mediated 
 - 162 -  
NF-κB activation, and this effect was much potent in the presence of LPS stimulation. Co-
expression of TLR6/2 and BCL10 or API2-MALT1 appeared to be synergistic in NF-κB 
activation as shown by the reporter assay (Figure 5.1 B), with API2-MALT1 showing the 
highest synergistic effect (Figure 5.1 B). In contrast, there was no co-operation between co-
expression of TLR6/1 and MALT lymphoma associated oncogenes. These results are 
consistent with the previous finding that TLR6 typically forms a heterodimer with TLR2 in 
response to stimulation by bacterial antigens (Shimizu et al., 2007; Takeuchi et al., 2001). 
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5.4.2 Cooperation of BCL10, MALT1, API2-MALT1 and immune receptor 
signalling in NF-κB activation in B-cells 
 
To further understand the potential co-operation between MALT lymphoma associated 
oncogenes and immunological stimulation in NF-κB activation, NF-κB reporter assays in B- 
and T- cell lines were performed in the presence of stimulation to TLR, antigen receptors and 
CD40. 
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Figure 5.2. BCL10, MALT1 and API2-MALT1 mediated NF-κB activation, with and without 
LPS stimulation in BaF3 murine B-cells. 
BaF3 B-cells were co-transfected with vector (pIRESpuro2) or plasmids containing HA-tagged BCL10, FLAG-
tagged MALT1 and API2-MALT1 (AM) as indicated, together with NF-κB luciferase reporter gene. The 
transfected cells were seeded in multi-well plate, cultured for 18 hours and then treated with 10μg/ml LPS or 
vehicle alone for 6 hours. NF-κB activities were measured in triplicate experiments and recorded as fold 
increase of the vector control. Western blot in the lower panel shows appropriate expression of the various 
constructs. 
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In BaF3 B-cells, expression of each of the three MALT lymphoma associated oncogenes 
yielded moderate increase of NF-κB activity with API2-MALT1 showing the greatest NF-κB 
activity in comparison with vector control (Figure 5.2). LPS stimulation of BaF3 B-cells 
transfected with the pIRES control vector produced a mean of 19.7s fold increase of NF-κB 
activity over un-stimulated cells (Figure 5.2). The expression of the three oncogenes in BaF3 
cells was comparable as shown in the Western blots (Figure 5.2). Thus, it can be concluded 
that the expression of each of the three oncogenes enhanced the LPS mediated activation of 
NF-κB in BaF3 B-cells in a synergistic manner with fold increase of 29.1, 34.5, and 33.3 for 
BCL10, MALT1 and API2-MALT1 respectively (Figure 5.2). Similar results were also seen 
in WEHI cells (Figure 5.3). 
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Figure 5.3 - BCL10, MALT1 and API2-MALT1 mediated NF-κB activation, with and without 6 
hours of LPS, anti-IgM and CD40-L stimulation in WEHI murine B-cells.  
WEHI B-cells were co-transfected with vector (pIRESpuro2) or plasmids containing HA-tagged BCL10, FLAG-
tagged MALT1 and API2-MALT1 (AM) as indicated, together with NF-κB luciferase reporter gene. The 
transfected cells were seeded in multi-well plates, cultured for 18 hours and then treated with 10μg/ml LPS, 
0.1μg/ml CD40 ligand (with 1μg/ml CD40 enhancer), 10μg/ml anti-IgM or vehicle alone for 6 hours where 
indicated. NF-κB activities were measured in triplicate experiments and recorded as fold increase of the vector 
control. Western blot in the lower panel shows appropriate expression of the various constructs. 
 
The expression of the three oncogenes in WEHI cells was comparable as shown in the 
Western blots (Figure 5.3). However, unlike LPS stimulation, antigen receptor stimulation by 
anti-IgM showed variable co-operation with the expression of MALT lymphoma associated 
oncogenes in NF-κB activation in WEHI cells (Figure 5.3). BCL10 expression slightly 
enhanced anti-IgM mediated NF-κB activation in an additive manner (Figure 5.3). However 
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both MALT1 and API2-MALT1 expression failed to enhance anti-IgM mediated NF-κB 
activation. Similarly, stimulation using CD40L enhanced NF-κB activation mediated by the 
expression of BCL10 (but not MALT1 or API2-MALT1) in an additive manner (Figure 5.3). 
 
5.4.3  Cooperation between  BCL10, MALT1, API2-MALT1 immune 
receptor signalling on NF-κB activation in Jurkat T cells 
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Figure 5.4 - BCL10, MALT1 and API2-MALT1 mediated NF-κB activation, with and without 6 
hours of CD3/CD28 stimulation in Jurkat T cells. 
Jurkat T cells were co-transfected with vector (pIRESpuro2) or plasmids containing HA-tagged BCL10, FLAG-
tagged MALT1 and API2-MALT1 (AM) as indicated, together with NF-κB luciferase reporter gene. The 
transfected cells were seeded in multi-well plates, cultured for 18 hours and then treated with 1μg/ml anti-CD3 
and 1μg/ml anti-CD28 or vehicle alone for 6 hours where indicated. NF-κB activities were measured in 
triplicate experiments and recorded as fold increase of the vector control. Western blot in the lower panel shows 
appropriate expression of the various constructs. 
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The expression of the three oncogenes in Jurkat T cells was comparable as shown in the 
Western blots (Figure 5.4). Thus it can be concluded that the expression of BCL10, MALT1 
and API2-MALT1 alone showed 5.0, 2.7 and 19.2 fold increase of NF-κB activity 
respectively in Jurkat T cells (Figure 5.4). Co-stimulation of CD3 and CD28 produced a 
mean of 2.7 fold increase of NF-κB activity over un-stimulated cells (Figure 5.4). In 
comparison with the control, CD3/CD28 co-stimulation clearly enhanced BCL10 but not 
MALT1 or API2-MALT1 mediated NF-κB activation (Figure 5.4). 
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5.4.4  Investigation of the effect of BCL10 and MALT1 expression on their 
sub-cellular localisation 
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Figure 5.5 - Immunohistochemistry on cell clots expressing various MALT lymphoma 
associated oncogenes. 
BJAB B-cell lines that express various inducible MALT lymphoma associated oncogenes were generated and 
used for investigation of their subcellular localisation. The expression of MALT lymphoma associated 
oncogenes were induced by doxycycline (Dox) and cells were harvested at 9, 16 and 24 hours followed by 
preparation of cell clots and immunocytochmistry with antibodies against BCL10 or C-terminal MALT1 where 
indicated. For each cell line, a control of cells without  doxycycline treatment was used as reference. 
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BJAB cells transfected with vector only showed weak cytoplasmic BCL10 and MALT1 
expression (Figure 5.5 A). In contrast, BJAB cells transfected with inducible BCL10 
expression construct showed both strong nuclear and cytoplasmic expression in a proportion 
(10 - 15%) of cells after 9 hours induction by doxycycline, which increased to around 60% of 
cells at 24 hours induction (Figure 5.5 B). Interestingly, in BJAB with inducible MALT1 
expression, immunostaining showed strong BCL10 in the cytoplasm, suggesting that MALT1 
resulted in BCL10 accumulation and retainment in the cytoplasm (Figure 5.5 C). In BJAB 
cells with both BCL10 and MALT1 inducible expression, BCL10 was largely in the 
cytoplasm at 9 and 16 hours, but was predominantly in the nuclei at 24 hours after 
doxycycline induction (Figure 5.5 G and D). In contrast, co-expression of API2-MALT1 did 
not have any apparent effect on BCL10 sub-cellular localisation (Figure 5.5 E, F and H). 
Based on the co-localisation of BCL10 and MALT1 upon doxycycline induction, it can be 
hypothesised that these two molecules may interact. To investigate this further, co-
immunoprecipitation investigating the interaction of BCL10 with MALT1 was carried out 
next. 
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Figure 5.6 - Co-immunoprecipitation showing that expression of BCL10 leads to increased 
interaction with MALT1. 
BJAB B-cells expressing inducible HA-tagged BCL10 or both HA-tagged BCL10 and FLAG-tagged MALT1 
were treated with doxycycline (dox) for 24 hours. The protein extracts were subjected to co-immunopreciptation 
with HA antibody.  Both co-immunoprecipitated products and whole cell lysates were analysed by Western 
blotting with antibodies against BCL10 or C-MALT1 and β-actin where indicated. 
 
 
It is known that BCL10 interacts with MALT1 and mediates MALT1 oligomerisation in 
response to upstream signalling. In line with this, co-immunoprecipitation experiments 
showed that BCL10 was capable of interacting with both endogenous and exogenous MALT1 
(Figure 5.6 A and B). It is most likely that through such direct interaction, MALT1 affects the 
subcellular localization of BCL10 especially in the cytoplasm where over-expression of 
BCL10 leads to strong nuclear and cytoplasmic accumulation of BCL10 initially (Figure 5.5 
B). In addition, subcellular localization data (Figure 5.5 D) and co-IP data (Figure 5.6 B) 
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showed more BCL10 in the presence of MALT1 indicating the possibility that increased 
MALT1-BCL10 interaction might lead to more BCL10 expression. 
 
 
5.4.5 Effect of BCL10, MALT1 and API2-MALT1 expression on canonical 
NF-κB pathway activation 
 
 
 
Figure 5.7 - Activation of canonical NF-κB pathway by BCL10, MALT1 and API2-MALT1 and 
association of IκBβ degradation with BCL10 expression. 
Various BJAB B-cells and Jurkat T cells expressing  inducible BCL10, MALT1, API2-MALT1 were subjected 
to doxycycline (dox) treatment for 18 hours, followed by stimulation with 10μg/ml LPS for BJAB and 1μg/ml 
anti-CD3/anti-CD28 for Jurkat for 30 minutes, 2, 6 hours where indicated. Protein extracts from each 
experiment were subjected to Western blotting with IκBα and IκBβ and β-actin as the loading control. The 
bands were quantified and the ratio of each over β-actin is calculated in the tables accompanying each figure. 
 
 
The effect of over-expression of BCL10, MALT1 and API2-MALT1 on canonical NF-κB 
pathway was investigated using various BJAB B-cells and Jurkat T-cell lines that inducibly 
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or stably expressed these proteins. As expected, LPS stimulation, induced prominent IκBα 
degradation in both B- and T- cells (Figure 5.7 A-E). Very interestingly, expression of 
BCL10 together with LPS stimulation, also caused IκBβ degradation in BJAB B-cells (Figure 
5.7 A-C). IκBβ degradation was strongest with stable BJAB BCL10 cell lines (Figure 5.7 B), 
possibly due to the fact that the inducible cell lines have the Tet element which may slightly 
affect the expression of the transgene. 
 However, neither LPS stimulation alone nor its combination with MALT1 or API2-MALT1 
expression induced IκBβ degradation (Figure 5.7 D and E).  In Jurkat T cells, expression of 
BCL10, together with CD3/CD28 stimulation, also induced IκBβ degradation (Figure 5.7 F). 
All other regulators of the canonical NF-κB pathway including the NF-κB negative 
regulators, IκBε; 3 central molecules, IKKα, IKKβ and NEMO; and 5 NF-κB subunits 
including c-Rel, RelB, p65, p50/p105 and p52/p100 did not show any significant difference 
among the three MALT lymphoma associated oncogenes when they were over-expressed 
(data not shown). 
Similar experiments were carried out with anti-IgM stimulation in BJAB cells but no IκBβ 
degradation was seen in presence or absence of expression of the above MALT lymphoma 
associated oncogenes (data not shown).  
Taken together, these results suggest that under these conditions, expression of BCL10 may 
trigger the release of NF-κB dimer inactivated by IκBβ. In this context, BCL10 may play a 
more significant role than MALT1 or API2-MALT1. 
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5.5 Discussion 
 
In this chapter, the potential cooperation between MALT lymphoma associated oncogenes 
and immune receptors stimulation in NF-κB activation was investigated and the common and 
distinct features of MALT lymphoma associated oncogenes in the activation of the canonical 
NF-κB pathway were explored. 
 
5.5.1 Cooperation between the expression of MALT lymphoma associated 
oncogenes and TLR stimulation 
 
Reporter assay results in Jurkat T cells showed a synergy between MALT lymphoma 
associated oncogenes, in particular BCL10 and API2-MALT1, and TLR6/2 expression on 
NF-κB activation upon LPS stimulation. Similarly, in BaF3 and WEHI B-cells, co-expression 
of TLR6/2 enhanced BCL10 and API2-MALT1 mediated NF-κB activation in the presence 
of LPS stimulation.   
Based on the results of in vitro assays and expression microarray data, it is pertinent to 
speculate that TLR signalling may play a role in the pathogenesis of translocation positive 
MALT lymphoma. This is further supported by the following observations: 1) H. pylori 
activates NF-κB via both the classical and alternative pathway in B lymphocytes and this 
effect is dependent on LPS but not the Cag pathogenecity island (Ohmae et al., 2005); and 2) 
H. pylori associated LPS induced NF-κB activation requires TLR2/TLR6 or TLR2/TLR1 
complex but not those containing TLR4 (Yokota et al., 2007), which typically recognises 
LPS from other Gram-negative bacteria (Akira et al., 2004).  
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5.5.2 Effect of antigen receptor stimulation on MALT lymphomagenesis 
The three recurrent translocations identified in MALT lymphoma all induce 
lymphomagenesis through constitutive activation of the NF-κB pathway (Zhou et al., 2005). 
Functional analysis presented here showed that expression of BCL10, MALT1 and API2-
MALT1 alone was capable of activating NF-κB in both B- and T- cells which are in line with 
the literature findings. In addition, the in vitro experiments showed that the expression of 
BCL10 enhanced the antigen receptor CD40 mediated NF-κB activation in B-cells. This 
finding is important in the context of MALT lymphoma as the lymphoma cells express 
functional BCRs and remain responsive to antigen, at least in the earlier stages of the disease 
(Hussell et al., 1993b). For example, in an early study by Hussell et al., gastric MALT 
lymphoma cells are stimulated to proliferate through CD40-CD40L interactions with T cells 
that recognise H. pylori antigens (Hussell et al., 1993b). If these gastric MALT lymphoma 
cells already over-express BCL10, API2-MALT1 or MALT1, then the activation of NF-κB 
by CD40 stimulation will be most likely enhanced. In addition, the only case that responded 
to anti-idiotype antibody stimulation and showed enhanced MALT lymphoma cell 
proliferation was a t(1;14) positive case (Hussell et al., 1993b) suggesting that a combination 
of high BCL10 protein expression and surface immune receptor stimulation may play an 
important role in MALT lymphoma development. 
Recent study showed that CD40 signalling can enhance both API2-MALT1 and MALT1 
mediated NF-κB activation in B-cells in vitro (Ho et al., 2005), however the results in this 
thesis showed that out of the three MALT lymphoma oncogenes, only BCL10 over-
expression moderately enhanced CD40 mediated NF-κB activation. This discrepancy might 
be due to the fact that the study by Ho et al. used a different strain of the BJAB cell line to 
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the one used in this thesis which had high constitutive NF-κB activity. Another possible 
explanation might be that the NF-κB activation was assessed indirectly by measuring the 
degradation of IκBα (which is transiently degraded) (Ho et al., 2005) rather than by 
measuring the level of NF-κB transcriptional activity as done in the present study.  
Taken together, it is tempting to speculate that the microbe mediated immune responses 
including help from T cells may also play a role in the pathogenesis of translocation positive 
MALT lymphoma. The potential involvement of TLR, CD40 and IgM signalling in 
translocation positive MALT lymphoma may explain the finding that rare cases of 
translocation positive gastric MALT lymphoma responded to H. pylori eradication (Liu et al., 
2002b; Wundisch et al., 2005). The finding that API2-MALT1 and BCL10 mediated the 
strongest NF-κB activity is interesting considering the fact that both are highly expressed in 
translocation positive MALT lymphoma cases. Thus, the constitutive NF-κB activation seen 
in translocation positive MALT lymphoma may be, at least in part, due to preferential 
expression of the API2-MALT1 or BCL10 oncogenic products. 
 
5.5.3 BCL10 expression associated with IκBβ degradation 
 
All cell lines showed an intact IkBα mechanism, however unlike MALT1 and API2-MALT1, 
the expression of BCL10 also induced IκBβ degradation in the presence of CD3/CD28 and 
LPS stimulation in both Jurkat T- and BJAB B-cells respectively. IκBα and IκBβ interact 
with various NF-κB/Rel dimers with similar affinity, but recent studies demonstrated that 
they have slightly different mechanisms and operate through distinct properties. IκBα can 
shuttle NF-κB/Rel complexes in and out of the nucleus, whereas IκBβ is more efficient at 
sequestering NF-κB/Rel complexes in the cytoplasm. IκBβ causes cytoplasmic retention of 
NF-κB due to the masking of two NLSs on the NF-κB dimers. Interaction between the NF-
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κB/IκBβ complex and the small guanosine triphosphatases κB-Ras-1, -2 also contributes to 
the NF-κB activation. When binding to κB-Ras, IκBβ cannot be phosphorylated by IKK, thus 
blocking the NF-κB activation signal from IKK (Fenwick et al., 2000). The differential 
control between IκBα and IκBβ may lead to biphasic activation of NF-κB. IκBα is promptly 
upregulated upon NF-κB activation and thus controls the fast transient activation of NF-κB, 
whereas IκBβ controls the persistent activation of NF-κB (Ladner et al., 2003). It can be 
speculated that BCL10 may affect the regulation of this biphasic activation of NF-κB, and 
thus lead to further NF-κB activation and perhaps the expression of a different set of NF-κB 
target genes. 
 
5.5.4 BCL10 sub-cellular localisation and its relationship with MALT1 
expression 
 
The temporal interplay between API2-MALT1, MALT1 and BCL10 in cellular localisation 
in vivo showed that over-expression of BCL10 leads to the movement of excess BCL10 to the 
nucleus. This confirms the observation that tumour cells with t(1;14)(p22;q32)/BCL10-IGH 
show strong BCL10 nuclear expression (Liu et al., 2001b), but interestingly the results also 
showed that over-expression of BCL10  led to the presence of BCL10 in both the cytoplasmic 
and nuclear compartments. Over-expression of MALT1 resulted in strong homogeneous 
cytoplasmic localisation of both BCL10 and MALT1. But over-expression of API2-MALT1 
had no effect on BCL10 localisation probably because MALT1 expression is reduced by half 
due to the API2-MALT1 fusion, hence the expected reduced efficiency of the nuclear export 
of BCL10. In cells with t(1;14)(p22;q32)/BCL10-IGH, MALT1 endogenous expression may 
not be sufficient for the export of over-expressed BCL10, resulting in BCL10 nuclear 
retention. Finally, in cells with t(14;18)(q32;q21)/IGH-MALT1, the over expression of 
MALT1 results in an increased retention of BCL10 in the cytoplasm, mimicking the 
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phenomenon seen in t(14;18) MALT lymphomas, where both proteins are thus strongly 
expressed in the cytoplasm (Ye et al., 2005). In addition, subcellular localization and co-IP 
data showed more BCL10 in the presence of MALT1 reflecting the possibility that increased 
MALT1-BCL10 interaction might lead to increase in BCL10 expression. 
The phenomenon of nuclear BCL10 warrants further investigation, as it may have an 
unidentified role in the deregulation of NF-κB or other cellular pathways that may be linked 
to MALT lymphomagenesis. Also, BCL10 does not contain NLS, so the mechanism by 
which it moves to the nucleus remains to be investigated. Co-immunoprecipitation results 
showed that over-expression of BCL10 protein was able to interact with both endogenous and 
exogenous MALT1. 
Taken together, it can be suggested that MALT1 and BCL10 may play an important role in 
the generation of the CBM complex, facilitating the initial surface receptors’ signal 
transduction to NF-κB. Following stimulation of surface receptors such as LPS, IgM or CD40 
in B- cells or CD3/CD28 in T- cells, over-expression of BCL10 also leads to the degradation 
of IκBβ, facilitating the activation of NF-κB pathway. Thus, BCL10 probably plays a dual 
role in the NF-κB pathway by transducing the signals from B- and T- cells to the NF-κB 
subunits as well as facilitating NF-κB activation partly via IkBβ degradation.  
In addition to the mechanistic details of how MALT lymphoma associated oncogenes affects 
NF-κB activation, the data also showed the heterogeneity of MALT lymphoma in that 
translocation positive MALT lymphoma has four recurrent translocations, each having 
different mechanisms of NF-κB activation. Also, other translocation positive MALT 
lymphoma rearrangements were recently found such as t(1;14)(p22;q32)/CNN3-IGH, 
t(5;14)(q34;q32)/ODZ2-IGH and t(9;14)(p24;q32)/JMJD2C-IGH (Vinatzer et al., 2008) 
which so far do not seem to be directly affecting the NF-κB pathway. Some of the 
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translocation negative MALT lymphomas have recently been shown to be associated with 
negative regulators of NF-κB such as A20 deletion (Chanudet et al., 2010; Kato et al., 2009). 
Taken together, it can be concluded that at the molecular level, different molecules and 
pathways play a role in the pathogenesis of MALT lymphoma. Thus it would be useful to use 
the expression microarray data to identify putative phenotypic markers that are specifically 
highly expressed in both translocation positive and negative MALT lymphoma. This will aid 
in the diagnosis and prognosis of MALT lymphoma and may provide further insights into the 
molecular pathogenesis of MALT lymphoma. 
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CHAPTER 6 – Identification of MALT lymphoma 
specific phenotypic markers using gene  
expression microarray 
 
 
6.1 Introduction 
Currently, there is no MALT lymphoma specific phenotypic marker. The differential 
diagnosis of MALT lymphoma includes the reactive inflammatory processes that typically 
precede the lymphoma including H. pylori gastritis, lymphoepithelial sialadentis, Hashimoto 
thyroiditis and other small B-cell lymphomas such as follicular lymphoma, mantle cell 
lymphoma and small lymphocytic lymphoma. Distinction from reactive processes is based 
mainly on the presence of destructive infiltrates of extra-follicular B cells, typically with the 
morphology of marginal zone cells (Wotherspoon et al., 1993). Immunophenotyping and 
molecular genetics analysis is used in borderline cases to assess B-cell clonality to help 
establish or exclude a diagnosis of MALT lymphoma, however molecular analysis may also 
demonstrate clonal B cells in some non-neoplastic MALT proliferations or persistant clonal 
population in gastric MALT lymphomas even after histologic complete remissions 
(Wundisch et al., 2003). Distinction from other small B-cell lymphomas is based on a 
combination of the characteristic morphologic and immunophenotypic features such as the 
presence of a diffuse infiltrate of CD20+, IgM+, IgD- B cells beyond the reactive follicles 
outside the mantle zone. Once the marginal zone phenotype is established, light chain 
restriction in this marginal zone population or if present, within the plasma cells, would 
define the diagnosis. Thus, MALT lymphoma diagnosis is rather difficult as well as prone to 
errors (Pongpruttipan et al., 2007) and having a marker specific for MALT lymphoma would 
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lead to more accurate MALT lymphoma diagnosis and would help both haemtopathologists 
and non-haemtopathologists to make a correct diagnosis. 
 
6.2 Aims of the study 
 
1) To identify genes highly and specifically expressed in MALT lymphoma by 
comparing the gene expression microarray data of MALT lymphoma with those of 
FL, MCL, SMZL and CLL; 
2) To validate the putative phenotypic markers identified by the gene expression 
microarray study in a large cohort of FFPE MALT lymphomas, FL, MCL and SMZL 
specimens using qRT-PCR and immunohistochemistry. 
 
6.3 Experimental design 
 
 
6.3.1  Case selection 
 
A total of 77 cases from five different lymphoma subtypes with expression microarray data 
were included in this study. These were composed of 26 cases of MALT lymphomas (21 
from stomach, 3 from lung, 1 from ocular adnexa and 1 from liver) with Affymetrix HG-
U133A/B GeneChips; 7 cases of nodal FL; 8 cases of nodal MCL; 14 cases of SMZL and 22 
cases of CLL with Affymetrix HG-U133plus2 GeneChip. The CLL expression microarrays 
were from a previous study carried out by Calin et al. (Calin et al., 2008), while all the other 
expression microarray data were obtained as part of  this study. 
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6.3.2 Identification of genes highly and specifically expressed in MALT 
lymphoma by gene expression microarray analysis 
 
After normalisation using RMA, the MALT lymphoma, SMZL, CLL, FL and MCL gene 
expression microarrays were subjected to the following two different analyses: Firstly, One-
way ANOVA with Bonferroni multiple testing correction using Genespring GX 7.3.1 and 
secondly, Baysian statistics using in house programs written in R (version 2.8.0). Genes that 
had p < 0.05 were considered significant. Probes that were common in the two analyses were 
further filtered using SOM and Volcano plot and finally narrowed down using fold change 
calculation on the raw expression data as well as literature search of the genes preliminarily 
identified. Supervised clustering was carried out using Pearson correlation and average 
linkage as the similarity measure and clustering algorithm respectively within Genespring 
GX 7.3.1 (Figure 6.1). 
 
6.3.3 Validation of genes highly expressed in MALT lymphoma by qRT-
PCR and immunohistochemistry 
 
The genes that were found to be specifically expressed in MALT lymphoma were validated 
by qRT-PCR and immunohistochemistry. mRNA expression was measured using qRT-PCR 
on a total of 79 cases of lymphoma including 44 MALT lymphomas (38 from stomach, 4 
from lung, 1 from ocular adnexa and 1 from liver); 13 nodal FL; 11 nodal MCL and 11 
SMZL. No CLL samples were available thus no CLL cases were included in the downstream 
validation. 18s rRNA was used as the housekeeping gene. RNA was extracted from 
microdissected tumour cells of FFPE tissue specimens of MALT lymphoma cases and qRT-
PCR was carried out as described in Chapter 2. Where possible, primer pairs were designed 
to span exons to prevent any amplification of genomic DNA and to target up to 150bp (Table 
3 in section 2.2.6), and were thus suitable for FFPE tissues. The results were presented as ∆Ct 
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values, so the higher the value, the lower the transcript expression, and vice versa. The Mann-
Whitney U Test was used to determine whether there were statistically significant differences 
in the expression of a particular transcript between the various lymphoma groups. 
Immunohistochemistry using Lactoferrin antibody was carried out by Dr. Hongtao Ye on 5 
gastric MALT lymphoma, 2 FL and 2 MCL specimens using 1:200 dilution of rabbit 
polyclonal antibody (product no. ab15811, Abcam) as based on the information given, 
seemed suited for immunohistochemistry on FFPE tissue. 
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6.4 Results 
 
 
6.4.1 Identification of genes highly and specifically expressed in MALT 
lymphoma 
 
The strategy used to combine HG-U133A&B microarray data of MALT lymphoma with HG-
U133plus2 microarray data of FL, MCL, SMZL and CLL is summarised in Figure 6.1. 
RMA normalisation of MALT lymphoma
samples on U133A & B
RMA normalisation of all U133plus
CLL, SMZL, FL and MCL
Median polishNormalised MALT and
other lymphomas
Median polish
Bayesian statistical
analysis using Limma
and E-Bayes
Multivariate ANOVA
across all 77 samples
(Welch test)
4907 probes 390 probes
234 probes common to both analysis
178 probes
5 probes
Volcano  plot and SOM
Biological  insight
 
Figure 6.1 - Summary of bioinformatics strategy to combine MALT lymphoma, FL, MCL, 
SMZL and CLL microarray data and identify the genes highly and specifically expressed in 
MALT lymphoma. 
Both the U133AB and U133plus2 sets were normalised using RMA and combined using median polish. The 
normalised set was then subjected to multivariate ANOVA and Bayesian statistics (using eBayes) analysis. 
Common probes from both analyses were reduced by subjecting them to self organising maps (SOM) and 
volcano plot analyses. The remaining probes were further reduced using biological knowledge and studies form 
the literature. 
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Multivariate ANOVA with Bonferroni’s stringent multiple testing criterion yielded 4907 
probes whereas Baysian statistical analysis (which tends to shrink the data and eliminate non-
variant probes using model fitting) gave rise to 390 probes. The common set between the two 
analyses was 234 probes. SOM and Volcano plot analysis further filtered the set to 178 
probes. The 178 probes were ranked according to their fold change between MALT 
lymphoma and the other lymphomas. The top 20 probes were selected and known genes that 
are expressed in non-neoplastic cells were excluded.  
Using this approach, 5 probes were selected; 2 probes mapped to Dermatopontin, one to 
Decorin, one to Tetraspanin 8 and one to Lactoferrin. Fold change, minimum and maximum 
raw expression signals and coefficient of variation were calculated for the 5 probes across the 
26 MALT lymphoma and the 51 other lymphoma cases separately (Table 6.1). The 
descriptive statistics showed that Lactoferrin had the lowest CV (67%) and the highest 
average (1027.05) in the MALT lymphoma group indicating that Lactoferrin is expressed 
uniformly at higher level in the MALT lymphoma group (Table 6.1). Plot of the raw 
expression microarray Lactoferrin data confirmed that it is most highly expressed in MALT 
lymphoma group compared to the other 3 genes (Figure 6.1). This in addition to the fact that 
a literature search showed Lactoferrin to inhibit the immunostimulatory effect on human B 
cells (Britigan et al., 2001) and might play a role in lymphocyte migration in lymphoid 
malignancy (de Sousa et al., 1978) making it the most likely phenotypic marker and was used 
for downstream validation. 
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A 
      
B    
Lactoferrin
  
Figure 6.2 - (A) Supervised hierarchical clustering of MALT lymphoma, FL, MCL, SMZL and 
CLL (B) Volcano plot of MALT v other lymphomas with an arrow showing Lactoferrin position 
near the top. 
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Figure 6.3 - Variation of the raw gene expression microarray data of Lactoferrin across the 5 
lymphoma groups.  
Five probes came in the final analysis two of them localised to the Dermatopontin gene. The groups used are; 26 
MALT lymphomas, 14 SMZLs, 22 CLLs, 7 FLs and 8 MCLs. 
 
 
 
 
Table 6.1 - Descriptive statistical properties of the 5 potential phenotypic marker probes 
calculated for MALT and other lymphomas separately. 
 
Probe Name Gene Name Fold Change MALT Average MALT SD MALT CV MALT Max MALT Min ymphomas AveragLymphomas SD Lymphomas CV
202018_s_at Lactoferrin 9.61 1027.05 683.09 0.67 3081.00 274.80 106.92 133.93 1.25
203824_at Tetraspanin 8 23.59 266.72 468.33 1.76 1887.00 10.85 11.30 7.02 0.62
211896_s_at Decorin 8.29 457.07 519.97 1.14 1829.00 34.28 55.13 105.75 1.92
213068_at Dermatopontin 7.66 173.85 167.19 0.96 666.10 17.90 22.70 34.23 1.51
213071_at Dermatopontin 13.00 220.28 161.25 0.73 718.10 77.23 16.94 17.33 1.02  
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6.4.2 Validation of Lactoferrin expression in MALT lymphoma 
 
The expression of Lactoferrin in MALT lymphoma and other lymphoma subtypes was first 
compared using qRT-PCR on microdissected tumour cells from FFPE tissues. All the 
expression values of Lactoferrin in SMZL were negative, most likely due to tissue 
degradation and thus the SMZL data were not used in the analysis.  Lactoferrin mRNA 
expression was the highest in the 44 MALT lymphomas group as compared to 11 MCL and 
13 FL.  
Although the range of Lactoferrin expression in MALT lymphoma was rather large, there 
was only small overlap between MALT lymphoma and FL or MCL. Not surprisingly, the 
Mann-Whitney U test showed a significant difference in the gene expression between MALT 
lymphoma and FL or MCL (Figure 6.4). Thus Lactoferrin could be a potential marker for 
MALT lymphoma. 
To further validate this, immunohistochemistry was performed with Lactoferrin antibody 
(ab15811) on 5 gastric MALT lymphoma, 2 FL and 2 MCL. The preliminary 
immunohistochemical results showed high and scattered staining in MALT lymphoma 
compared to tonsils (Figure 6.5). The intensity and distribution of staining was similar 
between five cases of MALT lymphoma, FL and MCL (data not shown), probably because 
this anti-Lactoferrin antibody seem to detect inflammatory infiltrating tissue which can occur 
as a result of the lymphoma so it was a poor choice to use for this study. Thus, 
immunohistochemistry need to be repeated with perhaps a different anti-Lactoferrin antibody 
such as the polyclonal rabbit anti-human (product no. A0061, DakoCytomation, Cambridge, 
UK) or the monoclonal mouse anti-human (Clone 1A1, product no. H86024M, Meridian Life 
Science, Maine, USA) where both were successfully used on clear cell carcinomas FFPE 
tissue (Giuffre et al., 2007). Another antibody is the polyclonal rabbit anti-human anti-
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Lactoferrin (product no. 07-685, Upstate (Millipore), Massachusetts, USA) which was 
successfully used on nasopharyngeal carcinoma tissue microarray (Zhou et al., 2008).  
However, it has also been shown that Lactoferrin binding in B-lymphocytes may increase 
during certain stages of cell maturation (Butler et al., 1990) and Lactoferrin is expressed in 
cells from the upper gastrointenstinal tract (possibly related to mucosal defence mechanisms) 
but has low background staining (Mason et al., 1978), thus immunostaining with either of the 
two antibodies mentioned above need to be interpreted with caution. 
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Figure 6.4 - Validation of Lactoferrin expression in 44 MALT, 13 FL and 11 MCL lymphomas 
by real-time quantitative RT-PCR. 
This was performed in triplicate using RNA samples extracted from tumour cells microdissected from paraffin-embedded 
tissue sections. Asterisk indicates statistical significant differences between FL, MCL and combined FL with MCL and 
MALT lymphoma group by Mann-Whitney non-parametric statistical test. The medians are indicated by horizontal bars in 
the rectangular boxes. Error bars show the standard deviation of the results in each group. High values reflect low transcript 
expression and vice versa.  
 
  
 
      MALT lymphoma          Tonsil 
 
Figure 6.5 - Validation of Lactoferrin expression in MALT lymphomas by 
immunohistochemistry. 
Summary of Lactoferrin immunohistochemistry showing high and scattered staining in MALT lymphoma compared to 
tonsils. The pattern of staining between MALT lymphoma, FL and MCL was similar. 
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6.5 Discussion 
 
By analysis of gene expression profiles of MALT lymphoma, FL, MCL, SMZL and CLL, 
several genes including Lactoferrin were found to be highly expressed in MALT lymphoma 
whereas the other genes were not found to be highly expressed in MALT lymphoma (Figure 
6.3). High expression of Lactoferrin in MALT lymphoma was also confirmed by qRT-PCR 
and awaiting further validation by immunohistochemistry. 
Lactoferrin belongs to a family of iron-binding proteins that modulate iron metabolism, 
haematopoiesis and immunologic reactions. Lactoferrin is an iron binding glycoprotein with 
approximate weight of 78 kDa. It is present in secretary fluids of mammals and contained in 
secondary granules of neutrophils (Boxer et al., 1982) that defends against microbial 
pathogens in innate immunity. It has been shown to be bacteriostatic and bactericidic against 
various infectious agents including H. pylori (Ellison, III, 1994). The specific receptor for 
Lactoferrin has been reported on several cell types including mitogen-stimulated human 
peripheral blood lymphocytes (Maneva et al., 1983), macrophages (Maneva et al., 1983), 
platelets and epithelial cells of human mammary gland (Bennett et al., 1983). It is thought 
that receptor binding is the first step in cell functions related to Lactoferrin. For instance, 
interaction of Lactoferrin with cells of the immune system induces the release of cytokines 
(Van Snick et al., 1976) and can protect mice against a lethal dose of  E. coli  in experimental 
infection (Van Snick et al., 1976). Lactoferrin is also capable of promoting the proliferation 
of phytohaemagglutinin-stimulated human peripheral blood lymphocytes (Maneva et al., 
1983), as well as both human B- and T- cell lines (Dagg et al., 1981). 
Unmethylated CpG dinucleotide motifs in bacterial DNA, as well as oligodeoxynucleotide 
(ODN) containing these motifs, are potent stimuli for many host immunological responses. 
Lactoferrin has been shown to inhibit CpG (ODN) stimulation of CD86 expression in the 
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human Ramos B-cell line leading to a decrease in the cellular uptake of ODN, a process 
required for CpG bioactivity (Britigan et al., 2001). Lactoferrin binding of CpG-containing 
ODN may serve to modulate and terminate host response to immunostimulatory molecules 
such as Heparin and LPS at mucosal surfaces and sites of bacterial infection (Britigan et al., 
2001). 
Lactoferrin has also been shown to play a role in the control of lymphoid cell migration (de 
Sousa et al., 1978) perhaps via the control of chemokines and cytokine release. Thus, 
Lactoferrin plays an important role in B-cell physiology. 
Mounting evidence from the literature suggest that there is a link between increase in 
Lactoferrin expression and H. pylori infection and gastric inflammation. Microarray analysis 
of antral biopsies from patients with and without H. pylori infection showed Lactoferrin 
expression to be 4.2 folds higher in patients with H. pylori  infection versus normal controls 
(Mannick et al., 2004). Microarray and qRT-PCR analysis showed Lactoferrin expression 
was upregulated in gastric biopsies with H. pylori  infection with 19.4 fold change in H. 
pylori  positive compared to negative biopsies by qRT-PCR (Wen et al., 2004). In a similar 
study, Lactoferrin expression had 14.6 and 16.8 fold induction in H. pylori  positive 
compared to negative biopsies using microarray and qRT-PCR respectively (Wen et al., 
2007). Molecular analysis of H. pylori associated gastric inflammation in chronically infected 
and immune mice, showed Lactoferrin to be expressed 38 fold higher in H. pylori  infected 
mice compared to naïve animals (Rahn, 2003). In addition, a study by Zou et al showed that 
supplementation with Lactoferrin could be effective in increasing eradication rates of anti-H. 
pylori  therapy, and could be helpful for patients with H. pylori  eradication failure (Zou et 
al., 2009) and Hirata et al. showed that faecal Lactoferrin levels were elevated and this was 
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found to be useful in the detection of colorectal diseases including MALT lymphoma (Hirata 
et al., 2007). 
Analyses of B-cell malignancies comprising cells representing different maturational stages 
showed variable Lactoferrin expression (Butler et al., 1990). Acute lymphoblastic leukaemia 
(ALL) derived from progenitor B cells, and hairy cell leukaemia (HCL) derived from late 
activated memory B cells do not express surface Lactoferrin. In addition, EBV-transformed 
B-cell lines, representing activated B cells, were virtually negative for Lactoferrin. The same 
study showed that CLL had the highest percentage of surface Latoferrin positivity (Butler et 
al., 1990). Microarray analysis in this thesis showed that mRNA expression of Lactoferrin in 
CLL is minimal. However the CLL microarray data were obtained from a study by Calin et 
al. (Calin et al., 2008) in public domain and no CLL tissue was available, thus it was not 
possible to confirm this finding by qRT-PCR as was the case with FL and MCL. If the qRT-
PCR results confirm the microarray data, it can be hypothesised that perhaps the binding (but 
not the expression) of Lactoferrin to B lymphocytes might increase during certain stages of 
cell maturation. This might slightly reduce the use of Lactoferrin as a potential phenotypic 
marker for MALT lymphoma, however the diagnosis of MALT lymphoma is not usually 
confused with CLL/SLL, as the latter typically is CD5+ and CD23+. Furthermore, the disease 
usually manifests as CLL (rather than SLL) with an associated with lymphocytosis at 
presentation, a feature not associated with MALT lymphoma. Attempts of Lactoferrin 
immunohistochemistry with commercial antibody failed to yield any conclusive results and 
validation of Lactoferrin expression in MALT lymphoma remains to be investigated. 
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CHAPTER 7 – GENERAL DISCUSSION 
 
 
7.1 MALT lymphoma is a distinct entity within the lymphomas 
but with heterogeneity between MALT lymphoma with and 
without chromosome translocation as indicated by gene 
expression profiling 
 
Gene expression microarray results showed that MALT lymphoma is an entity distinct from 
other lymphoma subtypes, FL (thought to originate from germinal centre B cells) and MCL 
(thought to originate from the mantle zone B cells) (Kuppers, 2005). Significantly, MALT 
lymphomas expressed at high levels, many of the genes related to response to external biotic 
stimulus. On the other hand, in FL, immune response related genes were highly expressed, 
and in MCL, cell cycle related genes were highly expressed.  
Unsupervised clustering between translocation positive and negative MALT lymphomas 
showed no clear separation between these cases indicating overlap in the molecular 
mechanism between the two groups. In all unsupervised clustering analyses, translocation 
negative MALT lymphomas with BCL10 nuclear staining tended to cluster with translocation 
positive cases suggesting that such cases at the molecular level resemble more to those with 
chromosome translocation. 
 
7.2 Overview of the molecular mechanisms underlying the 
pathogenesis of MALT lymphoma 
 
Although unsupervised clustering analyses showed considerable overlap in the gene 
expression profiles between MALT lymphomas with and without chromosome translocation, 
there was a significant difference in the expression of NF-κB target genes between the two 
subgroups. Exhaustive and systematic GSEA of various molecular pathways and biological 
processes, showed that gene sets related to inflammation, immune responses, chemokine and 
 - 194 -  
GPR signalling, were differentially over-represented between these different subgroups.  
Importantly, several of these molecular pathways or biological processes also lead to NF-κB 
activation.  These findings were also reinforced by independent analyses of differentially 
expressed genes between MALT lymphomas with and without translocation using 
hypergeometric tests.  These observations provide several novel insights into the molecular 
mechanisms of both translocation-positive and negative MALT lymphomas which potentially 
explain their different clinical and histological presentations. 
 
7.2.1 Aberrant molecular mechanisms of translocation positive MALT 
lymphoma 
 
GSEA and leading edge analyses revealed a common core subset of genes that were 
overexpressed in translocation positive cases and a high proportion of them were NF-κB 
target genes involving multiple related biological processes or molecular pathways. 
Potentially critical immune receptors highly expressed in translocation positive MALT 
lymphoma were TLR6, CD40, CD83, CD1D and CD69 as shown by GSEA of gene 
expression microarray study in this thesis. 
TLR6 typically forms heterodimers with TLR2 on the cell surface to recognize bacterial 
antigens (Gomariz et al., 2007). TLR2/TLR6 signalling activates not only the IKK complex 
that leads to activation of the NF-κB transcriptional factor, but also the MAP kinase p38 and 
Jun amino-terminal kinase (JNK) that lead to activation of the AP-1 transcriptional factor 
(Akira et al., 2004).  Hence, over-expression of TLR6 in translocation-positive MALT 
lymphoma could potentially augment the NF-κB activity mediated by MALT lymphoma 
associated oncogenic products and also activate the MAP kinase pathways.  Data from this 
thesis in Baf3 B cells and Jurkat T cells showed that expression of TLR6, in the presence of 
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TLR2, enhanced both BCL10 and API2-MALT1 mediated NF-κB activation. This effect was 
particularly significant upon LPS stimulation suggesting a potential biological cooperation 
between MALT lymphoma associated translocations and TLR signalling in 
lymphomagenesis. In addition, data from this thesis demonstrated that TLR6 with TLR2 
enhanced API2-MALT1, BCL10 and MALT1 mediated AP-1 activation in BJAB B cells 
regardless of LPS stimulation.  
The growth of gastric MALT lymphoma cells is critically dependent on their cognate 
interaction with H. pylori specific tumour infiltrating T cells, involving co-stimulatory 
molecules such as CD40/CD40L (D'Elios et al., 2003; Hussell et al., 1996). A recent study 
showed that CD40 signalling could enhance both API2-MALT1 and MALT1 mediated NF-
κB activation in B cells (Ho et al., 2005). In addition, previous studies have also indicated a 
role of B-cell receptor signalling in H. pylori induced MALT lymphomagensis (Craig et al., 
2010).  In this thesis, the potential cooperation between expression of MALT lymphoma 
associated oncogenes and BCR and CD40 signalling were investigated. As expected, 
functional studies in WEHI B cells showed additive effect between CD40L stimulation and 
BCL10 in NF-κB activation. GSEA of the expression microarray data demonstrated that the 
expression of co-stimulating molecules CD40 and CD83 was enriched in translocation 
positive MALT lymphoma, further supporting their role in lymphomagenesis. In line with 
this hypothesis, the GSEA also revealed up-regulation of CD1D in translocation positive 
MALT lymphoma, which is involved in the presentation of microbial lipid and lipopeptide 
antigens to T cells (Brigl et al., 2004). Thus, it is tempting to speculate that the microbe 
mediated immune responses including T cells may also play a role in the pathogenesis of 
translocation positive MALT lymphoma. The potential involvement of TLR, CD40 and 
CD83 signalling in translocation positive MALT lymphoma may explain the finding that rare 
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cases of translocation positive gastric MALT lymphoma respond to H. pylori eradication (Liu 
et al., 2002b; Wundisch et al., 2005). 
CD69 is an early cell activation antigen expressed on the surface of activated immune cells 
by small subset of T and B cells in peripheral lymphoid organs (Hara et al., 1986). Although 
the precise function of CD69 in B cells is largely unknown, it is a well-described activation 
marker in several cell types, and its expression is up-regulated in marginal zone B cells upon 
TLR stimulation (Rubtsov et al., 2008). CD69 is frequently expressed in low-grade B-cell 
lymphomas, and in FL, its expression is associated with poor treatment outcome (de Jong et 
al., 2009; Erlanson et al., 1998). Also, it has been shown that CD69 functions downstream of 
IFNα and IFNβ, and possibly other activating stimuli, to promote lymphocyte retention in 
lymphoid organs (Shiow et al., 2006). The finding here of enriched expression of CD69 in 
translocation-positive MALT lymphoma further implicates its role in lymphomagenesis. 
Among the genes up-regulated in translocation positive cases, IRF4 showed a significant 
increase in cases with t(1;14) chromosomal translocation. IRF4 encodes a transcriptional 
factor and is expressed in activated B cells and cells showing plasma cell differentiation 
(Pernis, 2002). It is required during an immune response for lymphocyte activation and the 
generation of immunoglobulin-secreting plasma cells. In line with its known expression 
pattern, IRF4 is highly expressed in the plasma cell component of MALT lymphoma. 
Furthermore, plasma cell differentiation of neoplastic B cells is most prominent in MALT 
lymphoma with t(1;14) translocation. IRF4 is transcriptionally activated by t(6;14)(p25;q32) 
in multiple myeloma where gene expression profiling and genome wide chromatin 
immunoprecipitation analysis uncovered an extensive network of IRF4 target genes and 
showed that although IRF4 is not genetically altered in most myelomas, they are nonetheless 
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addicted to an aberrant IRF4 regulatory network that fuses the gene expression programmes 
of normal plasma cells and activated B cells (Shaffer et al., 2008). Strong IRF4 expression 
has also been found in several lymphoma subtypes including lymphoplasmacytic lymphoma, 
75% of diffuse large B-cell lymphoma and primary effusion lymphoma, which are not 
associated with t(6;14) (Falini et al., 2002).  IRF4 is one of the molecules found in the ABC-
DLBCL signature (Alizadeh et al., 2000). The oncogenic activity of IRF4 is thought to be 
related to its transcriptional repression of IFN-inducible genes, and thus the suppression of 
the anti-proliferative effects of IFN (Hrdlickova et al., 2001; Pernis, 2002). NFκB 
transactivates IFN, and IFNα and IFNβ were moderately up-regulated in t(11;18) or t(1;14) 
positive MALT lymphoma. A simultaneous up-regulation of IRF4 may block the side-effects 
of NF-κB on IFN activation. 
In addition to immune receptors discussed above, several potentially critical chemokine 
receptors were highly expressed in translocation positive MALT lymphoma and they 
included CCR2, CXCR4, CCR5 and CCR7 as shown by GSEA of gene expression 
microarray study in this thesis.  
Several homeostatic chemokines have been shown to play an important role in mucosal 
immunology including germinal centre formation, homing and trafficking of activated 
mucosal B cells. Germinal centre formation involves the trafficking and positioning of 
lymphocytes in the organized lymphoid tissue (Moser et al., 2001) and homing mechanisms 
play a role in B-cell recruitment to the secondary lymphoid tissue. CCR7 expression is up-
regulated in activated B cells allowing them to acquire the capacity to migrate into the T-cell 
zone and to follicles in Peyer’s patches, where the CCR7 ligands, CCL19 and CCL21 are 
highly expressed (Okada et al., 2002; Reif et al., 2002). CCR7 is shown to play a central role 
 - 198 -  
in regulation of normal mucosal lymphocyte re-circulation and homeostasis, particularly in 
the stomach (Hopken et al., 2007). CXCR4 is expressed in B cells at multiple stages of their 
development. It is required for retention of B-cell precursors in the bone marrow. CXCR4-
deficient B-cell precursors that migrated prematurely became localised in splenic follicles 
despite their unresponsiveness to CXCL13. CXCR4 is also critical for B-cell homing to the 
Peyer’s patches and splenic marginal zone (Nie et al., 2004). In both low grade B-cell NHL 
and classic Hodgkin lymphomas, CCR7 and CXCR4 over-expression were associated with a 
wide lymph node spread, supporting their role in lymphoma pathogenesis (Lopez-Giral et al., 
2004; Hopken et al., 2002; Trentin et al., 2004). 
B cells express CCR5 on their cell surfaces, and RANTES, one of four chemokine ligands of 
CCR5, is mitogenic for B cells (Rabkin et al., 1999). Thus, it is tempting to speculate that 
RANTES and hence CCR5 may play a role in lymphoma expansion by avoiding immune 
surveillance. 
CCR2 (CC chemokine receptor 2) is a receptor for MCP-1 which attracts monocytes and T 
cells to sites of injury as part of the inflammatory response. Two isoforms of CCR2, namely 
CCR2A and CCR2B have been cloned (Charo et al., 1994; Charo, 1999). It has been 
suggested that these two isoforms of the receptor might be splice variants of a single gene 
(Charo et al., 1994). CCR2B is the major form of the receptor readily detected in monocytes, 
whereas CCR2A is less abundant (Charo, 1999). The physiological role of CCR2A is not 
fully understood (Charo, 1999). Data in this thesis has shown that CCR2A and CCR2B were 
differentially expressed between translocation positive and negative MALT lymphoma cases 
with greater variability in CCR2A expression. Flaishon et al. described a novel role for CCR2 
and its ligand CCL2/JE in inhibiting the chemotactic response of immature B cells to the 
chemokine CXCL12/stromal cell-derived factor 1 (SDF-1), suggesting that CCR2 and its 
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ligand act as negative regulators of the homing of immature B cells (Flaishon et al., 2004). 
They also showed that CCR2 is transcribed in immature B cells, while its mRNA is 
dramatically down regulated at the mature B cells stage. CCR2-deficient mice showed 
massive accumulation of immature B cells in the lymph nodes in comparison with wild type 
mice (Flaishon et al., 2004). Beside its expression in immature B cells, CCR2 is found to be 
expressed in mature B-cell neoplasms such as marginal zone B-cell lymphoma (Trentin et al., 
2004). It has been shown that CCR2 is up-regulated in response to the formation of 
superoxide free radical molecules and that IL-2 induced the expression of CCR2 in T 
lymphocytes, which correlated with the response of these cells to MCP-1 in chemotaxis 
assays (Loetscher et al., 1996). Also, IL-10 selectively up-regulated the expression of CCR2 
in monocytes by prolonging the mRNA half-life (Sozzani et al., 1998). More recently, CCR2 
was shown to mediate hematopoietic stem and progenitor cell trafficking to sites of 
inflammation (Si et al., 2010). However, it is still unclear how the up-regulation of CCR2 
expression contributes to MALT lymphoma development or whether it is induced by the 
presence of oxygen free radicals which would occur during H. pylori mediated inflammatory 
responses. It may be that infection with H. pylori leads to chronic inflammation which may 
later cause the B cells to initiate the expression of CCR2 amongst other chemokines leading 
to their trafficking to inflammation sites. Once the inflammation subsides, CCR2 expression 
becomes reduced, however some of the cells within the inflammatory site may acquire an 
oncogenic even such as t(11;18)/API2-MALT1 leading to the constant expression of CCR2 
via aberrant NF-κB and MAPK pathways activation. Over-expression of CCR2A and B, 
CCR5 and CXCR4 has been shown to activate NF-κB, Jak/STAT and MAPK pathways 
(Okada et al., 2002). This, together with the TCR, BCR and CD40 signalling may form a 
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positive feedback autoregulatory loop in API2-MALT1 or BCL10 mediated NF-κB 
activation, thus leading to constitutive NF-κB activation. 
 
7.2.2 Aberrant molecular mechanisms of translocation negative MALT 
lymphoma 
 
In contrast to translocation-positive MALT lymphoma, translocation-negative cases were 
characterised by expression of a strong inflammatory gene signature.  GSEA and leading 
edge analysis also revealed common core subset genes involving several related biological 
processes or molecular pathways, which were enriched in translocation-negative MALT 
lymphoma.  The top examples included proinflammatory cytokines IL8 and IL1β, molecules 
involved in B- and T- cell interaction such as CD86, CD28 and ICOS, several chemokine and 
chemokine receptors, NR4A3 (also known as MINOR) and TLR2 (Figure 3.10). 
IL8 and IL1β are the hallmark of a proinflammatory cytokine profile in response to H. pylori 
infection.  IL8 is critical for neutrophil infiltration and activation, while IL1β induces gastrin 
release, inhibits acid secretion and promotes apoptosis of epithelial cells (McNamara et al., 
2008).  The finding of over-expression of these proinflammatory cytokines in translocation-
negative gastric MALT lymphomas, indicates the presence of active H. pylori infection. In 
keeping with this, translocation-negative gastric MALT lymphomas show a higher number of 
blast cells than translocation-positive cases (Okabe et al., 2003). In addition, a number of 
chemokines and chemokine receptors was highly expressed in the translocation-negative 
cases. This may reflect the trafficking and retention of various immune cells in response to an 
active H. pylori infection.  
Most importantly, GSEA showed up-regulated expression of the surface molecules involved 
in B- and T- cell interaction namely CD86, CD28 and ICOS in translocation-negative gastric 
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MALT lymphoma. Although residual reactive follicles may be present and contribute to the 
high CD86, CD28 and ICOS expression in translocation negative cases, the germinal centre 
markers CD10 and BCL6 were expressed in much lower levels in MALT lymphoma (Figure 
3.3). More importantly, over-expression of CD86 in tumour cells was clearly demonstrated 
by qRT-PCR on microdissected samples and immunohistochemistry. In line with the these 
findings, a previous study showed significantly higher CD86 expression in gastric MALT 
lymphomas that responded to H. pylori eradication than those resistant to the therapy (66% 
VS 10%) (de Jong et al., 2001).  Although the chromosome translocation status in these cases 
is not available, it is most likely that the cases responded to H. pylori were translocation-
negative (Liu et al., 2002b).  Taken together, these findings suggest that there is an active 
immune response to H. pylori infection in translocation-negative gastric MALT lymphoma, 
and this most likely underscores the tumour cell survival and expansion, and thus determines 
its response to H. pylori eradication. 
NR4A3 is another molecule significantly enriched and over-expressed in translocation 
negative MALT lymphoma.  NR4A3 is a member of the nerve growth factor-1B (NGF1B, or 
NR4A1 or Nur77) subfamily of nuclear orphan receptors.  In T cells, NGF1B and NR4A3 are 
involved in TCR mediated cell death and thymocyte negative selection (He, 2002).  These 
nuclear orphan receptors are also involved in the apoptotic process of other cell types in 
response to external signals (Hashida et al., 2007).   The function of NR4A3 in B cells is 
currently unclear.   Nonetheless, NR4A3 is one of the top over-expressed genes in cured, as 
opposed to fatal/refractory, DLBCL (Shipp et al., 2002).  It is possible that over-expression 
of NR4A3 in lymphoma cells may predispose them to apoptosis following H. pylori 
eradication and elimination of the microbial mediated immune stimulation. 
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7.2.3 Molecular mechanisms of BCL10, MALT1 and API2-MALT1 
mediated NF-κB activation 
 
Cytospin and immunohistochemistry data from this thesis showed that over-expression of 
BCL10 led to its subcellular localisation in the nucleus. Co-immunoprecipitation data showed 
that over-expression of BCL10 led to its interaction with MALT1 in BJAB B cells. 
Functional data showed that only BCL10 over-expression with LPS stimulation led to IκBβ 
degradation. In addition, subcellular localization and co-IP data showed more BCL10 in the 
presence of MALT1 reflecting the possiblity that increased MALT1-BCL10 interaction might 
lead to increase in BCL10 expression. However, BCL10 was shown to interact with 
transcription factor IIB which plays an important role in the assembly of transcription 
activators that make up the RNA polymerase II pre-initiation complex (Liu et al., 2004c) 
suggesting a possible role as a transcriptional activator. Taken together, it can be 
hypothesised that excess BCL10 interacts with MALT1 either by affecting its stabilisation or 
its expression. Either way, the cytoplasmic level of BCL10 and MALT1 needs to be 
maintained to allow the formation of the CBM signalosome upstream of the NF-κB subunits. 
Closer to the NF-κB subunits, BCL10 over-expression together with stimulation by LPS in B 
cells or CD3/CD28 in T cells stimulation led to constitutive NF-κB activation via IκBβ 
degradation. It has been shown that TCR/CD28 co-stimulation induces IκBα, IκBβ and IκBε 
degradation (Li et al., 2005). IκBα and IκBβ use slightly different mechanisms of NF-κB 
activation. One hypothesis proposes that IκBα masks the NLS of p65 in addition to the fact 
that it contains nuclear export sequencing that enables newly synthesized IκBα to shuttle 
nuclear NF-κB/Rel dimers into the cytoplasm (Phelps et al., 2000). In contrast, IκBβ does not 
contain nuclear export sequence and is able to mask the NLS domains of both p65 and p50. 
While detailed control of IκB nuclear import and export has yet to be defined, these unique 
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properties of IκBα and IκBβ are thought to provide the fine tuned regulation of NF-κB/Rel 
proteins, whereby IκBα controls transient NF-κB/Rel activation and IκBβ regulates sustained 
NF-κB/Rel activity. Studies using embryonic fibroblasts derived from various IκB knockout 
mice (Hoffmann et al., 2002), showed that IκBα resulted in high oscillatory NF-κB nuclear 
activity, whereas IκBβ displayed a constant steady increase in nuclear NF-κB activity that 
plateaued without subsequent decline, allowing sustainable NF-κB activation in the case of 
prolonged stimulation (Hoffmann et al., 2002). Also, studies have shown that when IκBβ is 
degraded, NF-κB activation becomes persistent; even though newly synthesized IκBα 
accumulates to high levels in unstimulated cells. This is partly because the newly synthesised 
IκBβ is an unphosphorylated protein that binds to a portion of newly made NF-κB and 
sequesters it from IκBα. The unphosphorylated IκBβ, however, fails to mask the NLS and 
DNA binding domain on NF-κB, resulting in the nuclear uptake of the unphosphorylated NF-
κB/IκBβ complex (Suyang et al., 1996). Thus, data from this thesis showed that over-
expression of BCL10 leads to IκBβ degradation causing constitutive NF-κB activation. This 
partly explains the biochemical mechanisms behind the NF-κB reporter assay observations 
showing that BCL10 expression together with surface receptor stimulation led to increased 
NF-κB activation. In addition, phosphorylated BCL10 was shown to form a complex with 
another NF-κB inhibitor, BCL3, to enter the nucleus (Yeh et al., 2006), thus it might be that 
BCL10 may move to the nucleus with BCL3. However, details of BCL10 nuclear import and 
export as well as the function of nuclear BCL10 remain to be determined. Collectively, it can 
be hypothesised that BCL10 may indirectly (e.g. via interaction with the IKK complex or 
some unknown molecule) degrades IκBβ, since BCL10 is not part of the transcription factor 
complex that binds the NF-κB promoter, nor does it affect the ability of NF-κB to bind the 
DNA. This degradation of IκBβ may cause different NF-κB to transactivate slightly different 
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set of NF-κB target genes thus explaining the slightly different gene expression profiles of the 
NF-κB target genes between MALT lymphoma with and without chromosome translocation. 
A hypothesis on the molecular mechanisms underlying MALT lymphoma with and without 
chromosomal translocation can be generated from the data described above. In translocation 
positive MALT lymphoma, over-expression of API2-MALT1, BCL10 or MALT1 activates 
the canonical NF-κB pathway. Canonical NF-κB activation is augmented by B-cell receptor 
signalling, TLR signalling and potentially CCR2 signalling. The non-canonical NF-κB 
pathway may be activated by CD40 and LTβ receptor signalling. Activation of the canonical 
and non-canonical NF-κB pathways leads to enhanced expression of the NF-κB target genes, 
particularly TLR6, CCR2A, CCR2B CD69, IRF4 and BCL2. Over-expression of these 
immune receptors may provide a further positive feedback to the activation of the NF-κB 
pathways. In addition, expression of TLR6 and CCR2 may trigger activation of the MAPK 
pathway. Over-expression of BCL2 is expected to promote tumour cell survival. In essence, 
the above chromosome translocations cause constitutive NF-κB activation with expression of 
their target genes forming a potential positive feedback loop, and the relentless NF-κB 
activation, which in the case of gastric MALT lymphoma confers its resistance to H. pylori 
eradication (Figure 7.1) 
In translocation negative MALT lymphoma, the ongoing inflammatory and immune 
responses maintain active cognate B- and T- cell interaction via co-stimulating molecules 
CD86/CD28, B7RP1/ICOS, which are the major determinants of tumour cell survival and 
thus explain, in the cases of gastric MALT lymphoma, their responses to H. pylori 
eradication (Figure 7.1). 
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Figure 7.1 - Summary and hypothesis on molecular mechanisms of MALT lymphoma with and 
without chromosomal translocation. 
In translocation positive MALT lymphoma, over-expression of API2-MALT1, BCL10 and MALT1 activates the 
canonical NF-κB pathway (e.g. in the case of BCL10 via degradation of IκBβ), leading to enhanced expression 
of the NF-κB target genes, particularly TLR6, CCR2, CD69 and BCL2. Over-expression of TLR6 may provide a 
further positive feedback to the activation of the NF-κB pathway.  Similar positive feedback may also be 
expected from the CCR2 signalling, and in addition both TLR6 and CCR2 may trigger activation of the MAPK 
pathway. The pathogenic implication of enhanced CD69 expression is currently unknown. Over-expression of 
BCL2 is expected to promote the tumor cell survival. In essence, the above chromosome translocations cause 
constitutive NF-κB activation with the expression of their target genes forming a potential positive feedback 
loop, and the relentless NF-κB activation, which in the case of gastric MALT lymphoma, confers its resistance 
to H. pylori eradication.     
In translocation negative MALT lymphoma, the ongoing inflammatory and immune responses maintain active 
cognate B- and T- cell interaction via the co-stimulating molecules; CD86/CD28, B7RP1/ICOS, which are the 
major determinants of tumor cell survival and thus explain, in the cases of gastric MALT lymphoma, their 
responses to H. pylori eradication. 
 
 
 
 
 
 
 - 206 -  
7.3 MALT lymphoma specific phenotypic marker identification 
 
Comparison of MALT expression microarray data with other lymphomas demonstrated 
Lactoferrin to be highly expressed in MALT lymphoma but not in other lymphoma subtypes. 
This was confirmed by qRT-PCR showing Lactoferrin to be significantly over expressed in 
all MALT lymphoma cases compared to FL or MCL. Currently, the only reported marker for 
marginal zone lymphomas is myeloid cell nuclear differentiation antigen (MNDA), a nuclear 
protein expressed by myeloid cells and a subset of B cells (Kanellis et al., 2009). It was 
shown to be expressed in normal tissue by a subset of the marginal zone B cells as well as 
subgroups of CLL, MCL and DLBCL, but it is highly expressed by MALT, SMZL and nodal 
marginal zone lymphoma (NMZL) and rarely expressed in FL making it potentially a useful 
marker for distinguishing between NMZL and FL (Kanellis et al., 2009). Both microarray 
and qRT-PCR results from this thesis showed that Lactoferrin mRNA is more highly 
expressed in MALT compared to other lymphomas. It can be hypothesised that if the 
Lactoferrin protein expression follows a similar pattern as its mRNA expression, then 
Lactoferrin may prove to be a better phenotypic marker for MALT lymphoma than MNDA. 
Lactoferrin belongs to a family of iron-binding proteins that modulate iron metabolism, 
haematopoiesis and immunologic reactions. It has been shown that Lactoferrin which is 
present at mucosal surfaces and neutrophil specific granules (Baggiolini et al., 1970) 
(Raphael et al., 1989), readily binds CpG-containing DNA which binds to B cells via 
interaction with DNA on the cell surface (Bennett et al., 1983), mediated through the highly 
charged N-terminal sequence of Lactoferrin (Kawasaki et al., 2000). Lactoferrin inhibited 
CpG ODN stimulation of CD86 expression in the human Ramos B cell line and decreased 
cellular uptake of ODN, a process required for CpG bioactivity. Lactoferrin binding of CpG-
containing ODN may serve to modulate and terminate host response to immunostimulatory 
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molecules such as CD86 and CD80 at mucosal surfaces and sites of bacterial infection. 
(Britigan et al., 2001). In addition, various studies show that there is an increase in 
Lactoferrin expression and H. pylori infection and gastric inflammation (Mannick et al) (Wen 
and Wen). Also, clinical studies showed that supplementation with Lactoferrin could be 
effective in increasing eradication rates of anti-H. pylori  therapy, which could be helpful for 
patients with H. pylori  eradication failure (Zou et al.) and that fecal Lactoferrin levels were 
elevated and this was found to be useful in the detection of colorectal diseases including 
MALT lymphoma (Hirata et al.). 
Since the starting point of MALT lymphoma is thought to be infection with a pathogen and 
most of the samples analysed were H. pylori positive gastric MALT lymphoma, this may 
explain why Lactoferrin seem to be more highly expressed in MALT compared to other 
lymphomas. Besides its inhibitory effect on CpG-containing ODN in human B cells, 
Lactoferrin has been shown to affect phenotypic changes in immature B-cell populations and 
has an effect on the antigen presenting function of these cells (Zimecki et al., 1995). 
Lactoferrin also plays a role in the maturation of cells of the immune system and, together 
with the demonstration of the involvement of Lactoferrin in the maturation of T cells 
(Zimecki et al., 1991), this provides evidence that Lactoferrin can enhance the induction 
phase of the immune response. 
In conclusion, Lactoferrin is a likely phenotypic marker for MALT lymphoma but further 
confirmation by immunohistochemistry is needed. 
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7.4 Conclusions 
 
The results detailed in this study allow the following conclusions to be drawn: 
1) Unsupervised clustering of MALT lymphoma with FL and MCL shows that MALT 
lymphoma is a distinct entity. Nonetheless, there is an overlap in the gene expression 
profiles between translocation positive and negative MALT lymphomas as both 
activate NF-κB pathway but leading to the expression of different sets of NF-κB 
target genes. 
2) Translocation positive MALT lymphoma was characterised by an enhanced 
expression of NF-κB target genes, particularly CCR2, TLR6, CD69, IRF4 and BCL2. 
3) Translocation negative MALT lymphoma was featured by active inflammatory and 
immune responses to H. pylori infection. Tumour cell interaction with infiltrating T 
cells through co-stimulatory molecules (especially CD86/CD28) may have an 
important role in their survival and clonal expansion. 
4) In vitro assays show cooperation between the expression of MALT lymphoma 
associated oncogenes and signalling via surface receptors including BCR, TLR and 
TCR. Such cooperation may be operational in vivo. 
5) BCL10 expression with surface receptor stimulation leads to IκBβ degradation. Over-
expression of BCL10 together with LPS stimulation in BJAB B cells may also 
activate NF-κB inactivated by IκBβ. 
6) Comparison of MALT lymphoma expression microarrays with other lymphomas 
showed Lactoferrin to be a putative MALT lymphoma specific marker. 
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7.5 Future perspectives 
 
 
This thesis has identified novel mechanisms involved in MALT lymphoma pathogenesis, 
however many questions remain to be addressed. 
 
7.5.1 CCR2 involvement in the molecular mechanism of MALT 
lymphomagenesis 
 
Genes highly expressed in translocation positive MALT lymphoma include CCR2A and B 
isoforms. It would be useful to determine the role of each of these in MALT 
lymphomagenesis. This can be done in a similar way to the functional experiments carried 
out on TLR6 by identifying which pathways (e.g. NF-κB and MAPK) they affect and 
whether there is a synergy between them and MALT lymphoma associated oncogenes in the 
activation of those pathways. Once this is established, it would be helpful to construct 
inducible stable cellular models with each of the above genes together with MALT 
lymphoma associated oncogenes to confirm any synergy between each of the above genes 
and MALT lymphoma associated oncogenes. Migration assays can be carried out on the 
cellular model to study the effect of CCR2 expression on B-cell migration. Expression 
microarray experiments can be carried out on the cellular models by expression of CCR2 
alone and together with MALT lymphoma associated oncogenes. GSEA and GO analysis 
will then lead to the identification of the specific pathways affected by the above genes that 
may be involved in MALT lymphomagenesis. Validation of genes involved in those 
pathways can be carried out on MALT lymphoma patient samples. 
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7.5.2 Nuclear BCL10 function 
Identification of BCL10 binding partners would help to determine the functions of nuclear 
BCL10 which may help to explain its role in the regulation of the NF-κB pathway and its 
interaction with MALT1. Co-immunoprecipitation of nuclear BCL10 can be carried out by 
isolating the nuclear BCL10 fraction from BCL10 BJAB cells. BCL10 has been shown to 
form a complex with BCL3 which is a transcriptional co-activator of NF-κB (Yeh et al., 
2006), thus co-IP products of nuclear BCL10 can be investigated for the potential presence of 
NF-κB subunits as potential binding partners by Western blotting. Co-IP extracts can also be 
investigated for the presence of unknown binding partners. Extracts can be separated by 
PAGE and the proteins visualised by silver staining. The proteins within bands unique to 
extracts from cells expressing nuclear BCL10 protein can be identified by mass spectrometry. 
Confirmation of the identity of any putative nuclear BCL10 binding partners can then be 
achieved by Western blotting of co-IP products for the presence of these targets. Site-specific 
mutagenesis of BCL10 expression constructs could be carried out to determine the exact 
region of the BCL10 protein required for binding to these partners. 
BCL10 has been shown to bind to transcriptional activator TBII (Liu et al., 2004b). The role 
of BCL10 as a transcriptional activator could be investigated by Chromatin 
immunoprecipitation (ChIP) assay on cell lines with over-expressed BCL10 and compared to 
those with normal BCL10 expression. This will answer the question whether BCL10 may 
play a role as a transcriptional activator and if so whether it affects MALT1 expression 
amongst other genes which might partly explain the mechanism by which over-expression of 
BCL10 leads to MALT1 interaction. 
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7.5.3  Lactoferrin  expression  in  MALT lymphoma  by 
immunohistochemistry 
 
A practically useful specific marker of MALT lymphoma needs to be developed. Lactoferrin 
seems to be the most promising candidate as confirmed by qRT-PCR. However, the initial 
Lactoferrin antibody used to validate the microarray and qRT-PCR produced inconclusive 
immunohistochemical data and the immunohistochemistry need to be repeated with a 
different Lactoferrin antibody. Two antibodies; the polyclonal rabbit anti-human (product no. 
A0061, DakoCytomation, Cambridge, UK) and the monoclonal mouse anti-human (Clone 
1A1, product no. H86024M, Meridian Life Science, Maine, USA) were successfully used on 
FFPE tissue of clear cell carcinoma (Giuffre et al., 2007). Another antibody is the polyclonal 
rabbit anti-human anti-Lactoferrin (product no. 07-685, Upstate (Millipore), Massachusetts, 
USA) which was successfully used on nasopharyngeal carcinoma tissue microarray (Zhou et 
al., 2008). MNDA was shown to be a useful marker for distinguishing between NMZL and 
FL. Thus comparison between MNDA and the above two Lactoferrin marker on the same 
series of NHL B-cell lymphomas including CLL/SLL is warranted. 
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Appendix I – Details of bioinformatics analysis 
 
I.I Preprocessing algorithm for Affymetrix expression arrays 
 
Preprocessing Affymetrix expression arrays usually involves three steps: background 
adjustment, normalisation and summarisation. The bioconductor software 
(http://www.bioconductor.org) which use the R programming platform (http://www.r-
project.org/), implements a wide range of methods for each of these steps. Self-contained 
routines for background correction and normalisation usually take an AffyBatch as input and 
return a process AffyBatch. Routines for summarisation produce exprSet objects containing 
expression summary values. 
There are currently 4 main algorithms that can be used for preprocessing the samples; MAS5, 
RMA, gcRMA and dChip. Literature studies comparing the above algorithms showed that 
dChip does not perform in a consistant manner, however none of the comparison studies 
showed the best algorithm to use to preprocess data from Affymetrix expression arrays. Some 
studies preferred MAS5 while others suggested that either RMA or gcRMA is best. 
Therefore, for this thesis a novel strategy was used to preprocess the raw CEL files using 
both gcRMA and MAS5. This was followed by non-specific filtering of the probes to 
eliminate non-variant probes.  
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The algorithm for MAS5 non-specific filtering was as follows: 
 
FOR (each probe) 
{ 
 IF ((probe raw value > 50) in > x MALT lymphoma samples)) THEN 
 { 
  Label that probe as variant and keep 
 } 
  
 ELSE 
  
 { 
  Discard that probe and move to the next probe 
 } 
} 
 
x = is the group containing the least samples  
 
So x in this thesis = 2 because the group containing the least samples is the t(14;18) and this 
has 2 cases 
 
 
 
 
The algorithm for gcRMA non-specific filtering was as follows: 
 
FOR (each probe) 
{ 
 
 Calculate the CV for the probe across all samples 
 
 IF (probe CV > 10% across all MALT lymphoma samples) THEN 
 { 
  Label that probe as variant and keep 
 } 
  
 ELSE 
  
 { 
  Discard that probe and move to the next probe 
 } 
} 
 
 
Once this is done, a new set of probes is constructed from common probes that passed both 
gcRMA and MAS5 preprocessing. 
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The advantage of using this strategy is that MAS5 is used to filter the probes on their absolute 
values, thus it will keep the low copy variant probes as well as the obvious highly variant 
probes. gcRMA is used to eliminate any non-variant probes across all samples, which is good 
where some probes might be high due to the tissue specificity and not because their 
contribution to the tumour part of the sample. 
This strategy is totally unsupervised and proved to be the best for normalising and filtering 
probes from difficult studies such as in this thesis where; firstly, there are no controls as such, 
thus the comparison is made between groups of the same entity i.e. MALT lymphoma. 
Secondly, the number of cases in some of the groups is very small to be statistically feasible 
e.g. only two cases of t(14;18) and 4 cases of t(1;14) (3 t(1;14) and 1 t(1;2)) were available. 
Systematic testing of individual preprocessing algorithms and combination of (RMA and 
MAS5) and (RMA and gcRMA) followed by false discovery rate (FDR) multiple testing 
corrections showed the consistant loss of probes mapping to BCL10, TLR6 and CD69.  
However gcRMA and MAS5 gave the best trade-off with MAS5 giving high number of 
probes with some false positive but gcRMA giving lower number of probes with few false 
positive. This strategy was used as the initial step for analysis of all the array data in this 
thesis. 
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I.II Analysis of differentially expressed genes 
 
Many microarray studies are designed to detect genes associated with different groups 
(phenotypes), for example in this thesis, the comparison of MALT lymphoma with and 
without chromosome translocation cases and comparison of MALT lymphoma against other 
lymphomas. The distribution of gene expression data is generally parametric thus the array 
data was log transformed in order to make the distribution of the replicated measurements per 
gene roughly symmetric and close to normal. A variance stabilizing transformation derived 
from an error model for microarray measurements was employed to make the variance of the 
measured intensities independent of their expected value. This can be advantageous for gene-
wise statistical tests that rely on variance homogeneity, because it will diminish differences in 
variance between experimental conditions that are due to differences in the intensity level, 
but differences in variance between conditions may also have gene-specific biological 
reasons, and these will remain untouched. 
 
Generally, for the comparison of MALT lymphoma with and without chromosomal 
translocation in chapter 3, t-test (ANOVA on two groups) was applied with the error model 
to obtain set of genes that are differentially expressed between the two groups. However, for 
the phenotypic marker study in chapter 6, multiple group ANOVA and eBayes which is part 
of the limma package in bioconductor, were applied separately to the same set of probes and 
the common probes from each analysis were combined to create a new set. 
 
eBayes fits the probe data to a linear model and works best when the variability of the log-
ratios is as homogenous as possible across the probes, whereas multiple group ANOVA can 
cope with slight heterogeneity in the data. eBayes is more stringent because it shrinks the data 
and results in few genes across the groups whereas multiple group ANOVA is less stringent 
and give larger set of genes with more false positives even after the stringent Bonferroni 
multiple testing correction. Thus a combination of both for the phenotypic marker study 
proved the best strategy. Finally in order to manage the vast amount of testing between the 
groups, a relational database management software was constructed as described in Appendix 
II. 
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I.III Construction and annotation of gene sets for GSEA 
 
Creation and annotation of human immune gene sets 
 
The Gene Set Enrichment Analysis (GSEA) is a powerful technique for elucidating various 
groups of genes that may be important from gene expression data. However, one drawback of 
the current implementation of GSEA is that the gene sets are only as good as the annotation 
and the immunology gene set annotations from GO are poor and do not follow a certain 
pathway. Thus in addition to running the 4395 pathways as mentioned in section 2.2.5.4, the 
challenge was to see which of the immune system pathways are significantly enriched in 
MALT lymphomas with and without chromosome translocations. For this thesis, the genes 
and proteins of the essential human immunome were identified and collected by literature 
search, reviewing the existing databases such as Immunome at: 
http://bioinf.uta.fi/Immunome/, ImmTree at: http://bioinf.uta.fi/ImmTree/, immune pathways 
in GeneGo (http://www.genego.com/) and immune pathways in Ingenuity 
(http://www.ingenuity.com/). It is difficult to strictly define immunome genes. In this thesis, 
a pragmatic approach was taken, where the gene products have to be essential for immunity, 
but not be widely expressed in many cells and tissues. Using this strategy and in house 
software tools such as relational database management systems, human immune gene sets 
were created that broadly fall into the following categories:  
 
1) Antigen Presentation 
2) CD genes 
3) Cellular Immunity 
4) Chemokine 
5) Complement System 
6) Humoral Immunity 
7) Inflammation 
8) Innate Immunity 
9) Phagocytosis 
10) Transcription Factor 
11) B-cell receptor signalling 
12) T-cell receptor signalling 
13) TLR signalling pathway 
13) Chemotaxis of leukocytes 
14) Immune response to bacteria 
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Creation and annotation of NF-κB target genes set 
 
NF-κB target gene is defined in broad terms as a gene that has a κB site in its promoter. To 
date there is no comprehensive list of NF-κB target genes, thus a comprehensive list of NF-
κB target genes was collated by bioinformatics, literature search and Internet search of NF-
κB target genes list at: http://people.bu.edu/gilmore/nf-kb/target/index.html and 
http://bioinfo.lifl.fr/NF-KB/  
 
 
Bioinformatics strategy 
 
Bioinformatics search algorithm is summarised as follows: 
 
 
 
Find promoter of gene of interest
Using TRANSFAC
Does the promoter
have NF-κB site?
NO
Preliminary candidate for NF-κB 
inducible gene
Check using Ensembl, SwissProt and other software if the human 
NF-κB site is conserved in mouse or Drosophilla genome 
The gene of interest is NF-κB inducible
YES
YES
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This strategy identified the following genes: 
 
Gene symbol Gene full  name
TRIP10 thyroid hormone receptor interactor 10
IL32 interleukin 32
RCP9 calcitonin gene-related peptide-receptor component prot
ANKRD1 ankyrin repeat domain 1 (cardiac muscle)
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b
AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol de  
LDHB lactate dehydrogenase B
TEAD1 TEA domain family member 1 (SV40 transcriptional enh  
PRDM2 PR domain containing 2, with ZNF domain
BACE2 beta-site APP-cleaving enzyme 2
SUV39H1 suppressor of variegation 3-9 homolog 1 (Drosophila)
IL1F9 interleukin 1 family, member 9
ALOX12B arachidonate 12-lipoxygenase, 12R type
CARD15 caspase recruitment domain family, member 15
CD74 CD74 antigen (invariant polypeptide of major histocomp     
CXCL2 chemokine (C-X-C motif) ligand 2
DEFB4 defensin, beta 4
IL15RA interleukin 15 receptor, alpha
TPMT thiopurine S-methyltransferase
TLR6 toll-like receptor 6
TLR4 toll-like receptor 4
SH3BGRL3 SH3 domain binding glutamic acid-rich protein like 3
PLA2G2E phospholipase A2, group IIE
ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 m  
CSF2RA colony stimulating factor 2 receptor, alpha, low-affinity 
MMP8 matrix metallopeptidase 8 (neutrophil collagenase)
CCL7 chemokine (C-C motif) ligand 7
TNFRSF21 tumor necrosis factor receptor superfamily, member 21
PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-depend
LAMC2 laminin, gamma 2
BCL2L10 BCL2-like 10 (apoptosis facilitator)
TNFSF6 tumor necrosis factor superfamily, member 6
CD105 homodimeric transmembrane protein which is a major gl     
TNFRSF6 tumor necrosis factor receptor superfamily, member 6, d  
TNFSF5 tumor necrosis factor superfamily, member 5
BM2 influenza B virus BM2
HC3 proteasome subunit HC3
SIAT8A ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransfer  
TBR tuberin
TNFRSF5 tumor necrosis factor receptor superfamily, member 5, d  
RBCK1 RanBP-type and C3HC4-type zinc finger containing 1
CCR2A chemokine (C-C motif) receptor 2 isoform A
CCR2B chemokine (C-C motif) receptor 2 isoform B  
 
Those genes are not found on the websites mentioned above or literature search. 
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Literature search 
 
Literature search identified the following genes: 
 
BIRC2, ICAM1, CX3CL1, NR4A3 and BCL10 
 
 
 
Internet search  
 
Internet search of NF-κB target genes list was carried out at:  
 
http://people.bu.edu/gilmore/nf-kb/target/index.html and http://bioinfo.lifl.fr/NF-KB/  
 
Summary of the categories and genes found in each is presented in the following table: 
 
 
Category Number of  Genes
Cytokines/Chemokines and their 
modulators
29
Immunoreceptors 20
Acute phase proteins 1
Stress response genes 5
Growth factors, ligands and their 
modulators
15
Early response genes 3
Proteins involved in antigen 
i
1
Cell adhesion molecules 6
Cell surface receptors 10
Regulators of apoptosis 9
Transcription factors 20
Viruses 4
Enzymes 33
Miscellaneous 41
Total no. 200  
 
 
Using all 3 strategies but removing duplication a total of 271 NF-κB target genes were 
identified. A full list is provided in the complementary DVD attached to the back cover of 
this thesis. 
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Overall, a total of 4395 gene sets were identified including 56 custom sets which was 
constructed as mentioned in this appendix. 
 
Gene set details are summarised in the following table: 
 
Name of Gene set
No. of 
gene 
sets
No of 
genes Source Description
NF-kB target genes 1 271 http://www.nf-kb.org; http://bioinfo.lifl.fr/NF-KB; http://people.Genes contain kB binding sites in their promoters and are transactivated by NF-kB 
Gene Sets from Immunome Database
Innate immunity 1 44 http://bioinf.uta.fi/Immunome
Antigen processing and presentation 1 45 http://bioinf.uta.fi/Immunome
Inflammation 1 131 http://bioinf.uta.fi/Immunome
Phagocytosis 1 18 http://bioinf.uta.fi/Immunome
Cellular Immunity 1 100 http://bioinf.uta.fi/Immunome
Humoural Immunity 1 103 http://bioinf.uta.fi/Immunome
Transcription factor 1 38 http://bioinf.uta.fi/Immunome
Complement System 1 56 http://bioinf.uta.fi/Immunome
Chemokine receptors 1 240 http://bioinf.uta.fi/Immunome
Cluster of differentiation (CD) 1 301 http://bioinf.uta.fi/Immunome
Gene Sets in biological processes annotated from Gene Ontology
Immunologially imporant genes 1 1327 http://wiki.geneontology.org/index.php/Immunologically_Imp Genes related to immunological process and listed according to their priority score
B and T cell receptor signalling pathway 1 113 http://www.geneontology.org/ Contains 69 and 44 genes for B and T cell receptor signalling respectively
Immune response (GO:0006955) 1 596 http://www.geneontology.org/ immune response genes derived from gene ontology root category of the term GO:0006955
Adaptive immune response (GO:0002250) 1 43 http://www.geneontology.org/ adaptive immune response genes derived from gene ontology root category of the term GO:0002250
Activation of immune response (GO:0002253) 1 41 http://www.geneontology.org/ activation of immune response genes derived from gene ontology root category of the term GO:0002253
Regulation of adaptive immune response (GO:0002819) 1 11 http://www.geneontology.org/ genes from regulation of adaptive immune response derived from gene ontology root category of the term GO:0002819
Immunoglobulin mediated immune response (GO:0016064) 1 14 http://www.geneontology.org/ genes involved in immunoglobulin mediated immune response derived from gene ontology root category of the term GO:0016064
Innate immune response (GO:0045087) 1 62 http://www.geneontology.org/ genes involved with innate immune response derived from gene ontology root category of the term GO:0045087
Regulation of innate immune response (GO:0045088) 1 14 http://www.geneontology.org/ genes involved with regulation of innate immune response derived from gene ontology root category of the term GO:0002250
Regulation of immune response (GO:0050776) 1 77 http://www.geneontology.org/ genes involved in regulation of immune response derived from gene ontology root category of the term GO:0050776
Negative regulation of immune response (GO:0050777) 1 9 http://www.geneontology.org/ genes involved with negative regulation of immune response derived from gene ontology root category of the term GO:0050777
Positive regulation of immune response (GO:0050778) 1 60 http://www.geneontology.org/ genes involved with positive regulation of immune response derived from gene ontology root category of the term GO:0050778
Lymphocyte mediated immunity (GO:0002449) 1 38 http://www.geneontology.org/ genes involved in lymphocyte mediated immunity derived from gene ontology root category of the term GO:0002449
T cell mediated immunity (GO:0002456) 1 11 http://www.geneontology.org/ genes involved in t cell mediated immunity derived from gene ontology root category of the term GO:0002456
Humoral immune response (GO:0006959) 1 45 http://www.geneontology.org/ genes involved in humoral immune response derived from gene ontology root category of the term GO:0006959
Adaptive immune response (GO:0002250) 1 97 http://www.geneontology.org/ genes involved in adaptive immune response derived from gene ontology root category of the term GO:0002250
Anti apoptosis (GO:0006916) 1 165 http://www.geneontology.org/ genes involved in anti-apoptosis derived from gene ontology root category of the term GO:0006916
Caspase activation (GO:0006919) 1 40 http://www.geneontology.org/ genes involved in caspase activation derived from gene ontology root category of the term GO:0006919
Inflammatory response (GO:0006954) 1 294 http://www.geneontology.org/ genes involved in inflammatory response derived from gene ontology root category of the term GO:0006954
I-kappaB kinase NF kappaB cascade (GO:0007249) 1 41 http://www.geneontology.org/ genes involved in I-kappaB kinase NF kappaB cascade derived from gene ontology root category of the term GO:0007249
Activation of NF kappaB inducing kinase (GO:0007250) 1 13 http://www.geneontology.org/ genes involved in the activation of NF kappaB inducing kinase derived from gene ontology root category of the term GO:0007250
T cell activation (GO:0042110) 1 59 http://www.geneontology.org/ genes involved in T cell activation derived from gene ontology root category of the term GO:0042110
B cell activation (GO:0042113) 1 43 http://www.geneontology.org/ genes involved in B cell activation derived from gene ontology root category of the term GO:0042113
Chemokine (GO:0042379) 1 50 http://www.geneontology.org/ genes relating to chemokines derived from gene ontology root category of the term GO:0042379
Positive regulation of I kappaB kinase NF kappaB cascade (GO:0043123) 1 101 http://www.geneontology.org/ genes involved in the positive regulation of I kappaB kinase NF kappaB cascade derived from gene ontology root category of the term GO:00
Innate immune response (GO:0045087) 1 105 http://www.geneontology.org/ genes involved in the innate immune response derived from gene ontology root category of the term GO:0045087
Lymphocyte activation (GO:0046649) 1 137 http://www.geneontology.org/ genes involved in lymphocyte activation derived from gene ontology root category of the term GO:0046649
Regulation of T cell activation (GO:0050863) 1 70 http://www.geneontology.org/ genes involved in the regulation of T cell activation derived from gene ontology root category of the term GO:0050863
Regulation of lymphocyte activation (GO:0051249) 1 120 http://www.geneontology.org/ genes involved in the regulation of lymphocyte activation derived from gene ontology root category of the term GO:0051249
Gene sets derived from pathways annotated by GeneGo
B Cell Lymphoma 1 50 http://www.genego.com/ Genes involved in B cell lymphoma derived from the GeneGo Metacore software
T Cell Receptor Signalling 1 46 http://www.genego.com/ Genes involved in T cell receptor signalling derived from the GeneGo Metacore software
TLR Signalling Pathway 1 82 http://www.genego.com/ Genes involved in TLR signalling pathway derived from the GeneGo Metacore software
CD28 1 71 http://www.genego.com/ CD28 pathway related genes derived from the GeneGo Metacore software
ICOS 1 93 http://www.genego.com/ Genes that are linked to ICOS pathway, derived from the GeneGo Metacore software
Chemotaxis Leukocyte 1 110 http://www.genego.com/ genes that are involved chemotaxis leukocyte, derived from the GeneGo Metacore software
Immune Response Bacteria 1 47 http://www.genego.com/ genes that are involved in bacterial immune response pathway derived from the GeneGo Metacore software
BCR Pathway 1 75 http://www.genego.com/ genes related to B cell receptor signalling pathway, derived from the GeneGo Metacore software
TCR CD28 costimulation leading to NFkB 1 70 http://www.genego.com/ genes involved in T-cell receptor signalling and CD28 costimulation leading to NFkB activation derived from the GeneGo Metacore software
Gene set derived from Pathways annotated by Ingenuity Systems
Antigen Receptor GO 1 17 http://www.ingenuity.com genes to do with antigen receptor signalling derived from the gene ontology part of the Ingenuity pathway analysis software
B cell activation 1 95 http://www.ingenuity.com genes to do with b cell activation derived from the gene ontology part of the Ingenuity pathway analysis software
B cell receptor signalling 1 60 http://www.ingenuity.com genes to do with b cell receptor signalling derived from the gene ontology part of the Ingenuity pathway analysis software
Chemokine signalling 1 36 http://www.ingenuity.com genes to do with chemokine signalling derived from the gene ontology part of the Ingenuity pathway analysis software
T cell activation GO 1 95 http://www.ingenuity.com genes to do with t cell activation derived from the gene ontology part of the Ingenuity pathway analysis software
T cell receptor signalling 1 57 http://www.ingenuity.com genes to do with t cell receptor signalling derived from the gene ontology part of the Ingenuity pathway analysis software
TLR signalling 1 33 http://www.ingenuity.com genes to do with TLR signalling derived from the gene ontology part of the Ingenuity pathway analysis software
Gene Sets from Molecular Signature Database   
This is derived from the Broad Institute website at : http://www.broad.mit.edu/gsea/msigdb/downloads.jsp and enriched using IPA and 
GeneGo Metacore software. The molecular signature pathways that are derived are from version 2.5. 
C2: Curated gene sets derived from online pathway database and publicatio 1892 http://www.broad.mit.edu/gsea/msigdb/index.jsp C2 curated gene sets derived from online pathway database and publications
C2: Canonical pathway gene sets from pathway databases 639 http://www.broad.mit.edu/gsea/msigdb/index.jsp Canonical pathway gene sets from pathway databases including the followings 
C2: BioCarta gene sets 249 http://www.biocarta.com/ BioCarta gene sets
C2: GenMAPP gene sets 138 http://www.genmapp.org/ GenMAPP gene sets
C2: KEGG gene sets 200 http://www.genome.jp/kegg/ KEGG gene sets
C5: GO biological process gene sets 825 http://www.broad.mit.edu/gsea/msigdb/index.jsp GO biological process gene sets
C5: GO molecular function gene sets 396 http://www.broad.mit.edu/gsea/msigdb/index.jsp GO molecular function gene sets
Total number of gene sets 4395
Total number of custom sets 56  
 
 
Finally, in order to manage and query the vast amount of data gathered from microarrays and 
gene set enrichment analysis, a relational database management software was constructed and 
included in the complementary DVD attached to the back cover of this thesis. 
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Appendix II – In house software for gene expression 
microarray analysis 
 
Two main programming languages were used to write custom made software for analysis of 
microarray data generated from this thesis; R programming platform with use of some of the 
bioconductor libraries and Visual Basic programming platform embedded within Microsoft 
Access in order to write the relational database management software.  
 
II.I R software 
 
R custom software were used to preprocess and analyse the 24 CEL files from MALT 
lymphoma and 15 CEL files from FL and MCL microarray data, as well as to help post 
process some of the GSEA data and carry out unsupervised clustering and statistical analysis 
e.g. for qRT-PCR and identification of differentially expressed genes using Bayesian analysis 
such as eBayes. 
 
A list of all the custom software is included in the complementary DVD attached to the back 
cover of this thesis. 
 
The main software R code for pre-processing and analysing microarray data from both the 
U133A&B and U133plus2 platforms is as follows: 
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# Analysis of U133A&B MALT lymphoma and U133plus2 FL and MCL 
# Software written by Rifat Hamoudi, 2010 
 
library(affy)   
library(gcrma) 
library(genefilter) 
library(gplots) 
library(annotate) 
library(hgu133a.db) 
library(hgu133b.db) 
library(hgu133aprobe) 
library(hgu133bprobe) 
library(gsubfn) 
 
 
########################################################### 
#  
#  Read the U133plus chips of FL & MCL 
# 
########################################################### 
 
 
setwd("/media/disk/RawArrayData/Cel Files/U133/FL_MCL") 
 
MCL_FL<-ReadAffy() # read affy files after changedir. Read into 
AffyBatch object 
 
sampleNames(MCL_FL) 
 
 
sampleNames(MCL_FL)[1] <- "FL14" 
sampleNames(MCL_FL)[2] <- "FL16" 
sampleNames(MCL_FL)[3] <- "FL17" 
sampleNames(MCL_FL)[4] <- "FL18" 
sampleNames(MCL_FL)[5] <- "FL19" 
sampleNames(MCL_FL)[6] <- "FL20" 
sampleNames(MCL_FL)[7] <- "FL21" 
sampleNames(MCL_FL)[8] <- "MCL22" 
sampleNames(MCL_FL)[9] <- "MCL23" 
sampleNames(MCL_FL)[10] <- "MCL24" 
sampleNames(MCL_FL)[11] <- "MCL25" 
sampleNames(MCL_FL)[12] <- "MCL26" 
sampleNames(MCL_FL)[13] <- "MCL27" 
sampleNames(MCL_FL)[14] <- "MCL28" 
sampleNames(MCL_FL)[15] <- "MCL29" 
 
gcrma_mcl_fl <-gcrma(MCL_FL) # normalization via gcrma 
mas_mcl_fl <- mas5(MCL_FL, sc=100) # normalization via MAS5 
 
 
 
# MCL FL groups definition 
 
flnum <- seq(1:7) 
mclnum <- c(8,9,10,11,12,13,14,15) 
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allnum <- c(flnum, mclnum) 
 
# GCRMA groups implementation 
 
flgc <- gcrma_mcl_fl[,flnum] 
mclgc <- gcrma_mcl_fl[,mclnum] 
allflmclgc <- gcrma_mcl_fl[,allnum] 
 
 
# MAS5 groups implementation 
 
flmas <- mas_mcl_fl[,flnum] 
mclmas <- mas_mcl_fl[,mclnum] 
allflmclmas <- mas_mcl_fl[,allnum] 
 
 
# filter stuff on MAS5 abs values 
 
f1<-kOverA(7, 50) # if a gene is 50 or more raw value in more than 7 
samples then pass it 
ff <-filterfun(f1) 
masselect_flmcl <-genefilter(mas_mcl_fl, ff) 
sum(masselect_flmcl) 
esetmasflmcl <- mas_mcl_fl[masselect_flmcl,] 
 
# filtering gcRMA on CV 
 
cvfun <- cv(0.1, 1.0) 
ffun <- filterfun(cvfun) 
gcselect_flmcl <- genefilter(gcrma_mcl_fl, ffun) 
sum(gcselect_flmcl) 
esetgcrmaflmcl <- gcrma_mcl_fl[gcselect_flmcl,] 
 
 
# Extract the correct set on gcRMA and MAS5 
 
selectgenes_flmcl <- intersect(featureNames(esetmasflmcl), 
featureNames(esetgcrmaflmcl)) 
selectgenes_flmcl 
length(selectgenes_flmcl) 
 
esetgcgoodflmcl <- gcrma_mcl_fl[selectgenes_flmcl,] # gcRMA 
esetgcgoodflmcl 
 
esetmasgoodflmcl <- mas_mcl_fl[selectgenes_flmcl,] # MAS5 
esetmasgoodflmcl 
 
 
 
gn <- featureNames(MCL_FL) 
ps <- probeset(MCL_FL, gn[1:2]) 
probeNames(MCL_FL)[1:5] 
 
gcrmaflmclexp <- exprs(gcrma_mcl_fl) 
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# eliminate AFFX and _x_ 
idsflmcl <- featureNames(esetmasgoodflmcl) 
ids.affx <- grep("^AFFX", idsflmcl) 
#noX <- grep("_x_", ids) 
ids.noaffx_flmcl <- setdiff(c(1:length(idsflmcl)), ids.affx) 
#ids.noaffx <- setdiff(c(1:length(idsflmcl)), noX) 
 
esetgcfinalflmcl <- esetgcgoodflmcl[ids.noaffx_flmcl,] 
esetgcfinalflmcl 
 
esetmasfinalflmcl <- esetmasgoodflmcl[ids.noaffx_flmcl,] 
esetmasfinalflmcl 
 
 
 
########################################################### 
#  
#  Read U133A MALT lymphomas 
# 
########################################################### 
 
setwd("/media/disk/RawArrayData/Cel Files/U133/MALT/HG133_A") 
 
MALT_A<-ReadAffy() # read affy files after changedir. Read into 
AffyBatch object 
 
sampleNames(MALT_A) 
 
sampleNames(MALT_A)[1] <- "11_18_G0015_A" 
sampleNames(MALT_A)[2] <- "11_18_G5125_A" 
sampleNames(MALT_A)[3] <- "11_18_G5661_A" 
sampleNames(MALT_A)[4] <- "11_18_G6071_A" 
sampleNames(MALT_A)[5] <- "11_18_86_14635_Samp11V_A" 
sampleNames(MALT_A)[6] <- "11_18_95_10509_Samp1F_A" 
sampleNames(MALT_A)[7] <- "11_18_92_10232_Samp2F_A" 
sampleNames(MALT_A)[8] <- "11_18_96_8361_Samp3F_A" 
sampleNames(MALT_A)[9] <- "11_18_97_107717_Samp7V_A" 
sampleNames(MALT_A)[10] <- "1_14_Bel_A" 
sampleNames(MALT_A)[11] <- "1_14_G0186_A" 
sampleNames(MALT_A)[12] <- "1_14_G0262_A" 
sampleNames(MALT_A)[13] <- "1_2_G6389_A" 
sampleNames(MALT_A)[14] <- "14_18_02_101211_Samp8V_A" 
sampleNames(MALT_A)[15] <- "14_18_97_21350_Samp16V_A" 
sampleNames(MALT_A)[16] <- "3_14_G0046_A" 
sampleNames(MALT_A)[17] <- "NEG_G0019_A" 
sampleNames(MALT_A)[18] <- "NEG_G0055_Nuc_A" 
sampleNames(MALT_A)[19] <- "NEG_G0078_Nuc_A" 
sampleNames(MALT_A)[20] <- "NEG_G5018_A" 
sampleNames(MALT_A)[21] <- "NEG_G6352_Nuc_A" 
sampleNames(MALT_A)[22] <- "NEG_88_20237_Samp12V_A" 
sampleNames(MALT_A)[23] <- "NEG_92_8149_Samp4F_A" 
sampleNames(MALT_A)[24] <- "NEG_91_6360_Samp5F_A" 
sampleNames(MALT_A)[25] <- "NEG_96_9991_Samp6F_A" 
sampleNames(MALT_A)[26] <- "NEG_89_01810_Samp13V_A" 
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gcrmamalt_a<-gcrma(MALT_A) # normalization via gcrma 
masmalt_a <- mas5(MALT_A, sc=100) # normalization via MAS5 
 
 
# groups definition 
 
neg_A <- c(17,18,19,20,21,22,23,24,25,26) 
tr11_18_A <- c(1,2,3,4,5,6,7,8,9) 
tr1_14_A <- c(10,11,12,13) 
tr14_18_A <- c(14,15) 
 
t11_18set_A <- c(tr11_18_A,neg_A) 
t1_14set_A <- c(tr1_14_A, neg_A) 
t14_18set_A <- c(tr14_18_A, neg_A) 
 
 
# GCRMA groups implementation 
 
posneggcrmav_A <- c(tr1_14_A, tr11_18_A, tr14_18_A, neg_A) 
posneggcrma_A <- gcrmamalt_a[,posneggcrmav_A] 
pData(posneggcrma_A)$sample <- c(1:25) 
 
t11_18gc_A <- gcrmamalt_a[,t11_18set_A] 
t1_14gc_A <- gcrmamalt_a[,t1_14set_A] 
t14_18gc_A <- gcrmamalt_a[,t14_18set_A] 
 
 
# MAS5 groups implementation 
 
posnegv_A <- c(tr1_14_A, tr11_18_A, tr14_18_A, neg_A) 
posnegmas_A <- masmalt_a[,posnegv_A] 
pData(posnegmas_A)$sample <- c(1:25) 
 
t11_18mas_A <- masmalt_a[,t11_18set_A] 
t1_14mas_A <- masmalt_a[,t1_14set_A] 
t14_18mas_A <- masmalt_a[,t14_18set_A] 
 
 
 
########################################################### 
#  
#  Read U133B MALT lymphomas 
# 
########################################################### 
 
 
setwd("/media/disk/RawArrayData/Cel Files/U133/MALT/HG133_B") 
 
MALT_B<-ReadAffy() # read affy files after changedir. Read into 
AffyBatch object 
 
sampleNames(MALT_B) 
 
sampleNames(MALT_B)[1] <- "11_18_G0015_B" 
sampleNames(MALT_B)[2] <- "11_18_G5125_B" 
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sampleNames(MALT_B)[3] <- "11_18_G5661_B" 
sampleNames(MALT_B)[4] <- "11_18_G6071_B" 
sampleNames(MALT_B)[5] <- "11_18_86_14635_Samp11V_B" 
sampleNames(MALT_B)[6] <- "11_18_95_10509_Samp1F_B" 
sampleNames(MALT_B)[7] <- "11_18_92_10232_Samp2F_B" 
sampleNames(MALT_B)[8] <- "11_18_96_8361_Samp3F_B" 
sampleNames(MALT_B)[9] <- "11_18_97_107717_Samp7V_B" 
sampleNames(MALT_B)[10] <- "1_14_Bel_B" 
sampleNames(MALT_B)[11] <- "1_14_G0186_B" 
sampleNames(MALT_B)[12] <- "1_14_G0262_B" 
sampleNames(MALT_B)[13] <- "1_2_G6389_B" 
sampleNames(MALT_B)[14] <- "14_18_02_101211_Samp16V_B" 
sampleNames(MALT_B)[15] <- "14_18_97_21350_Samp8V_B" 
sampleNames(MALT_B)[16] <- "3_14_G0046_B" 
sampleNames(MALT_B)[17] <- "NEG_G0019_B" 
sampleNames(MALT_B)[18] <- "NEG_G0055_Nuc_B" 
sampleNames(MALT_B)[19] <- "NEG_G0078_Nuc_B" 
sampleNames(MALT_B)[20] <- "NEG_G5018_B" 
sampleNames(MALT_B)[21] <- "NEG_G6352_Nuc_B" 
sampleNames(MALT_B)[22] <- "NEG_88_20237_Samp12V_B" 
sampleNames(MALT_B)[23] <- "NEG_92_8149_Samp4F_B" 
sampleNames(MALT_B)[24] <- "NEG_91_6360_Samp5F_B" 
sampleNames(MALT_B)[25] <- "NEG_96_9991_Samp6F_B" 
sampleNames(MALT_B)[26] <- "NEG_89_01810_Samp13V_B" 
 
gcrmamalt_b <-gcrma(MALT_B) # normalization via gcrma 
masmalt_b <- mas5(MALT_B, sc=100) # normalization via MAS5 
 
 
# groups definition Bchips 
 
neg_B <- c(17,18,19,20,21,22,23,24,25,26) 
tr11_18_B <- c(1,2,3,4,5,6,7,8,9) 
tr1_14_B <- c(10,11,12,13) 
tr14_18_B <- c(14,15) 
 
t11_18set_B <- c(tr11_18_B,neg_B) 
t1_14set_B <- c(tr1_14_B, neg_B) 
t14_18set_B <- c(tr14_18_B, neg_B) 
 
 
# GCRMA groups implementation 
 
posneggcrmav_B <- c(tr1_14_B, tr11_18_B, tr14_18_B, neg_B) 
posneggcrma_B <- gcrmamalt_b[,posneggcrmav_B] 
pData(posneggcrma_B)$sample <- c(1:25) 
 
t11_18gc_B <- gcrmamalt_b[,t11_18set_B] 
t1_14gc_B <- gcrmamalt_b[,t1_14set_B] 
t14_18gc_B <- gcrmamalt_b[,t14_18set_B] 
 
 
# MAS5 groups implementation 
 
posnegv_B <- c(tr1_14_B, tr11_18_B, tr14_18_B, neg_B) 
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posnegmas_B <- masmalt_b[,posnegv_B] 
pData(posnegmas_B)$sample <- c(1:25) 
 
t11_18mas_B <- masmalt_b[,t11_18set_B] 
t1_14mas_B <- masmalt_b[,t1_14set_B] 
t14_18mas_B <- masmalt_b[,t14_18set_B] 
 
 
 
 
########################################################### 
#  
#  MALT_A nonspecific filtering 
# 
########################################################### 
 
# filter stuff on MAS5 abs values A chip 
 
f1<-kOverA(2, 50) # if a gene is 50 or more raw value in more than 2 
samples then pass it 
ff <-filterfun(f1) 
masselect_malt_a <- genefilter(masmalt_a, ff) 
sum(masselect_malt_a) 
esetmasposneg_a <- posnegmas_A[masselect_malt_a,] 
 
# filtering gcRMA on CV 
 
cvfun <- cv(0.1, 1.0) 
ffun <- filterfun(cvfun) 
gcselect_malt_a <- genefilter(gcrmamalt_a, ffun) 
sum(gcselect_malt_a) 
esetgcrmaposneg_a <- posneggcrma_A[gcselect_malt_a,] 
 
# Extract the correct set on gcRMA and MAS5 
 
selectgenes_malt_a <- intersect(featureNames(esetmasposneg_a), 
featureNames(esetgcrmaposneg_a)) 
selectgenes_malt_a 
length(selectgenes_malt_a) 
 
esetgcgoodposneg_a <- posneggcrma_A[selectgenes_malt_a,] # gcRMA 
esetgcgoodposneg_a 
 
esetmasgoodposneg_a <- posnegmas_A[selectgenes_malt_a,] # MAS5 
esetmasgoodposneg_a 
 
gn_a <- featureNames(MALT_A) 
ps_a <- probeset(MALT_A, gn_a[1:2]) 
probeNames(MALT_A)[1:5] 
 
gcrmamaltexp_a <- exprs(gcrmamalt_a) 
 
# eliminate AFFX and _x_ 
ids_a <- featureNames(esetgcgoodposneg_a) 
ids.affx_a <- grep("^AFFX", ids_a) 
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ids.noaffx_malt_a <- setdiff(c(1:length(ids_a)), ids.affx_a) 
 
#noX <- grep("_x_", ids) 
#ids.noaffx <- setdiff(c(1:length(ids)), noX) 
 
 
esetgcfinalposneg_a <- esetgcgoodposneg_a[ids.noaffx_malt_a,] 
esetgcfinalposneg_a 
 
esetmasfinalposneg_a <- esetmasgoodposneg_a[ids.noaffx_malt_a,] 
esetmasfinalposneg_a 
 
 
########################################################### 
#  
#  MALT_B nonspecific filtering 
# 
########################################################### 
 
 
# filter stuff on MAS5 abs values B chip 
 
f1<-kOverA(2, 50) # if a gene is 50 or more raw value in more than 2 
samples then pass it 
ff <-filterfun(f1) 
masselect_malt_b <- genefilter(masmalt_b, ff) 
sum(masselect_malt_b) 
esetmasposneg_b <- posnegmas_B[masselect_malt_b,] 
 
# filtering gcRMA on CV 
 
cvfun <- cv(0.1, 1.0) 
ffun <- filterfun(cvfun) 
gcselect_malt_b <- genefilter(gcrmamalt_b, ffun) 
sum(gcselect_malt_b) 
esetgcrmaposneg_b <- posneggcrma_B[gcselect_malt_b,] 
 
 
# Extract the correct set on gcRMA and MAS5 
 
selectgenes_malt_b <- intersect(featureNames(esetmasposneg_b), 
featureNames(esetgcrmaposneg_b)) 
selectgenes_malt_b 
length(selectgenes_malt_b) 
 
esetgcgoodposneg_b <- posneggcrma_B[selectgenes_malt_b,] # gcRMA 
esetgcgoodposneg_b 
 
esetmasgoodposneg_b <- posnegmas_B[selectgenes_malt_b,] # MAS5 
esetmasgoodposneg_b 
 
 
 
gn_b <- featureNames(MALT_B) 
ps_b <- probeset(MALT_B, gn_b[1:2]) 
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probeNames(MALT_B)[1:5] 
 
gcrmamaltexp_b <- exprs(gcrmamalt_b) 
 
# eliminate AFFX and _x_ 
ids_b <- featureNames(esetgcgoodposneg_b) 
ids.affx_b <- grep("^AFFX", ids_b) 
ids.noaffx_malt_b <- setdiff(c(1:length(ids_b)), ids.affx_b) 
 
#noX <- grep("_x_", ids) 
#ids.noaffx <- setdiff(c(1:length(ids)), noX) 
 
 
esetgcfinalposneg_b <- esetgcgoodposneg_b[ids.noaffx_malt_b,] 
esetgcfinalposneg_b 
 
esetmasfinalposneg_b <- esetmasgoodposneg_b[ids.noaffx_malt_b,] 
esetmasfinalposneg_b 
 
 
################################################## 
# 
# Map all the MALT_A probes on the FLMCL 
# 
################################################## 
 
maltprobes_a <- featureNames(esetmasfinalposneg_a) 
 
esetfinalflmclgc_a <- gcrma_mcl_fl[maltprobes_a,] 
esetfinalflmclmas_a <- mas_mcl_fl[maltprobes_a,] 
 
 
################################################## 
# 
# Map all the MALT_B probes on the FLMCL 
# 
################################################## 
 
maltprobes_b <- featureNames(esetmasfinalposneg_b) 
 
esetfinalflmclgc_b <- gcrma_mcl_fl[maltprobes_b,] 
esetfinalflmclmas_b <- mas_mcl_fl[maltprobes_b,] 
 
 
 
################################################## 
# 
# Find common probes between MALT_A and MALT_B and FLMCL 
# 
################################################## 
 
# MALT_A 
 
flmclmaltprobes_a <- intersect(featureNames(esetmasfinalflmcl), 
featureNames(esetmasfinalposneg_a)) 
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instersectflmclmaltgc_a <- esetgcgoodflmcl[flmclmaltprobes_a,] 
instersectflmclmaltmas_a <- esetmasgoodflmcl[flmclmaltprobes_a,] 
 
instersectmaltgc_a <- esetgcgoodposneg_a[flmclmaltprobes_a,] 
instersectmaltmas_a <- esetmasgoodposneg_a[flmclmaltprobes_a,] 
 
 
# MALT_B 
 
flmclmaltprobes_b <- intersect(featureNames(esetmasfinalflmcl), 
featureNames(esetmasfinalposneg_b)) 
instersectflmclmaltgc_b <- esetgcgoodflmcl[flmclmaltprobes_b,] 
instersectflmclmaltmas_b <- esetmasgoodflmcl[flmclmaltprobes_b,] 
 
instersectmaltgc_b <- esetgcgoodposneg_b[flmclmaltprobes_b,] 
instersectmaltmas_b <- esetmasgoodposneg_b[flmclmaltprobes_b,] 
 
 
########################### write out ################################# 
 
setwd("/media/Linux/malt_flmcl_res") 
 
# MALT_A writeout 
 
write.table(exprs(posnegmas_A), file="MALT MAS5 Achip 22283.xls", 
append = FALSE, sep="\t", eol="\n", row.names=TRUE, col.names=TRUE, 
qmethod=c("escape", "double")) 
 
write.table(exprs(posneggcrma_A), file="MALT GCRMA Achip 22283.xls", 
append = FALSE, sep="\t", eol="\n", row.names=TRUE, col.names=TRUE, 
qmethod=c("escape", "double")) 
 
write.table(exprs(esetgcfinalposneg_a), file="MALT GCRMA Filtered Achip 
norm 8181.xls", append = FALSE, sep="\t", eol="\n", row.names=TRUE, 
col.names=TRUE, qmethod=c("escape", "double")) 
  
write.table(exprs(esetmasfinalposneg_a), file="MALT MAS5 Filtered Achip 
raw 8181.xls", append = FALSE, sep="\t", eol="\n", row.names=TRUE, 
col.names=TRUE, qmethod=c("escape", "double")) 
 
 
# MALT_B writeout 
 
write.table(exprs(posnegmas_B), file="MALT MAS5 Bchip 22645.xls", 
append = FALSE, sep="\t", eol="\n", row.names=TRUE, col.names=TRUE, 
qmethod=c("escape", "double")) 
 
write.table(exprs(posneggcrma_B), file="MALT GCRMA Bchip 22645.xls", 
append = FALSE, sep="\t", eol="\n", row.names=TRUE, col.names=TRUE, 
qmethod=c("escape", "double")) 
 
write.table(exprs(esetgcfinalposneg_b), file="MALT GCRMA Filtered Bchip 
norm 8622.xls", append = FALSE, sep="\t", eol="\n", row.names=TRUE, 
col.names=TRUE, qmethod=c("escape", "double")) 
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write.table(exprs(esetmasfinalposneg_b), file="MALT MAS5 Filtered Bchip 
raw 8622.xls", append = FALSE, sep="\t", eol="\n", row.names=TRUE, 
col.names=TRUE, qmethod=c("escape", "double")) 
 
 
 
# FLMCL writeout 
 
write.table(exprs(mas_mcl_fl), file="FLMCL MAS5 U133plus2 54675.xls", 
append = FALSE, sep="\t", eol="\n", row.names=TRUE, col.names=TRUE, 
qmethod=c("escape", "double")) 
 
write.table(exprs(gcrma_mcl_fl), file="FLMCL GCRMA U133plus2 
54675.xls", append = FALSE, sep="\t", eol="\n", row.names=TRUE, 
col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(esetgcfinalflmcl), file="FLMCL GCRMA Filtered 
U133plus2 norm 10652.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
  
write.table(exprs(esetmasfinalflmcl), file="FLMCL MAS5 Filtered 
U133plus2 raw 10652.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
 
 
 
# FLMCL on MALT writeout 
 
write.table(exprs(esetfinalflmclgc_a), file="FLMCL_MALT_GC Achip 
8181.xls", append = FALSE, sep="\t", eol="\n", row.names=TRUE, 
col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(esetfinalflmclmas_a), file="FLMCL_MALT_MAS Achip 
8181.xls", append = FALSE, sep="\t", eol="\n", row.names=TRUE, 
col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(esetfinalflmclgc_b), file="FLMCL_MALT_GC Bchip 
8622.xls", append = FALSE, sep="\t", eol="\n", row.names=TRUE, 
col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(esetfinalflmclmas_b), file="FLMCL_MALT_MAS Bchip 
8622.xls", append = FALSE, sep="\t", eol="\n", row.names=TRUE, 
col.names=TRUE, qmethod=c("escape", "double")) 
 
 
 
# FLMCL on MALT intersect writeout 
 
write.table(exprs(instersectflmclmaltgc_a), file="FLMCL_MALT_A_GC FLMCL 
intersect 3871.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(instersectflmclmaltmas_a), file="FLMCL_MALT_A_MAS 
FLMCL intersect 3871.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
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write.table(exprs(instersectmaltgc_a), file="FLMCL_MALT_GC MALT_A 
intersect 3871.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(instersectmaltmas_a), file="FLMCL_MALT_MAS MALT_A 
intersect 3871.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(instersectflmclmaltgc_b), file="FLMCL_MALT_B_GC FLMCL 
intersect 3034.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(instersectflmclmaltmas_b), file="FLMCL_MALT_B_MAS 
FLMCL intersect 3034.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(instersectmaltgc_b), file="FLMCL_MALT_GC MALT_B 
intersect 3034.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
 
write.table(exprs(instersectmaltmas_b), file="FLMCL_MALT_MAS MALT_B 
intersect 3034.xls", append = FALSE, sep="\t", eol="\n", 
row.names=TRUE, col.names=TRUE, qmethod=c("escape", "double")) 
 
 
 
 
 
II.II Visual Basic software for relational database management 
software 
 
Two relational database management software (RDBMS) were written for this thesis. Firstly, 
an RDBMS entitled “ArrayExplorer RDBMS” which allowed the query and data 
management generated from the microarray experiments. Secondly an RDBMS entitled 
“GSEA RDBMS” which contained query and data management functionalities that helped in 
collating the information generated from GSEA. 
 
Both of these software are included in the complementary DVD attached to the back cover of 
this thesis. 
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Appendix III – GSEA results 
 
III.I NF-κB target gene set 
 
A list of 271 NF-κB target genes was compiled as described in appendix I.III. 223 genes were 
obtained from the website:  
 
However the remaining 48 genes were obtained through bioinformatics and literature search 
as described in appendix I.III. The 48 genes are listed below: 
 
Gene symbol Gene full name Source
TRIP10 thyroid hormone receptor interactor 10 bioinformatics
IL32 interleukin 32 bioinformatics
RCP9 calcitonin gene-related peptide-receptor component protbioinformatics
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) bioinformatics
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b bioinformatics
AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol de  bioinformatics
LDHB lactate dehydrogenase B bioinformatics
TEAD1 TEA domain family member 1 (SV40 transcriptional enh  bioinformatics
PRDM2 PR domain containing 2, with ZNF domain bioinformatics
BACE2 beta-site APP-cleaving enzyme 2 bioinformatics
SUV39H1 suppressor of variegation 3-9 homolog 1 (Drosophila) bioinformatics
IL1F9 interleukin 1 family, member 9 bioinformatics
ALOX12B arachidonate 12-lipoxygenase, 12R type bioinformatics
CARD15 caspase recruitment domain family, member 15 bioinformatics
CD74 CD74 antigen (invariant polypeptide of major histocomp     bioinformatics
CXCL2 chemokine (C-X-C motif) ligand 2 bioinformatics
DEFB4 defensin, beta 4 bioinformatics
IL15RA interleukin 15 receptor, alpha bioinformatics
TPMT thiopurine S-methyltransferase bioinformatics
TLR6 toll-like receptor 6 bioinformatics
TLR4 toll-like receptor 4 bioinformatics
SH3BGRL3 SH3 domain binding glutamic acid-rich protein like 3 bioinformatics
PLA2G2E phospholipase A2, group IIE bioinformatics
ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 m  bioinformatics
CSF2RA colony stimulating factor 2 receptor, alpha, low-affinity bioinformatics
MMP8 matrix metallopeptidase 8 (neutrophil collagenase) bioinformatics
CCL7 chemokine (C-C motif) ligand 7 bioinformatics
TNFRSF21 tumor necrosis factor receptor superfamily, member 21 bioinformatics
PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-dependbioinformatics
LAMC2 laminin, gamma 2 bioinformatics
BCL2L10 BCL2-like 10 (apoptosis facilitator) bioinformatics
TNFSF6 tumor necrosis factor superfamily, member 6 bioinformatics
CD105 homodimeric transmembrane protein which is a major gl     bioinformatics
TNFRSF6 tumor necrosis factor receptor superfamily, member 6, d  bioinformatics
TNFSF5 tumor necrosis factor superfamily, member 5 bioinformatics
BM2 influenza B virus BM2 bioinformatics
HC3 proteasome subunit HC3 bioinformatics
SIAT8A ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransfer  bioinformatics
TBR tuberin bioinformatics
TNFRSF5 tumor necrosis factor receptor superfamily, member 5, d  bioinformatics
RBCK1 RanBP-type and C3HC4-type zinc finger containing 1 bioinformatics
CCR2A chemokine (C-C motif) receptor 2 isoform A bioinformatics
CCR2B chemokine (C-C motif) receptor 2 isoform B bioinformatics
BIRC2 baculoviral IAP repeat-containing 2 Blood, 15th of August, 2005 ; 106(4) : 1392 - 1399
ICAM1 intercellular adhesion molecule 1 (CD54), human rhinovi  Blood, 15th of August, 2005 ; 106(4) : 1392 - 1399
CX3CL1 chemokine (C-X3-C motif) ligand 1 Blood, 15th of August, 2005 ; 106(4) : 1392 - 1399
NR4A3 nuclear receptor subfamily 4, group A, member 3
Journal of Biological Chemistry, 12th of August, 2005 ; 280(32) 
: 29256-29262
BCL10 B-cell CLL/lymphoma 10
Journal of Biological Chemistry, 6th of January, 2006 ; 281(1) : 
167 - 175  
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III.II Leading edge core set of NF-kB target genes enriched in 
MALT lymphoma with and without chromosome translocation 
 
      
Rank Gene Description
Chromosome 
Band
Entre
z ID
Signal 
to 
noise 
Enrichment 
Score
Expression of genes enriched in translocation negative MALT lymphoma  
1 CXCL5 chemokine (C-X-C motif) ligand 5 4q12-q13 6374 0.530 0.020
2 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxy 1q25.2-q25.3 5743 0.519 0.039
3 NR4A3 nuclear receptor subfamily 4, group A, member 3 9q22 8013 0.485 0.057
4 CCL11 chemokine (C-C motif) ligand 11 17q21.1-q21.2 6356 0.455 0.073
5 PTGIS prostaglandin I2 (prostacyclin) synthase 20q13.13 5740 0.416 0.087
6 IL8 interleukin 8 4q13-q21 3576 0.395 0.100
7 MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 11q22.3 4314 0.388 0.114
8 CXCL2 chemokine (C-X-C motif) ligand 2 4q21 2920 0.372 0.126
9 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 4q21 2919 0.370 0.140
10 CD86 CD86 molecule 3q21 942 0.359 0.152
11 CCL2 chemokine (C-C motif) ligand 2 17q11.2-q12 6347 0.346 0.161
12 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 2q33-q34 3485 0.323 0.169
13 GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) 14q11.2 3002 0.322 0.181
14 VEGF vascular endothelial growth factor 6p12 7422 0.313 0.190
15 SOD2 superoxide dismutase 2, mitochondrial 6q25.3 6648 0.313 0.202
16 IL11 interleukin 11 19q13.3-q13.4 3589 0.313 0.214
17 PLAU plasminogen activator, urokinase 10q24 5328 0.311 0.225
18 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 1p22.2 2633 0.310 0.237
19 SDC4 syndecan 4 20q12 6385 0.292 0.242
20 AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid b10p15-p14 1646 0.288 0.251
21 IER3 immediate early response 3 6p21.3 8870 0.277 0.256
22 EGR1 early growth response 1 5q31.1 1958 0.268 0.262
23 TNC tenascin C 9q33 3371 0.268 0.272
24 PENK proenkephalin 8q23-q24 5179 0.258 0.278
25 KITLG KIT ligand 12q22 4254 0.252 0.283
26 PRF1 perforin 1 (pore forming protein) 10q22 5551 0.245 0.289
27 GADD45B growth arrest and DNA-damage-inducible, beta 19p13.3 4616 0.237 0.292
28 FN1 fibronectin 1 2q34 2335 0.236 0.301
29 THBS2 thrombospondin 2 6q27 7058 0.232 0.308
30 NQO1 NAD(P)H dehydrogenase, quinone 1 16q22.1 1728 0.232 0.317
31 TEAD1 TEA domain family member 1 (SV40 transcriptional enhancer factor) 11p15.2 7003 0.229 0.323
32 AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1q42-q43 183 0.219 0.323
33 IL1B interleukin 1, beta 2q14 3553 0.196 0.311
34 GIF gastric intrinsic factor (vitamin B synthesis) 11q13 2694 0.195 0.317
35 RBCK1 RanBP-type and C3HC4-type zinc finger containing 1 20p13 10616 0.195 0.324
36 CYP7B1 cytochrome P450, family 7, subfamily B, polypeptide 1 8q21.3 9420 0.188 0.324
37 IL10 interleukin 10 1q31-q32 3586 0.186 0.329
38 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 1q32.2 1999 0.183 0.332
39 TLR2 toll-like receptor 2 4q32 7097 0.181 0.337
40 PTX3 pentraxin-related gene, rapidly induced by IL-1 beta 3q25 5806 0.180 0.343
41 BMP2 bone morphogenetic protein 2 20p12 650 0.177 0.346
42 IL1RN interleukin 1 receptor antagonist 2q14.2 3557 0.173 0.348
43 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) 19p13.3 2208 0.167 0.346
44 UGCG UDP-glucose ceramide glucosyltransferase 9q31 7357 0.167 0.352
45 BDKRB1 bradykinin receptor B1 14q32.1-q32.2 623 0.165 0.354
46 HPSE heparanase 4q21.3 10855 0.162 0.356
47 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene 7p12 1956 0.158 0.357
48 BAX BCL2-associated X protein 19q13.3-q13.4 581 0.150 0.353
49 CCL4 chemokine (C-C motif) ligand 4 17q12 6351 0.150 0.358
50 DIO2 deiodinase, iodothyronine, type II 14q24.2-q24.3 1734 0.146 0.357
51 ORM1 orosomucoid 1 9q31-q32 5004 0.146 0.363
52 XDH xanthine dehydrogenase 2p23.1 7498 0.146 0.368
53 CXCL9 chemokine (C-X-C motif) ligand 9 4q21 4283 0.145 0.372
54 TFF3 trefoil factor 3 (intestinal) 21q22.3 7033 0.144 0.377
55 PTAFR platelet-activating factor receptor 1p35-p34.3 5724 0.144 0.382
56 TNFRSF21 tumor necrosis factor receptor superfamily, member 21 6p21.1-p12.2 27242 0.141 0.383
57 KCNK5 potassium channel, subfamily K, member 5 6p21 8645 0.139 0.383
58 JUNB jun B proto-oncogene 19p13.2 3726 0.136 0.384
59 ICOS inducible T-cell co-stimulator 2q33 29851 0.130 0.378
60 TLR4 toll-like receptor 4 9q32-q33 7099 0.127 0.378
61 DEFB4 defensin, beta 4 8p23.1-p22 1673 0.125 0.378
62 UBE2M ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast) 19q13.43 9040 0.124 0.382
63 ADH1A alcohol dehydrogenase 1A (class I), alpha polypeptide 4q21-q23 124 0.123 0.384
64 ICAM1 intercellular adhesion molecule 1 19p13.3-p13.2 3383 0.118 0.378
65 BCL2L1 BCL2-like 1 20q11.21 598 0.117 0.381
66 FAS Fas (TNF receptor superfamily, member 6) 10q24.1 355 0.114 0.378
67 BGN biglycan Xq28 633 0.113 0.382
68 PAX8 paired box 8 2q12-q14 7849 0.113 0.386
69 CTSB cathepsin B 8p22 1508 0.112 0.387
70 ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 9q31.1 19 0.111 0.390  
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Expression of genes enriched in translocation positive MALT lymphoma  
146 KLK3 kallikrein-related peptidase 3 19q13.41 354 -0.165 -0.161
147 UCP2 uncoupling protein 2 (mitochondrial, proton carrier) 11q13 7351 -0.171 -0.160
148 MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1 19q13.1-q13.4 11184 -0.183 -0.161
149 IFI44L interferon-induced protein 44-like 1p31.1 10964 -0.188 -0.157
150 CCR5 chemokine (C-C motif) receptor 5 3p21 1234 -0.199 -0.157
151 IRF7 interferon regulatory factor 7 11p15.5 3665 -0.202 -0.150
152 PRDM2 PR domain containing 2, with ZNF domain 1p36.21 7799 -0.208 -0.145
153 BCL2L10 BCL2-like 10 (apoptosis facilitator) 15q21 10017 -0.218 -0.142
154 CCR7 chemokine (C-C motif) receptor 7 17q12-q21.2 1236 -0.231 -0.137
155 IRF4 interferon regulatory factor 4 6p25-p23 3662 -0.262 -0.134
156 LTB lymphotoxin beta (TNF superfamily, member 3) 6p21.3 4050 -0.263 -0.124
157 REL v-rel reticuloendotheliosis viral oncogene homolog (avian) 2p13-p12 5966 -0.272 -0.116
158 C4BPA complement component 4 binding protein, alpha 1q32 722 -0.273 -0.105
159 TLR6 toll-like receptor 6 4p14 10333 -0.287 -0.097
160 BCL10 B-cell CLL/lymphoma 10 1p22 8915 -0.290 -0.086
161 CD69 CD69 molecule 12p13-p12 969 -0.352 -0.078
162 TFEC transcription factor EC 7q31.2 22797 -0.364 -0.065
163 BCL2 B-cell CLL/lymphoma 2 18q21.33 596 -0.396 -0.051
164 CCR2B chemokine (C-C motif) receptor 2 isoform B 3p21.31 7E+05 -0.500 -0.034
165 CCR2A chemokine (C-C motif) receptor 2 isoform A 3p21.31 7E+05 -0.927 0.000  
 
 
 
 
 
 
 
 
 
The original dissertation included a number of articles which were removed for copyright reasons in 
this electronic copy. They are indexed on the item’s homepage.  
